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Dendograms in microbial phylogenetics and epidemiological
typing (Symposium arranged with ESGM)
S8
Evolutionary trees in microbiology
B. Hall (Bellingham, US)
Phylogenetic trees are just tools for representing the relation-
ships among organisms. The focus of this presentation is on the
interpretation of phylogenetic trees, rather than on construction
of those trees. Elements that will be considered are: what are
branches and nodes and what do they mean? Trees are typically
drawn so that they appear to depict the order of descent from
common ancestors, i.e. the direction of evolution. That appear-
ance is often misleading. Direction of evolution and order of
descent are only shown by rooted trees, whereas most
phylogenetic methods produce unrooted trees. What informa-
tion is required to root a tree? Trees of microbial isolates often
include zero-length branches. What do zero-length branches
really mean? Trees are only estimates of historical relationships
they are not facts. How do we determine the reliability of those
estimated trees? Recombination can dramatically affect the
validity of phylogenetic trees. What do we do when there is
too much recombination to construct valid phylogenetic trees?
S9
Representations of strain similarities in
molecular microbial typing
P. Vauterin (Ghent, BE)
This talk covers a variety of grouping techniques that are used to
represent the relations between strains using molecular typing
data. For each technique, the strong and weak points are
discussed, and guidelines are given to come to a reliable
interpretation of the results. The emphasis is on traditional
hierarchical cluster analysis tools, and we elaborate on the limits
of their applicability. In particular, the loss of information
introduced by cluster analysis is discussed, as well as the
problem to degenerate solutions. The particular challenges
associated with the analysis and interpretation of modern
large data sets potentially include thousands of organisms,
which are also covered. We also discuss novel grouping
techniques, such as minimum spanning trees and self-organiz-
ing maps, and show how these tools can be used complemen-
tary to traditional cluster analysis to gain further insight in the
structure of the data.
Antimicrobial resistance in anaerobic bacteria. Experiences in
Europe and North America (Symposium arranged with
ESGARAB)
S11
Antimicrobial susceptibility patterns in different
European countries
E. Nagy (Szeged, HU)
Antibiotic susceptibility testing of clinically relevant anaerobes
in different clinical microbiological laboratories in Europe is less
and less frequently carried out due to the fact, that clinicians
treat many presumed anaerobic infections empirically. Even less
data are available about the antibiotic resistance levels among
the anaerobic normal ﬂora isolates developed due to the use of
antibiotics for infections caused by aerobic or facultative
anaerobic pathogens. New antibiotics with anti-anaerobic activ-
ity may be tested on "old" isolates instead of using "recent"
clinical isolates, which may create false susceptibility data and
incorrect recommendations for treatment of anaerobic infec-
tions. Most systemic data in Europe are available for few genera
and species of anaerobic bacteria such as Bacteroides fragilis and
related species, Fusobacterium spp., Propionibacterium acnes,
Clostridium perfringens, and Clostridium difﬁcile. Two Europe-
wide resistance studies were carried out during the past
15 years involving almost all European countries evaluating
the development of resistance among B. fragilis and related
species. A similar study was done with clinical isolates of
Propionibacterium acnes and Peptostreptococci. Expressed differ-
ences were found in resistance levels between different Bacter-
oides species and between different areas of Europe for
clindamycin, erythromycin, ampicillin and moxiﬂoxacin. The
same is true for Propionibacterium acnes. Resistance genes
responsible for carbapenem and nitro-imidazole resistance can
be found more frequently among clinical and normal ﬂora
isolates, than the expressed resistance. Despite of the fact that
most anti-anaerobic drugs show good activity against anaerobic
clinical isolates, the number of the resistant isolates is increasing
parallel with the time. Accumulation of resistance markers can
be observed among Bacteroides strains. Reported cases will be
discussed where clinical failure was due to the presence of
multi-resistant anaerobic pathogens.
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Pathogenesis and prevention of nosocomial infections-new aspects
(Symposium arranged with ESGNI)
S12
Infections associated with intravascular devices
B. Rijnders (Rotterdam, NL)
Notwithstanding the progress in our understanding of the
pathogenesis of foreign body infection, catheter-related infection
(CRI) continues to be part of the daily life in the ICU, oncology
or haematology unit. The consequential morbidity and longer
hospital stay brings about considerable costs. However, several
interventions can reduce the incidence of CRI. 10 years ago,
catheters coated or impregnated with antiseptics or antibiotics
became part of our armament against CRI. However, indiscrim-
inate prophylactic use of antibiotics increases the risk of
antimicrobial resistance. Furthermore the minocyclin-rifampin
impregnated catheter (the only antibiotic impregnated catheter
with well documented efﬁcacy) is not available in Europe.
A catheter impregnated with chlorhexidine/silver sulfadiazine
(CS) on the outer surface is available in Europe and has been
shown to have the incidence of CRI. Two recent clinical studies
show that an improved version of this catheter (with CS on the
inner and outer surface) reduces catheter colonization with 45–
72%. In vitro evidence about the use of antiseptic agents as a
substitute for antibiotic locks for the prevention of endoluminal
CRI is available. However, evidence from prospective random-
ized controlled clinical trials on the use of antiseptic locks is still
scarce. Several clinical studies and a meta-analysis support the
use of chlorhexidine as the preferred disinfectant prior to
catheter insertion. Recent evidence supports the use of a
chlorhexidine impregnated sponge that is placed around the
insertion site of the catheter to prevent recolonization of the
insertion site and therefore also exoluminal CRI of short-term
central venous as well as arterial catheters. In general it is correct
to state that microorganisms on the outer surface of the catheter
(exoluminal) are the source of infection in most of the CRI in
short-term catheters and microorganisms on the inner surface
(endoluminal) become more important with longer duration of
catheter use. This difference is however gradual. Therefore in
most settings interventions directed against exoluminal as well
as endoluminal CRI should be combined. Despite the above-
mentioned new developments, the implementation of a struc-
tured teaching program on CRI (with a special emphasis on the
adherence to full-sterile barrier precautions, chlorhexidine based
skin disinfections and removal of the catheter as soon as
possible) remains the cornerstone of CRI prevention.
S14
Ventilator-associated pneumonia
W. Kru¨ger (Tubingen, DE)
Several factors contribute to the pathogenesis of VAP; therefore,
several approaches have to be followed in order to prevent
pathogens from invading the lung. Aspiration of contaminated
oral secretions is considered to be the main mechanism. This is
also true for incubated patients, where micro-aspiration occurs
besides or within the folds of the inﬂated cuff of the endotra-
cheal tube. Moreover, the oral cavity of severely ill patients is
typically colonized with gram-negative rods, which is usually
not the case in healthy subjects. Consequently, many VAP
prevention measures aim at the reduction of aspiration of
contaminated oral secretions. Deeply sedated patients may not
be able to swallow their oral secretions. Oral hygiene and
suctioning are important parts of nursing care, which also
contribute to the reduction of aspiration. However, the subglot-
tic space can usually not be emptied of secretions by oral
suctioning. One approach is suctioning of subglottic secretions
using a special endotracheal tube with an additional dorsal
lumen right above the cuff. Whereas several researchers could
not ﬁnd a beneﬁt, at least two studies showed subglottic
suctioning to be effective for reducing the incidence of VAP (9,
10). However, it is deﬁnitely not indicated to replace a regular
endotracheal tube by a subglottic suction tube in a patient, who
is already intubated. It has clearly been shown that reintubation
is a risk factor for the development of pneumonias. This is most
likely due to aspiration occurring during the deﬂation of the
endotracheal tube and during the process of intubation. This
also means that thorough precautions have to be taken, when an
endotracheal tube has to be changed for medical reasons: enteral
feeding should be stopped several hours in advance, the patient
should be placed in a semi-recumbent position, the stomach and
oral cavity are suctioned as well as the subglottic space, which
can be visualized and suctioned during laryngoscopy before the
cuff of the endotracheal tube is to be deﬂated. Reduction of
microbial colonization of the oral cavity is a causal approach for
the prevention of VAP. It has been shown in patients undergo-
ing cardiac surgery, that a 0.12% oral chlorhexidine solution can
reduce the incidence of postoperative pneumonias, but it is still
unclear, whether this should generally be recommended for
surgical patients (4). Recent investigations point to the import-
ance of bacterial colonization of teeth in the pathogenesis of
VAP (5). However, antiseptic gels applied to the gingiva and
teeth were so far not effective for prevention of VAP (6).
Likewise iseganan, an antimicrobial peptide applied to the oral
cavity was also not effective, as shown in a recent multi centre
placebo-controlled double-blind trial (7). Topical application of
antibiotics into the oropharynx is part of several trials using
selective digestive decontamination (SDD) and the exclusive
administration to the oral cavity (SOD: selective oral decontam-
ination) was effective in reducing VAP in ICU patients (1).
Meanwhile, 3 independent clinical trials have shown a survival
beneﬁt for critically ill patients treated with SDD (2, 3, 8), but the
fear of increased selection pressure has hampered widespread
use of SDD in critically ill patients.
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News in the ﬁeld of toxoplasmosis (Symposium arranged with
ESGT)
S15
Past, present and future drug treatment of
Toxoplasma gondii
F. Derouin (Paris, FR)
An ideal anti-Toxoplasma drug would be preferentially parasi-
ticidal against the different parasitic stages, prevent stage
differentiation from tachyzoite to bradyzoite, would penetrate
into cysts and be well distributed in the main sites of infection.
Based on in vitro and in vivo data recorded for the last 35 years, it
appears that no such a drug exists today and that no marketed
new compound can be expected for several years, despite the
recent identiﬁcation of new potential drug targets (apicoplast,
parasite penetration). Among drugs that can be used safely for
treatment of congenital or cerebral toxoplasmosis, no drug or
drug regimen is as effective as the combination of pyrimetham-
ine + sulfadiazine. Among the ‘‘new’’ macrolides, azithromycin
seems to be the most efﬁcient in vivo and synergizes with
pyrimethamine. Some new ﬂuoroquinolones are active in vivo
and in vitro but their potential toxicity is a concern for treatment
congenital toxoplasmosis. Atovaquone remains of interest for
reduction of parasite burden in a long-term treatment strategy
and a second line treatment in case of intolerance to sulfona-
mides or pyrimethamine. Cotrimoxazole is effective in vitro and
in vivo against tachyzoites and remains the ﬁrst line drug
combination for primary prophylaxis of toxoplasmosis in
immunocompromised patients. Interestingly, anti-HIV protease
inhibitors are inhibitory for T. gondii in vitro at a concentration
that can be achieved in human. It should be noted that for most
drugs, experimental data are dramatically lacking for treatment
of ocular toxoplasmosis and on the efﬁcacy of long-term
treatment of chronic infection on brain cyst burden. Indeed,
signiﬁcant progresses can be noted on the in vitro and in vivo
methods of investigation of drugs, including the use of trans-
formed parasite expressing enzyme activity or bioluminescence,
the development or QSAR methods and high throughput
screening for the activity small molecules against parasitic
enzymes or T. gondii penetration into cells. One can expect this
will result in identiﬁcation of new drug strategies for the future.
This review also points out major lacks of information on the
susceptibility of T. gondii strains according to their genotypes.
Marked differences of susceptibility have been occasionally
reported but need to be conﬁrmed, on the basis of the new
knowledge on strain genotyping. Similarly, the possible exist-
ence of natural or drug selected resistance need also to be
investigated.
S16
Detection and genotyping of Toxoplasma gondii
by real-time PCR and pyrosequencing
B. Edvinsson, M. Lappalainen, B. Evenga˚rd for the European
Study Group on Toxoplasmosis (ESGT)
Objectives: Toxoplasma gondii is a protozoan parasite with
worldwide distribution. Primary infections in humans are
usually asymptomatic or characterized by non-speciﬁc
symptoms. The infection is, however, severe or fatal in patients
with a suppressed immune system, and is heremost often caused
by chronic infections that become reactivated. Rapid and
sensitive diagnosis by PCR may be of importance for the
survival of these patients. PCR techniques used to detect the
parasite in patient samples are not yet standardized. We have
compared the performance of two real-time PCR assays targeting
two different repetitiveDNAelements of T. gondii. We also aimed
to develop a pyrosequencing assay to discriminate between the
three main genotypes of T. gondii; i.e. type I, II and III.
Methods: The sensitivities for detecting T. gondii by real-time
PCRwhen targeting the 35-fold repeatedB1geneor a 200–300 fold
repeated 529 bp elements were compared. The impact on the
diagnostic sensitivity when using two different types of internal
ampliﬁcation controls, either ampliﬁed by the primers used for
detection of T. gondii or by a different set of primers, was tested.
For genotyping, real-time PCR and pyrosequencing were used to
analyse a fragment of the GRA6 gene in 21 T. gondii isolates.
Results: The sensitivity was higher when the 200–300 fold
repeated 529 bp element was used. The diagnostic performance
of the real-time PCR targeting the 529 bp elements was not
affected by inclusion of an internal ampliﬁcation control. The
Pyrosequencing assay discriminated between type I, II and III
T. gondii.
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Conclusions: Real-time PCR, including an internal
ampliﬁcation control, can be used to detect low amounts of T.
gondii in a sample by ampliﬁcation of a part of the 529 bp
elements. This may be of importance if the aim is a sensitive and
rapid diagnosis of toxoplasmosis in immunocompromised
patients. Pyrosequencing can be used for rapid and high
throughput genotyping of the parasite in clinical ﬁndings, and
should help to further elucidate if there are differences in the
clinical manifestations of toxoplasmosis caused by type I, II or III
T. gondii.
How to prevent microbial bioﬁlm formation on medical devices
(Symposium arranged with ESGB)
S18
Drug releasing polyurethanes able to inhibit
microbial bioﬁlm growth on medical devices
G. Donelli (Rome, IT)
In recent years, a number of different strategies have been
developed to prevent medical device-associated infections,
including device coating with antimicrobial agents able to
inhibit bacterial colonization and bioﬁlm formation. However,
the possible emergence of multi-drug-resistant microorganisms,
as consequence of the sub-inhibitory antibiotic concentrations
released from the implanted device, is regarded as a signiﬁcant
risk. On the other hand, the largely increased antibiotic
resistance is a well established feature of microbial species
growing in sessile mode to form a bioﬁlm, such as Staphylococ-
cus, Pseudomonas and Candida spp. which are the most fre-
quently implicated bugs in device colonization. In order to
inhibit microbial colonization of medical devices and to min-
imize multi-drug resistance, we designed experimental models
based on the adsorption on functionalized polyurethanes of:
(i) a water-insoluble antibiotic not used for systemic therapy;
(ii) two water-soluble antibiotics, belonging to different classes,
both commonly used in systemic therapy; (iii) ions of transition
metals known for their broad spectrum of antimicrobial activity
as possible adjuvants of antibiotics; (iv) an antifungal drug
highly effective for treatment of Candida infections and (v) pore-
former molecules able to improve the antibiotic loading and
control its release. In particular, we developed new drug-
releasing polymers loaded with: (i) usnic acid as a water-
insoluble antibiotic molecule able to exert its activity at the
device level; (ii) rifampin and cefamandole nafate as an
association of two water-soluble antibiotics exhibiting two
different modes of action; (iii) silver ions and ciproﬂoxacin
exhibiting a synergistic role; (iv) ﬂuconazole as a wide-
spectrum antifungal drug and (v) albumin and polyethylengly-
col as pore formers promoting the release of rifampin,
cefamandole nafate and ﬂuconazole from polyurethanes. The
results of these in vitro studies suggest that the combined
entrapping of antibiotic or antifungal drugs and pore-formers in
these functionalized polyurethanes seem to be promising both
in preventing bacterial colonisation and bioﬁlm formation and
controlling the emergence of microbial resistance.
Antimicrobial utilisation in Europe: future directions (Symposium
arranged with ESGAP)
S20
Mapping antibiotic consumption and resistance
in the community
M. Heginbothomfor the Welsh Antibiotic Study Group
Surveillance is critical to the understanding of antibiotic resist-
ance and the ability to control its spread. It facilitates the
monitoring of trends, informs clinical practice, guides interven-
tion, allows assessment of the effects of change and the detection
of new and untoward events. Timely feedback of consumption
and resistance data to stakeholders creates ownership and aims
to improve prudent prescribing. However, the impact of any
surveillance information can be greatly inﬂuenced by its
presentation. Geographical Information System (GIS) is map-
ping and analysis technology that allows large quantities of
information to be visualized and analysed within a geographic
context. GIS mapping provides a powerful medium for the
dissemination of surveillance data. Various surveillance groups
use GIS technology to map resistance data at country and
regional level e.g. European Antimicrobial Resistance Surveil-
lance System; NPHS Wales have used GIS technology to map
resistance, consumption, deprivation and practice demography
data at Local Health Board and General Practice level. European
surveillance data mapped by country and region will be
reviewed. Welsh surveillance data mapped by LHB and general
practices will be presented, and the factors and determinants of
antibiotic consumption and resistance discussed. The merits of
using GIS for surveillance purposes will be open for debate.
S22
Point-prevalence surveys of anti-infective use
B. Dean Franklin (London, UK)
Surveys of anti-infective use have been carried out twice a year.
For the last six years at Hammersmith Hospitals NHS Trust,
using point prevalence methodology. A team of clinical phar-
macists collect data on all inpatients scheduled to receive one or
more systemic anti-infective on the day of the study, as well as
the total number of patients seen. Data collection takes place
over a four-day period; one quarter of the wards are surveyed
on each day. Systemic anti-fungal and anti-viral drugs are
included. The information obtained includes the number of
patients scheduled to receive one or more anti-infective on the
day of the study, number of anti-infective per patient, percent-
age of anti-infective are given intravenously, as well as details of
the combinations and durations prescribed. Use of anti-infective
on the Trust’s reserved list is examined in more detail. The
trust’s antibiotic steering group uses the results obtained to
highlight areas for intervention. These have included targeting
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areas for intravenous to oral switch, agreeing local policies
where there was no standard practice, and identifying clinical
areas where inappropriate combinations were being used. The
results are fed back to clinical directorates as part of their
performance management information. More recently, ten local
hospitals have collected equivalent data as part of a bench-
marking exercise. This presentation will illustrate the informa-
tion obtained, and discuss the advantages and disadvantages of
this approach to study anti-infective use.
Nosocomial mould infections (Symposium arranged with EFSIG)
S24
Source of moulds in the hospital setting
J.-P. Gangneux (Rennes, FR)
Moulds are ubiquitous in nature and reproduce bymaking spores
able to travel through air. They can cause illness, in particular the
thermotolerant Aspergillus species that produce numerous coni-
dia 2–4 m in diameter. Invasive aspergillosis (IA) is a major
opportunistic infection among patients with severe and pro-
longed neutropenia. Spore inhalation is the usual route of
infection, but other routes may exist. The nosocomial origin of
aspergillosis has been demonstrated in epidemic situations with
airborne spore transmission via unﬁltered air, and massive
environmental contamination during construction and renova-
tion work both inside and outside the hospital. Air control
measures are currently the more effective way of signiﬁcantly
reducing the incidence of nosocomial aspergillosis. Patient rooms
should have adequate capacity to minimize accumulation of
fungal spores using high-efﬁciency particulate air ﬁltration,
laminar air ﬂow systems, high rates of room-air changes, positive
pressure, and well-sealed rooms. Innovative systems producing
puriﬁed air may represent an interesting alternative to the air
ﬁltration. Monitoring of environmental fungal contamination is
strongly recommended to detect increases in conidia density and
to assess air ﬁltration efﬁciency. The follow-up of the air and
surface fungal loads is highly recommended in hospital units,
which beneﬁt from air control measures, in addition to speciﬁc
investigations in case of Aspergillus infection. It requires efﬁcient
biocollectors, adequate surface sampling methods and suitable
culture conditions that must be evaluated before. Progress in
terms of air ﬁltration leaded to decrease of IA in neutropenic
patients during the ﬁrst few weeks after bone marrow transplan-
tation, but delayed IA still occur. The sources and routes of spore
transmission remain unclear, and alternative sources of contam-
ination should be more investigated and controlled. Opportun-
istic fungal pathogens have been recovered from several hospital
water distribution systems in theUSA and authors suggested that
aspergillosis is waterborne. However, the environmental risk of
IA linked to water should be interpreted according to the local
situation, because differences in water collection and treatment
exist. Besides, several foods can be colonized by moulds and can
lead to spore absorption or aerosolization and subsequent
systemic infection. It has been previously recommended that
immunocompromised patients should avoid such contaminated
foods but one alternative is to disinfect potentially contaminated
foods, especially with regard to A. fumigatus. Lastly, the clothing
of visitors and medical staff, and carriage by personal and
medical materials are potential vectors of spores. Preventive
measures might then be appropriate.
S25
Post-operative aspergillosis
A. Pasqualotto (Manchester, UK)
Aspergillus spp. is ubiquitous, aerobic fungi that occur in soil,
water, and decaying vegetation; the organism also survives
well in air, dust, and moisture present in health-care facilities.
Similar to other ﬁlamentous fungi, Aspergillus species are
usually acquired from an inanimate reservoir, more commonly
by the inhalation of small airborne spores. While invasive
aspergillosis typically affects severely immunocompromised
patients, cases of surgical site infections have been reported in
immunocompetent individuals. The aim of this presentation is
to summarize the world literature regarding this topic. This
will be illustrated by the presentation of three cases, originated
from personal knowledge of the authors, and not part of any
outbreak. The ﬁrst of these cases was a man who underwent
elective aortic valve replacement and died of Aspergillus
endocarditis. The second was a teenager who underwent
elective neurosurgery for Chiari I malformation, received
4 weeks of postoperative dexamethasone and died despite
amphotericin B therapy. The third was a woman who devel-
oped a cerebral abscess due to Aspergillus fumigatus after
neurosurgery augmented with dexamethasone and recovered
following voriconazole treatment. Medline, LILACS and
EMBASE databases were searched and references from rele-
vant articles were reviewed. Conference abstracts were
reviewed as well. After Frank and Alton ﬁrstly published
their study of postoperative aspergillosis in 1933, more than
500 cases have been reported. Cardiac and ophthalmologic
surgery, and surgical dental procedures provided the most
commonly reported cases. Postoperative cases of endocarditis
and aortitis affected mostly immunocompetent male patients
submitted to aortic valve replacement. Median time from the
surgery to the diagnosis was 2.7 months. An antemortem
diagnosis occurred in only 43.1%, and blood cultures are rarely
positive (6.4%). Mortality for these conditions was 92.7%.
Vascular graft aspergillosis occurred after a median time of
8 months after surgery. Aspergillus graft infections usually
occur on the suture line of a previous aortotomy, and deﬁnitive
diagnostic procedures for these patients were generally culture
of the excised aortic graft or the peripheral embolus and biopsy
of the contiguously affected vertebral disk space. Most of the
patients with postoperative aspergillosis following neurosur-
gery had received treatment with corticosteroids, and mortality
for this condition was 68.0% surprisingly low if we consider
the mortality rates for immunosuppressed patients with
disseminated aspergillosis involving the central nervous
system. Aspergillus wound infections occurred after a median
time of 17 days after surgery, and many of these patients were
immunosuppressed. Aspergillus ﬂavus was the aetiology of
36.8% of these infections. Successful treatment for postopera-
tive aspergillosis requires rapid diagnosis, surgical debride-
ment and antifungal therapy, probably voriconazole. In order
to improve the outcome, better diagnostic methods are needed,
particularly for cases of endocarditis and aortitis. In most
patients, the source was presumed to be airborne infection
during the surgical procedure. Prevention of these infections
requires special care with the ventilation system in the
operating room, proper disinfection techniques, and appropri-
ate storage of surgical materials. A single proven postoperative
case of aspergillosis is sufﬁcient to initiate epidemiological
investigations.
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Nosocomial infections due to emerging moulds
M. Cuenca-Estrella (Madrid, ES)
Opportunistic molds have emerged during the past decade as
important causes of morbidity and mortality in some group of
patients. At present Aspergillus spp. is one the most common
cause of infection in bonemarrow/stem cell transplant recipients
and mucorales are increasingly reported as causing lethal
infections, despite aggressivemedical and surgical interventions.
In addition, rare emerging molds are becoming a more common
cause a deep and invasive fungal infections. Both hyaline
hyphomycetes and black fungus species are increasingly repor-
ted as causing nosocomial mycoses (pneumonia, CNS infections
and disseminated infections) refractory to conventional therapy.
Fusarium spp. has been implicated in nosocomial outbreaks of
respiratory and disseminated mycosis. Scedosporium spp. cause
disseminated and localized infections in hospitalized patients.
Paecilomyces lilacinus and Scopulariopsis brevicaulis are rare emer-
ging hyphomycete that can cause nosocomial invasive infections
in immunocompromised patients, and Alternaria spp. has been
described in cases of deep infection in solid organ transplant
recipients. Several factors have been signalled as causes of the
emergence of rare moulds at hospital. Environmental changes,
antimicrobial pressure, an expanding population of immuno-
compromised hosts and an increasing of capabilities to identify
rare fungi are the most commonly argued. It should be noted that
emergent fungal infections would continue to increase in these
settings. Efforts should be made to identify nosocomial emerging
molds at species level and to know susceptibility proﬁle of these
organisms. Correct characterization of these species can be
signiﬁcant at therapeutic level in view of their distinct antifungal
susceptibility proﬁle. DNA ampliﬁcation-base methods could be
used for characterization of emerging pathogens. Early diagnosis
procedures and new therapeutic approaches can be also needed.
Guidelines for Helicobacter pylori infections revisited. The
Maastricht-3 2005 consensus report (Symposium arranged with
EHSG)
S27
Indications for H. pylori eradication revisited
E. Kuipers (Rotterdam, NL)
The Nobel prize of Medicine 2005 has been awarded for the
discovery of H. pylori as an important human pathogen. In the
past 25 years since this initial discovery, much research has been
performed to ﬁnd optimal therapies for this bacterial infection,
and to determine the beneﬁts of H. pylori eradication in patients
with various upper gastrointestinal and other conditions. Over
the past decade, repeated international consensus meetings have
on the basis of this literature gradually developed and adapted
guidelines for the management of H. pylori infection. The
Maastricht guidelines developed under the authority of the
EuropeanH. pylori Study Group have over the years in particular
had an impact on the clinical approach to the H. pylori-positive
patient. These Maastricht guidelines have recently been revised
(1) and focus on indications for therapy, diagnostic approaches,
and treatment issues. Conditions that had been accepted in
previous Maastricht guidelines as strong, deﬁnite indications for
H. pylori treatment were again accepted as such. These included
in particular peptic ulcer disease and gastric B-cell MALT-
lymphoma, but also atrophic gastritis and 1st degree relatives of
gastric cancer patients. Furthermore, H. pylori eradication was
accepted as an appropriate option for H. pylori-positive patients
with investigated non-ulcer dyspepsia, whereasH. pylori test and
treat was accepted as an appropriate option for patients with
uninvestigated dyspepsia. Routine testing for Helicobacter pylori
was not recommended in GERD, but the consensus committee
advised to consider H pylori testing in patients on long-term
maintenance therapy with PPIs. H. pylori eradication was
considered to be of value in chronic NSAID users but insufﬁcient
to completely prevent NSAID-related ulcer disease H. pylori
infection should be sought for and treated in patients with either
unexplained iron deﬁciency anaemia, or ITP. These indications
and their background will be discussed during the meeting.
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S28
Diagnosis and treatment of resistant H. pylori
infection
F. Me´graud (Bordeaux, FR)
The management of H. pylori infection has been well established
during the last 10 years. Recommendations were made in the
Maastricht Conference in 1996, and were updated in 2000. Most
of them have been used in other consensus conferences
worldwide. Nevertheless, some points have emerged these
past 4 years, which led to questions and discussions at the
Maastricht-3 Conference.
Diagnosis pre treatment: With regard to diagnostic tests, the
discussion focused on the value of non-invasive tests other than
the urea breath test (UBT). A ﬁrst statement concluded that
serology could be considered as a diagnostic test in some
situations, e.g. bleeding ulcers, gastric atrophy, MALT
lymphoma and current use of PPI or antibiotics. Indeed, PPI
are a source of false negative results for all diagnostic tests
except serology, and should be stopped at least 2 weeks before
performing the test. In contrast, it was stated that neither the
doctor tests (near-patient tests) nor the detection of H. pylori
antibodies in urine and saliva, had any current role in the
management of H. pylori infection. The situation is different for
the stool test, which was considered acceptable, on the same
grounds as UBT for H. pylori diagnosis, especially in the case of
implementation of the test and treat strategy. The importance of
performing culture for clarithromycin susceptibility testing,
before using clarithromycin-based treatment as a ﬁrst line
treatment, was hardly debated. Culture was recommended if
primary resistance to this antibiotic was higher than 15–20% in
the respective geographical area or population, as well as after 2
treatment failures. The importance of monitoring the primary
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antibiotic resistance in reference laboratories in different areas
was also stressed. In the event that clarithromycin susceptibility
testing under such circumstances is impossible, this antibiotic
should not be used. In contrast, it was agreed that testing
metronidazole susceptibility is not routinely necessary in the
management of H. pylori infection. Metronidazole susceptibility
testing needs further standardization before being
recommended as a ﬁrst line treatment.
How to treat? The recommended ﬁrst line therapy therefore
remains PPI-clarithromycin-amoxicillin or metronidazole if the
primary resistance to clarithromycin in the area is lower than
15–20%. There is a small advantage to using metronidazole
instead of amoxicillin and therefore, this combination was found
to be preferable in areas where the prevalence of metronidazole
resistance is lower that 40%. The consensuswas also that a 14-day
rather than 7-day treatment duration had a slight advantage in
terms of treatment success. However, a 14-day treatment is not
cost effective in most countries. Another addition to the
Maastricht-2 Consensus is that bismuth-based quadruple
therapies, when available, are acceptable as alternative ﬁrst line
therapies. With regard to second line therapies, bismuth-based
quadruple therapies remain the best option. If unavailable, PPI-
amoxicillin or tetracycline and metronidazole are recommended.
As previously proposed, the rescue therapy after failure of 2
courses of different therapies should be based on antimicrobial
susceptibility testing. For follow-up after H. pylori eradication,
UBT remains the preferred test. If unavailable, a laboratory-based
stool test preferably using monoclonal antibodies, could be used.
The timing of this follow-up should be at least 4 weeks after the
end of eradication treatment.
S29
Prevention of gastric cancer by H. pylori
eradication
P. Malfertheiner (Magdeburg, DE)
In the light of the most recent clinical developments in the
management of H. pylori infection, the European Helicobacter
Study Group (EHSG) organized the Maastricht III Consensus
Report that involved 50 participants from 26 countries around
the world. This abstract provides a brief summary of some novel
and major aspects relevant for clinician routine. In the new
edition of the Maastricht guidelines three areas have been
addressed: (a) Indications/contraindications for H. pylori erad-
ication, with special focus on dyspepsia, patients exposed to
NSAIDs or Aspirin, and the relationship with GERD; (b)
Diagnostic procedures-Standard and rescue therapy of H. pylori
infection and (c) Prevention of gastric cancer and other compli-
cations related to H. pylori. Selected recommendations and
statements are listed as follows: (a) Indications/contraindications
for H. pylori eradication and relevant statements.
Uninvestigated dyspepsia: H. pylori test and treat is an
appropriate option for patients with uninvestigated dyspepsia.
NSAIDs: (i) In patients who are naı¨ve NSAIDs users, H. pylori
eradication may partially prevent peptic ulcers and/or bleeding;
(ii) In patients on long term NSAIDs and peptic ulcer and/or
ulcer bleeding, PPI maintenance therapy is superior to H. pylori
eradication in preventing ulcer recurrence and/or bleeding.
Aspirin: Patients who are on long-term aspirin with ulcer
disease and signiﬁcant clinical bleeding should be tested for
H. pylori and if positive receive eradication therapy.
GERD: H. pylori eradication does not cause GERD.
Atrophic gastritis: H. pylori eradication halts the extension of
atrophic gastritis and may lead to regression of atrophy. The
effect on intestinal metaplasia is uncertain.
Iron Deﬁciency Anaemia: H. pylori infection should be sought
for and treated in patients with unexplained iron deﬁciency
anaemia.(b) Diagnosis of H. pylori infection:(i) The non-invasive
tests that can be used for the test and treat strategy are UBT and
the stool antigen tests. Certain kits for serology with high
accuracy can also be applied; (ii) PPI is a source of false negative
diagnostic tests except serology, PPI should be stopped for at
least 2 weeks before to perform diagnostic test and (iii) it is
recommended to follow up patients after H. pylori eradication
with UBT, if available. If this diagnostic procedure is not
available, a laboratory-based stool test, preferably using
monoclonal antibodies, could be used
(c) Prevention of gastric cancer: (i) H. pylori eradication
prevents development of preneoplastic changes (intestinal
metaplasia, atrophic gastritis) of the gastric mucosa; (ii)
eradication of H. pylori has the potential to reduce the risk of
gastric cancer development and (iii) the optimal time to
eradicate H. pylori is before preneoplastic conditions (atrophy,
intestinal metaplasia) are present
Treatment strategy: First line therapy for H. pylori eradication:
PPI-clarithromycin - amoxicillin or metronidazole therapy
remains the recommended ﬁrst line therapy in populations with
less than 15–20% clarithromycin resistance prevalence in
population in less than 40% metronidazole resistance
prevalence PPI-clarithromycin - metronidazole is preferable.
Quadruple therapies are alternative ﬁrst line therapies.
In case of failure – second line therapy: Bismuth-based
quadruple therapies remain the best second line therapy, if
available, if not, PPI-Amoxicillin or tetracycline and
metronidazole are recommended.
Subsequent failures – rescue therapy: The rescue therapy
should be based on antimicrobial susceptibility testing
New diagnostic techniques for the microbiological laboratory and
general practitioner
S36
Breakthroughs in bacterial detection,
identiﬁcation and typing
M. Struelens (Brussels, BE)
In 2005, a number of novel methods applicable in the clinical
microbiology laboratory have been reported for the detection,
identiﬁcation to species level and sub-typing of bacterial
pathogens. Breakthroughs have been made in rapid detection
of bloodstream infections in neonates and adult patients with
sepsis by use of broad range bacterial DNA detection and
identiﬁcation. Successful methods include universal gene ana-
lysis by real-time PCR, PCR-DNA micro-array hybridization, or
PCR-pyrosequencing testing of blood specimens. Also, several
highly accurate sequence-based methods were developed and
validated for identiﬁcation of clinical cultures of staphylococci,
mycobacteria, nocardia, and Burkholderia species. Progress has also
been achieved in rapid detection of carriers of multi-resistant
bacteria, especially methicillin-resistant S. aureus (MRSA) from
superﬁcial swabs. Several chromogenic selective culture media
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have shown sensitivity of 80–90% with excellent speciﬁcity for
MRSA detection within 20–24 hours of incubation. Real-time
PCR based on the orfX-SCCmec junction has shown similar
accuracy for MRSA detection within 2 hours after specimen
collection. For tuberculosis, advances were made in rapid
detection, identiﬁcation to species level and detection of rifam-
pin and isoniazid resistance directly in clinical specimens by
molecular methods, including PCR-pyrosequencing. Epidemio-
logical typing has beneﬁted greatly from the extension and
validation of sequence-based systems and databases, including
novel MLST schemes for Acinetobacter and B. cepacia complex.
Single nucleotide polymorphism analysed by rapid methods
like real-time PCR with melt curve analysis or allele-speciﬁc
PCR have been developed for E.coli and Campylobacter. VNTR-
MLVA schemes have also been validated for rapid typing of
several human pathogens. In general, most publications focus
on the ‘‘proof of concept’’ of these rapid and highly informative
molecular assays at the level of clinical accuracy. There is
however, too few evaluation of the clinical utility/superiority of
these assays in routine application in terms of cost-effectiveness
of medical/public health interventions based on test results.
Thus, the need for funding this kind of intervention research
should urgently be addressed by health technology assessment
authorities.
S37
Progress in detection of bacteria responsible for
infections in challenging clinical situations and
of antimicrobial resistance
R. Leclercq (Caen, FR)
Identiﬁcation by conventional techniques of bacteria responsible
for infections remains challenging in situations when these
bacteria are rare in the clinical sample or difﬁcult to grow or
when antibiotic treatment has been administered early. Bone
and joint infections, endocarditis and meningitis are examples of
these types of situation. Another challenging issue is the rapid
detection of bacteria in case of severe infection or for prevention
of neonatal infection by group B. streptococci. Several molecular
homemade or commercially available techniques can now be
used which provide reliable results. Detection of antimicrobial
resistance might be useful when resistance is poorly expressed
in conventional tests or for epidemiologic purposes. In partic-
ular, detection of methicillin resistance in staphylococci has been
the subject of extensive works. Several methods are now
available which allow the detection of PLP2a expression or of
the mecA gene. Several commercial kits are available for the
detection of the mecA gene that is generally based on DNA
ampliﬁcation followed by hybridization. These kits generally
allow species identiﬁcation in the same experiment. Similarly,
identiﬁcation of vancomycin resistance genes in enterococci can
be performed using either homemade multiplex PCR or com-
mercial kits. The cost of these techniques is decreasing but
remains to be balanced with the beneﬁts that are expected from
their use.
S38
Molecular diagnostics in virology, overcoming
the hurdles
H.G.M. Niesters (Rotterdam, NL)
The advantages of molecular diagnostics in virology has become
clear for a growing number of clinically important questions,
and has left from the research state to become integrated in the
routine diagnostic setting. The repertoire of assays available was
mostly focussing on the detection of the blood-borne viruses
(HBV, HCV and HIV-1), but due to the availability of new and
easy-to-use technologies (mostly real-time ampliﬁcation based)
the detection of every target is possible. Targets like the
herpesviruses and a large panel of viruses infecting the
respiratory tract, are already routinely detected in larger
(university) hospitals. This is also pushed by the "urgent" need
to be prepared for the detection of new and emerging viruses,
like SARS and inﬂuenza virus (whether H7N7 or H5N1), but
also due to the possibilities to develop assays within a relative
short period of time for the newly detected viruses, like the
coronaviruses HKU and NL-63, and BOCA virus, which has
increased our insight in the clinical implications of these viruses
in respiratory tract infections. More knowledge with easy-to-use
real time technologies, the improved isolation and detection
platforms, the availability of better controlled proﬁciency panels
for an increasing number of targets, and the introduction of
universal internal controls, have all resulted in a better and more
standardized assay performance. This resulted not only in a
discrepancy of the number of commercially available assays
used for virological targets compared to in-house develop
assays, but also in the acceptability of molecular diagnostics,
simply because clinical decisions can now be better made due to
the information provided. The last two hurdles, costs and time-
to-result are very close to be solved. The developments of
molecular technologies and assays during the last years, as well
as the detection of new pathogens which in most cases cannot be
detected by other technologies like virus culture or serology,
and the improved quality control possibilities, has generated
from virology a dynamic discipline with an impact in good
clinical practice. Although improvements are always possible,
like multiplexing, small volumes, very fast turn-around-time,
DNA chip technology, the ﬁnish is just around the corner.
S40
Mycology
E. Roilides (Athens, GR)
Invasive fungal infections (IFIs) have become a major cause of
increased morbidity and mortality in immunocompromised
patients. While a number of new antifungals have been lately
introduced in the ﬁght against opportunistic fungi, patients with
these generally devastating diseases have had very dismal
prognosis partly due to the late diagnosis of IFIs. Historically,
microscopic examinations of body ﬂuids or tissue biopsies as
well as culture of the material on appropriate culture media have
been the principal modalities for diagnosis of IFIs. High resolu-
tion CT scans serially performed have been proven to be sensitive
tool of diagnosis of fungal pneumonias in haematological
patients. Lung densities with halo sign and central cavitation of
small nodules with air crescent formation can be found in adult
patients and they are very useful signs of invasive aspergillosis
(IA). Recently, novel diagnostic methods both serological and
molecular have been developed and evaluated as well as
improved culturing techniques. Identiﬁcation now is performed
more accurately to the species level with the use of automated
methods and genetic sequencing. Evaluation of susceptibility of
clinical fungal isolates to antifungal drugs is also more wide-
spread and more standardized. Correlation between in vitro and
in vivo effectiveness has been achieved at least in the case of
Candida infections. Among serological methods, galactomannan
assay has become very helpful in the early diagnosis of IA and its
sequential performance in high-risk patients has been shown to
help. Its use is still problematic in young pediatric patients in
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whom the assay has given low speciﬁcity with a high number of
false positive results as well as low sensitivity in certain cases
such as chronic granulomatous disease. Evaluation of galacto-
mannan in body ﬂuids other than blood is also feasible and
provides important information; it needs, however, further
standardization. b-glucan is another metabolite that is increased
in serum of patients with fungal infections and speciﬁcally with
invasive candidiasis. It is being under intense study. Detection of
nucleic acids of fungi by the use of polymerase chain reaction
(PCR) is a powerful method for rapid identiﬁcation of fungi; this
method, however, needs further development and standardiza-
tion before it is widely applied in the clinical microbiology lab.
These techniques coupled with enhanced radiology are expected
to enable the physician to diagnose serious fungal infections
earlier in their course increasing the chance for an improved
outcome.
Neurological sequelae of bacterial and viral infections
S41
Campylobacter-induced Guillain-Barre´ syndrome
H.P. Endtz (Rotterdam, NL)
Almost 150 years after its ﬁrst description by Gustave Landry,
the Guillain-Barre´ syndromes (GBS) are the leading cause of
acute autoimmune neuromuscular paralysis worldwide. Major
advances have been made in recent years unravelling the
pathophysiological mechanisms of GBS. Overall, approx. 60% of
the cases was preceded by infections, mostly ﬂu-like infections
or gastroenteritis caused by Campylobacter jejuni. The discovery
of ganglioside mimics on microbial glycans has been quintes-
sential and human as well as animal studies now support an
important role for molecular mimicry in the pathogenesis of
GBS. Evidence is accumulating that genetic polymorphism of
C. jejuni determines the anti-ganglioside antibody reactivity and
the clinical presentation of GBS. Genes involved in the synthesis
and transfer of sialic acid appear to play a crucial role. In mice,
injection of wild type GBS strains induces anti-ganglioside
antibodies whereas Cst-II knockout mutants do not. Acute
motor axonal neuropathy (AMAN) and Fisher’s syndrome in
particular, have been associated with anti-GM1/GD1a and anti-
GQ1b antibodies, respectively. B-cell tolerance may explain the
fact that most C.jejuni infections are not followed by GBS,
although the mechanism is still poorly understood. Being
carbohydrates, human gangliosides elicit a T-cell-independent
humoral response. However, for reasons not speciﬁed here,
T-cells also are likely to play an important role in the pathogenesis
of GBS but their role is not clear yet. Recent attempts to identify
human immunosusceptibility factors have been unsuccessful.
Further research is clearly needed in order to discover new
treatment modalities. Recent developments in the biosynthesis
surface-boundgangliosidederivativesmayopennewavenues for
novel and speciﬁc diagnostic and therapeutic approaches.
S42
The involvement of Chlamydia pneumoniae in
multiple sclerosis
E. Fainardi (Ferrara, IT)
Multiple Sclerosis (MS) is a presumed autoimmune chronic
inﬂammatory demyelinating disease of the Central Nervous
System (CNS) of unknown aetiology. Epidemiological observa-
tions indicate that exposure to an environmental factors, such as
a virus, in combination with genetic predisposition could be
implicated in MS pathogenesis. However, direct evidences for
an infectious aetiology in MS are still lacking. Recently, a
potential role of a causative agent of MS has been suggested for
Chlamydia pneumoniae, a Gram-negative, obligate intracellular
bacterium that can induce a chronic infection and presents a
high seroprevalence in adults. After the initial high rates
reported for molecular and culture demonstration of C. pneu-
moniae in cerebrospinal ﬂuid (CSF) of MS patients, the associ-
ation between C. pneumoniae and MS was intensively
investigated. Epidemiological studies reported that seropositiv-
ity for C. pneumoniae was strongly related to the risk of clinical
exacerbation and progressive disease, but only moderately
linked with the risk of developing MS. Conﬂicting results
were obtained with the use of different techniques. In polym-
erase chain reaction (PCR) and isolation studies, CSF evidence of
C. pneumoniae in MS was either less frequent than previously
described, with equivalent amounts in MS and other neurolog-
ical diseases, or absent. Evidence of C. pneumoniae infection was
not observed in MS brain lesions. An intrathecal production of
anti-C. pneumoniae antibodies within the CNS was found in a
variable proportion of patients with MS and other neurological
disorders or undetectable. C. pneumoniae was able to induce an
experimental autoimmune encephalomyelitis (EAE), the animal
model of MS, in rats. The presence of C. pneumoniae in brain
tissue and CSF was recently demonstrated in a subgroup of MS
patients at immunohistochemical, molecular and ultrastructural
levels. This growing body of data argues against a central role
for C. pneumoniae as a candidate in MS pathogenesis and
suggests that an association between C. pneumoniae and MS is
not selectively restricted to MS, but is shared by other neuro-
logical conditions. These ﬁndings also raise the possibility that
C. pneumoniae is present in a subset of patients with MS in which
C. pneumoniae could cause a brain chronic persistent infection
acting as a cofactor in the development of the disease. Never-
theless, the actual involvement of C. pneumoniae in MS still
remains matter of debate.
S43
Neurological complications of reactivated
Varicella Zoster virus infection
T. Bergstro¨m (Go¨teborg, SE)
Varicella Zoster virus (VZV) infections of the central nervous
system (CNS) constitute a major part of the burden of disease of
this virus. The clinical scope includes encephalitis, brain stem
encephalitis, myelitis, cerebellitis, cerebral vasculitis, ventriculi-
tis, facial palsy, radiculitis and meningitis. Recently, improved
diagnostics has revealed that VZV is a major CNS virus in
several European countries. We here present clinical and
laboratory data on 76 cases, collected during 1992–2005 in the
Go¨teborg area, in whom VZV DNA was detected by PCR in the
cerebrospinal ﬂuid (CSF). During the last three-year period, the
yearly incidence of VZV CNS infections rose sharply to become
the most frequently detected virus in CSF at our laboratory. This
shift coincided with the introduction of a novel TaqMan PCR
system based on the gene coding for glycoprotein B. The age-
related incidence was surprisingly evenly distributed with the
exception of a peak at 70–80 years. In line with studies by others,
a large proportion of the cases had no skin lesions, i.e. neither
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shingles nor zoster. These two ﬁndings are compatible with that
VZV might recur more often during life than previously thought
and that manifestations in ‘‘CNS only’’ might be a clinically
important part of the VZV disease spectrum. Viral DNA
quantities in the CSF were found to be high as compared with
similar data from CNS infections caused by herpes simplex
virus 1 and 2. We suggest that VZV should be sought for in all
cases of CNS infections of suspected viral origin that recom-
mendations regarding doses and duration of antiviral therapy of
such VZV infections should be thoroughly discussed, and that
long-term follow-up studies of neurological outcome should be
performed.
S44
Possible viral aetiology of multiple sclerosis
P.G.E. Kennedy (Glasgow, UK)
The demyelinating disease Multiple Sclerosis (MS) is the most
important cause of neurological disability in young adults in
Northern temperate regions. While the disease is probably
multifactorial in aetiology, several lines of evidence indicate that
there is a strong environmental element in its causation. A
possible viral component to MS pathogenesis has been consid-
ered a possibility for many years, and while there is a long list of
viruses that have been reported to be present in MS brain tissues
using various techniques, previous reports of virus isolation
have generally not been conﬁrmed. This whole subject has
therefore remained highly controversial. More recently, many
groups have used sophisticated molecular virological tech-
niques in attempts to address this issue. It is also possible that a
virus may only be involved in the initial stages of MS-the so-
called ‘hit and run’ scenario- in which case evidence of active
viral infection in MS brain tissue would not be expected. Also, if
MS is truly a heterogeneous disease, then a virus or indeed any
other aetiological component may be involved in some cases but
not others. This talk will give a broad overview of past and
current attempts to identify viruses, viral nucleic acids and viral
antigens in MS tissue. It will also focus on recent work that has
implicated a possible role of Human Herpes Virus-6 (HHV-6) in
MS, primarily studies that have suggested that viral DNA and
RNA is increased in MS lesions compared with normal tissues,
although the data in that area too remains controversial as the
possible role of human endogenous retroviruses (HERV) in MS
which will also be mentioned. There has also been recent
interest in abnormal immune responses to EBV in MS patients.
The latter indicates that a viral infection and altered immunity in
MS are not necessarily inconsistent.
Evolution of b-lactamases
S46
CTX-M b-lactamases: the molecular story of a
clinical success in community and hospital
R. Canton (Madrid, ES)
CTX-M extended-spectrum related b-lactamases were ﬁrst
detected in human clinical isolates nearly simultaneously in
Germany and Argentina in 1989. Since then a dramatic increase
in prevalence has been observed all over the world both in the
nosocomial and community settings. Factors fuelling this situ-
ation include genetic aspects related to efﬁcient blaCTX-M gene
dissemination and enzymatic expression, bacterial host-speciﬁc
features and frequent co-resistance to other antimicrobials.
blaCTX-M genes are linked to apparently simple genetic struc-
tures including IS sequences (ISEcp1-like insertion sequences)
and integrons (In60-like integrons) and to a lesser extent to
phage-related constructions. These genetic supports are inserted
in higher-order genetic complex structures such us transposable
elements (Tn21-like transposons) and plasmids, which undoubt-
edly facilitate the mobility of blaCTX-M genes. The allodemic
population structure, commonly associated to CTX-M produ-
cing isolates, illustrates this situation. Nevertheless, successful
epidemic CTX-M producing clones have been also identiﬁed not
only in the nosocomial setting but also in the community.
blaCTX-M gene environments and surrounding structures might
have also facilitated the acquisition of other resistance cassettes
or their integration in structures previously harbouring these
resistance cassettes. Co-resistance, including aminoglycosides,
ﬂuoroquinolones, trimethoprim and sulfonamides facilitates
successful maintenance of CTX-M producing isolates and co-
selection within bacterial communities. Intestinal colonization
with CTX-M producing E. coli isolates has been increasingly
recognized suggesting a potential source for clinical isolation.
Nevertheless, CTX-M producing isolates have been associated
with phylogenetic group D, commonly associated with extra
intestinal pathogenic isolates but also with ﬂuoroquinolone
resistant isolates. On the other hand, enzymatic expression of
early CTX-M ESBL yields higher resistance to cefotaxime than
ceftazidime. However, CTX-M producing isolates have com-
pensated this partial resistance phenotype with amino acid
substitutions that expand the hydrolytic properties of CTX-M
enzymes to ceftazidime and/or with the acquisition of other
ESBL, mainly from SHV or TEM families, which generally affect
both expanded spectrum cephalosporins. Continuous evolu-
tion of CTX-M enzymes and successful persistence and mobil-
ization of blaCTX-M genes allow maintenance and increasing
isolation of CTX-M producing isolates in clinical setting.
S47
The role of integrons in the spread of
b-lactamases
G.M. Rossolini (Siena, IT)
Objectives: Mobile b-lactamase genes are carried on a broad
repertoire of genetic elements, including transposons, composite
transposons, integron-borne gene cassettes and integron-
associated CR1 structures. The objective of this presentation
will be to review and discuss the role of the integron system in
the dissemination of clinically-relevant b-lactamase genes.
Methods: A comprehensive review of the scientiﬁc literature, of
sequence databases, and of experimental results derived from the
molecular characterization of b-lactam resistant clinical isolates
was carried out to generate an updated compilation of
b-lactamases encoded by integron-associated genes. Comparative
analysis of integron structures containing b-lactamase genes was
used to deduce information on their phylogeny.
Results: Genes encoding b-lactamases of all known molecular
classes (A through D) can be found as integron-associated. A
number of class A, class B and class D b-lactamase genes are
carried on mobile gene cassettes inserted into integrons, while
some additional class A and some class C b-lactamase genes are
found in integron-associated CR1 structures. From the clinical
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standpoint, the most important b-lactamase genes carried on
gene cassettes are those encoding the metallo-b-lactamases of
the IMP-, VIM-, GIM- and SIM-types, and those encoding some
extended-spectrum serine b-lactamases (ESBLs) of molecular
classes A (e.g. the VEB- and GES-type enzymes) and D (e.g.
some members of the OXA-2 and OXA-10 lineages). The other
integron-associated b-lactamase genes of clinical importance are
those encoding class A ESBLs of some CTX-M-type lineages
(CTX-M-2 and CTX-M-9) and those encoding AmpC-like
enzymes of the DHA and CMY/MOX lineages, carried CR1
structures.
Conclusions: Integrons play an important role in the dissem-
ination and expression of several emerging clinically relevant
b-lactamase genes among major gram-negative pathogens
including members of the family Enterobacteriaceae, Pseudomonas
aeruginosa and Acinetobacter spp. The considerable structural
diversity of integrons carrying the same b-lactamase-encoding
cassettes underscores the role of cassette mobility in the
dissemination of these resistance determinants. The presence
of additional integron-associated recombination mechanisms
enhances the potential of these elements in the dissemination of
b-lactamase genes in the clinical setting.
Quinolone resistance and efﬂux
O50
Type II topoisomerase mutations in Enterobacter
cloacae clinical isolates harbouring QNR and
implication for quinolone resistance
E. Cambau, C. Lascols, J. Robert, V. Cattoir, V. Jarlier,
C.J. Soussy (Creteil, Paris, FR)
Objectives: QNR is a new mechanism of resistance to
quinolones due to the protection of DNA gyrase by the QNR
protein. First described in Escherichia coli and Klebsiella
pneumoniae, recent studies showed that in France it is
disseminated mainly in Enterobacter cloacae. Although qnr was
known to confer a low level of resistance to quinolones, most of
the clinical E. cloacae qnr-positive strains harboured a high level
of ﬂuoroquinolone resistance suggesting associated mechanisms
of quinolone resistance.
Methods: Detection of mutation in the quinolone resistance-
determining region (QRDR) of the DNA gyrase (gyrA, gyrB) and
topoisomerase IV (parC and parE) genes was performed for 22
qnr-positive strains of E. cloacae isolated in 3 hospitals in Paris.
MICs of nine quinolones were determined by the E-test method.
Results: Two mutations, one in gyrA (S83I or S83F or S83Y)
associated to one in parC (S80I), were observed in 11 qnr-positive
strains. One mutation, in gyrA only (S83I or S83F or S83Y), was
observed in 8 of the qnr-positive strains. The 3 remaining strains
showed wild-type sequences of QRDR in gyrA, gyrB, parC and
parE. All qnr-positive strains were intermediate or resistant to
nalidixic acid, peﬂoxacin, norﬂoxacin, oﬂoxacin, and
moxiﬂoxacin but 3 strains were susceptible to ciproﬂoxacin
(CIP) and 2 to levoﬂoxacin (LVX) based on EUCAST-CASFM
breakpoints. Geometric mean CIP MICs were 23 mg/l (range
4–> 32 mg/l) for qnr-positive strains with 2 topoisomerase
mutations, 1.9 mg/l (range 0.12–8 mg/l) for qnr-positive
strains with 1 topoisomerase mutation and 0.53 mg/l for
strains devoid of topoisomerase mutations (range 0.38–
0.75 mg/l). When transferred by conjugation from E. cloacae to
E. coli BM13, qnr was shown to confer a low level of quinolone
resistance with CIP MIC of 0.1 mg/l and LVX MIC of 0.25 mg/l
but a 10- to 24-fold increase in MICs of all quinolones.
Conclusion: 19/22 (86 %) of the E. cloacae clinical strains that
harbour qnr also harboured topoisomerase mutations that
explain their high level of quinolone resistance. None of the 9
quinolones tested can easily detect for the presence of qnr except
in E. cloacae strains devoid of topoisomerase mutations where a
low level of quinolone resistance may indicate the presence of
qnr.
O51
Emergence of plasmid-mediated quinolone
resistance QnrS determinant in enterobacterial
isolates in Europe
L. Poirel, C. Leviandier, P. Nordmann (Le Kremlin Bicetre, FR)
Objectives: The plasmid-mediated quinolone-resistance
determinant QnrA has been identiﬁed previously in
Enterobacteriaceae from USA, Asia and Europe and QnrS has
been found in a Shigella ﬂexneri isolate in Japan. Our goal was to
look for QnrA and QnrS determinants in a collection of 185
nalidixic-acid resistant enterobacterial isolates recovered in
Biceˆtre hospital, France, during a six-month period in 2005
and in 187 extended-spectrum b-lactamase (ESBL)-positive
enterobacterial isolates recovered in a three-year period (June
2002–June 2005). A previous study performed in our hospital
from a collection of 297 nalidixic acid resistant Escherichia coli
isolates recovered in 2003 identiﬁed QnrA in a single isolate
whereas presence of qnrS gene had not been tested in that study
or in any other study so far.
Methods: PCR were performed using speciﬁc primers for the
qnrA and qnrS genes. Cloning and PCR experiments were
performed to identify the upstream- and downstream-located
regions of both genes. Pulsed-ﬁeld gel electrophoresis (PFGE)
was performed to compare the genotypes of the strains
identiﬁed as Qnr positive.
Results: Among the 185 nalidixic acid-resistant but ESBL
negative isolates recovered in 2005, one QnrA-positive
Klebsiella pneumoniae isolate, one QnrS-positive Serratia
marcescens isolate and four QnrS-positive Enterobacter cloacae
isolates (corresponding to two different clones by PFGE) were
identiﬁed. Most of these determinants were found to be
transferable by conjugation or transformation to E. coli.
Among the ESBL-positive isolates, no Qnr-positive isolate was
identiﬁed in 2002. In 2003 and 2004, only a single QnrA-positive
Escherichia coli isolate (VEB-1 positive) and a single QnrA-
positive E. cloacae isolate (SHV-12 positive) were identiﬁed,
respectively. In 2005 (six months), one QnrA-positive
Enterobacter aerogenes isolate (CTX-M-1 and SHV-12-positive)
and three QnrS-positive isolates (one CTX-M-1-positive E. coli,
one TEM-52-positive E. cloacae and one SHV-12-positive
E. cloacae) were identiﬁed. All these Qnr-positive isolates were
resistant to nalidixic acid.
Conclusion: This works demonstrates further that Qnr
determinants are emerging in Europe, and that the QnrS
determinant might be more prevalent that QnrA. This is the
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second identiﬁcation of QnrS after that from Japan. Noteworthy,
QnrS-positive isolates are not always ESBL producers.
O52
Detection of qnrS in clinical isolates of
Enterobacter cloacae in Spain
M.E. Cano, J.M. Rodrı´guez-Martı´nez, J. Agu¨ero, A. Pascual,
J.M. Garcı´a-Lobo, C. Velasco, L. Martı´nez-Martı´nez (Santander,
Seville, ES)
Objective: To determine the presence of the qnrA and qnrS
genes in clinical isolates of Enterobacter species in two hospitals,
located in Santander (North of Spain) and Seville (South of
Spain).
Methods: We evaluated 202 clinical isolates of E. cloacae
(n = 155) and E. aerogenes (n = 47), collected at the Univ. Hosp.
Marque´s de Valdecilla (Santander) and the Univ. Hosp.Virgen
Macarena (Seville) between January 2004 and October 2005.
Identiﬁcation and susceptibility testing were performed by the
MicroScan WalkAway 96 System (Dade Behring) in Santander
and by the Vitek 2 System (bioMerieux) in Seville. The isolates
had different resistant phenotypes, including AmpC
hyperproduction, ESBL production, resistance or decreased
susceptibility to quinolones, and/or resistance to
aminoglycosides. All 202 isolates were screened with a double
PCR assay using speciﬁc primers: a multiplex PCR for intI1,
orf513 and qnrA and another PCR for qnrS. qnr-positive results
were conﬁrmed by DNA sequence analysis. REP-PCR typing
was performed in orf513 and qnr containing isolates. In qnr-
positive isolates intermediate or susceptible to CIP by the
automated system, the MICs of ciproﬂoxacin (CIP) and nalidixic
acid (NA) were additionally determined by E-test.
Results: qnrS was detected in 22 E. cloacae among the 118
isolates of this species from Santander (18.6%). A BLAST
analysis of the nucleotide sequences revealed 100% identity
with the previously published qnrS sequence. Neither qnrA nor
qnrS genes were detected in E. clocae from Seville nor in E.
aerogenes from both locations. Five different REP-PCR proﬁles
were obtained for the qnrS-positive E. cloacae, containing 14, 4, 2,
1 and 1 isolates respectively. All qnrS-positive isolates were
resistant to CIP (MIC > 2 mg/l), except 4 clonally related
isolates, which were susceptible to both CIP (MIC: 0.38 mg/l),
NA (MIC 6–8 mg/l), 1 strain CIP-intermediate (MIC: 1.5 mg/l)
and NA-resistant (MIC: 48 mg/l). Although 31 isolates of E.
cloacae carried orf513, none of the studied organisms contained
qnrA. In contrast, qnrS was found in 2 clonally related isolates
bearing orf513.
Conclusions: E. cloacae containing the qnrS gene has been
detected in Northern Spain. Some of these isolates were
intermediate or susceptible to ciproﬂoxacin.
O53
Determination of the QNR–DNA gyrase
interaction site by a genetic approach
A. Cesaro, V. Cattoir, C. Lascols, C.J. Soussy, E. Cambau (Creteil,
FR)
Objectives: QNR is a new mechanism of quinolone resistance
due to the protection of gyrase by the QNR protein. Since
quinolone inhibition of gyrase is hampered by Qnr, we
hypothesized that the Qnr-gyrase interaction occurs at a site
closed to that of interaction of quinolones, i.e. the quinolone
resistance-determining region (QRDR) in the GyrA and GyrB
subunits.
Methods: First, in vitro selection of quinolone resistant mutants
was performed comparatively with a wild-type (WT) reference
Escherichia coli strain and with an E. coli transconjugant
harbouring the qnrA gene. Selection was carried out using
nalidixic acid (NAL), ciproﬂoxacin (CIP) and moxiﬂoxacin
(MOX). Mutants were chosen on the basis of quinolone MICs
and mutations in the gyrA and gyrB QRDRs were determined.
Second, qnrA was introduced by conjugation into E. coli strains
referenced for gyrA mutations (S83L, D87Y, D87G, D87N), gyrB
mutations (D426N, K447E), gyrA + parC (S83L + S80R), and
gyrA + parE (S83L + L445H).
Results: For the WT E. coli, gyrA mutation was observed in 10/
10 mutants selected by NAL, 7/7 mutants selected by CIP and in
5/12 mutants selected by MOX. For the E. coli qnr+, gyrA
mutation was observed in 18/22 mutants selected by NAL, 1/11
mutants selected by CIP and 0/18 mutants selected by MOX.
Analysis of the gyrA mutations showed that whereas 68% (15/
22) of the mutations occurred at the codon 87 (D87G, D87H,
D87N or D87Y) in mutants selected from the WT E. coli, only 1/
19 harboured a D87Y mutation in mutants selected from E. coli
qnr+. Conversely, 95 % (18/19) of the mutations observed in
mutants selected from the E. coli qnr+ occurred at the codon 83
(all S83L) but 7/22 for WT E. coli mutants. In all 18 one step-
mutants and in all 8-second-step mutants selected by MOX from
E. coli qnr+, no mutation was observed either in the QRDRs in
gyrA, gyrB, parC and parE, or in the entire gyrA and gyrB genes,
whereas selection by MOX from the E. coli wild-type resulted in
5 gyrA mutants (D87N [n = 3] or D87G [n = 2]). After
introduction of qnr in the strains referenced for topoisomerase
mutations, MICs of CIP and MOX increased 2- to 16-fold. NAL
MICs did not increase whatever the topoisomerase mutation
harboured by the recipient strain.
Conclusion: From the results of the two approaches, D87 seems
to be one of the amino acid involved in QNR-gyrase interaction,
and S83 seems to preferentially interact with NAL and CIP in
presence of QNR but not with MOX.
O54
Putative implication of YceE (transporter protein)
and ompN (porin) in the resistance to quinolones
in Escherichia coli
A. Fabrega, J. Sanchez-Cespedes, M.M. Tavio, M. Ruiz,
J. Vila (Barcelona, Las Palmas, ES)
Objectives: The interplay between decreased permeability and
increased efﬂux may play an important role in the acquisition of
quinolone-resistance in Escherichia coli. The main objective of this
study was to investigate the expression of outer membrane
protein(s) and efﬂux pump(s) as a mechanism of resistance to
quinolones in two isogenic quinolone-susceptible and resistant
E. coli strains following a genomic and proteomic approach.
Methods: A quinolone-resistant mutant was selected with
norﬂoxacin from an E. coli clinical isolate. Norﬂoxacin
accumulation in both wild-type and mutant strains was
determined by a ﬂuorescent assay. DNA microarrays
containing the whole genome of E.coli were used to analyse
the differential expression of genes. RT-PCR was used to
conﬁrm DNA microarrays results. 2D-gel electrophoresis was
used to perform a protein analysis in both strains.
Results: Accumulation assay demonstrated that the quinolone-
resistant E.coli mutant strain presented a lower intracellular
norﬂoxacin accumulation than the wild-type strain. DNA
microarrays showed that 27 genes were over expressed in the
mutant, among which acrA, acrB, yceE and ompN were found;
whereas only 8 genes were down-regulated, among which ompF
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was found. RT-PCR analysis conﬁrmed the increased expression
of acrA, acrB, yceE and ompN, and the decreased expression of
ompF. 2D-gel electrophoresis conﬁrmed the lower expression of
ompF and showed the overexpression of TolC in themutant strain.
Conclusions: It is known that AcrAB/TolC plays an important
role in quinolone-resistance acquisition in E.coli. However, the
overexpression of yceE and OmpN may also play a role in
quinolone resistance acquisition in this microorganism.
O55
Potential of ﬂuoroquinolones to induce the
expression of the acrAB efﬂux pump and the
global regulator marA in Salmonella hadar
S. Schmidt, P. Heisig (Hamburg, DE)
Objectives: Fluoroquinolones (FQs) are often the antibiotics of
choice to combat gastrointestinal, respiratory and urinary tract
infections as well as infections of the skin and soft tissue (SST).
However, bacterial resistance is becoming an increasing problem.
Resistance to FQs is acquired by alterations of the target
(mutations in type II topoisomerase genes gyrAB, parC) as well
as by decreased uptake and increased efﬂux. One important
multidrug resistance (mdr) efﬂux pump in Salmonella is AcrAB-
TolC, consisting of an RND-type transporter (AcrB), a membrane
fusion protein (AcrA) and an outer membrane channel (TolC).
Enhanced expression of the efﬂux system can be due to e.g.
mutations in the gene acrR for the local regulator AcrR or an
altered expression of the global regulator system marRAB. The
question addressed in the present study is, if in addition FQs are
capable of inducing the expression of the AcrAB efﬂux pump
and/or global regulator systems like MarRAB.
Methods: Salmonella Hadar was cultivated in the presence of the
respective FQ (0.5 · MIC, which corresponds to approximately
1% of the concentration achieved in the tissue during therapy, as
well as 50 · MIC for ciproﬂoxacin) and harvested at OD600 nm
0.7. After isolation of total RNA (Qiagen RNeasy Mini Kit) and
reverse transcription using gene speciﬁc primers, expression
changes of acrA and marA genes were determined by real-time
PCR using SYBR Green.
Results: After induction with norﬂoxacin a 6.2-fold
upregulation in acrA gene expression was determined, whilst
marA gene expression was upregulated 3.8-fold. The presence of
moxiﬂoxacin during cultivation led to a 1.8-fold upregulation in
acrA gene expression, however no expression change in marA
was observed. Exposition neither to ciproﬂoxacin (0.5 and
50 · MIC) nor to levoﬂoxacin, oﬂoxacin, marboﬂoxacin,
pradoﬂoxacin, garenoxacin nor BayY3118 (0.5 · MIC) resulted
in any expression changes in acrA or marA, respectively.
Conclusions: From the assortment of structurally diverse FQs
only norﬂoxacin and to a lesser extend moxiﬂoxacin are able to
effect an increased acrA and marA expression. Regarding the
resistance development it is reassuring to observe that the
induction of mdr efﬂux by FQs is not of clinical relevance in
Salmonella.
O56
Horizontal gene transfer contributes to
ﬂuoroquinolone resistance in Streptococcus
pyogenes
C.B. Duesberg, S. Malhotra-Kumar, T. Welte, H. Goossens,
M.W.R. Pletz (Hannover, DE; Antwerp, BE)
Objectives: To date, reports on S. pyogenes resistant to
ﬂuoroquinolones have been rare, but a recent Belgian
surveillance study found a prevalence of 5.4% among nearly
2800 patients with tonsillopharyngitis due to S. pyogenes
(Malhotra-Kumar et al. Clonal spread of ﬂuoroquinolone non-
susceptible Streptococcus pyogenes. J Antimicrob Chemother 2005;
55:320–325). Fluoroquinolone resistance in S. pyogenes arises due
to mutations in the topoisomerase type II enzymes. These
mutations can arise spontaneously, or they can be acquired by
horizontal gene transfer. Acquisition of ﬂuoroquinolone
resistance by interspecies recombination has already been
described in Pneumococci, but not in S. pyogenes. The aim of the
present investigation was to elucidate the contribution of
horizontal gene transfer to the acquisition of ﬂuoroquinolone
resistance in S. pyogenes.
Methods: Fluoroquinolone-resistant S. pyogenes previously
characterized for resistance mechanisms during the
surveillance study cited above were studied. Presence of the
D91N substitution in parC, which is not a feature of wild type S.
pyogenes, was used as a marker for selecting isolates. Of the 34
isolates studied, 21 were non-susceptible (ciproﬂoxacin
MIC‡ 2 mg/l) and 13 were susceptible to ﬂuoroquinolones.
The sequences of the ﬂuoroquinolone resistance determining
region of parC were used to perform a BLAST search. The ﬁrst
26 hits were chosen for further analysis. Alignments were
conducted by ClustalX, and phylogeny was constructed by the
Bayesian method. Recombination was statistically conﬁrmed
using the maximum chi-squared test.
Results: Phylogenetic analysis revealed evidence of horizontal
gene transfer in 13 isolates (38.2%) belonging to different emm-
types and pulsed ﬁeld gel electrophoresis clusters. In all 13
isolates recombination with the bovine pathogen Streptococcus
dysgalactiae subsp. dysgalactiae was conﬁrmed by a maximum
chi-squared test at a statistically signiﬁcant (p < 0.05) or highly
signiﬁcant level (p < 0.001).
Conclusions: Our results prove that horizontal gene transfer
from other streptococcal species contributes to ﬂuoroquinolone
resistance in S. pyogenes. S. pyogenes exhibiting evidence of
horizontal transfer were more likely to be ﬂuoroquinolone-
resistant. Thus, ﬂuoroquinolone use in agriculture might also
indirectly impact resistance in the human pathogen S. pyogenes.
O57
New mutation at the position 81 in GyrA in
clinical strains of Mycobacterium tuberculosis
resistant to quinolone: report of two clinical cases
and functional analysis of DNA gyrase mutant
enzymes
S. Matrat, N. Veziris, V. Jarlier, E. Cambau, C. Truffot-Pernot,
J. Camuset, E. Bouvet, A. Aubry (Paris, Cre´teil, Argenteuil, FR)
Objectives: Fluoroquinolone resistance is emerging in
M. tuberculosis (Mtb) with increasing drug use. DNA gyrase is
the sole target of quinolone in Mtb (lack of topoisomerase IV).
Mutations in the heterotetramer GyrA2GyrB2 are associated
with resistance to quinolones. We report two cases of infection
with multidrug resistant tuberculosis (MDR-TB) strains carrying
a new G81A mutation in GyrA. We also investigated the role of
the amino acid at this position in the resistance to quinolones in
Mtb.
Methods: Two mutant genes were produced by site-directed
mutagenesis of the wild type gyrA gene from Mtb strain H37Rv:
gyrA g263c (as found in our clinical strains, see results) and gyrA
g262t (as found by Takiff in an in vitro mutant selection, AAC,
1994). GyrA and GyrB subunits (WT and mutants GyrA G81A
and GyrA G81C) were overexpressed in Escherichia coli, puriﬁed
and used to reconstitute highly active gyrase complex. MICs and
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enzyme inhibition (concentration of drug required to inhibit the
supercoiling activity of the enzyme by 50% = IC50) were
determined for moxiﬂoxacin, gatiﬂoxacin, oﬂoxacin,
levoﬂoxacin and enoxacin.
Results: Two men aged 24 and 45 years old, both with a
previous story of TB, born in Algeria and Congo respectively,
had MDR TB caused by Mtb strain carrying a G81A mutation in
GyrA. One had cavitary pulmonary TB, was AFB positive and
HIV negative. The other one had both pulmonary and
extrapulmonary TB, was AFB positive and HIV positive. Both
had been treated by ﬂuoroquinolone within the months before
the diagnosis of MDR-TB. MICs and IC50s of quinolones were 2
to 16 fold and 3 to 32 fold higher than for the WT for the GyrA
G81A mutant and for the GyrA G81C mutant, respectively.
Conclusion: We demonstrated unequivocally that modifying
the amino acid at position 81 (whatever G81A or G81C) in GyrA
subunit of DNA gyrase lead to quinolone resistance in Mtb. This
point contributes to clarify the nature of the drug-enzyme
binding pocket in Mtb, which most likely include the aminoacid
81.
Viruses and viral diagnostics
O58
HCMV infects and replicates in the adrenal gland
M. Trevisan, G. Masi, R. Cusinato, K. Fincati, A. Loregian,
G. Palu`, L. Barzon (Padua, IT)
Although one of the clinical pictures of human cytomegalovirus
(HCMV) infection is adrenal involvement reported especially in
AIDS patients, the association of this herpesvirus with adrenal
gland disease has never been cleared. Moreover, recent inves-
tigations have shown that a higher frequency of HCMV in
malignant tumour tissues, but its role in the pathogenesis of
adrenal tumours has not been explored so far. Therefore, in this
study we investigated the presence of HCMV in a large series of
normal and tumour adrenal samples and the effect of HCMV
infection on adrenocortical carcinoma (ACC) cells in vitro. A
total of 100 adrenal tissues (53 adrenocortical adenomas, 11
ACCs, 17 pheochromocytomas, 2 myelolipomas, 1 primary
adrenal non-Hodgkin’s lymphoma, and 16 normal adrenal
tissues) were examined using quantitative PCR. HCMV DNA
was detected in 19% adrenocortical adenomas, 12% pheochro-
mocytomas and 1 normal adrenal tissue, but not in malignant
tumours. The positive samples were conﬁrmed by immunoh-
istochemical evaluation of HCMV immediate-early gene expres-
sion. To verify the ability of HCMV to infect adrenocortical cell
lines in vitro, the NCI-H295 and SW13 ACC cell lines and
primary ACC cell cultures were infected with clinical isolates of
HCMV and with the HCMV strain AD169. All the HCMV
strains employed resulted in productive replication in ACC
cells, as demonstrated by the expression of both early (pp72) and
late (pp65) viral antigens. Analysis of the kinetics of viral
replication in ACC cells showed efﬁcient production of infec-
tious viral particles, even if at lower levels than in MRC5 cells.
Viral and cellular gene expression proﬁle after AD169 infection
of ACC cell lines were assessed by quantitative RT-PCR and
DNA microarray analysis, respectively, in a time-course experi-
ment. Evaluation of a total of 22 000 human genes with
microarray analysis demonstrated that AD169 infection induced
genes promoting cell proliferation and repressed genes that
prevent cell migration and invasiveness. These results demon-
strates that the human adrenal gland is a target for HCMV
infection. HCMV modulates several cellular pathways in vitro,
including cell growth and stress response. These data represent
the basis for further investigation on the effect of HCMV on
adrenal function and diseases.
O59
Simultaneous detection of the human
cytomegalovirus DNA and RNA by targeting the
UL73/74 gene region using multiplex real-time
polymerase chain reaction assays
Y.-J. Chan, J.-C. Lin, C.-H. Tsai, W.-S. Weng, D.M-T. Ho
(Taipei, TW)
Objectives: Reactivation of cytomegalovirus (CMV) among
immunocompromised patients may result in severe
complications. A timely and accurate diagnostic method for
CMV infections is crucial. Polymerase chain reaction (PCR)-
based methods have been reported but are complicated by
potential contamination, latent CMV infection and strain
variations. A quantitative real-time PCR method that detects
both CMV DNA and RNA may be one of the solutions.
Methods: By cDNA cloning, we obtained clones encompassing
the CMV UL73/74 region and encoding a spliced mRNA, which
was used as the standard. This region contained both conserved
and variable sequences. We designed primers and analysed 21
clinical viral isolates covering the four major CMV UL 73
genotypes in the junction region of the UL73/74 mRNA by
restriction mapping and sequencing. We designed primers and
junction TaqMan probes to detect 104 clinical buffy coat samples
by real-time reverse transcriptase PCR system (rRT-PCR). The
performance of the rRT-PCR was compared to our established
in-house real-time PCR (ir-PCR) using the same UL73/74
control standard. Finally, we developed a multiplex real-time
PCR and RT-PCR assay (mr-PCR/RT-PCR) to simultaneously
detect the existence of both CMV DNA and RNA for 6 clinically
samples suspecting CMV infections.
Results: Of the 21 clinical CMV isolates, genotyping revealed all
four known genotypes in the ratio of 5:6:4:5 (one possible mix
infection) with two junction sequences. The rRT-PCR
successfully detected spliced mRNA from different genotypes.
The sensitivity for rRT-PCR was 10 copies of the plasmid
standard, which was comparable to our previous developed ir-
PCR. Good linearity was observed between 100 to 1 000 000
copies. Of the 104 clinical samples, 13 samples were positive by
both rRT-PCR and ir-PCR (mean, 97 300 copies/ml). There were
43 samples tested positive by the ir-PCR (mean, 1585 copies/ml)
and negative by the rRT-PCR, but in no case was the rRT-PCR
result positive and the ir-PCR result negative. There were 48
samples tested negative by both methods. The mr-PCR/RT-PCR
simultaneously detected both DNA (mean, 281 000 copies/ml)
and RNA (mean, 76 600 copies/ml) for all the 6 clinical samples.
Conclusion: The rRT-PCR is as sensitive as the ir-PCR and
detected CMV spliced RNA. A multiplex real-time PCR and RT-
PCR is feasible for the UL73/74 region in detecting CMV for
clinical samples. It might be helpful to monitor the clinical CMV
activity by this new real-time system.
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O60
Prospective comparison of real-time quantitative
PCR on blood with rapid culture of urine and
throat samples for monitoring cytomegalovirus
infection in haematopoietic stem cell transplant
recipients
I. Thoelen, W. Laffut, K. Van Vaerenbergh, M. Develter,
K. Theunissen, J. Maertens, J. Van Eldere (Leuven, BE)
Objectives: Human cytomegalovirus (CMV) remains a signiﬁ-
cant cause of morbidity and mortality in immunocompromised
patients. Effective pre-emptive antiviral treatment depends on
early detection of CMV infection, before the onset of symptoms.
In this study, we prospectively evaluated the use of real-time
quantitative PCR (RT-PCR) on whole blood versus virus
isolation from urine and upper respiratory tract (URT) samples
for monitoring CMV infection in haematopoietic stem cell
transplant (HSCT) patients.
Methods: 84 HSCT patients were included in the study. At 998
time points, blood, urine and URT samples were simultaneously
taken. An in-house CMV-speciﬁc RT-PCR on whole blood and
virus culture on the urine and URT specimens, using the rapid
shell vial technique, were performed.
Results: In 889 of 998 linked samples both PCR and virus
isolations were negative. Of 90 linked samples with a positive
RT-PCR, only 3 had a positive virus culture from both isolation
sites (urine and URT) and 78 had negative culture results both
for urine and throat samples. Copy numbers in the RT-PCR
positive and urine and throat culture negative cases ranged
from 500 to 1 100 000 copies/ml. Whereas discordant cases
with low RT-PCR copy numbers might have been due to the
low sensitivity of the culture methods, discordant cases with
high copy numbers could have been due to concurrent
antiviral therapy. Of 78 linked samples, 24 had high copy
numbers (more than 5000) and negative cultures. Of these 24
linked samples, 20 were taken under antiviral treatment
(treatment with IV/peroral ganciclovir (6 cases), IV foscavir
(4 cases) or IV cidofovir (10 cases)). Positive RT-PCR and
positive culture results for one sample were observed in 9
cases (all urine positive isolations). A negative RT-PCR
combined with one or two positive isolations was observed
in 19 of 998 linked samples. 15 of these samples had a positive
urine culture with negative RT-PCR and negative throat
cultures. These samples were from 2 patients with intermit-
tently positive urine cultures.
Conclusions: Our data suggest that virus isolation by the shell
vial technique should not be used for monitoring CMV infection
in HSCT patients because of the high number of false negative
results due to low sensitivity of the culture technique or
concurrent antiviral therapy. RT-PCR on whole blood seems a
more sensitive tool to guide pre-emptive therapy.
O61
Diagnostic relevance of screening clinical
specimens from patients attending infectious
diseases and haematology units for HHV6 DNA:
a two-year experience
G. Parruti, A. Manna, A. Di Girolamo, M. Ciotti, D. Racciatti,
G. D’Amico, C. Favalli, E. Pizzigallo, D. D’Antonio (Pescara,
Chieti, Rome, IT)
Objectives: HHV6 (Human Herpes Virus 6) is a member of the
bherpesvirinae subfamily in the Herpesviridae family. It has a
yet incompletely deﬁned cell tropism and its clinical spectrum is
currently being clariﬁed, both in the immunocompetent and in
the immunocompromised host. We introduced the use of tools
for molecular diagnosis of HHV6 active replication into routine
clinical practice at our Institutions late in 2003. Here we
summarize the preliminary results of our 2-year experience in
terms of diagnostic efﬁciency.
Methods: Sample preparation for DNA isolation, commercially
available kits were used, according to manufacturers’
instructions. DNA extraction from large clinical samples (such
as plasma, serum, cerebrospinal ﬂuid, urine, sputum,
broncoalveolar lavage ﬂuid) was mainly performed using the
QIAamp DNA Mini Kit (QIAgen GmbH, Hilden, Germany).
Detection of positive samples for HHV6:Clinical specimens were
scored as positive for HHV6 when they tested as positive for the
Herpesvirus-Consensus PCR (Argene Biosoft) ampliﬁcation
product, again positive for the HHV6 ampliﬁcation product
and negative for HSV type 1, HSV type 2, Varicella-Zoster virus,
Epstein-Barr virus and Cytomegalovirus ampliﬁcations.
Quantisation of HHV-6 DNA. Quantisation of HHV6 DNA
was performed using standard curves generated by TaqMan
probes and primers in an ABI 7000 machine (Q-HHV-6 Real
Time System -Amplimedical Bioline).
Results: During 2004 and 2005 (January through October), 1207
samples were processed at our Institutions, 987 of which (81.7%)
collected at Haematological Units. Thirty-two samples (2.7%)
from 19 patients turned out to be positive: 16 of them were from
immunocompetent patients (8 patients), the remaining 16 were
from immunocompromised patients (11 patients, 1 of whom
was HIV positive). Among immunocompetent patients, 2 had
persistent fever with rash; one had persistent fever only, while
the remaining 5 had recurrent or persistent stomatitis. Among
immunocompromised patients, 9 had a diagnosis of
haematological malignancy.
Conclusion: Molecular diagnosis of HHV6 active replication
seems to be an interesting tool to diagnose a wide range of
persistent or recurring clinical conditions. It seems to be
particularly promising when used to screen previously
unrecognized conditions in the immunocompetent host, as in
the case of recurrent stomatitis or persistent fever with rash.
O62
Echovirus 9: a prominent enterovirus causing
CNS disease in Kuwait
A. Dalwai, S. Ahmad, A. Pacsa, W. Al-Nakib (Kuwait, KW)
Objectives: Enteroviruses in general are recognized as the
major cause of aseptic meningitis particularly in children;
however, they appear to vary in their neurotropism and
neurovirulence. Some types may be overrepresented as
etiological agents of CNS disease than others. The aim of this
study was to genotype the prevalent enteroviruses causing CNS
disease in Kuwait and to study the association between a
particular enterovirus with the severity of the disease.
Methods: Detection of enteroviral RNA was based on semi-
nested RT-PCR ampliﬁcation of a portion of the 5’UTR of the
enteroviral genome followed by Southern hybridization with an
enterovirus speciﬁc probe to conﬁrm the results. The enterovirus
was genotyped by sequencing of the 5’UTR and the VP4
encoding region, and the sequence was analysed by BLAST
analysis, CLUSTALW alignment and PHYLIP phylogenetic
analysis package.
Results: Enteroviral RNA was detected in the CSF of 26% (168/
647) of the CNS disease cases with a majority of the enterovirus
positive cases (82%; 138/168) being children less than 12 years
of age. Of the 8 different enteroviruses identiﬁed, echovirus 9
was the most common (45%; 66 of 147 genotyped), followed by
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echovirus 11 (18%; 27/147), coxsackievirus A7 (17%; 25/147)
and coxsackievirus B5 (10%; 14/147). In the severe CNS disease
cases (encephalitis and those cases presenting with febrile
convulsions/seizures), the occurrence of echovirus 9 was
signiﬁcantly higher (68%; 24 of 35 genotyped) than that
observed in less severe CNS disease cases presenting with
aseptic meningitis (37%; 42 of 112 genotyped). Echovirus 11 and
coxsackievirus B5, on the other hand were more frequent in less
severe CNS disease than in severe CNS disease cases.
Conclusions: Echovirus 9 was found to be the predominant
enterovirus associated with CNS disease in Kuwait and data
obtained through this study suggests that infection with
echovirus 9 may lead to a more severe CNS disease outcome.
Supported by Research Administration project grants MI 04/01,
YM 03/02 and College of Graduate Studies, Kuwait University.
O63
Detection of respiratory pathogens by real-time
PCR in clinical practice
J.W.A. Rossen, E.G. Klein Breteler, A.J. Weersink, R. Schuurman,
A.M. van Loon (Utrecht, NL)
Objectives: Few hospitals have introduced nucleic
ampliﬁcation techniques for the routine diagnosis of all
respiratory tract infections in adults. These diagnostic tests are
costly, and the diagnostic yield and feasibility of
implementation in routine diagnostic work-up has not been
evaluated sufﬁciently. The diagnostic value of real-time PCR
compared to conventional virus detection methods is evaluated
in a prospective study during one respiratory season.
Methods: Nose-throat swabs, nasopharyngeal washes,
nasopharyngeal aspirates, sputum samples, and
bronchoalveolar lavages of patients admitted to our general
hospital or to the children’s hospital were evaluated by virus
culture, direct immunoﬂuorescence assays (DIF) for adenovirus,
inﬂuenzavirus A/B, parainﬂuenzavirus 1 to 3 and RSV virus
and by real-time PCR for adenoviruses, coronavirus OC43, 229E
and NL63, inﬂuenzavirus A/B, parainﬂuenzavirus 1 to 4,
rhinoviruses, RS virus A/B, human metapneumovirus and
Chlamydia pneumoniae and Mycoplasma pneumoniae.
Results: Samples of 110 adults and 240 children were
included in this study. In adults, respiratory viruses were
detected by virus culture in 4 patients (4%) and by real-time
PCR in 65 patients (59%). Most frequent pathogens detected
were: rhinovirus (n = 22), inﬂuenzavirus (n = 20) and RSV
(n = 12). In 10 of the 65 positive patients (15%) more than one
virus was detected by real-time PCR. In children, respiratory
viruses were detected by virus culture in 34 patients (14%), by
DIF-assays in 63 patients (26%) and by real-time PCR in 179
patients (75%). The most frequent pathogens detected were:
RSV (n = 74), rhinovirus (n = 67), coronaviruses (n = 32) and
inﬂuenzavirus (n = 24). In 57 of the 179 positive patients
(32%) more than one virus was detected by real-time PCR.
Real-time PCR for RSV and adenovirus revealed signiﬁcant
differences in Ct-values between DIF positive and DIF
negative samples.
Conclusion: The sensitivity of real-time PCR is signiﬁcantly
higher compared to that of virus culture and DIF-assays.
Moreover, mixed infections were only detected using real-time
PCR and were not found by virus culture and/or DIF assays.
Thus, rapid detection of respiratory viruses by means of real-
time PCR increased the number of detected pathogens
considerably. The results of this study will be used to develop
a diagnostic algorithm for selective detection of speciﬁc
respiratory pathogens in different patient groups.
O64
Nucleic acid sequence based ampliﬁcation and
molecular beacon detection for the real-time
identiﬁcation of human metapneumovirus in
paediatric respiratory specimens
R. Manji, F. Zhang, C. Ginocchio (Lake Success, US)
Background: Human metapneumovirus (hMPV) may account
for about 10% of pediatric upper and/or lower respiratory tract
disease in which a respiratory virus, such as RSV, inﬂuenza or
parainﬂuenza, could not be detected. Studies have also
suggested that hMPV may contribute to increased severity of
disease when present with other viral pathogens. Most
laboratories cannot routinely diagnose hMPV infections since
the virus is slow growing and there are limited reagents for
conﬁrmation. The rapid diagnosis of hMPV infections is of
central importance for patient management (rational use of
antibiotics and antiviral agents), hospital infection control and
for understanding the epidemiological disease patterns of
hMPV. This study included a technical validation and
retrospective clinical evaluation of a real time NASBA assay
for the detection of hMPV in pediatric respiratory samples.
Methods: Samples tested included: dilution panels of an hMPV
viral isolate, isolates of common respiratory pathogens, and
frozen respiratory specimens (nasopharyngeal aspirates, washes
or swabs) from 232 children (age range: 5 days to 2 years) who
presented with respiratory disease. Nucleic acid (NA) isolation,
ampliﬁcation and detection were performed using NucliSens
EasyQ Basic Kit and NucliSens EasyQ hMPV reagents
(bioMe´rieux). Specimen nucleic acids and an hMPV speciﬁc
internal RNA control (IC) were co-extracted using NucliSens
Magnetic Extraction Reagents and the NucliSens miniMAG
instrument (bioMe´rieux) and co-ampliﬁed using a single hMPV
speciﬁc primer pair. Included in the reaction were an hMPV
speciﬁc molecular beacon (5’-FAM) and an IC speciﬁc molecular
beacon (5’-ROX). Target ampliﬁcation and continuous
monitoring of emitted ﬂuorescence were performed using a
NucliSens EasyQ analyser (bioMe´rieux).
Results: The limit of detection for hMPV was 2.5 TCID50 per
reaction and the 90% detection rate was 12.5 TCID50 per
reaction. The assay was 100% speciﬁc for hMPV, with no cross
reactivity detected to a panel of viral and bacterial respiratory
pathogens. The overall hMPV prevalence rate was 2.6% and the
rate for samples with no other viral pathogen detected was 3.8%.
One sample was also positive for RSV.
Conclusions: The NucliSens EasyQ hMPV assay demonstrated
excellent sensitivity and speciﬁcity. The assay was easy to use,
required minimal hands on time (1 hour) and easily provided a
same day result. Additional year round studies will provide
important epidemiologic data.
O65
Development of a real-time NASBA for human
metapneumovirus
E. Bufﬂier, H. Savelli, F. Jacobs, C. Moore, P. Van de Wiel
(Grenoble, FR; Boxtel, NL; Cardiff, UK)
Objective: The aim was to develop and evaluate human
Metapneumovirus (hMPV) reagents based on NASBA
ampliﬁcation and real-time detection with molecular beacons.
Methods: hMPV RNA is isolated using a semi automated
magnetic extraction method (NucliSensminiMag). An internal
control is added to the sample prior to nucleic acid extraction.
Primers are directed against the M-gene region of the hMPV
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genome (subtypes A1, A2, B1 and B2), and against the internal
control molecule. A FAM-labelled molecular beacon probe is
used to detect hMPV amplicons, while a ROX-labelled
molecular beacon is designed to detect the internal control
amplicons, ampliﬁed in the same reaction. Ampliﬁcation and
real-time detection reactions are performed in a NucliSens
EasyQ Analyser. The extraction and ampliﬁcation-detection
reactions to detect hMPV in nasal swab samples can be
performed within approximately 3.0 hours.
Results: The analytical sensitivity of the NASBA reaction was
determined to be close to 10 copies per input (90% hit rate) using
serial dilutions of in vitro hMPV RNA in direct ampliﬁcation,
while in combination with extraction, the sensitivity was found
to be 263 copies per input (90% hit rate). No cross reactivity was
observed with PIV 1, PIV 2, PIV 3, PIV 4, RSV A, RSV B, Sars
CoV, Inﬂuenza A and Inﬂuenza B. The NASBA real time reagents
to detect both hMPV and RSV were further investigated in a
clinical study performed in Cardiff in 2004–2005. Amongst 1158
clinical respiratory samples tested (Nasopharyngeal Swabs,
Nasal Swabs, Throat Swabs and Nasopharyngeal Aspirates)
the NASBA allowed to detect 22 hMPV positive samples (ca.
2%). Finally, the efﬁciency of the method to detect the four A1,
A2, B1 and B2 subtypes of hMPV was demonstrated on viral
stocks.
Conclusions: The data showed that the real-time hMPV
reagents allows a rapid and sensitive qualitative detection of
hMPV. The use of standardized reagents offers considerable
beneﬁts in a routine setting for the clinical management of
patients with hMPV infections.
O66
Viral induced asthma exacerbations not
associated with delayed viral clearance and
increased viral load
A.P.E. Sachs, L.J.R. van Elden, A.M. van Loon, G. Kimman,
T.J.M. Verheij, M. Nijhuis (Utrecht, Bilthoven, NL)
Introduction: Viral respiratory tract infections (RTI) are the
most common cause of asthma exacerbations. Especially human
rhino viruses (HRV) infections lead to more severe and longer
duration of lower respiratory tract (LRT) symptoms in
asthmatics than in non-asthmatics. Up-regulation of rhinovirus
speciﬁc intracellular adhesion molecule (ICAM-1) receptors in
asthmatics might be responsible for increased susceptibility to
HRV, as well as differences in immunological response,
resulting in delayed viral clearance.
Aim: Assessing the magnitude and duration of viral replication
and severity of symptoms in relation to various cytokines in
nasal washes in asthmatics and controls during naturally
occurring viral RTI.
Methods: In a prospective study, asthmatics aged 18–45 years,
were recruited according the Dutch asthma guidelines from
general practices, together with 44 healthy controls. Both groups
daily recorded signs and symptoms of the upper respiratory
tract (URT) and of the LRT, rated from 1 (mild) to 3 (severe).
Asthmatics recorded peak expiratory ﬂow (PEF) twice daily.
Participants contacted investigators if URT symptoms totalled 4,
and/or if LRT symptoms >5. Next, participants were visited
within 48 hours, with follow-up visits at day 3/4, day 5/6, after
2 and 8 weeks (baseline). During each visit a nasal wash was
collected from each nostril for viral cultures RT-PCR, and assays
for cytokines.
Results: 44 asthmatics and 44 controls enrolled in the study and
43/88 persons reported 57 episodes of RTI. In 33/57 (58%)
episodes a virus was found by PCR. Viral cultures had no
additional diagnostic value. No signiﬁcant differences observed
between number of U/LRTI caused by viruses in asthmatics
(16/33, 48%) and controls (17/33, 52%). Majority of URTIs
(n = 33) were caused by HRV. After ﬁrst symptoms of U/LRT
symptoms, in both groups, simultaneous clearance of viruses in
the URT has been observed. No differences in proinﬂammatory
cytokines can be determined in the URT in both groups. LRT
symptoms in asthmatics persisted for more than 1 week after
clearance of viruses. The actual URTI precedes the PEF
reduction as well as LRT symptoms.
Conclusion: Viral induced asthma exacerbations are not
associated with delayed clearance and increased viral load.
Incremental effects during maintenance therapy of intranasal
anti-viral and anti-inﬂammatory medication need to be studied.
O67
Quantitative detection of herpes simplex virus
DNA in the lower respiratory tract
J. Gooskens, K. Templeton, E. Claas, M. van Bussel, V. Smit,
A. Kroes (Leiden, NL)
Objectives: To compare quantitative herpes simplex virus
(HSV) DNA results from adult bronchoalveolar lavage (BAL)
specimens to clinical outcome.
Methods: An internally controlled, quantitative real-time PCR
(qPCR) assay targeting the UL30 gene encoding HSV DNA
polymerase was developed and validated. Adult BAL
specimens obtained during a 1-year period (Feb 2003–Feb
2004) were collected. HSV qPCR was retrospectively
performed on these specimens and results were compared to
patient characteristics and outcome. Differentiation of HSV1 and
HSV2 was performed by PCR. In addition, the presence of
Varicella-Zoster virus (VZV), cytomegalovirus (CMV), human
herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) were
determined by qPCR. Results were not used to assist clinical
management.
Results: A total of 57 BAL specimens were included, of which
41 of 57 (72%) were obtained from immunocompromised
patients. HSV DNA was detected in 11 of 57 specimens (19%)
with a mean viral load of 5.6 log (10) genome equivalents/ml
(range, log 2.9–log 8.1). Of these specimens, 8 contained HSV1, 1
contained HSV2, 2 contained undetermined HSV and none
contained both types. HSV DNA level equal or higher than
log 5.5 (n = 6, 11%) was signiﬁcantly associated with 30 day
mortality (OR 7.5, 95%CI 1.22–46.0). All patients with HSV levels
equal or higher than log 7.5 had severe respiratory failure. HSV
pneumonia was histologically proven in one patient with log 8.0
HSV DNA in BAL ﬂuid at autopsy. No patient with HSV DNA
levels below log 5.5 (n = 5) or with high levels of CMV (n = 2),
EBV (n = 7), VZV (n = 0) or HHV6 (n = 0) died within 30 days
of hospital admission.
Conclusion: Detection of high levels of HSV DNA in BAL ﬂuid
was associated with severe respiratory failure and with fatal
outcome among mainly immunocompromised patients. These
results suggest quantiﬁcation of HSV DNA is a potential
diagnostic tool in BAL ﬂuid of high-risk patients.
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Clinical epidemiology of nosocomial infections
O68
Surgical site infections in Europe: results from
HELICS surveillance 2004
C. De Laet, C. Suetens, J. Fabry (Brussels, BE; Lyon, FR)
Objectives: The HELICS project is a European-wide
surveillance programme for healthcare-associated infections. It
is a ‘network of networks’ with contributions from national
surveillance systems, using a minimal common dataset (http://
ipse.univ-lyon1.fr). In previous years we tested and reported on
the comparability of data. In 2004 routine surveillance started.
Methods: Data from 88 986 surgical procedures, routinely
collected by 14 European networks were analysed. Procedures
included are CABG, cholecystectomy, colon surgery, caesarean
section, hip prosthesis and laminectomy. Infection rates are
expressed as the proportion of surgical procedures leading to
surgical site infections (SSI) within 30 days. Incidence was also
expressed as incidence density: the number of in-hospital SSI
per 1000 patient-days. Incidences were calculated by surgical
procedure and stratiﬁed by NNIS risk index group. Time
dependent SSI rates were calculated using survival time analysis
to further enhance the interpretation of inter-country
differences.
Results: Overall thirty-day cumulative incidence of SSI ranged
from 1.1% (95%CI 1.0–1.3) for cholecystectomy to 8.5% (7.9–9.0)
for colon surgery (ﬁgure). Using incidence density the relative
importance of SSI increased for procedures associated with
short durations of stay (cholecystectomie and caesarean
section). Important inter-country differences were observed
although not all statistically signiﬁcant. Incidence increased
with increasing NNIS risk index levels. For all procedures,
rates increased during the ﬁrst days after surgery reaching a
peak at day 5–6, and decreasing thereafter. There were
important differences in length of stay between countries but
comparison of time dependent infection rates during the ﬁrst
week showed that signiﬁcant differences remained after this
adjustment.
Conclusion: The reported incidences are of a similar
magnitude as reported for previous years. Inter-country
comparisons are important to identify opportunities for
improvement, but the observation of different SSI rates
cannot be simply assumed to be due to the quality of care.
Differences in duration of hospital stay and different
procedures for post-discharge surveillance can lead to
artiﬁcial differences. Moreover, rates are not constant but
vary with time since operation. It is important to recognise the
limitations of any single metric describing the SSI risk,
especially in the presence of different lengths of stay and
different post-discharge surveillance.
O69
Deep sternal wound infections following
coronary artery bypass graft surgery: risk factors
and implications
M. Paul, C. Madar, E. Raz, R. Holinger, A. Fraser, L. Leibovici,
B. Rubinovitch (Petah Tikva, IL)
Objectives: To assess the risk factors for Deep sternal wound
infections (DSWIs) following coronary artery bypass graft
(CABG), accounting for peri-operative glucose, oxygenation,
and temperature control.
Methods: Prospective cohort study conducted in Rabin Medical
Center, Israel including consecutive patients undergoing CABG
during 2004. The dataset comprised of 154 peri-operative
variables. Data were collected by daily chart review on ward
using a case report form and merged with hospitals’ electronic
records. Continuous measurements of oxygen and temperature
throughout surgery were included in the analysis. Follow-up for
DSWIs was performed 60 days following surgery. DSWIs were
deﬁned by CDC criteria. Dichotomous variables were compared
using a chi-square test; continuous variables were compared
using nonparametric tests. A multivariate stepwise logistic
regression model was constructed using variables found
signiﬁcant on univariate analysis (p < 0.05). Odds ratios (95%
conﬁdence intervals) are reported.
Results: 809 patients (79% male) undergoing CABG were
included. CABG was elective in 31%. An additional operation,
mostly valve replacement, was performed in 15%. Off-pump
CABG was performed in 22%. Median patient age was 67 years
(31–91); 21% were above 75. Diabetes and chronic obstructive
pulmonary disease (COPD) necessitating chronic therapy were
present in 41% and 6% of patients, respectively. DSWIs occurred
in 29 patients (3.6%). Variables independently associated with
DSWIs included intra-operative glucose (OR 6.0, 1.3–26.5, for
mean glucose > 140 mg/dl); COPD (OR 4.4, 1.4–13.7); and an
operation additional to CABG (OR 3.3, 1.2–8.7). Haemoglobin
A1C levels, hypothermia and post-operative hypoxemia were
not signiﬁcantly associated with DSWIs. The Euroscore was
associated with DSWIs on univariate, but not with multivariate
analysis. Post-operative hospital stay was longer among patients
with DSWI compared to those without DSWI (median 31 vs.
5 days, respectively, p < 0.001). Thirty-day mortality was not
signiﬁcantly different with or without DSWI (0% vs. 5%,
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respectively), while 6 months mortality was signiﬁcantly higher
with DSWI (34.5% vs. 7.6%, p < 0.001).
Conclusion: DSWIs following CABG have grave implications.
Modiﬁable risk factors include intra-operative glucose control
and, potentially, COPD. Further studies should assess whether
better preparation of COPD patients lowers DSWI rates.
O70
Diagnosis and microbiology of prosthetic
shoulder infection
K. Piper, P. Anguita Alonso, M. Jacobson, A. Trampuz,
R. Coﬁeld, J. Sperling, J. Sanchez Sotelo, D. Osmon, R. Patel
(Rochester, US)
Objectives: Criteria for the diagnosis of prosthetic shoulder
infection (PSI) have not been established. We evaluated
characteristics of prosthetic shoulder infection and analysed
the accuracy of various diagnostic criteria.
Methods: Patients undergoing shoulder arthroplasty revision
or resection at Mayo Clinic, Rochester MN from August 2004
through October 2005 were studied. PSI was diagnosed if at least
one of the following was present: intraoperative purulence,
histopathologic acute inﬂammation, a sinus tract, a positive
synovial ﬂuid culture or at least two periprosthetic tissue
cultures positive with the same organism. Medical records were
abstracted for age, gender, time to prosthesis failure, synovial
ﬂuid leukocyte count and differential (aspirated < 3 months
before surgery), and synovial ﬂuid and periprosthetic tissue
culture results. In addition, the explanted shoulder implants
were vortexed and sonicated in 400 ml Ringers solution (herein
deﬁned as sonicate ﬂuid), followed by a 1000-fold concentration
and indirect immunoﬂuorescence with monoclonal antibodies
against staphylococci and Propionibacterium acnes.
Results: Of the 42 patients studied, 28 had aseptic failure and 14
PSI. The median age was 67 years (range, 40–81 years); 43%
were female. The median time to clinical failure of the prosthesis
was 39 months (range, 0–17 years). Causative organisms were
identiﬁed in 10/14 infected patients (71%) and included P. acnes
(n = 7), Staphylococcus aureus (n = 1), coagulase negative
Staphylococcus sp. (n = 1) and Pseudomonas aeruginosa (n = 1).
Four infected patients (29%) with P. acnes had no histopathologic
acute inﬂammation, intraoperative purulence or a sinus tract.
Synovial ﬂuid leukocyte count and differential were not
predictive of infection. The sensitivity for infection of
immunoﬂuorescence on concentrated sonicate ﬂuid was 89%
(8/9); speciﬁcity was 100%.
Conclusions: While inﬂammatory response markers such as
histopathology, synovial ﬂuid leukocyte count, and purulence
are good predictors of prosthetic hip and knee infection, they
were not sensitive for diagnosing PSI (i.e., 29% of infections
would have been missed using these criteria). This likely relates
to low virulence of the predominant pathogen, P. acnes. For
accurate diagnosis of infection, synovial ﬂuid and periprosthetic
tissue cultures were needed. Indirect immunoﬂuorescent
microscopy on concentrated sonicate ﬂuid is a promising
diagnostic test and deserves further investigation.
O71
The association between ventilator-associated
pneumonia and ICU-mortality: approximation of
attributable mortality
M. Koeman, E. Hak, A. de Smet, G. van der Heyden,
M.J.M. Bonten (Utrecht, NL)
Background: Estimates of attributable mortality (AM) due to
ventilator-associated pneumonia (VAP), based upon risk factor
and matched-cohort analyses have ranged from 0–76%. We used
associations between relative risk reductions (RRR) of VAP
incidence (due to prevention) and ICU-mortality to determine
AM. If AM would be 100%, a 50% RRR of VAP should yield a
50% RRR of ICU-mortality. Our objective, therefore, was to
estimate crude relative AM of VAP upon outcomes of
randomized studies on VAP prevention.
Methods: A systematic search through MEDLINE, Cochrane
Library and reference lists of relevant studies to identify
randomized VAP prevention trials published until 2003
providing data on VAP incidence and ICU-mortality. For each
study, the methodological study quality (MQS) was assessed
(ranging from 0–13 points), based on allocation, concealment,
blinding of the intervention, patient selection and
characteristics, and on the deﬁnition of pneumonia. RRR of
VAP and ICU-mortality were calculated. Main outcome
measures were crude relative attributable ICU-mortality of
VAP, which was estimated by the ratio of RRRs of mortality
and VAP, as well as on crude patient data of pooled trial
populations.
Results: Sixty trials were identiﬁed, with 11 176 patients and
2126 VAP events. Six trials compared two intervention groups to
control patients and, therefore, 66 group comparisons were
included. Signiﬁcant RRR of VAP were reported in 30 of 66
trials, whereas 3 of 66 trials reported signiﬁcant RRR of ICU-
mortality due to preventive measures. Overall trial quality was
8.4 ± 2.1. RRR of VAP were highest for antibiotic containing
strategies (0.55 (95%CI: 0.47–0.64) for SDD and 0.64 (95%CI:
0.46–0.82) for other types of antibiotic prophylaxis), whereas the
lowest were found among stress ulcus prophylaxis interventions
with RRRvap of 0.12 (95%CI: 0.02–0.23). No signiﬁcant VAP
reduction was found for ventilator circuit changing and enteral
feeding modulation. A signiﬁcant RRR for mortality was only
found for the pooled SDD studies ; 0.14 (95%CI: 0.06–0.23). No
signiﬁcant associations between MQS and RRR of VAP or ICU-
mortality and relative attributable mortality were found. The
pooled crude relative attributable mortality of VAP (CAM),
based upon all individual trials, was 23%, with wide variation
between individual studies.
Conclusions: The crude relative attributable mortality of VAP
was estimated to be 23%.
O72
Pattern and dynamics of airways colonisation in
mechanically ventilated patients
J-E. Berdal, J. Bjørnholdt, A. Blomfeldt, G. Bukholm,
N. Smith-Erichsen (Nordbyhagen, NO)
Objective: To investigate patterns and dynamics of microbial
colonization of the upper and lower airways in ventilated
patients.
Methods: Seventy-four mechanically ventilated patients were
consecutively recruited, and oropharyngeal, tracheal and
bronchoalveolar ﬂuid specimens were collected 48 hours after
intubation and thereafter every 72 hours until a total of 5 sample
sets had been collected or the patient was extubated. Samples
were quantitatively analysed and the dominant isolates
genotyped.
Results: Percentage of samples showing growth above the
accepted threshold for Ventilator Associated Pneumonia
(> 104 cfu/ml) was 36% to 54%, median 47%, from day 2 to 14
after the initiation of mechanical ventilation. Correlation
analysis showed a high degree of correlation for the dominant
isolate from the three sampling sites on each sampling occasion.
The same isolate was found with a high degree of correlation on
two subsequent sampling occasions i.e. sampled 72 hours apart.
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However no correlation was found when comparing isolates in
individual patients sampled more than 72 hours apart.
Conclusion: On all sampling occasions, a high percentage of
ventilated patients showed growth above the accepted threshold
values for Ventilator Associated Pneumonia, questioning the
speciﬁcity of this diagnostic criterion for the diagnosis of VAP.
The microbial ﬂora of the airways in ventilated is stable over a
period of 72 hours, however when samples are collected more
than 72 hours apart, results and thus choice of antibiotic
treatment cannot be predicted based on results of previous
samplings. On a genotypic level there is a high correlation
between the dominant isolate found in oropharyngeal, tracheal,
and bronchoalveolar ﬂuid. Further studies are warranted to
investigate whether less invasive sampling (i.e. oropharyngeal)
is sufﬁcient to determine the most likely involved pathogen in
ventilator-associated pneumonia.
O73
Factors inﬂuenced treatment failure in
pneumococcal pneumonia with bacteraemia
V. Huang, I. Pencu, S. Oprea, M. Zervos (Atlanta, Royal Oak,
Detroit, US)
Objective: To conduct a retrospective study to compare
outcomes of patients with pneumococcal pneumonia with
bacteraemia over a 5-year period.
Methods: We identiﬁed 128 consecutive patients with clinical
criteria for pneumonia and positive blood cultures. There were
70 females and 58 males. The majority of patients were elderly
with mean age of 70 years (28–98 years). In addition, these
patients have history of smoking (51%), underlying medical
condition (67%), and most common being chronic lung disease
(26%). Six patients were treated as outpatients.
Results: Overall 28% of patients failed initial therapy. Death
occurred in 12.5%. The failure rate among bacteraemic patients
with cardiovascular disease was 7.7 times higher than the failure
rate among patients with no underlying medical conditions, 54%
vs. 7% (p = 0.001). Patients with no underlying conditions had
the lowest failure rate. Rates of Streptococcus pneumoniae
resistance to penicillin were 22 % and macrolides 20%.
Multiple logistic regression analysis demonstrated the cure
rate for groups treated with diverse antibiotics were not
signiﬁcantly different: 70% in levoﬂoxacin group (n = 51), 89%
in ceftriaxone plus azithromycin IV followed by oral
azithromycin group (n = 56), and 84 % in azithromycin alone
group (n = 21). Overall, the failure rate in patients with a
resistant pathogen was similar to patients with pathogens
susceptible to the initial agent, 28% vs. 29%. The majority of
patients (83%), who failed therapy, had coexistent illnesses and
high severity risk PSI scores (63%). No patients failed outpatient
therapy.
Conclusion: The results from this study demonstrated that
antimicrobial resistance was not a factor associated with
treatment failure. Underlying disease is the most important
predictor of outcome and mortality in community-acquired
pneumonia due to S. pneumoniae complicated by bacteraemia.
O74
Efﬁcacy of the use of through-catheter leukocyte
cytospin blood culture for monitoring
haemodialysis catheter colonization.
A prospective study designed to prevent
bloodstream-related infections
J.L. del Pozo, A. Aguinaga, M. Alonso, A. Serrera, S. Hernaez,
M.J. Garrido, N. Garcı´a-Ferna´ndez, J. Leiva (Pamplona, ES)
Objectives: Permanent tunnelled central venous catheters are
commonly used to provide vascular access in patients on
maintenance haemodialysis. Infection is one of the leading
complications. According to several authors, catheter
colonization precedes bloodstream infection. The aim of this
study was to detect catheter colonization, and establish a pre-
emptive therapy based in catheter antibiotic lock in order to
prevent development of catheter-related bloodstream infection
(CRBI). Besides, we evaluated the impact of this monitoring
system on the life spam of the catheters.
Methods: During a 24-month period (July 2003 to July 2005), 34
haemodialysis patients with tunnelled catheters were
prospectively followed up. The study was carried out in a 350-
bed university hospital in which 50 patients are maintained on
chronic intermittent haemodialysis. All patients were evaluated
by extracting a through-catheter leukocyte cytospin blood
culture every 15 days. If the culture was positive, paired
quantitative blood cultures were obtained through the two
lumens of the catheter and a peripheral vein, in order to assess
absence of related bacteraemia. A pre-emptive therapy
consisting in a 21 days antibiotic lock regimen was then
started if coagulase negative staphylococci (CNS) were isolated.
For isolates other than CNS, decision about conservative
treatment was individually taken.
Results: A total of 37 haemodialysis catheters inserted in 34
patients were evaluated. There were 31 episodes of catheter
colonization occurred in 13 patients. At the time of colonization,
the catheters were in place for a mean of 562 days (range: 16 to
1475 days). Coagulase negative staphylococci were the most
common microorganism isolated (90% of all isolated
microorganisms). Pre-emptive therapy with teicoplanin
(10 mg/ml) locks was able to eradicate catheter colonization in
29% of the cases. Relapsing colonization occurred in 61.2% of the
cases. Only 1 patient required catheter removal due to an
infectious complication (CRBI). Catheter was removed in other
two patients due to non-infectious complications. The mean
duration of catheter use was 239 days (range: 9 to 483 days)
after treatment of a colonization episode.
Conclusion: This study shows the utility of intracatheter
leukocyte cytospin blood culture to early detection of
haemodialysis catheter colonization, and shows that eradication
of bioﬁlm-related microorganisms is possible without removal of
the catheter.
O75
Risk factors and treatment outcome of
bloodstream infections caused by Pseudomonas
aeruginosa isolates producing the PER-1
extended-spectrum b-lactamase
A. Endimiani, B. Pini, F. Luzzaro, G. Amicosante,
G.M. Rossolini, A. Toniolo (Varese, L’Aquila, Siena, IT)
Objectives: Clinical signiﬁcance of bloodstream infection (BSI)
due to Pseudomonas aeruginosa (Pa) has received large attention.
In contrast, the clinical impact of BSI caused by ESBL-positive
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isolates has not been investigated. The PER-1 ESBL is a common
enzyme conferring high-level resistance to anti-pseudomonal
cephalosporins. This study was initiated to evaluate risk factors
and treatment outcome of BSI episodes caused by PER-1-
positive Pa strains (PER-1-P-Pa).
Methods: From January 1998 to September 2004, 26 BSI cases
due to ceftazidime-resistant Pa strains were observed at the
Ospedale di Circolo, Varese, Italy. MIC values of anti-
pseudomonal drugs were determined by the E-test method
(AB Biodisk, Solna, Sweden). The double-disk synergy test was
used to detect ESBL production. Molecular methods (PCR
ampliﬁcation and DNA sequencing) were used to characterize
ESBL types. Clinical records of BSI-patients were examined
retrospectively. Demographic data, underlying diseases
(according to McCabe-Jackson classiﬁcation and Charlson
weighted index), risk factors, antimicrobial therapy, and
treatment outcome were investigated by comparing cases due
to ESBL-positive to those due to ESBL-negative Pa isolates.
Unpaired Student’s t-test, Mann-Whitney U-test, and Chi-square
were used for statistical analysis.
Results: Nine Pa isolates were found to express the PER-1 ESBL
whereas the remaining 17 were PER-1-negative (PER-1-N-Pa).
Severe sepsis (P = 0.03), bladder and intravascular catheters
(both, P = 0.01), immunosuppressive therapy (P = 0.04), and
mechanical ventilation (P = 0.03) were signiﬁcantly associated
with BSI due to PER-1-P-Pa. Empirical treatment (P = 0.02) and
treatment after ID/AST (P < 0.01) were less adequate in PER-1-
P-Pa cases. Hospital admission and longer mean length of
hospital stay after BSI onset (P = 0.07 and P = 0.08, respectively)
was possibly related to expression of the PER-1 enzyme. Overall,
77.8% BSI cases due to PER-1-P-Pa vs. 28.6% cases due to PER-1-
N-Pa isolates failed to respond (P < 0.03). Notably, all cases due
to PER-1-P-Pa that were treated with carbapenems failed to
respond. In contrast, 7/8 cases due to PER-1-N-Pa given
carbapenems were responders.
Conclusions: Therapeutic failure and poor outcome are
associated with BSI episodes caused by PER-1-P-Pa strains.
Thus, recognition and prompt reporting of ESBL-production
appears a critical factor for the management of patients with
serious P. aeruginosa infections.
O76
Is transmission of MRSA frequent between
patients sharing the same hospital room?
D.S. Blanc, C. Balmelli, C. Petignat, G. Zanetti, P. Francioli
(Lausanne, CH)
Objectives: To evaluate the transmission of MRSA between
patients hospitalized in the same room.
Methods: Analysis of the results of screening for MRSA of
roommates of patients found to be MRSA positive. PFGE typing
of MRSA isolates from the index case and the roommates.
Setting: Tertiary care hospital of 890 beds, with a proportion of
11 % of S. aureus that were resistant to methicillin (MRSA).
Results: During the year 2004, there were 73 occasions in which
a patient was found to be MRSA positive (index case) while
hospitalized with other patients in the same room. A total of 210
roommates were screened for MRSA, of whom 21 (10%) were
found to be positive. Comparison of isolates of the index cases
and of MRSA positive roommates revealed that the PFGE
patterns were indistinguishable in 11/21 instances, suggesting
transmission. However, in 10/21 instances, isolates were not
indistinguishable, suggesting that the roommates were
contaminated by another source than the index case. Thus,
MRSA was probably acquired in only 11/210 (5.2%) patients
who were sharing a room with an index case.
Conclusion: In our setting, transmission of MRSA between
patients hospitalized in the same room does not seem to be
frequent. However, this study also revealed that half of the
MRSA positive roommates had isolates different from the index
patient. Thus, interpretation of the screening results in terms of
transmission should be cautious.
O77
Outbreak of Burkolderia cenocepacia bacteraemia
associated with disinfection napkin
contamination in haemodialysis
M. Solbiati, B. Allegranzi, G. Lo Cascio, M.G. Bonora,
C. Loschiavo, N. Tessitore, R. Fontana, E. Concia (Verona, IT)
Objective: We investigated an outbreak of bacteraemia
involving 38 patients at two Haemodialysis Units located in
two different hospitals in Verona and occurring from November
2004 to January 2005.
Methods: Blood cultures were performed from patients having
intra- and post-dialytic chills and fever. Investigations to
identify source of infection, including echocardiography, were
performed. As soon as Burkholderia cepacia complex was isolated
from the ﬁrst two blood samples, investigation cultures were
carried out on deionised and tap water, dialysate ﬂuid, dialyser
blood compartments, dialysate concentrate, disinfectant
solution. Afterwards samples were taken from disinfection
napkins contained in a commercial sterile dressing kit used to
handle central venous catheters (CVCs). Phenotypic and
molecular identiﬁcation of B. cepacia were performed by
standard biochemical procedures and by restriction fragment
length polymorphism-PCR (RFLP-PCR) analysis respectively.
Strain clonality was analysed by pulsed-ﬁeld gel electrophoresis
(PFGE).
Results: Seventy-nine episodes of bacteraemia occurred in 38
patients undergoing haemodialysis and having CVC. One case
of endocarditis was diagnosed. CVC was removed in 33/38
patients. B. cepacia complex was isolated from all blood cultures
and disinfection napkins from one batch. RFLP-PCR analysis
conﬁrmed this ﬁnding from blood and napkin cultures and B.
cenocepacia (genomovar III B) was identiﬁed and demonstrated
to be clonally identical or strictly related using PFGE. Following
CVC substitution and 5-day combination antibiotic therapy, all
patients improved, but 32 relapsed after a mean of 2 weeks and
needed 6–8 weeks of treatment to be cured. No death
attributable to the infection was observed.
Conclusions: Chronic haemodialysis patients are at high risk of
infection, frequently caused by typical nosocomial bacteria and
hepatitis viruses, commonly transmitted by contamination of the
haemodialysis system and/or the vascular catheter from
environmental surfaces or hands of personnel. Only few cases
of infection due to B. cenocepacia in haemodialysis patients are
reported in the literature. Our investigation showed that
commercial napkins soaked in disinfectant were the source of
infection and that contamination occurred at the time of
manufacture. Despite antibiotic susceptibility in vitro, the
detected infections were difﬁcult to eradicate, probably due to
bacteria persistence in bioﬁlm on CVCs.
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Bioﬁlms – a highly organised community
O93
AGR-genotyping of bioﬁlm producing
Staphylococcus aureus
V. Caﬁso, T. Bertuccio, M. Santagati, V. Demelio, D. Spina,
S. Stefani (Catania, IT)
Objectives: This study investigated the possible correlation
between bioﬁlm production and the accessory regulatory genes
(agr) in a sample of S.aureus isolated from catheter-associated
infections.
Methods: We analysed: (i) the ability to produce bioﬁlm in a
static system by a specthrophotometrical quantitative assay;
(ii) the agr-genotype and (iii) the expression of ica-operon and its
correlation with agr functionality and the activity of the two
transcriptional regulators sarA and rsbU by RT-PCR.
Results: Our results, applying a new ScaI-RFLP method for agr-
typing, show that strong bioﬁlm producing strains belong
predominantly to the agr-type I and II and are found in
methicillin-resistant strains. We found two agr-variants, and
sequence analysis revealed that these isolates contained an IS256
copy within the agr-locus I: in two strains, indicated as IA–
variant, this element is located in the intergenic region between
agrD and agrC and has the same transcription direction as the P2
agr-operon; on the contrary, in one strain (IB-variant), this
insertion sequence is integrated into agrC and caused the
interruption of this gene at the nucleotide position 1114 of the
agr published sequence (GeneBanK AJ617710) but the IS has an
opposite transcriptional direction with respect to the agr genes.
The study of ica expression in all agr-types, including the three
agr-variants, was performed and correlated with agr
functionality and with two transcriptional regulators sarA and
rsbU. Our results suggest that agr polymorph II and IB-variant
strains produce large amounts of bioﬁlm, possess a defective agr
system in which sarA may activate the ica-operon expression by
repressing icaR transcription, but they are, at the same time,
defective in haemolysin activity and lack the transcription of the
o´B activator rsbU.
Conclusion: It is possible to hypothesize that, in agr polymorph
I and II strains, which are the most diffused in nosocomial
settings, bioﬁlms represent a selective advantage in catheter-
associated and chronic-infections because microrganisms are
able to thrive in the hosts contributing signiﬁcantly to
pathogenesis.
O94
Structural comparison of bioﬁlms formed by
Staphylococcus aureus, Staphylococcus
epidermidis, and other coagulase-negative
staphylococci
M.A. Horstkotte, S. Stepanovic, M. Lang, D. Mack,
J.K. Knobloch (Hamburg, DE; Belgrade, CS; Swansea, UK)
Objectives: Due to their ability to form multi-layered bioﬁlms
S. aureus and S. epidermidis as well as other coagulase-negative
staphylococci are the most prevalent pathogens in foreign body
related infections. However, bioﬁlm formation of different
staphylococcal species seem to be mediated by different
mechanisms.
Methods: The bioﬁlm structure as well as single cells
embedded within the bioﬁlm were analysed using confocal
laser scanning microscopy. Clinically relevant isolates of
S. aureus, S. epidermidis, S. lugdunensis, S. sciuri, S. hominis,
S. haemolyticus, and S. simulans were investigated. Cells were
stained with SYTO 9 and N-acetylglucosamine as a marker for
the polysaccharide intercellular adhesin (PIA), was detected by
staining with TRITC labelled wheat germ agglutinin (WGA).
PIA-synthesis of individual strains was conﬁrmed by dot blot
analysis using a PIA-speciﬁc antiserum.
Results: All strains investigated displayed highly structured, 10
to 30 lm thick bioﬁlms. However, signiﬁcant amounts of PIA
were only detected in bioﬁlms of S. epidermidis and S. aureus.
Large masses of PIA were distributed irregularly within
S. epidermidis bioﬁlms, whereas in S. aureus bioﬁlms, all cells
were homogenously surrounded by a thin PIA layer. In PIA-
dependent bioﬁlms the cells were rigidly coupled to each other.
For bioﬁlms of S. sciuri a compact structure with motionless cells
was observed, too. However, PIA was not detected in this
species. In contrast, to the bioﬁlms with rigid cell-to-cell contacts
bioﬁlms of S. simulans displayed a sponge-like structure in
which individual cells or smaller cell clusters were ﬁxed
together by elastic cell-to-cell contacts. Within these bioﬁlms
few structures were stained by WGA but PIA could not be
detected with PIA-antibodies, indicating that a PIA independent
polysaccharide could be involved in bioﬁlm formation in this
species. In bioﬁlms formed by S. haemolyticus, S. hominis, and
S. lugdunensis large rigid cell clusters could be detected to which
single cells or smaller cell clusters were ﬁxed by elastic cell-to-
cell contacts. Thereby, the ratio between motionless and elastic
ﬁxed cells varied between various species.
Conclusions: At least three different types of cell-to-cell
contact within staphylococcal bioﬁlms were detected among
the species investigated. Thereby, the PIA independent rigid
and elastic cell-to-cell contacts could be observed in parallel in
two species.
O95
Differential importance of protein and
polysaccharide intercellular adhesin mediated
bioﬁlm formation in Staphylococcus aureus and
Staphylococcus epidermidis from prosthetic joint
infections
H. Rohde, E. Burandt, L. Frommelt, N. Siemssen, C. Burdelski,
C.-J. Wang, S. Scherpe, J.K.-M. Knobloch, J. Kaplan, D. Mack
(Hamburg, DE; Newark, US; Swansea, UK)
Objectives: Nosocomial staphylococcal foreign-body infections
are a major problem in modern medicine, demanding new
therapeutic and preventive strategies. The usefulness of known
virulence factors as vaccine candidates is critically restricted by
their prevalence in natural staphylococcal populations. As
bioﬁlm formation is essential for the pathogenesis of
Staphylococcus epidermidis and Staphylococcus aureus foreign-
body infections this study examined the distribution of genes
involved in bioﬁlm formation, the bioﬁlm phenotype and
production of polysaccharide intercellular adhesin (PIA) in
clonal independent S. aureus and S. epidermidis strains isolated
from persistent prosthetic joint infections after total hip
arthroplasty (THA) or total knee arthroplasty (TKA).
Results: A bioﬁlm-positive phenotype was detected in all
S. aureus and 69.2 % of S. epidermidis strains. There were no
major differences in the distribution of factors mediating
primary attachment between S. aureus and S. epidermidis
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strains from TKA and THA. icaADBC, encoding the synthesis
apparatus for PIA, was detected in all S. aureus strains, but 38.5%
of S. epidermidis strains were icaADBC-negative. 50 % of those
produced trypsin sensitive bioﬁlms, indicating that in these
strains protein factors like the highly prevalent accumulation
associated protein (Aap) is sufﬁcient for intercellular adhesion.
Protease-sensitive bioﬁlms were exclusively found in
S. epidermidis strains from THA, representing 37 % of all
bioﬁlms in this population. In contrast, both trypsin and PIA-
cleaving dispersin B disintegrated S. aureus bioﬁlms, indicating
that in this species PIA and proteins act cooperatively in bioﬁlm
formation regardless of the infection site.
Conclusion: Our ﬁndings suggest that PIA and protein factors
are of differential importance for the pathogenesis of S.
epidermidis in PJI after THA and TKA, implicating icaADBC
cannot serve as a general virulence marker in this species. In S.
aureus bioﬁlm formation proteins are of overall importance and
future work should focus on the identiﬁcation of functionally
active molecules.
O96
The role of the quorum-sensing ‘‘target of RNAIII
activating protein’’ and ‘‘RNAIII-inhibiting
peptide’’ in staphylococcal bioﬁlm formation and
control in vitro
C.A. Fux, D. Nguyen, S. Wilson, N. Balaban, P. Stoodley (Berne,
CH; Pittsburgh, Bozeman, North Grafton, US)
Objectives: Staphylococci are the leading cause of device-related
infections. By forming bioﬁlms, involved bacteria increase
tolerance to antibiotics and host immunity. Recently, the
‘‘RNAIII-inhibiting peptide’’ RIP was found to reduce
staphylococcal surface attachment and bioﬁlm-related
infections. Its mode of action remains unclear. RIP inhibits the
phosphorylation of the ‘‘target of RNAIII activating protein’’
TRAP and thus the expression of agr. Agr knockout strains, on
the other hand, have been associated with increased surface
adhesion and bioﬁlm formation. This discrepancy suggests that
RIP and TRAP might be more directly involved in bioﬁlm
control. We evaluated their role in bioﬁlm growth under static
and ﬂow conditions.
Methods: We compared S. aureus wild type (WT), the WT with
exogenous RIP, and a TRAP- mutant. Also, we tested the effect
of RIP on 120 hours bioﬁlm in a catheter infection model.
Surface area coverage (SAC), bioﬁlm thickness, roughness and
biomass were quantiﬁed by digital time lapse and confocal
microscopy as well as bacterial counts.
Results: Neither TRAP inactivation nor the addition of RIP
affected planktonic growth, in both the static and the ﬂow-cell
bioﬁlm model, TRAP inactivation and to a lesser extent the
addition of RIP signiﬁcantly increased surface attachment and
bioﬁlm biomass for up to 24 hours. At later timepoints up to
96 hours, however, no signiﬁcant differences in SAC, bioﬁlm
thickness or biomass could be found. Interestingly, the WT
strain always grew rougher (i.e. less homogeneous) bioﬁlm.
Measuring exclusive static growth, bacterial counts of WT
bioﬁlms were signiﬁcantly higher at 24 hours and 96 hours
(p < 0.01). The addition of RIP to vancomycin did not improve
bacterial clearance of mature catheter bioﬁlms.
Conclusion: The reported effectiveness of RIP against infections
in animal models is not due to the abolishment of bioﬁlm
formation per se, but is more likely related to a reduction of
initial surface attachment, the down-regulation of protective and
aggressive virulence factors as well as an altered bioﬁlm
architecture. It is not clear at this point how switching from a
rough to a ﬂat architecture may reduce virulence and increase
antibiotic susceptibility.
O97
Using an efﬁcient anti-bioﬁlm procedure to
improve the safety of paciﬁers
E. Comina, K. Marion, F. Renaud, E. Bergeron, J. Freney (Lyon,
FR)
Objectives: Many parents refuse the use of paciﬁers because
they consider them as non-hygienic supplies. However, recent
publications have highlighted the role of paciﬁers in the
prevention of Sudden Infant Death. The aim of this study was
ﬁrst to assess the bacterial contamination of the surface of
paciﬁer and then, to develop a cleaning method to avoid bioﬁlm
growth and improve the safety of paciﬁers.
Methods: 25 used latex or silicone paciﬁer nipples were
provided by various day care centers. Bioﬁlm was searched on
their surface using ﬁrst direct staining with crystal violet
microscopy and image analysis, and then bacterial
enumeration after scrapping. A bioﬁlm reactor system was set-
up. It was ﬁlled with a contaminated media made of artiﬁcial
saliva supplemented with LB broth and inoculated with 3
different strains. This reactor was used to test 4 different
cleaning procedures (stasis, brushing, spray and steam
sterilization) the three ﬁrst treatments including the
Pronetron, a new anti-bioﬁlm product.
Results: 80% of the paciﬁers studied presented a bioﬁlm with
living cells on their surface, 80% of them had a surface coverage
upto 50%. The two main bacterial genus isolated were
Staphylococcus and Candida. Latex was more contaminated than
silicone, 89% of latex nipples contained more than 1000 cfu/
cm2. The bioﬁlm reactor system ﬁlled with artiﬁcial saliva and
10% of LB broth enabled a massive bioﬁlm growth within 7 days
on latex nipples, which covered a surface of almost 80% and
contained 8.10E7 cfu/cm2. The most efﬁcient treatment for
bacterial kills was water steam sterilization but led to the
lowest bioﬁlm detachment. Brushing with Pronetron had the
best efﬁcacy both on bioﬁlm detachment and residual living
cells. This treatment was reproduced on 4 different samples
under more realistic conditions (LB broth reduced to 1%). The
thickness of the bioﬁlm formed on the control was signiﬁcantly
reduced (55% coverage and 2.10E5 cfu/cm2). Analysis revealed
no bioﬁlm on the treated surfaces. Only a very few isolated
living cells remained. Averages and standard deviations were
calculated for each parameter (n = 4). The low standard
deviations showed a good reproducibility of the cleaning
method.
Conclusion: A daily cleaning with a very quick and easy
system made of a simple dental brush combined to an efﬁcient
anti-bioﬁlm agent will give a boost to the use of paciﬁers, whose
advantages seam to be underestimated.
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Clinical features and molecular epidemiology of
coronavirus HKU1 associated community-
acquired pneumonia
P.C.Y. Woo, S.K.P. Lau, H-W. Tsoi, Y. Huang, R.W.S. Poon,
C-M. Chu, R.A. Lee, W-K. Luk, G.K.M. Wong, B.H.L. Wong,
V.C.C. Cheng, B.S.F. Tang, A.K.L. Wu, R.W.H. Yung, H. Chen,
Y. Guan, K-H. Chan, K-Y. Yuen (Hong Kong, HK)
Objectives: Recently, we described the discovery of a novel
group 2 coronavirus, coronavirus HKU1 (CoV-HKU1), from a
patient with pneumonia. In this study, we examined the clinical
features and molecular epidemiology of CoV-HKU1-associated
community-acquired pneumonia.
Methods: We prospectively collected nasopharyngeal aspirates
(NPAs) from patients with community-acquired pneumonia
during a 12-month period. A 453-bp fragment of the RNA-
dependent RNA polymerase (pol) gene of CoV-HKU1 was
ampliﬁed from the extracted RNA by RT-PCR using CoV-HKU1
speciﬁc primers. The epidemiological, clinical, laboratory and
radiological features of patients with pneumonia associated with
CoV-HKU1 were analysed. Speciﬁc antibodies were detected
using a recombinant CoV-HKU1 nucleocapsid protein based
ELISA. The complete pol, spike and nucleocapsid genes of the
CoV-HKU1 were ampliﬁed and sequenced. RNA extracted from
208 nasopharyngeal swabs and faecal samples from 56 wild and
domestic animals in Hong Kong and southern China were
subject to RT-PCR of pol gene of CoV-HKU1 using CoV-HKU1
speciﬁc primers.
Results: RNA extracted from NPAs in 10 (2.5%) out of 418
patients with community-acquired pneumonia was positive for
CoV-HKU1. No epidemiological linkage was identiﬁed among
the 10 cases. All cases occurred in spring and winter (January–
May). Four patients had underlying diseases of the respiratory
tracts. Without a diagnostic test, the illness was not
distinguishable from other community-acquired pneumonia
clinically. Only two had symptoms of the upper respiratory
tract and one had extra-pulmonary symptoms. In the six
patients with serum samples available, all showed a four-fold
change in IgG titre and/or the presence of IgM against CoV-
HKU1. No other respiratory pathogen was detected in any of the
patients. The two patients who died had lower haemoglobin
concentration (P = 0.04), monocyte count (P = 0.04), serum
albumin (P = 0.04) and oxygen saturation on admission
(P = 0.03) and bilateral involvement (P = 0.003) and more
number of zones involved (P = 0.01) on chest radiograph.
Sequence analysis of the complete pol, spike and nucleocapsid
genes revealed the presence of two genotypes of CoV-HKU1.
None of the animal samples was positive for CoV-HKU1 RNA.
Conclusions: CoV-HKU1 accounts for 2.5% of community-
acquired pneumonia, with two genotypes in the study
population. Without diagnostic tests, the illness was clinically
indistinguishable from other community-acquired pneumonia.
O99
Stability of SARS coronavirus to high
temperature and high relative humidity
W.H. Seto, K.H. Chan, S.Y. Lam, M. Peiris (Hong Kong, HK)
The stability of the novel SARS coronavirus (SARS CoV) virus at
different temperatures and relative humidity was evaluated.
Ten microlitre of 107 TCID50 per ml of virus was incubated at
different temperatures (38C, 33C, 28C) at different relative
humidity (> 95%, 80–89%) for 3 hr, 7 hr, 11 hr, 13 hr and 24 hr,
and the residual viral infectivity was titrated. High relative
humidity (> 95%) at comparatively low temperature (28C and
33C) didn’t affect the virus stability signiﬁcantly. Higher
temperature at 80–90% relative humidity affected the virus
infectivity 0.25–2 log 10 loss of titre for up to 24 hr. However if
the relative humidity is maintained at > 95%, virus stability was
adversely affected with further 1.5 log loss of titre for each time
point up to 24 hr (0.38–3.38 log 10). We conclude that high
temperature at high relative humidity has synergistic effect on
inactivation of SARS CoV viability. This may help explain the
low transmissibilility of SARS in tropical areas like Malaysia and
Indonesia where patients are placed in naturally ventilated
wards, while Singapore, with air-conditioned wards had a
relatively large outbreak. Similarly large outbreaks occur in the
winter of non-tropical areas like Hong Kong when the humidity
and temperature was low.
O100
First identiﬁcation of Toscana virus and other
phleboviruses in sandﬂies from southern France
R.N. Charrel, A. Izri, S. Temmam, P. Delaunay, I. Toga, P. Marty,
H. Dumon, X. de Lamballerie, P. Parola (Marseille, Paris, Nice,
FR)
Toscana virus (TOSV) is an arthropod-borne virus vectored by
sand ﬂies. TOSV infection has long been recognized in central
Italy. However, it is an emerging cause of meningitis and
encephalitis in Spain and France. However, the ecology and
epidemiology of TOSV in France is poorly understood.
Objectives: During summer 2005, sand ﬂies captures were
organized in the surroundings of two large cities (Marseilles and
Nice), in the vicinity of dog kennels and horse stables. Pools
were constituted in respect of the trapping location, sex and
species identiﬁcation with a maximum of 30 individuals per
pool. PCR assays targeting three genomic regions were used,
and ﬁnal identiﬁcation was done via sequencing.
Methods: Pools were constituted in respect of the trapping
origin, sex and species. They were tested by RT-PCR with
primers targeting either the polymerase gene of Phleboviruses
or speciﬁcally TOSV, or the nucleoprotein gene.
Results and discussion: A total of 725 sand ﬂies were trapped
and identiﬁed by morphological keys. Positive results were
obtained with TOSV speciﬁc primers for 3 pools collected in
Marseille. Sequence analysis showed that these pools contained
a virus most closely related to but distinct from TOSV since an
82.3% and 96% identity at the nucleotide and amino acid level
respectively was observed with the TOSV strain isolated in Italy.
This is the ﬁrst time that TOSV is detected in sandﬂies from
southern France. One pool included Sergentomyia minuta sand
ﬂies, and this constitutes the ﬁrst detection of TOSV in this
species. S. minuta readily bite reptiles, but its afﬁnity to bite
humans is poorly known. This sandﬂy could however play a
role in the maintenance of TOSV in the nature. Three pools were
found to be positive with Phlebovirus generic primers whereas
they were negative with TOSV speciﬁc primers. Sequence
analysis indicated a high genetic diversity with recognized
phleboviruses for which sequence data are available. This
indicates that this virus could represent a new species within
the genus Phlebovirus. However another phlebovirus, Arbia
virus, has been repeatedly isolated in Italy, though no sequence
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data is available. Arbia virus is currently being sequenced to
determine the nature of the phlebovirus detected in these 3
pools. This study showed that TOSV (and another phlebovirus)
are distributed throughout coastal south-eastern France.
O101
Imported cases of chikungunya virus infection
from eastern Africa
R.N. Charrel, P. Brouqui, H. Tissot-Dupont, X. de
Lamballerie (Marseille, FR)
On April 5th 2005, ProMED posted a report on an outbreak of
chikungunya virus (CHIKV) infection conﬁrmed in Ngazidia,
the largest island of Comoros located off the east coast of Africa.
On May 18th 2005, cases of CHIKV infection were laboratory-
conﬁrmed in Mauritius and Reunion islands. From January 2005
and during 5–6 months period, approximately 5000 cases were
recorded in the different islands of Comoros. In the Reunion
island (700 000 inhabitants) most cases occurred in April and
May 2005 in urban settings (cities of Saint-Denis, Le Port and
Saint-Pierre). Clinical manifestations were characterized by
fever (99%), arthralgia (98%), myalgias (97%), headache (81%)
and skin rash (49%). A total of almost 3200 cases were
registered, with more than 880 conﬁrmed via serological testing.
In Mauritius island, a total number cases estimated at 3600
occurred between April and late June 2005.
Objectives: Marseille city hosts the second larger community of
Comorian in the world with a total number of 70 000
individuals. Since they operate frequent back and forth travels
between Comoros islands and Marseille, the aim of this study
was to investigate the impact of CHIKV African outbreak onto
the population residing in Marseille.
Methods: CHIKV (strain Ross) was used to infect Vero cells and
to produce an immunoﬂuorescence assay to detect anti-CHIKV
IgG and IgM. Sera were diluted 1:20 in PBS before testing.
A total of 97 sera collected from patients returning from
Comoros, Reunion, and Mauritius islands admitted in one of
the infectious disease units of the Public Hospital System of
Marseille were tested. Early serum specimens were tested via
PCR and virus isolation was attempted in C6/36 cells.
Results: Of these 97 sera, 15 were found to have antibody
against CHIKV with 10 showing either IgM or seroconversion.
The results of PCR testing and virus culture will be discussed.
Interestingly, the clinical features in those returning patients
were not similar to those reported in Reunion island. Hospital
admission was motivated by fever, but a minority complained
about arthralgia. This will be discussed.
O102
Crimean-Congo haemorrhagic fever in the East
Black Sea region of Turkey: a report of 78 cases
N. Sucu, K. Aydin, I. Ko¨ksal, R. Caylan, G. Yilmaz (Trabzon, TR)
Objectives: Crimean-Congo haemorrhagic fever virus
(CCHFV) belongs to the genus Nairovirus in the Bunyaviridae
family and causes a potentially fatal disease. After a short
incubation period, Crimean-Congo haemorrhagic fever (CCHF)
is characterized by acute febrile syndrome (a sudden onset of
high fever, severe headache, dizziness and myalgia). In severe
cases, haemorrhagic manifestations develop. Two outbreak of
CCHF occurred in the East Black Sea region of Turkey during
spring and summer of 2004 and 2005 years. In this study, we
report 78 cases who suspected as CCHF during the outbreak.
Methods: Patients with acute febrile syndrome were admitted
to our hospital between May and August 2004–2005. Seventy-
eight patients were analysed for the epidemiological and clinical
features and mortality. The diagnosis was conﬁrmed with
ELISA and/or RT-PCR.
Results: Fifty-six (72%) of patients were female and twenty-two
(28%) were male. The mean age was 47.7 (range 12–77). Malaise
(98.7%), fever (84.6%) and muscle ache (57.6%) were the most
common presenting symptoms. Sixty percent of patients had
history of tick bite, and 83% of handling livestock. At
admittance, white blood cell and platelet count were lower
than normal value, generally. But alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and lactate
dehydrogenase (LDH) levels were higher than normal level
(mean value: 2.5 · 103/ll, 69 · 103/ll, 191 U/l, 475 U/l,
1125 U/l, respectively). Thirty-nine (50%) patients were
treated with oral ribavirin. Thirty (34%) patients were replaced
with platelet and/or erythrocyte suspensions. Fifty-four (70%)
patients had immunoglobulin M antibodies and/or PCR results
positive for CCHFV in the serum samples. Three (3.8%) patients
died.
Conclusion: CCHF is being epidemic in recent years in Turkey.
East Black Sea Region is also very important region for this
disease. Our CCHF cases had lower mortality rate than other
reports. It could be explained by early deﬁning of the disease
during the outbreak, supportive therapy.
The year in infectious diseases medicine
S103
The year in infectious diseases medicine
S. Esposito, S. Bosis, N. Principi (Milan, IT)
This year had signiﬁcant achievements in pediatric infectious
diseases, including substantial progress in the area of respirat-
ory infections and vaccines. The severe acute respiratory
syndrome (SARS) was defeated, with the World Health Organ-
ization that showed great leadership during a period of crisis.
Avian inﬂuenza virus strains have caused recent localized
outbreaks, and threaten to escalate to pandemic status. Remark-
able progress has been made in studies of epidemiology and
pathogenesis of human metapneumovirus since its discovery in
2001. Novel coronaviruses have been identiﬁed in Europe and
the U.S. that appear to play an important and previously
unrecognized role in pediatric diseases. The growing use of
specialised diagnostic techniques has allowed a considerable
amount of new information to be obtained concerning the role of
Mycoplasma pneumoniae and Chlamydia pneumoniae: they seem to
play a more signiﬁcant role in causing respiratory tract infec-
tions than previously thought; they have been associated with
tonsillitis and they are also frequent in children aged less than
ﬁve years. Regarding vaccines, it has been demonstrated that the
increased use of inﬂuenza vaccine among children could reduce
illness in household or community contacts. Clinical trials have
also highlighted that pneumococcal conjugate vaccines prevent
invasive disease, pneumonia, and acute otitis media in vaccin-
ated children and reduce nasopharyngeal carriage of vaccine-
type pneumococci with dramatic effects on adult disease. More-
over, phase III trials on human papillomavirus vaccines as well
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as rotavirus vaccines are now in progress and there is wide
spread optimism for the prospects of regulatory approval for
general distribution of these vaccines in 1–2 years. Furthermore,
substantial progress has been made in management of children
and adolescents with HIV infection as well as in the approach to
infections in pediatric transplant recipients. The year also
introduced several new challenges, such as the emergence of
community strains of methicillin resistant Staphylococcus aureus,
problems related to nosocomial infections and the evolution of
travel diseases.
The hyper-virulent strain of Clostridium difﬁcile: sharing
experiences in Europe and North America (Symposium arranged
with ESGCD)
S107
Spread of the new variant 027 of Clostridium
difﬁcile in the Netherlands and Europe
E.J. Kuijper, M. Delme´e, F. Barbut, M. Rupnik, J. Brazier (Leiden,
NL; Maribor, SI; Paris, FR; Brussels, BE; Cardiff, UK)
A new strain of Clostridium difﬁcile has been recently reported
from Canada and the United States as a cause of outbreaks often
associated with increased disease severity. The increased viru-
lence is considered to be associated with the production of a
binary toxin and an increased production of toxins A and B.
Characterization of this strain revealed that it belongs to
toxinotype III, pulsed-ﬁeld gel electrophoresis (PFGE) type
NAP1, restriction endonuclease analyis group BI and PCR
ribotype 027. In the period February until June 2004, this strain
was also recognized in the UK at an outbreak involving 150
patients with 12 deaths at the Stoke Mandeville Hospital. Since
then, 302 isolates of type 027 were referred to the Reference
laboratory in Cardiff from 44 hospitals. After the recognition of
the ﬁrst outbreak of Clostridium difﬁcile-associated diarrhoea
(CDAD) in July 2005 due to type 027 among 45 patients at St.
Jansdal hospital in Harderwijk with 3 deaths, the strain thus far
caused outbreaks in 8 hospitals and 1 nursing home in the
Netherlands. In 2 additional hospitals, the strain has been found
in isolated cases of CDAD without an outbreak. In total, 86
isolates belonging to 027 have been found in the Netherlands. In
September 2005, the PCR ribotype 027 strain was isolated from 4
patients with CDAD in Ieper, Belgium. Subsequently, the same
pattern was identiﬁed among strains from three outbreaks that
had occurred in Brussels in 2003–2004 involving 17, 6 and 5
patients, respectively. In Ostende (Belgium) another outbreak
was found with 4 patients. The PCR ribotype 027, toxinotype III
strain has a characteristic antimicrobial susceptibility pattern,
since it is resistant to the newer ﬂuoroquinolones and to
erythromycin, but susceptible to clindamycin. The strain also
has the binary toxin genes and contains an 18bp deletion in a
toxin regulator gene (tcdC). Genes encoding TcdA and TcdB
demonstrate numerous nucleotide sequence changes compared
to strains belonging to toxinotype 0. The European Study Group
of Clostridium difﬁcile (ESGCD) has undertaken a survey and
collected 494 strains from 14 European countries, which are
currently under investigation. Preliminary results indicate that
of 168 toxinogenic isolates derived from 4 countries, toxinotype
III was found in 13 (7.7%). We conclude that C. difﬁcile ribotype
027, toxinotype III is already in Europe since 2003 and is now
rapidly spreading.
S108
Clostridium difﬁcile-associated disease: a growing
threat to U.S. public health
C. McDonald (Atlanta, US)
Several lines of evidence suggest a changing epidemiology of
Clostridium difﬁcile-associated disease (CDAD). First, there have
been increased reports of individual hospital outbreaks, in
many instances associated with increased deaths and colec-
tomies. Second, there has been a sharp increase since 2000 in
the number and rate of U.S. acute care hospital discharges
coded for CDAD. Finally, national surveys conducted over the
past year and a half suggest that 30–40% of U.S. infectious
disease physicians have perceived increases in the incidence,
severity, and likelihood of CDAD recurrence. Possible reasons
for this increase in incidence and disease severity could
involve trends in antimicrobial or other drug (i.e., stomach
acid suppressing medication) usage, changes in infection
control practices (i.e., hand hygiene or environmental surface
disinfection), or the emergence of one or more strains of
C. difﬁcile with increased antimicrobial resistance and/or
virulence. Indeed just such a novel strain has emerged and
appears responsible for outbreaks in the United States, Canada,
and, most recently, England. This strain possesses somewhat
unique toxin gene variations, including a deletion in a putative
negative regulator (tcdC) for toxins A and B and genes for an
additional toxin known as binary toxin. Although this strain
has been isolated infrequently from U.S. patients over the past
20 years, it has recently (since 2000) appeared as a cause of
major outbreaks; one reason for this may be the emergence of
increased resistance to ﬂuoroquinolones in this strain, possibly
providing it a selective advantage over other strains. There is
also evidence to suggest that this strain produces much greater
quantities of both toxins A and B and that this strain produces
these toxins earlier during log phase growth. Experiences to
date suggest that control of hospital outbreaks caused by this
strain can be difﬁcult to achieve and will likely require
multifaceted interventions including careful attention to infec-
tion control practices as well as some form of antimicrobial
usage restrictions. Finally, the most recent development in
changing epidemiology of CDAD is what appears to be
increasingly severe disease in previously low risk populations
including individuals with little or no exposure to either
healthcare settings or antimicrobials. Improved surveillance
will be necessary to more fully understand the magnitude of
community-acquired CDAD and possible reasons for recent
increases in its incidence.
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Blood-borne viruses in health care facilities-the silent enemy?
S109
An overview of transmission of BBV in
healthcare facilities
S. Mehtar on behalf of HSRC, MRC & CADRE
There are an estimated 5 million HIV infected people in South
Africa, and until recently, sexual transmission was considered to
be the main, if not only, route of transmission for blood borne
viruses such as HIV. The WHO reported that unsafe injections
(and other health delivery practice) might contribute up to 15%
of these infections particularly in children. Following a pub-
lished report from Tygerberg Hospital, Stellenbosch Uni, where
14 children were found to be HIV infected whose biological
mothers were HIV uninfected, a large cross-sectional with a
nested case control study was undertaken to identify risk factors
in children under the age of 9 years old who were HIV infected
with an uninfected biological mother. Evaluation of infection
control practices in all dental and mother and child healthcare
facilities were undertaken in one province of South Africa.
Fifteen percent of the children who had been tested between the
ages of 2–9 years were found to be HIV infected, however there
were 7 children (1.4%) who were HIV infected yet their
biological mothers were HIV uninfected. The infection control
(IC) study protocol assessed knowledge of the health staff,
provision for IC and safe practice at ward or unit level and
actual clinical practice among dental and maternity staff.
Cleaning and sterilization of critical items were tested for the
presence of occult blood as a surrogate marker for IC practice.
Expressed breast milk (EBM) was sent for viral load estimation.
Findings suggest that transmission via unsafe injections,
improper cleaning and sterilization of instruments (25% of
items were found to be contaminated with blood) and poorly
labelled expressed breast milk (RNA viral load of 1500 copies/
ml or higher found in 30% of EBM) from an HIV infected mother
could contribute to transmission of HIV and other blood borne
viruses in health care facilities. Africa is not unique in this
regard. Reports of hepatitis B and C from the reuse of multi-dose
vials have been reported from Sweden, Denmark and the United
States. There is clearly a risk of transmission of blood borne
viruses in both high and low income countries, and it is most
likely due to the lack of proper care during healthcare proce-
dures than economics.
Viral congenital paediatric diseases
S111
Congenital CMV infection: current controversies
S. Stagno (Birmingham, US)
CMV is the leading cause of congenital viral infections
worldwide with an incidence ranging from 0.2 to 2 percent
of all live births. Only 5 to 10 percent of all cases of congenital
CMV infection are symptomatic at birth and the majority of
these children go on to develop severe neurologic sequelae. In
contrast, only 8 to 15 percent of patients with clinically
inapparent infection in the neonatal period develop sequelae.
Sensorineural hearing loss is the most signiﬁcant complication.
It is bilateral in 50 percent, progressive in 50 percent, and late
appearing in 20 percent of patients. Predictors of hearing loss
include the presence of petechiae and thrombocytopenia,
hepatosplenomegaly with laboratory evidence of hepatitis,
and intracranial calciﬁcations. The progressive nature and
delayed onset of hearing loss demonstrate the inadequacy of
mass screening for hearing based on testing newborn infants.
Prenatal diagnosis can be achieved by testing amniotic ﬂuid
with PCR or culture obtained after 20 weeks of gestation.
Quantitative PCR has a good predictive value for symptomatic
infection. Children with congenital CMV infection following
ﬁrst trimester maternal infection are more likely to have CNS
sequelae, especially hearing loss, than those whose mothers
were infected later in pregnancy. Mothers known to have been
infected with CMV months to years before conception have a
1/100 to 1/300 risk of having a congenitally infected infant. It
appears that maternal reinfection with different strains and
short duration of preconceptional immunity inﬂuence outcome.
Preconceptional maternal immunity is less than perfect in
preventing foetal infection and foetal damage. This issue raises
concerns about the future development of a vaccine. However,
there is provocative new data from non-randomized studies
suggesting that treatment with CMV-speciﬁc hyperimmune
globulin and ganciclovir for primary CMV infection during




Molecular methods in the diagnosis of human
brucellosis
J. Solera, M.J. Castan˜o, E. Navarro (Albacete, ES)
Brucella spp. is endemic worldwide, and infection causes
signiﬁcant morbidity in developing countries. Due to the
heterogeneous and non-speciﬁc clinical symptoms of brucello-
sis, diagnosis always requires laboratory conﬁrmation. The
diagnosis of brucellosis is currently based on isolation of Brucella
or detection of an immune response by classical serological
methods and the presence of characteristic clinical ﬁndings.
However, in situations in which these criteria are unsatisfactory,
new and improved diagnostic methods are needed. Real-time
PCR has revolutionized the way clinical microbiology laborat-
ories diagnose many human microbial infections. In the last
year, three real-time PCR assays for detection and quantiﬁcation
of Brucella spp. and B. melitensis have been developed using the
LightCycler  (Roche). Overall, use of real-time PCR for Brucella
suffers from a lack of sensitivity, a lack of standardization, and
variable results depending on the laboratory in which it is
performed. The use of real-time PCR for detection and quan-
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tiﬁcation of Brucella DNA, and its utility in the diagnosis and
follow-up of patients with brucellosis will be reviewed.
Recently, a quantitative real-time PCR (Q-PCR) technique has
been developed in our laboratory to monitor evolution of
B. melitensis DNA load from initial diagnosis through to post-
therapy follow-up in brucellosis patients. We collected 180
peripheral-blood samples from 18 brucellosis patients. Sensitiv-
ity of Q-PCR for both initial infections and relapses was 100%,
similar to the results obtained by Queipo-Ortun˜o et al. Despite
positive response to treatment and sharp decline in bacteria load
after initiating therapy, 50% of patients (7 relapse and 2 non-
relapse subjects) were low level-positive Q-PCR upon ﬁnalizing
treatment. At conclusion of follow-up, almost 40% of patients (4
relapse and 3 non-relapse cases), most of them asymptomatic,
continued with low bacteria DNA loads. In conclusion, our data
suggest that brucellosis may be a chronic, relapsing disease
comparable with those caused by intracellular pathogens such
as Mycobacterium tuberculosis, where the bacteria persist during
and after therapy, despite appropriate antibiotic treatment and
good host response. In order to better understand the course of
brucellosis, the signiﬁcance of the persistence of B. melitensis
DNA in brucellosis patients and the nature of relapse, pros-
pective studies including larger, more homogeneously treated
samples should focus on monitoring the long-term post-therapy
course of the disease.
S114
What’s new in the treatment of human brucellosis
G. Pappas (Ioannina, GR)
Brucellosis is the most common zoonotic disease worldwide,
recently re-emerging in new foci of the developing world, and
entering the developed world through the evolution of interna-
tional travel and food trafﬁcking. Its treatment principles have
remained unchanged since the last issue of the World Health
Organization recommendations, although various clinical and in
vitro trials have attempted to improve the overall outcome,
which is currently marred by relapse rates at about 10% overall,
and difﬁculties in treating serious disease complications. The
advances in treating brucellosis can be categorized as follows: (i)
use of alternative regimens incorporating other aminoglyco-
sides; (ii) use of alternative regimens incorporating classic and
newer quinolones; (iii) modiﬁcation of the duration of treatment;
(iv) re-appraisal of traditional alternative agents as co-trimoxaz-
ole; (v) attempts at monotherapy; (vi) evaluation of newer agents
as tigecycline and (vii) Modiﬁcation of major pathogenetic
events of the disease. Although these aspects have been the
subjects of debate for the past decade, deﬁnite conclusions
cannot be drawn since the applicability of laboratory studies to
clinical practice is limited in brucellosis, and the existing clinical
trials are often illdesigned and conﬂicting in their results.
Dissemination of molecular resistance traits
O115
Comparative genomic analysis of community-
acquired ST80-SCCmec IV Staphylococcus aureus
isolates by high-density microarray
R.V. Goering, A.R. Larsen, R. Skov, F.C. Tenover, K. Anderson,
P.M. Dunman (Omaha, US; Copenhagen, DK; Atlanta, US)
Objectives: Community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA) isolates producing Panton-
Valentine leucocidin (PVL) are now a worldwide concern. In
Europe, ST80-SCCmec IV (ST80-IV) isolates are the predominant
concern while, in the United States, these strains have appeared
as pulsed-ﬁeld types USA400 (ST1-SCCmec IV) and more
recently described USA300 (ST8-SCCmec IV). To better
understand the European situation, we compared the genomic
content of ST80-IV isolates with other MRSA strains by high-
density microarray analysis.
Methods: The genomic composition of two ST80-IV isolates was
assessed using Affymetrix S. aureus GeneChips (Affymetrix,
Santa Clara, CA). Puriﬁed chromosomal DNA from each isolate
was queried by hybridization for the presence or absence of the
7775 loci represented on the chip. These included resistance
determinants, exoenzymes, exo- or enterotoxins, and a variety of
virulence regulators and cell surface factors. The results were
compared to microarray data recently obtained for S. aureus
USA100, 300, 400 and 500 isolates (Tenover, et al., J. Clin.
Microbiol., in press, 2005).
Results: Overall, the ST80-IV isolates were 97% related, differing
primarily in conserved hypothetical open reading frames and
intergenic sequences. In general, ST80-IV isolates were more
similar to USA400 than to USA300 isolates. For example, both
ST80-IV and USA400 isolates appear to share the same capsular
polysaccharide synthesis type and agr type. However, important
differences between these two strains were observed as in the
case of ﬁbronectin-binding proteins A and B (fnbA and fnbB),
which were absent from USA400 but present in ST80-IV isolates.
Analysis of all loci suggested the presence of gene combinations
potentially important in facilitating the persistence and spread of
these strains in a community environment.
Conclusion: High-density microarray analysis related ST80-IV
isolates more closely to other community-acquired, rather than
hospital-acquired, MRSA–consistent with clinical experience.
The similarities and differences noted between these and other
epidemic MRSA strains represent an important resource for
identifying gene combinations speciﬁc to ST80-IV isolates. These
data should help in strain identiﬁcation, epidemiological
analysis, and in providing a greater understanding of the
mechanisms by which clonal lineages such as ST80-IV persist
and spread in the community setting.
O116
Presence of PVL among erythromycin- and
methicillin-resistant community-acquired
Staphylococcus aureus isolated from children in
Texas from 1999 to 2002
N. Aydin, T. Bogdanovich, S. Chavez-Bueno, G. McCracken,
B. Bozdogan, P.C. Appelbaum (Aydin, TR; Hershey, Dallas, US)
Objectives: Panton-Valentin leucocidin (PVL) is a toxin found
in Staphylococcus aureus isolates associated with serious invasive
infections. The aim of this study was to determine the
prevalence of PVL among erythromycin-and methicillin-
resistant and clindamycin-susceptible community-acquired S.
aureus isolated from children in Texas during 1999–2002.
Methods: Erythromycin and methicillin resistant but
clindamycin susceptible strains (a total of 197) were tested.
Presence of PVL and the SCC type of strains were studied.
Relation between presence of PVL and macrolide resistance
mechanism was also studied.
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Results: Of 197 MRSA 11 (5.5%) were SCC II, and 185 (94%)
were SCC IV. The SCC type of one strain could not be
determined with the method used. The 11 SCC II strains were
all PVL (-) and carried erm(A) gene alone (9 strains) or with
msr(A) (2 strains). Among SCC IV strains, 173 were PVL (+) and
12 were PVL (-). Of 12 PVL (-) strains 2 carried erm genes: 1 erm
(C) alone and 1 erm (C) with msr (A) gene. Four strains carried
msr (A) alone. Of 173 PVL (+) strains, 128 had msr (A) alone, and
2 had erm (C); 20 strains had erm (C) and 1 strain was erm (A)-
positive. The prevalence of PVL in community-acquired strains
has been increasing progressively over 3 years: from 66.6% in
2000 to 90.3% in 2001 and 98.7% in 2002.
Conclusion: PVL is commonly present between macrolide-
resistant and clindamycin-susceptible SCC IV MRSA but
absent among SCC II strains with erm (A), isolated from
children in Texas.
O117
Identity of macrolide-resistant clones of
Streptococcus pyogenes in Portugal supports
Europe-wide dissemination of a few lineages
C. Silva-Costa, M. Ramirez, J. Melo-Cristino (Lisbon, PT)
Objectives: Although overall macrolide resistance has
remained stable in Portugal (27%), a rapid inversion of the
dominant phenotypes was noted with a sharp decrease in the
MLSB phenotype paralleled by an increase in the M phenotype.
To gain further insights into these changes we characterized 325
macrolide resistant isolates, previously characterized by T and
emm typing.
Methods: A combination pulsed-ﬁeld gel electrophoresis
(PFGE) and multi-locus sequence typing (MLST) was used.
The use of Cfr9I, an isoschizomer of SmaI to digest strains of the
M phenotype refractory to SmaI digestion allowed the direct
comparison of both MLSB and M isolates. The Bionumerics
software was used to create UPGMA dendrograms of SmaI/
Cfr9I fragment patterns. The Dice similarity coefﬁcient was used
with optimization and position tolerance settings of 1.0 and 1.5
respectively. PFGE clusters included isolates with ‡ 80%
relatedness on the dendrograms. MLST analysis was
performed on representatives of each major lineage. Bacitracin
susceptibility was determined for all the isolates by disk
diffusion.
Results: All the 325 isolates included in this study were
typeable by PFGE. PFGE and MLST were highly concordant
and identiﬁed eight major clones accounting for 92% of the
isolates, each exclusively associated with a single macrolide
resistance phenotype. Two major clones were found among
MLSB isolates characterized by sequence types (ST) 46 (T12/
emm22) and 52 (T28/emm28) whereas among M isolates clones
ST39 (T4/emm4) and ST28 (T1/emm1) dominated. The clone
deﬁned by ST52 corresponded to a bacitracin resistant clone
circulating in Europe and a novel variant expressing other
surface antigens (T12/emm22) was detected.
Conclusion: Although there was a large diversity among
macrolide resistance genotypes, notably among isolates
presenting the M phenotype, 8 clones accounted for the
majority of the isolates and the 4 most frequent lineages
represented 76% of the isolates analysed in the study period.
The presence of the four major clones in other European
countries was reported previously suggesting a Europe-wide
dissemination of a few macrolide resistance lineages.
O118
Rapid dissemination of MDR CTX-M-15-
producing K. pneumoniae epidemic clone in
Hungary
I. Damjanova, A´. To´th, Z. Ozsva´r, E. Bauer, J. Pa´szti,
M. Fu¨zi (Budapest, Sze´kesfehe´rva´r, HU)
Objectives: Multi-centre spread of MDR CTX-M-15-producing
K. pneumoniae epidemic clone was detected in Hungary in 2003.
Continuous screening for such isolates was performed from
January 2004 until October 2005 and results of this survey were
presented.
Methods: Three of 206 (2004) and 124 of 394 (2005) KP clinical
isolates submitted to the National ESBL Reference laboratory
from 23 Hungarian hospitals were selected according their high
resistance to cefotaxime, aminoglycosides, tetracycline and
ciproﬂoxacine. Susceptibility to antimicrobials by disc-
diffusion method and ESBL expression were detected
according to NCCLS criteria. Molecular typing was performed
by TEM-, SHV-, CTX-M, and ISEcp1 PCRs, sequence analysis of
PCR amplicons and XbaI-PFGE. Resistance to cefotaxime was
transferred by conjugation to rifampin-R E. coli J53. Plasmid
extraction was performed by alkaline lysis.
Results: A total of 127 ESBL-KP isolates were collected from
various hospital infection samples from 23 Hungarian hospitals.
Of these 42 isolates were collected from parallel nosocomial
outbreaks reported from ICUs of two different hospitals in 2005.
In the ﬁrst outbreak (Feje´r county) 29 isolates were recovered
from 25 inpatients (44% mortality; median age 64 years, range
43–81; median length of stay was 30 days, range 6–72) from
surgical wounds (8), lower respiratory tract (8), urine (6), blood
(4), conjunctiva (1), bile (1) and sputum (1). In the second
outbreak (Budapest) 13 isolates were recovered from 13
inpatients (median age 64.2 years, range 44–74; mean length of
stay was 27.3 days, range 11–87) from blood (8), urine (2),
trachea (1), sputum (1), vaginal secretion (1). Environmental
samples have not discerned any apparent source for these
outbreaks. PFGE analysis revealed strong clonal link between
the 127 isolates and those of previously described epidemic
clone. blaCTX-M-15 was detected on similar large plasmids in all
selected isolates and their transconjugants. ISEcp1 was not
found.
Conclusions: Till the end of 2004 the SHV was the most
common b-lactamase detected in KP nosocomial isolates in
Hungary. Since the beginning of 2005 the ESBL-KP clinical
isolates were predominantly CTX-M-15 producers. There was
evidence that the background of this ESBL change is the
countrywide spread of an MDR CTX-M-15-producing KP
epidemic clone. Their eruptive dissemination in 23
geographically distinct hospitals emphasizes the necessity of
immediate intervention and epidemiological monitoring.
O119
Evidence for low rates of ciproﬂoxacin and
rifampicin resistance in persistent Helicobacter
pylori infection
S.A. Chisholm, R.J. Owen (London, UK)
Objective: This study aimed to determine the rates of
ciproﬂoxacin (CIP) and rifampicin (RIF) resistance in English
dyspeptic patients with refractive H. pylori infection. These
agents are proposed components of ‘‘rescue’’ therapies in
instances when recommended ﬁrst-line, and possibly second-
line, therapies fail. However, few studies have monitored levels
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of resistance to these, particularly in patients that have failed
eradication therapy.
Methods: Primary antibiotic resistance was determined for all
isolates/specimens referred to our specialist unit from 2002–
2004. Isolates that were dually resistant to metronidazole (MTZ)
and clarithromycin (CLA) and recovered from patients that had
failed at least one eradication attempt (n = 25) were examined
by E-test for susceptibility to CIP and RIF. Additionally, CIP and
RIF susceptibilities were determined for eight-fullysensitive
isolates (n = 8), recovered pre-treatment.
Results: Of 138 isolates referred from 2002–2004, 64% (n = 89)
and 49% (n = 67) were MTZ and CLA resistant, respectively,
and 41% (n = 57) were dually resistant. The incidence of dual
resistance was higher (76%) in the 54 patients for whom
previous treatment failure was documented. In the treatment-
failure group, CIP MICs ranged from 0.016–0.125 mg/l for the
23 isolates that were CIP sensitive (< 1.0 mg/l). The two
remaining isolates were CIP resistant, with MICs of 2.0 mg/l
and > 32 mg/l. All eight of the pre-treatment isolates were CIP
sensitive. RIF MICs ranged from < 0.016–2.0 mg/l but all were
lower than the proposed resistance breakpoint (> 4 mg/l).
Raised MICs to RIF (> 1.0 mg/l) were observed in both the
treatment failure (n = 5) and the pre-treatment groups (n = 2).
Interestingly, the isolate that displayed high-level CIP resistance
(> 32 mg/l) and a RIF MIC of 1.0 mg/l showed reduced
susceptibility to tetracycline (MIC = 3.0 mg/l) in addition to
MTZ and CLA resistance.
Conclusions: Resistance to CIP and RIF was rare in dyspeptic
patients from the UK, even in patients infected with dually
resistant strains of H. pylori that had already failed at least one
eradication therapy. The identiﬁcation of multi-resistant strains
demonstrates the importance of testing susceptibilities of
refractive H. pylori to a wider range of therapeutic agents.
Diabetes and infection
O120
Stress hyperglycaemia as a prognostic factor in
patients with severe sepsis
L. Leonidou, M. Michalaki, A. Leonardou, E. Polyzogopoulou,
K. Fouka, M. Gerolimos, P. Leonardos, E. Giannoulaki,
V. Kyriazopoulou, C.A. Gogos (Patras, GR)
Objectives: Stress hyperglycaemia is a condition related to
transient elevation of the blood glucose levels due to various
kinds of stress, while severe sepsis, as a result of infection may
sometimes lead to organ dysfunction and death. The aim of the
present study was to investigate the impact of stress
hyperglycaemia on the survival of non-diabetic patients with
severe sepsis.
Patients and methods: The study included 242 non diabetic
patients (124 women and 118 men) with severe sepsis
hospitalized in three peripheral Hospitals in South-Western
Greece during an one-year period. The patients were divided
into two groups according to their glycaemic proﬁle at
admission: patients with baseline hyperglycaemia (group H)
and patients with normal glucose level (group N).
Hyperglycaemia was deﬁned as an admission or in-hospital
fasting glucose level of 126 mg/dl or more or a random blood
glucose level of 200 mg/dl or more, on 2 or more
determinations. Immunosuppressed patients were excluded.
The severity of sepsis was classiﬁed by the sepsis-related organ
failure assessment score (SOFA).
Results: Forty nine out of 242 patients (20.2%) had stress
hyperglycaemia. Patients in, group H were older than group N
(73.4 ± 13.8 years vs. 65.7 ± 21.4 years). The mean glucose
plasma level at admission in, group H was 198 ± 75.3 mg/dl.
There was no signiﬁcant difference in sex, BMI, CRP, blood
cultures, Hba1c and hospitalization days between the two
groups. Interestingly, 6.1 % of the hyperglycaemic patients
had a ﬁrst degree relative with diabetes, while the percentage in
normoglycaemics was 11.1%. Group H had a signiﬁcantly
higher SOFA score than group N (mean 4.9 ± 3.2 vs. 2.9 ± 2.5,
p < 0.05). The source of infection in all patients was the
following: respiratory tract 41.7%, urinary tract 34.5%, intra-
abdominal 14.9%, central nevrous system 3.4%, soft tissue 2.6%,
endocarditis 1.3%. The causes of infection were similar in both
groups. A signiﬁcantly higher percentage of septic patients with
stress hyperglycaemia died compared to patients with normal
baseline glucose level (43.8% vs. 13.0%, p < 0.001).
Conclusion: Stress hyperglycaemia is a common ﬁnding in
non-diabetic patients with severe sepsis and is not related to a
genetic predisposition to diabetes mellitus. It may be related to
cytokine related insulin resistance and seems to be a signiﬁcant
predictor of outcome in non-diabetic septic patients.
O121
Diabetes mellitus and 30-day and 90-day
mortality after hospitalization with pneumonia: a
population-based follow-up study of 41 793 adult
patients
R.W. Thomsen, J. Brommann, A. Riis, H.-H. Lervang,
H.C. Schønheyder, H.T. Sørensen (Aalborg, Aarhus, DK)
Objectives: Diabetes may be associated with increased
mortality after pneumonia due to decreased immunity,
impaired lung function, and hyperglycaemic derangement.
We examined diabetes as a predictor of 30-day and 90-day
mortality in a large cohort of adult patients hospitalized with
pneumonia.
Methods: Population-based cohort study in the three Danish
counties of North Jutland, Viborg and Aarhus between 1994 and
2003. Patients with a ﬁrst-time hospital discharge diagnosis of
pneumonia were identiﬁed in hospital discharge registries.
Information on diabetes and comorbidities was obtained from
discharge registries and prescription databases. All patients
were followed for 90 days after hospitalization through the
Danish Civil Registration System. We compared mortality rates
in patients with and without diabetes, adjusted for gender, age,
and comorbidity.
Results: A total of 41 793 adult patients were hospitalized with
pneumonia (median age 74 years); of these, 3928 patients (9.6%)
had diabetes. Overall mortality in diabetic patients compared
with other patients with pneumonia was 18.7% vs. 14.8% after
30 days, and 26.5% vs. 21.4% after 90 days. After adjustment,
mortality rates in patients with diabetes were only marginally
increased (mortality rate ratio = 1.12 (95%CI: 1.04–1.21) after
30 days, and 1.09 (95% CI: 1.02–1.16) after 90 days) compared
with non-diabetic pneumonia patients.
Conclusion: Our results corroborate previous reports
suggesting that diabetes has only a very limited inﬂuence on
outcome in patients hospitalized with pneumonia.
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O122
A clinical prediction rule for a complicated course
of urinary tract infections in patients with type 2
diabetes in primary care
L.M.A.J. Muller, K.J. Gorter, G.E.H.M. Rutten,
A.I.M. Hoepelman, E. Hak (Utrecht, NL)
Objective: Although it has been demonstrated that type 2
diabetes patients (DM2) have an increased risk of urinary tract
infections (UTIs), not much is known about predictors of a
complicated course. A safe and feasible management strategy
for patients at high or low risk of UTIs could improve efﬁcient
antimicrobial use and may direct preventive measures at those
who need it most. We developed a prediction rule for
complicated UTIs in DM2 patients in primary care.
Methods: We conducted a 12-month prospective cohort study,
including DM2 patients aged 45 years or older from the Second
Dutch National Survey of General Practice carried out in the
period 2000–2001. The primary outcome measure was a
complicated course, which was a composite of recurrent
cystitis, acute pyelonephritis and prostatitis. Multivariate
logistic regression analysis was performed to produce a
clinical prediction rule and area under the receiver-operating
curve (AUC) characteristics was calculated as a measure of
discriminative capacity. For score cut-off points, the following
test-characteristics were calculated: positive and negative
predictive value, sensitivity, speciﬁcity and proportion of
subjects selected.
Results: Mean age of the 6343 DM2 patients was 67 years (SD
11) and 46% was male. Overall, the incidence rate of the
outcome was 3 per 100 patient years (n = 179), 1 per 100 in
females and 2 per 100 in males. Independent predictors were
increasing age (odds ratio [OR], 1.02; 95% conﬁdence interval
[95% CI], 1.00–1.03), male sex (1.72; 1.25–2.35), number of
physician contacts (1.06; 1.05–1.07 per class), incontinence of
urine (1.87; 1.03–3.38), cerebrovascular disease or dementia
(2.14; 1.29–3.56) and renal disease (5.62; 2.11–14.95). The AUC
was 0.77 (95%CI 0.73–0.80). Subgroup analyses for gender
showed no differences in discriminative ability. Using a cut-off
score of 4 or more points (range 0–12) 60% of the DM2 patients
would be selected for tailored care whereas only 8% of the
patients with a complicated course of UTI would be missed.
Conclusion: We were able to derive an accurate model to
predict complicated UTIs in male and female DM2 patients in
primary care. If conﬁrmed in external populations, the model
may be used to improve management of UTIs in DM2 patients.
O123
Applicability of a clinical prediction rule for
lower respiratory tract infections in elderly
patients with diabetes mellitus: a subgroup
analysis
L.M.A.J. Muller, J. Bont, K.J. Gorter, G.E.H.M. Rutten,
T.J.M. Verheij, E. Hak (Utrecht, NL)
Objective: Among elderly persons, those with diabetes (DM)
have an elevated risk of complications from lower respiratory
tract infections (LRTI). Careful risk assessment using an accurate
and objective prediction rule could help general practitioners to
target management of these infections more efﬁciently. However
such a rule for an unselected population might be inaccurate for
this high-risk group. As part of a large retrospective cohort
study among elderly persons aged over 65 years, we conducted
a subgroup analysis to determine the applicability of a
developed prediction rule for the probability of a complicated
course of LRTI in those with diabetes.
Methods: In the original cohort study using the computerized
database of the University Medical Center Utrecht general
practitioners research network, 3166 general practitioner
attended episodes of acute bronchitis, exacerbation of COPD
or asthma or pneumonia were included. The outcome was a
composite of 30-day hospitalization or death following an
episode of LRTI. Potential predictors according to the
prediction rule in the unselected population were type of LRTI
diagnosis, age, presence of heart failure, predisone use,
hospitalization in preceding year and antibiotics in previous
month. For the high-risk group we were speciﬁcally interested
in the added value of diabetes speciﬁc variables as the presence
of cardiovascular co-morbidity and the use of insulin or oral
diabetes medications. Calibration was tested with the Hosmer-
Lemeshow goodness of ﬁt test and discriminative capacity was
estimated with the area under the receiver operating curve
(AUC).
Results: Among 445 episodes of LRTI among elderly patients
with DM, 68 endpoints occurred (attack rate 15%). Reliability of
the model was good (goodness-of-ﬁt test p = 0.54). The
discriminative properties of the original rule was acceptable
(AUC: 0.79, 95% conﬁdence interval: 0.72–0.86). In the low risk
group (£ 2 points), 6% of all patients ended with hospitalization
or death and 40% in the high risk group (‡ 6 points).
Conclusion: The prediction rule for the probability of
hospitalization or death derived from an unselected elderly
population with LRTI appeared to have acceptable
discriminative properties in diabetes patients also and may be
used to target management of these common diseases. Applying
this rule may safely restrict the need for treatment and help GPs
to target additional efforts to those patients who need it most.
O124
Diabetic foot infections: the evolving
characteristics, microbiology and determinants of
mortality
S. Gu¨ndes, Z. Yulugkural, M. Biyikli, B. Buyukarslan (Kocaeli,
TR)
Objectives: Foot infections in patients with diabetes mellitus
are among the most common bacterial infections encountered in
our clinical practice. The aim of the present study was to
evaluate aetiology, medical outcomes, including risks for
complications and mortality, in 68 adult patients hospitalized
for severe DFI.
Methods: This report describes a retrospective analysis of
medical records of 68 hospitalized patients who had been
admitted or consultated to Infectious Diseases Department for
severe DFI from January 2004 to November 2005 in a University
hospital.
Results: There were 40 males and 28 females. Average patient
age was 51.8 years. Most of the patients were in level 1, 2, or 3 on
Wagner Scale, only 23 (33.8%) of patients had combined
osteomyelitis and deep soft tissue infection. Forty-seven
bacteria were documented microbiologically in 39 cases
(57.3%). Staphylococcus aureus and Enterobacteriaceae being the
most common isolates. Overall, 25 patients (36.7%) were
discharged early (< 14 days) and 43 patients (63.2%) were
hospitalized for more than 14 days. Of these, 51 required early
surgical debridement (75%), 23 (33.8%) underwent at least one
digit amputation. Amputation was more common with level 4
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patients (62%) compared with those who had SSTI (30%) only.
Overall mortality was 14% factors associated with death were
male sex, presence of multiple comorbid conditions, congestive
hearth failure, morbid obesity, hypoalbuminaemia, renal
insufﬁciency, and shock.
Conclusion: DFIs are serious bacterial diseases that are often
underestimated and poorly recognised. Our ﬁndings indicate
that deep foot infections in patients with diabetes was a
heterogeneous entity, in which type and severity is related to
choice of treatment strategy and to outcome.
Pump it out and resist
O125
Which Mex efﬂux pumps are overexpressed in
multidrug-resistant Pseudomonas aeruginosa?
D. Hocquet, R. Fabre, M. Roussel-Delvallez, J.D. Cavallo,
B. Dehecq, P. Ple´siat (Besancon, Be´gin Saint-Mande´, Lille, FR)
Objectives: b-lactams (bLs), aminoglycosides (AGs) and
ﬂuoroquinolones (FQs) are substrates for one or several RND
efﬂux pumps (MexAB-OprM, MexCD-OprJ, MexEF-OprN and
MexXY/OprM) in Pseudomonas aeruginosa. The aim of this study
was to determine the prevalence of these efﬂux mechanisms in
resistant clinical strains of P. aeruginosa.
Methods: A hundred and seventy strains of P. aeruginosa with
reduced susceptibility to ticarcillin (MIC > or = 32 mg/l)
collected in 15 French hospitals in 2004 were analysed for the
overexpression of efﬂux genes mexB, mexC, mexE and mexY, by
real-time RT-PCR. MICs of antibiotics were determined by using
the conventional agar dilution method.
Results: 59% (n = 100), 65% (n = 110), 0.5% (n = 1) and 0.5%
(n = 1) of the selected isolates were found to overproduce
MexAB-OprM, MexXY, MexCD-OprJ, or/and MexEF-OprN,
respectively. 59% (61/103) of the strains resistant to both
ticarcillin and ciproﬂoxacin (MIC ‡ 2 mg/l overexpressed
MexAB-OprM. 78% (69/88) and 83% (86/103) of the bacteria
resistant to amikacin (MIC ‡ 8 mg/l) or ciproﬂoxacin exhibited
up-regulation of MexXY, respectively. Interestingly, 48% (49/
103) of the strains that were non susceptible to ciproﬂoxacin
overproduced both MexAB-OprM and MexXY. The prevalence
of the MexXY mechanism was correlated with the levels of
resistance to ciproﬂoxacin (39, 50, 64, 89, 93 and 100% of the
strains with MIC of ciproﬂoxacin of 2, 4, 8, 16, 32 and ‡ 64 mg/l
were MexXY-overproducers, respectively) and to amikacin (17,
37, 58, 68, 76, 100, 80 and 93 % of the strains with MIC of
amikacin of 1, 2, 4, 8, 16 and ‡ 32 mg/l).
Conclusion: These results show that in contrast to MexCD-OprJ
and MexEF-OprN, the systems MexAB-OprM and MexXY/
OprM are frequently up-regulated among clinical P. aeruginosa
isolates showing decreased susceptibilities to bLs, AGs and/or
FQs. Furthermore, drug efﬂux mediated by MexXY/OprM is
highly prevalent in isolates with strong levels of resistance to
AGs or FQs.
O126
Expression of mexY and gene PA5471 in drug-
induced amikacin resistant small colony variants
of P. aeruginosa
S. Islam, A. Vang, B. Wretlind (Stockholm, SE)
Objective: In P. aeruginosa the MexXY multidrug efﬂux system
contributes to the intrinsic and inducible resistance to a long
array of antibiotics including aminoglycosides and
ﬂuoroquinolones. P. aeruginosa has the ability to change
phenotype under special circumstances, such as growth in the
lungs of cystic ﬁbrosis patients. One such phenotype is small-
colony variants (SCV). This trend of changing to SCV goes
towards increased MIC values against antipseudomonal agents,
especially aminoglycosides. The inducibility of MexXY is
dependent on the drug ribosome interactions which results in
higher signal/s levels that upregulate this operon. It has been
reported that the operon PA5470–5471 has some role in drug
inducible overexpression of MexXY operon. In this study we
tried to explain the relationship between expression of PA5471
and aminoglycoside resistance in SCV mutants of P.aeruginosa.
Methods: Ten aminoglycoside induced SCV (MIC 48–
> 256 mg/l, wild type 2 mg/l) mutants have been isolated
and characterized from wild type strain PAO503. The
expression of mRNA for MexY pump protein and PA5471 was
determined by realtime PCR.
Results: The MexY mRNA is overexpressed in all of the strains
tested, ranging from 10 to 100 folds. Two out of 10 strains (MIC
amikacin 128 and > 256 mg/l), which overproduced PA5471
mRNA 41 · PAO503 and 83 · PAO503 respectively, have also
expressed ‡ 200 · PAO503 MexY mRNA. One strain (MIC
48 mg/l) with 0.4 fold down regulation of PA5471 produced
10 · PAO503 MexY mRNA. The rest of the strains produced
PA5471 mRNA similar to the wild type strain.
Conclusion: Elevated expression (> 40 · PAO503) of PA5471
mRNA suggests a role in upregulation of MexXY operon
(‡ 200 · PAO503), which is followed by higher MIC value for
aminoglycosides. These overall data suggest that PA5471 can
play an important role in highly elevated expression of MexY
and thereby might be necessary for the drug induced
aminoglycoside resistance in P. aeruginosa SCV. Similar
mechanisms are probably also relevant for P. aeruginosa strains
from CF patients.
O127
Contribution of efﬂux pumps overexpression to
carbapenem heteroresistance in Pseudomonas
aeruginosa
A. Ikonomidis, S. Pournaras, N. Spanakis, A. Tsakris,
N.J. Legakis, A.N. Maniatis (Larissa, Athens, GR)
Objective: To investigate the carbapenem heteroresistance
phenotype of Pseudomonas aeruginosa and examine its
molecular basis.
Materials and methods: Twenty consecutive clinical isolates of
P. aeruginosa that exhibited colonies grown within the apparent
zone of inhibition in disk diffusion were included in the study.
The isolates were screened by E-test to determine imipenem and
meropenem MICs and genotyped by pulsed-ﬁeld gel
electrophoresis (PFGE). The heteroresistant subpopulations
were substantiated by population analysis of each clone. RT-
PCR and exponential range analysis were performed to examine
the level of transcription of genes coding for efﬂux pumps,
particularly mexY and mexB. The contribution of the bacterium
cell wall to the heteroresistance was examined by RT-PCR of
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lpxC gene. The multicopy gene coding for 16S rRNA and the
single copy gene rpsL were used as internal control.
Results: Macrorestriction analysis of the isolates showed at
least nine unrelated genotypes. The MICs of the isolates for both
imipenem and meropenem ranged from 0.5 to 1 mg/l but all
isolates exhibited colonies grown also within the apparent inner
zone of inhibition of both imipenem and meropenem E-test
strips. Population analysis revealed subpopulations grown in
concentrations of 8 mg/l and 16 mg/l of meropenem and
imipenem, respectively. RT-PCR and exponential range
analysis of one isolate of each clone showed a substantial
increase in transcription levels of both mexY and mexB in
carbapenem subpopulations. No transcription variation of lpxC
was detected.
Conclusions: Efﬂux pumps seem to contribute to
heteroresistance of these isolates to carbapenems. This
phenotype is more readily observed in isolates with lower
levels of resistance. It is not yet known whether the use of
carbapenems would lead to selection of resistant subpopulations
that subsequently cause infections by resistant isolates or to
treatment failure.
O128
Identiﬁcation of novel mutations in MTR locus of
clinical isolates of Neisseria gonorrhoeae
M. Ali, V. Kumar, P. Sachdeva, U. Chaudhry, D. Saluja (Delhi,
IN)
Objectives: Active efﬂux of antimicrobial hydrophobic agents
is one of the most important bacterial defence systems against
inhibitory host factors. Two well-characterized MDR efﬂux
pumps mtrCDE and FarAB-mtrE exist in Neisseria gonorrhoeae.
The mtrCDE encoded efﬂux pump of Neisseria gonorrhoeae
mediates an energy dependent efﬂux process of structurally
diverse hydrophobic agents in gonococci. Strains of Neisseria
gonorrhoeae that show resistance to hydrophobic agents often
contain mutations in the coding region or promoter region of the
operon. The product of adjacent mtrR gene negatively regulates
the expression of mtrCDE operon. mtrE encodes a putative
lipoprotein of 48.5 kda, which is associated with the mtr
phenotype.
Methods: In an earlier study, we have reported mutations in the
QRDR region of gyrA and ParC gene in clinical isolates of
Neisseria gonorrhoeae showing high resistance to ciproﬂoxacin
(MIC ranging from 4 to 32 lg/ml) (1). To account for the
variation in MIC values of the samples showing similar
mutations in gyrA and parC gene, we checked for mutations in
mtrR and mtrE genes. The nucleotide sequence of PCR ampliﬁed
mtrR gene was analysed and compared with the nucleotide
sequence of wild types Neisseria gonorrhoeae.
Results: These isolates show a missense mutation Tyr105-His
located downstream of Helix- Turn- Helix motif of mtrR and a
base pair addition mutation in the promoter region of mtrR. The
nucleotide sequence of mtrE showed distinct mutations in
different clinical isolates invariably at the same positions viz.
Val204-Glu, Ala303-Gly, Leu455-Pro and Ser429-Ile.
Conclusion: We envisage that the altered DNA-mtrR protein
interaction, resulting in increased expression of proteins
involved in efﬂux of hydrophobic antibiotics, may be one of
the important mechanism by which pathogen becomes resistant
to ciproﬂoxacin.(1). Chaudhry U, Ray K, Bala M, Saluja D.
Mutation patterns in gyrA and parC genes of ciproﬂoxacin
resistant isolates of Neisseria gonorrhoeae from India. Sex Transm
Infect. 2002; 78:440–4.
O129
Acquired b-lactam resistance in three Escherichia
coli strains due to overexpression of AcrAB, TolC
and PBP3
M.M. Tavı´o, V. Aquili, N.T. Antunes, J. Sa´nchez-Cespedes,
Z. Gonza´lez-Lama, J. Vila (Las Palmas de Gran Canaria, Barcelona,
ES)
Objectives: In a previous study, three multidrug resistant
Escherichia coli mutants were selected in vitro (CazE7, CazE11
with ceftazidime and LmfE7 with lomeﬂoxacin) from two E. coli
susceptible clinical isolates. Mutants increased cyclohexane
tolerance and 2–256 fold-b-lactam MICs without increased
b-lactamase activity or decreased permeability. b-lactam
resistance has been described as the interplay between AcrAB
system and b-lactamases. The aim of this work was the study of
potential interplay between AcrAB-TolC overexpression and
penicillin binding protein (PBP) changes as mechanisms to
explain b-lactam resistance in the three mutants.
Methods: Inner and outer membrane proteins (IMP and OMP)
were analysed by SDS-PAGE. PBPs were detected with Bocillin
FL and Imperial Protein Stain (a formulation of coomassie R-
250). Expression of the acrA, acrB, marA and soxS genes was
studied by reverse transcription of total RNA and PCR of cDNA
(RT-PCR), using gapA gene as internal control of expression.
PCR products were separated in SDS-PAGE and silver stained.
Ag100 strain (induced or non-induced with 5 mM salicylate)
was the control strain.
Results: The level of expression of acrA and acrB genes was the
same in mutants and parent strains and higher than that found
in the non-induced Ag100 strain. The OMP TolC increased only
in the mutants, coinciding with their increased cyclohexane
tolerance. Neither parent strains nor any mutant showed marA
and soxS genes overexpression. NaCl at 1% induced OmpF
expression in CazE7, the single OmpF deﬁcient mutant. All
three mutants increased expression of PBP3. A 56-kDa IMP was
detected in CazE7.
Conclusion: (i) Increased expression of TolC and PBP3 in the
three mutants added to loss of OmpF in CazE7 explains 64–256-
fold increase in ceftazidime MICs and 4–8-fold increase in
aztreonam MICs in the mutants; (ii) Detection of a 56-kDa IMP
in CazE7 concurrent with loss of b-lactamase activity suggests
MppA over expression, a sensor protein of murein tripeptide
level and (iii) As osmoregulation of ompF gene expression was
intact in CazE7 strain and overexpression of marA and soxS
genes was not detected in the same strain, an increased
expression of rob gene might explain OmpF loss in CazE7.
Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006




Epidemiology and trend of leprosy disease in the
Iranian Qazvin province during 45 years (1958–
2003)
R. Qassemi Barqi (Qazvin, IR)
Introduction: Leprosy is a chronic infectious disease that has
been important along the history. Because of its ability to
establish disability, social excluding and stealth, leprosy exists in
110 country still, although there are most of leprosy cases in the
6 countries include: India, Brazil, Madagascar, Mozambique,
Nepal and Tanzania. Elimination of Leprosy is the goal of WHO.
Our country was arrived at the elimination of leprosy phase
from 1994.
Objective: The purpose of this study is to determine of Leprosy
trend during 45 years in the Qazvin province.
Materials &Methods: In this descriptive study all leprosy cases
that had been recorded during 45 years (1958–2003) in the
Qazvin province, were studied about age group, sex, clinical
symptoms, disability stage, incidence rate and typing based on
the documents of Leprosy surveillance system.
Results: During 45 years, 321 patients with leprosy had been
treated from them 177 (55%) cases were men and 144 (45%) cases
were women. Only 16 (5%) cases were in < 20 years old age
group. Most of patients (118 cases: 36.8%) had > 60 years old.
Multi Bacillary cases were 264 (82.2%) and Puci Bacillary cases
were 57 (17.8%). Lesion of macular and without sensation was
the most common sign. The most patients had been recorded
during 1971–1990. Leprosy disease has been at the elimination
phase (prevalence £ 1/10000 population) from 1995 in the
Qazvin province.
Discussion & Conclusion: Qazvin province is one of leprosy
endemic provinces that it has achieved to goal of the elimination
of Leprosy. Also less cases of Leprosy in < 20-year sold age
group indicates success of program for leprosy by using MDT in
the Qazvin province.
O131
Mycobacterium kansasii: results of a 10-year
study in Zaragoza, Spain
S. Terraza, J.A. Amiguet, P. Arazo, C. Ramos, A. Vitoria,
M.A. Lezcano, J. Cuesta (Zaragoza, ES)
Objectives: Clinical and epidemiological study of disease
caused by Mycobacterium kansasii in Zaragoza, Spain.
Methods: A retrospective study was carried out between
January 1990 and December 1999 in Miguel Servet Hospital,
Clı´nico Lozano Blesa Hospital, and Royo Villanova Hospital.
Diagnosis of the disease was performed according to American
Thoracic Society criteria.
Results: The patient charts of 94 patients in which an isolate of
M. kansasii had been recorded were reviewed. Sputum was by
far the most common source of isolates, accounting for 79.7%.
We considered 34 patients to be suffering from disease caused
by M. kansasii. The number increased for the second half of the
study period (13 vs. 21 cases). Pulmonary disease was the most
frequent clinical presentation (98.9%). Seventy nine percent of
all patients with disease were male. The mean age was
44 years. The most common risk factors associated with
disease due to M. kansasii were smoking (82.4%), infected
with the human immunodeﬁciency virus (HIV) (23.5%),
chronic obstructive pulmonary disease (17.6%), and
tuberculosis (17.6%). The mean CD4 cell count of the HIV-
infected patients at diagnosis was 45 · 106/l. The most
frequent clinical features were the respiratory symptoms
(85.3%), followed by fever (64.7%), and constitutional
symptoms (38.2%). Chest radiographs revealed cavitating
pulmonary disease in 82.3% of HIV-negative cases and in
12.5% of HIV-positive cases (p < 0.01). The incidence of
unilateral disease was 88.2% in HIV-negative patients and
25% in HIV-positive patients (p < 0.01). The most common
treatment regimen was rifampicin, isoniazid, and ethambutol
(85.3%), and the average duration was 13.3 months. Twenty-
one patients (70%) were initially treated for M. tuberculosis.
With treatment, all cases of non-HIV-associated disease had
favourable outcomes, but those of HIV-associated pulmonary
and disseminated disease were poor (37.5%).
Conclusion: The increasing incidence of disease causing
M. kansasii is surmised to be due to AIDS, and other factors
may be external factors causing either changes in the
distribution or virulence of mycobacteria in the environment.
Outcomes of therapy in HIV-negative patients were excellent,
but in HIV-positive patients were poor.
O132
Comparison of conventional antimicrobial
susceptibility and oligonucleotide chip system
for detection of drug resistance inMycobacterium
tuberculosis isolates
H. Park, E.J. Song, E.S. Song, E.Y. Lee, C.M. Kim, S.H. Jeong,
J.H. Shin, J. Jeong, S. Kim, Y.K. Park, G.-H. Bai, C.L. Chang
(Busan, Ulsan, Jinju, Seoul, KR)
Objectives: Rapid detection of drug resistance is critical to
manage tuberculosis patients. The clinical efﬁcacy of the
oligonucleotide chip technology for the detection of drug-
resistant tubercle bacilli was evaluated and compared with the
standard drug susceptibility testing.
Methods: Oligonucleotide chip detecting speciﬁc mutations in
the rpoB, and katG and inhA genes of M. tuberculosis was
designed. The probes detecting drug-resistance were as follows;
7 wild-type and 13 mutant-type probes for rifampin, and 2 wild-
type and 3 mutant-type probes for isoniazid. Target DNA of
M. tuberculosis was ampliﬁed by polymerase chain reaction,
followed by hybridization and scanning. Direct sequencing was
performed to verify the results of the oligonucleotide chip. The
results of mutations were compared with the results of
conventional antimycobacterial susceptibility test by using
Lowenstein-Jensen proportion method.
Results: Sixty-eight of seventy-six rifampin-resistant strains
(90%) had mutations in the rpoB gene. Forty-seven of eighty-
one isoniazid-resistant strains (58%) had mutations in the katG
gene or inhA gene. The mutations were easily detected by the
oligonucleotide chip system within a day.
Conclusion: The diagnostic oligonucleotide chip with
mutation-speciﬁc probes is a reliable and useful tool for the
rapid detection of drug-resistance against rifampin and
isoniazid in M. tuberculosis isolates.
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O133
Clinical and microbiological data of patients
infected with multidrug-resistant Mycobacterium
tuberculosis strains carrying gyrase mutations
N. Veziris, J. Robert, C. Truffot-Pernot, V. Jarlier, E. Cambau,
A. Aubry (Paris, Cre´teil, FR)
Objectives: In a previous study we demonstrated that
mutations in M. tuberculosis DNA gyrase are either associated
with ﬂuoroquinolone resistance (GyrA at position G81, A83 and
D87, GyrB at position N464), normal susceptibility (GyrA T73A)
or hypersusceptibility (GyrA T73A and A83G). As
ﬂuoroquinolone use is increasing in tuberculosis treatment, we
analysed the clinical characteristics and the M. tuberculosis (Mtb)
resistance pattern of the patients infected by a strain carrying
mutations in GyrA or GyrB subunits.
Methods: Retrospective review of characteristics of patients
infected with a multidrug resistant (MDR) strain of Mtb carrying
a mutation in gyrA and/or gyrB: (a) 18 patients with quinolone
resistant Mtb were included in the study, 16 with a strain
mutated in GyrA (A83V (n = 7); D87S (n = 1), A (n = 2), G
(n = 2) or N (n = 2); G81A (n = 2)) and 2 with a strain mutated
in GyrB (N464T or D) and (b) 5 patients infected with a strain
carrying a novel GyrA mutation leading to quinolone
hypersusceptibility in 4 cases (T73A + A83G), and in normal
susceptibility in 1 case (T73A).
Results: The 23 MDR patients were majority males (13 vs. 10),
had a mean age of 35 years were born outside Europe (n = 20).
A majority (n = 13) had been previously treated for tuberculosis,
5 were HIV positive, at least 19 had pulmonary tuberculosis and
14 were AFB positive. The mean number of resistance of the 23
Mtb strains was 9.2 resistances including isoniazid and
rifampin: 83% were resistant to pyrazinamide, 65% to
ethambutol, 65% to streptomycin, 61% to ethionamide, 48% to
cycloserine, 22% to kanamycin and 13% to para aminosalicylic
acid. Prior treatment history was available for 13 of the 18
patients infected with a ﬂuoroquinolone-resistant strain and all
of them received a ﬂuoroquinolone-containing regimen.
Conclusion: MDR-TB patients harbouring strains with gyrase
mutations had extreme drug resistant strains and were more
likely to be born outside Europe when compared to MDR-TB
patients previously reported in France between 1992 and 2002
(87% vs. 64%, p < 0.05).
O134
Implementation of automated mycobacterial
interspersed repetitive unit–variable number of
tandem repeat (MIRU-VNTR) typing in a routine
laboratory setting
C. Allix, P. Supply, M. Fauville-Dufaux (Brussels, BE; Lille, FR)
Objectives: Rapid detection, adequate therapy and contact
tracing to stop further transmission are key factors to control
tuberculosis (TB). The use of automated MIRU-VNTR typing
technique can greatly facilitate and accelerate the resolution of
problems typically encountered in clinical mycobacteriology
laboratories or in public health facilities.
Methods: Ampliﬁcation of 12 MIRU-VNTR genomic loci was
performed on heat-inactivated cultures using 4 different
multiplex PCR with ﬂuorescent primers. DNA fragments were
separated using the 3100-Avant ABI Genetic Analyser. Analysis
was performed with Genescan and Genotyper softwares
(Applied Biosystems).
Results:
Laboratory cross contamination: Suspicion of laboratory cross
contamination is the most frequent cause of genotyping analysis
requests by hospital laboratories. By using the MIRU-VNTR
method, the delay between the delivery of cultures to our
laboratory and a reliable genotyping result is reduced to just one
or two days.
Worsening of tuberculosis under treatment: A patient,
diagnosed with susceptible tuberculosis, received adequate
therapy. Meanwhile, she went to Africa for a journey of
8 weeks. When she came back, her tuberculosis had worsened.
The clinician suspected a re-infection by a multi-drug resistant
TB in Africa. MIRU-VNTR analysis rapidly showed that the
patient was still infected by the same strain.
Detection of unsuspected transmission: All isolates from
tuberculosis patients living in Brussels-Capital Region are sent
to Pasteur Institute of Brussels for a large-scale epidemiological
study. An unsuspected tuberculosis outbreak detected since
2003 and implying at least 41 patients was evidenced by the
MIRU-VNTR technique and was subsequently conﬁrmed by
IS6110 RFLP.
Conclusion: These examples illustrate how the use of
automated MIRU-VNTR technique can help in the resolution
of typical issues encountered in clinical mycobacteriology
laboratories. False-positive cultures for M. tuberculosis are more
frequent than suspected and can cause serious adverse effects on
clinical management of patients. From culture delivery to the
ﬁnal MIRU-VNTR results, the delay extends from 5 to 30 hours
depending on the number of isolates. In average, clear results
are obtained for 97% of all loci analysed. MIRU-VNTR swiftness,
rapidity and reliability are major arguments in favour of
implementation of this technique in reference laboratory, to
help clinicians, hospital laboratories and tuberculosis control
authorities.
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Current aspects on MRSA
S136
The current situation of community-acquired
MRSA in Europe
J. Etienne, T. Ferry, A. Tristan, G. Durand, M. Bes, G. Lina,
F. Vandenesch (Lyon, FR)
The overall percentage of S. aureus isolates expressing methicil-
lin resistance has increased signiﬁcantly in the community
during the past 2 decades. Community-MRSA (C-MRSA)
infections correspond to those associated to MRSA strains that
have emerged recently de novo in the community. They contain
frequently the Panton Valentine leukocidin genes. These
C-MRSA infections have emerged worldwide and are associated
with a limited number of clones that are highly epidemic in the
community. In Europe, the prevalence is low but increases
gradually. These strains tend to infect young patients, especially
children and young. Outbreaks of C-MRSA infections, especially
of skin and soft tissue infections have been described among
members of ‘‘closed populations’’. C-MRSA are mainly trans-
mitted from man to man by direct skin-to-skin contact, or
indirectly through contact by touching objects contaminated by
the infected skin of a person with MRSA. Most of the C-MRSA
infections are represented by superﬁcial skin and soft tissue
infections. These infections are usually non-severe, although
requiring frequently incision and surgical drainage. Deep-seated
infections associated with C-MRSA (e.g. necrotising pneumonia)
are rare, but are extremely severe and life-threatening infections.
Cases of osteomyelitis and septic arthritis caused by C-MRSA
have been reported, mainly in children. Recently, some cases of
pyomyositis due to C-MRSA have been described. Necrotizing
fasciitis due to C-MRSA is also an emergent severe infection.
Overall, the evidence of multiple disseminated abscesses in a
patient with MRSA bacteraemia is highly speculative to be due
to a PVL-positive strain. C-MRSA isolates are typically sensitive
to a wide variety of non-?b-lactam antibiotics including trim-
ethoprim-sulfamethoxazole, minocycline, ﬂuoroquinolones,
vancomyin, linezolid, quinupristin-dalfopristin, and daptomy-
cin. As C-MRSA are easily transmitted, patients with soft tissue
infections should be counselled on the importance of hand
hygiene, not sharing personal items such as towels, and
appropriate wound care.
S137
MRSA transmission dynamics in hospitals: will
control policies ﬁnally succeed?
B. Cooper (London, UK)
Successful control of a communicable disease requires one thing:
that the average number of secondary cases generated by a
typical primary case is less than one. When transmission is
reduced below this threshold, sustained spread of the pathogen
becomes impossible. Evidence form national surveillance data,
clinical intervention studies, and mathematical models is
reviewed and used to assess the possibilities for reducing
transmission below this level leading to the long-term control of
MRSA transmission in hospitals. Community MRSA reservoirs,
community transmission, misleading surveillance data, limited
infection control resources, and over-reliance on control meas-
ures of limited effectiveness all represent potential obstacles to
the successful control of MRSA in hospitals. The importance of
these obstacles will be considered, and means of overcoming
them discussed.
Mechanisms of infectious diseases: new science and novel insights
S141
Innate immunity and Streptococcus pneumoniae
R. Read (Shefﬁeld, UK)
Streptococcus pneumoniae is a major cause of morbidity and
mortality worldwide, and commonly colonizes the upper
respiratory tract. In some colonized individuals the organism
translocates to other tissues and causes life-threatening diseases
including pneumonia, bacteraemia and meningitis. The non-
immune host relies upon innate immunity for defence against
the pneumococcus, and because S. pneumoniae is relatively
resistant to complement-mediated killing (via the terminal
membrane attack complex) phagocytes (initially alveolar macr-
ophages, and subsequently recruited neutrophils) are of critical
importance. The major serum and mucosal ﬂuid opsonins apart
from immunoglobulin are the complement proteins which on
contact with pneumococci are activated with resulting stabilisa-
tion of C3b on the bacterial surface (which is recognized by
phagocyte receptors CR1 and CD11b/CD18). Other potential
opsonins include the collectins (e.g. MBL and surfactant proteins
with are recognized by collectin receptors) and CRP (probably
recognized by FcR). Pneumococci possess a number of elements
that can modify complement activation and consequent C3b
mediated opsonophagocytosis, including the polysaccharide
capsule, pneumolysin, PspA and PspC (or the alternative gene
product, Hic). The pneumococcus can manipulate initial innate
immunity by modifying the rate of decay of C3b to iC3b to C3d.
If phagocytosis proceeds, a number of cellular mechanisms
including generation of reactive oxygen species (ROS) and nitric
oxide facilitate general bacterial killing. Pneumococci are killed
by ROS but some studies have suggested pneumococci inhibit
spontaneous ROS production. In addition pneumococci express
manganese superoxide dismutase which limits ROS-mediated
killing. NO contributes to both bacterial killing and induction of
apoptosis in macrophages. There is no evidence that pneumococci
can detoxify or metabolize NO. Other microbicidal molecules
implicated in pneumococcal killing include cathepsin B and
b-defensins. Alveolar macrophages in the process of being
overwhelmed by pneumococci must recruit assistance from
neutrophils to clear the infection. This is initiated by chemokine
release by alveolar macrophages and also by alveolar epithelial
cells. Chemokine and cytokine induction occurs after activation
of Toll-like receptors and Nod proteins in response to a number
of pneumococcal products including peptidoglycan, lipoteichoic
acid and pneumolysin. Alveolar macrophage apoptosis is a
feature of both sub-clinical murine pneumococcal infection
models and established pneumococcal pneumonia. Inhibition of
in vivo macrophage apoptosis by caspase inhibition is associated
with decreased bacterial clearance and enhanced rates of
invasive pneumococcal disease. Therefore induction of macr-
ophage apoptosis by pneumococci may contribute to bacterial
killing although the mechanisms underlying this association
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remain to be deﬁned. Recent discoveries in each of these
elements of innate immunity to pneumococci will be discussed.
S142
Brucellosis: novel virulence determinants and
cellular organelles
J.-P. Gorvel (Marseille, FR)
The facultative intracellular pathogen Brucella is the causative
agent of brucellosis, a worldwide zoonosis that affects mammals,
including humans. Essential to Brucella virulence is its ability to
survive and replicate inside host macrophages. Understanding
the molecular interactions between Brucella and its replication
niche may lead to new tools useful for vaccine design. We have
shown in a model of Brucella abortus infection of murine bone
marrow derived macrophages that a fraction of the bacteria that
survive an initial host cell killing proceed to replicate in a
compartment segregated from the endocytic pathway. The
maturation of the Brucella-containing vacuole involves sustained
interactions and fusion with the endoplasmic reticulum (ER),
which creates a replicative compartment with ER-like properties.
The acquisition of ER membranes by replicating Brucella is
independent of ER-Golgi COPI vesicular transport, but depend-
ent of the COPII molecular system. A mutant of the VirB type IV
secretion system, which is necessary for intracellular survival,
was unable to sustain interactions and fuse with the ER, and was
killed via eventual fusion with lysosomes. Thus, we demonstrate
that live intracellular Brucella evade macrophage killing through
VirB-dependent sustained interactions with the ER. This leads to
hypothesis that Brucella effector molecules secreted by the type
IV secretion system may be target for future vaccine. Osmoreg-
ulated periplasmic glucans (OPGs) are general constituents of the
envelopes of gram-negative bacteria with glucose as the sole
constitutive. These molecules play a critical biological role as
shown by the fact that mutants unable to synthesize them are
avirulent in their plant or animal hosts. OPG in Brucella genus is
constituted by a cyclic b-1,2-glucan (CG) glucose backbone.
Results suggest an important role of CbG in Brucella virulence as
addition of this periplasmic sugar to liposomes extracted
cholesterol, caused haemolysis in erythrocytes and perturbed
lipid rafts in peritoneal macrophages. In addition, mutants
defective in periplasmic glucan production partially recovered
intracellular replication when CbG was added to bacterial
culturemedia prior tomacrophages infection. These data suggest
that CbGplays an important role in Brucella virulence at the onset
of infection and that drugs able to modulate the vacuolar
environment may lead to circumvent Brucella infection.
Foreign body infections
S145
Orthopedic infections: tricky to diagnose, hard to
treat
A. Trampuz (Basel, CH)
Orthopedic devices are increasingly used to alleviate pain (joint
prostheses) and to ﬁxate bone fractures (intramedullary nails,
external-ﬁxation pins, plates and screws). Infections associated
with orthopedic implants occur rare, but produce signiﬁcant
morbidity and consume substantial healthcare expenditures.
Implant-associated infections are typically caused by microor-
ganisms attached to a surface and embedded in an extracellular
matrix. This structure is called microbial bioﬁlm organized as
complex communities with structural and functional heterogen-
eity resembling multicellular organisms. Existence in bioﬁlms
renders these microorganisms difﬁcult to detect and hard to
eradicate. Prosthetic joint infection is usually deﬁned by the
presence one or more of the following criteria: (i) microbial
growth from synovial ﬂuid or intraoperative tissue (at least 2
positive cultures are required for low-virulent organisms); (ii)
visible purulence and (iii) acute inﬂammation on histopatho-
logical examination or presence of a sinus tract. Infections are
classiﬁed according to the onset of clinical symptoms after
implantation into early (<3 months), delayed (3–24 months) or
late (>24 months) infections. Early and delayed infections are
usually acquired during implant surgery (perioperatively),
whereas late infections are predominantly acquired by haema-
togenous seeding. A combination of clinical laboratory, histo-
pathology, microbiology and imaging studies are necessary for
accurate diagnosis of infection. New techniques to disrupt
microbial bioﬁlms (e.g. sonication of removed implants) and
molecular methods (e.g. quantitative PCR) can further facilitate
diagnostic accuracy. Successful treatment usually requires
adequate surgical procedure combined with long-term anti-
microbial therapy (3–6 months), ideally with an agent acting on
adhering stationary-phase microorganisms. Rifampin has an
excellent activity on bioﬁlm staphylococci, but must always be
combined with another drug (e.g. quinolones, b-lactams, glico-
peptides) to prevent emergence of resistance. Surgical modali-
ties include debridement with retention of the prosthesis, one-
stage or two-stage exchange, resection arthroplasty, arthrodesis
and amputation. Debridement with retention is a reasonable
option, if the duration of clinical signs and symptoms <3 weeks,
the implant is stable, the soft tissue is in good condition, and an
agent with activity against bioﬁlm microorganisms is available.
Antimicrobial clinical trials
O147
Skin disinfection with octenidine
dihydrochloride for central venous catheter
placement and care–a randomized controlled trial
M. Dettenkofer, C. Wilson, A. Gratwohl, D. Bolliger, C. Schmoor,
D. Heim, H. Bertz, D. Luft, S. Schulz, F.D. Daschner,
A.F. Widmer (Freiburg, DE; Basel, CH)
Objective: To investigate the efﬁcacy and tolerability of two
commercially available, alcohol-based antiseptic solutions for
preparation and care of central venous catheter (CVC) insertion
sites. One solution contained the bispyridine octenidine
dihydrochloride.
Methods: A double blind, randomized, controlled trial was
undertaken in the haematology units of university hospitals,
and in one surgical unit. Adult patients with a nontunneled
CVC were enrolled prospectively after informed consent and
randomly assigned to different skin disinfection regimens at the
insertion site: (a) 0.1% octenidine with 30% 1-propanol and 45%
2-propanol, (b) 74% ethanol with 10% 2-propanol. Treatments
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were compared with respect to (i) skin colonisation within the
ﬁrst 10 days after CVC insertion; (ii) positivity of the catheter tip
(> 15 CFU) and (iii) Occurrence of CVC related sepsis.
Quantitative skin cultures were obtained from the insertion
site at regular intervals, and cultures of the CVC tip on removal
were undertaken with the roll plate technique. CVC-related
bloodstream-infection (BSI) was deﬁned according to criteria set
up by the Centres for Disease Control and Prevention (CDC).
The statistical analysis was performed according to the
intention-to-treat principle. Statistical tests (alpha = 5%) of the
a-priori ordered hypotheses of equality of the treatment groups
with respect to the efﬁcacy criteria were performed by an
independent biostatistical department using linear regression
for criterion (1), and logistic regression for criteria (2) and (3).
Models included centre for adjustment.
Results: Four hundred patients with inserted CVC were
enrolled during 5/2002 and 4/2005. Both groups showed no
difference in patient characteristics (Table). Skin colonization at
the CVC insertion site during the ﬁrst 10 days showed a highly
signiﬁcant reduction (Group A vs. B: 0.21; CI95: 0.11–0.4,
P < 0.0001; analysis of 365 patients due to missing values).
Positivity of the catheter tip was signiﬁcantly lower for Group A
(7.9%) vs. B (17.8%): odds ratio = 0.40 (CI95: 0.20–0.81, P = 0.011;
analysis of 322 patients). There was no statistical difference in
the occurrence of CVC-related BSI. Side effects (i.e., burning)
showed no relevant difference between the groups.
Conclusion: Disinfection with an alcoholic skin antiseptic that
contains octenidine leads to a signiﬁcant decrease in skin and
catheter tip colonization and is a promising option for
prevention of CVC-related infection.
O148
Pooled analysis of the mortality and cardiac
safety of moxiﬂoxacin
S. Choudhri, F. Kru¨smann, C. Reiter (West Haven, US;
Wuppertal, DE)
Objectives: Moxiﬂoxacin (MXF) is an established treatment for
respiratory tract infections and is used as oral, intravenous, or
sequential (intravenous followed by oral) therapy. A pooled
analysis of all controlled MXF Phase II, III and IV studies, which
were transferred into the global integrated analysis database by
31 August 2005, was conducted to determine the cardiac safety
proﬁle and mortality risk for MXF vs. a range of comparator
treatments.
Methods: The pooled analysis included 7913 patients treated
with oral MXF and 7603 treated with comparator therapy in 34
oral studies and 2535 patients treated with MXF and 2574
patients treated with comparator therapy in 11 sequential
(intravenous/oral) studies. All patients included were
randomized, had received at least one dose of study drug and
were deemed valid for the safety analysis. Comparator drugs
included: cefuroxime, clarithromycin, levoﬂoxacin, amoxicillin/
clavulanic acid, oﬂoxacin, cephalexin, doxycycline,
azithromycin, amoxicillin, co-trimoxazole and ceﬁxime.
Dosages and indications were according to manufacturer’s
guidelines.
Results: Mortality and cardiac safety data for treatment with
oral and sequential MXF vs. comparator drugs are shown in the
Table.
There were no clinically signiﬁcant differences in estimated risk
between the MXF and comparator groups for any parameter.
Conclusions: In this large patient population pooled from a
range of clinical trials, MXF treatment did not result in an
increased risk of cardiac morbidity or mortality or of overall
mortality vs. comparator therapies.
O149
Short-course ﬂuoroquinolones vs single dose
fosfomycin for acute uncomplicated cystitis:
systematic review and meta-analysis
V. Rafalskiy, T. Perepanova, V. Bistryukov (Smolensk, Moscow,
RU)
Objectives: Acute uncomplicated cystitis (AUC) is one of the
most common bacterial infections in adults. Oral
ﬂuoroquinolones and fosfomycin are the antimicrobials often
recommended for AUC as second or ﬁrst-line therapy. The aim
of the study was to compare the efﬁcacy and safety of
quinolones vs. fosfomycin for AUC.
Methods: System review (SR) and meta-analysis (MA) of
randomized controlled trials (RCT) was performed. The search
via the Cochrane Register of Controlled Trials (Issue 2, 2005),
MEDLINE (1966–September 2005), EMBASE (1988–September
2005), reference lists of articles and abstracts from conference
proceedings without language restriction was carried out. RCTs
comparing short-course (SC) ﬂuoroquinolones (3–7 days) and
single dose (SD) fosfomycin in patients with AUC were selected.
Results: Only 3 RCT (Boerema 1990 [1], De Jong 1991 [2], Mon-
US-01 [3]) from 16 evaluated were included in MA. Fosfomycin
SD was compared with norﬂoxacin (two studies [1, 2]) or
ciproﬂoxacin (one study [3]) for 3–7 days. Pulled analysis of
these three studies was performed (tab). Clinical as well as
microbiological efﬁcacy of ﬂuoroquinolones SC was signiﬁcant
higher then fosfomycin SD. Odds ratio (OR) of eradication rate
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(at the end of therapy), sustain microbiological response (28–
40 days after the end of the therapy) and reinfection rate were
2.33 [1.40, 3.90], p < 0.001, 1.95 [1.36, 2.80], p < 0.0003, 0.62 [0.39,
0.99], p < 0.04. Sustain clinical response (28–40 days after the
end of the therapy) was also signiﬁcantly higher after SC
ﬂuoroquinolones– OR –2.59 [1.66, 4.06], p < 0.0001. Frequency of
adverse drug reactions during fosfomycin therapy was
signiﬁcant higher then during ﬂuoroquinolones therapy– OR –
0.29 [0.11, 0.76], p <0.01, particularly, the rate of diarrhoea
development – OR -0.14 [0.02, 0.77], p < 0.02.
Conclusion: There are signiﬁcantly higher clinical and
bacteriological efﬁcacy rate for short-course ﬂuoroquinolones
therapy vs. fosfomycin SD therapy for patients with AUC.
Adverse drug reaction particularly diarrhoea appeared
signiﬁcant more frequently during fosfomycin administration.
References:
(1). Boerema J.B., Willems F.T. Infection. 1990; 18 Suppl 2: S80–8.
(2). de Jong Z., Pontonnier F., Plante P. Urol Int. 1991; 46 (4):
344–8.
(3). Patel S.S., Balfour J.A., Bryson H.M. Drugs. 1997 Apr; 53 (4):
637–56.
O150
A clinical and laboratory evaluation of PAR-101
in patients with Clostridium difﬁcile-associated
diarrhoea
T.J. Louie, M. Miller, C. Donskey, K. Mullane, E.J.C. Goldstein,
D.M. Citron, M. Corrado, S.L. Gorbach, P. Sears, S. Shangle,
B. Walsh, Y.-K. Shue (Calgary, Montreal, CA; Cleveland, Chicago,
Santa Monica, New Hope, San Diego, US)
Background: PAR-101 is a new macrocyclic compound in phase
2 clinical development for the treatment of Clostridium difﬁcile-
associated diarrhoea (CDAD). PAR-101 has strong antimicrobial
activity against Clostridium difﬁcile as compared to current
therapies; MIC90 values vs. C. difﬁcile for PAR-101,
metronidazole, and vancomycin are 0.125, 0.5, and 2 mcg/ml,
respectively.
Methods: This proof of principle study assessed the safety,
tolerability, and pharmacokinetics of PAR-101 in 45 evaluable
subjects with mild-moderate disease. The oral doses of PAR-101
evaluated were 50, 100, and 200 mg bid administered daily for
10 days. The tolerability/safety was evaluated based on adverse
events, vital signs, ECG, clinical laboratory values, and physical
examination. The clinical evaluation included relief of symptoms
of CDAD, time to resolution of diarrhoea, and clinical recurrence.
Plasma and faecal samples were collected to investigate the
relationship among dose, concentration, and excretion of PAR-
101 in CDAD patients, as well as faecal microbiology.
Results: PAR-101 was well tolerated by all subjects at all doses.
Clinical response was very promising; 2 of 15 patients in the two
lower dose groups and 0 of 15 in the top dosing group were
transferred to conventional therapy for apparent treatment
failure (41/45 cured overall). Of the subjects that completed
therapy, 2/41 patients had recurrence of symptoms within the
6 weeks of follow-up, one each in the low and high dose groups.
After multiple dose oral administrations, plasma concentrations
of PAR-101 were typically <5 ng/ml (0.005 mcg/ml) across the
dose range, and no plasma level of PAR-101 exceeded 100 ng/
ml (0.1 mcg/ml), while faecal concentrations were high,
averaging 1433 mcg/g at the top dose, or over 10 000 times
the MIC90 for C. difﬁcile.
Conclusions: The clinical response, tolerability, and systemic
exposure data obtained support the further clinical development
of PAR-101 as an oral therapy for C. difﬁcile infection.
O151
Therapeutic drug monitoring in adult patients
receiving imipenem or cefepime therapy: one-
year single-centre experience
S. Vora, A A. Pascual, S. Bolay, P. Francioli, T. Calandra,
O. Marchetti (Lausanne, CH)
Background: Experimental evidence suggests that time of
b-lactam antibiotics blood levels above MIC is a key factor for
treatment efﬁcacy. Low levels may be associated with treatment
failure, while high levels may increase toxicity, especially in
patients with impaired renal function.
Objective: To report the experience with therapeutic drug
monitoring (TDM) in adult patients receiving imipenem (IMP)
or cefepime (CEF) therapy.
Methods: Retrospective analysis of consecutive IMP or CEF
TDM during a 1-year period. Initial drug dosing was based on
standard recommendations. IMP or CEF trough blood levels
(Cmin) were measured by HPLC. Interpretation of Cmin as
appropriate (A), inappropriate low (L) or inappropriate high (H)
was based on MIC (when available), clinical and microbiological
response, renal function, and drug blood levels reported in
clinical studies. For L or H drug levels, interventions were
proposed.
Results: 56 drug levels were measured (IMP, n = 30; CEF,
n = 26) in 29 haemato-oncology, 11 intensive care, and 16 other
adult patients. Treatment indications were microbiologically
(27) or clinically (7) documented infections or unexplained fever
(21). Daily dosing ranged from 500 to 4000 mg (IMP) and 500 to
6000 mg (CEF). TDM was performed 4 days (median, range 1–
25) after treatment initiation: Cmin ranged from 0 to 13 (IMP)
and 0.7 to 61 mg/l (CEF). Assessment of appropriateness of
blood levels is shown in table 1. Interventions in patients with L
IMP levels (range 0–1.5 mg/l) were: prolongation perfusion
time (n = 1), increase daily dosing (n = 8), repetition TDM
(n = 1) or change antibiotic (n = 1). All patients with H CEF
levels (range 5–61 mg/l) had impaired renal function (creatinine
clearance <70 ml/min). To prevent toxicity daily dose was
decreased (n = 5) or antibiotic was changed (n = 1); no data
(n = 2).
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Conclusions: Inter-individual variability of IMP or CEF blood
levels is large. Low or high drug levels were observed in a high
proportion of patients suggesting that TDM may help to ensure
that dosing of antibiotic therapy is appropriate. Prospective
studies are needed to conﬁrm the clinical utility of TDM.
O152
Integrated analysis of efﬁcacy of faropenem
medoxomil in the treatment of uncomplicated
skin and skin structure infections
E.E.L. Wang, R. Echols, R. Tosiello (Louisville, US)
Faropenem medoxomil (FM) is an oral penem with potent
activity against S. pyogenes and methicillin-susceptible S. aureus.
This integrated analysis was conducted to describe the efﬁcacy
of FM based on 2 non-inferiority design randomized clinical
trials (RCT).
Methods: Non-inferiority was deﬁned as the lower limit of the
95% CI being >10%. 7 days of 300 mg BID of FM was compared
with 7 days of either amoxicillin-clavulanate (AC) or cephalexin
(C). One study was conducted in Europe, Israel, and S. Africa
and the other in the USA.
Results: A total of 1180 subjects were enrolled consisting of 305
cellulitis, 249 impetigo, 277 furunculosis, and 349 simple abscess
cases. In study 1, FM was non-inferior to AC. In study 2, FM did
not meet the protocol-deﬁned criteria for non-inferiority. For the
pooled population from the 2 studies, non-inferiority of FM to
comparators was established for PP, ITT and microbiologically
evaluable populations. Clinical response for cellulitis was 86.8%
FM vs. 88.8 Comp; impetigo 87.6 FM vs. 95.6 Comp;
furunculosis 90.7 vs. 88.2 Comp; and simple abscess 87.8 FM
vs. 93.9 Comp. Microbiologic eradication for S. aureus was 91.7
FM vs. 91.6 Comp; for S. pyogenes was 95.1 FM vs. 97.8 Comp.
Conclusion: Although FM did not meet the non-inferiority
criteria in one RCT, it met it in the other, and in the pooled
analysis. FM is effective in all four clinical infection types
making up uncomplicated skin and skin structure infections
(uSSSI) and it is highly efﬁcacious for both S. aureus and
S. pyogenes, the major pathogens of uSSSI.
O153
One-week once-daily triple therapy with
esomeprazole, moxiﬂoxacin and rifabutin is
effective in the treatment of Helicobacter pylori
resistant to both metronidazole and
clarithromycin
S. Miehlke, W. Schneider-Brachert, A. Morgner, A. Madisch, C.
Kirsch, E. Ba¨stlein, C.Haferland, C. Jebens,H.Knoth,M. Stolte,N.
Lehn (Dresden, Regensburg, Cologne, Go¨rlitz, Ju¨lich, Bayreuth, DE)
Objectives: Failure of standard triple therapy aiming at
eradication of H. pylori often leads to post-treatment resistance
to metronidazole (MET) and/or clarithromycin (CLA).
Subsequent treatment of these patients remains a clinical
challenge. We evaluated the efﬁcacy and tolerability of a
convenient triple therapy using esomeprazole, moxiﬂoxacin
and rifabutin for eradication of H. pylori resistant to both MET
and CLA in a prospective open-label study.
Methods: Consecutive patients with H. pylori infection resistant
to both MET & CLA (E-test) were treated with esomeprazole
40 mg, moxiﬂoxacin 400 mg and rifabutin 300 mg, each given
orally once daily in the morning for 7 days. Follow-up
endoscopy including histology and H. pylori culture was
performed 6 to 8 weeks after treatment.
Results: Between January 2004 and October 2005, 86 patients
were enrolled (56 female, 30 male, median age 52 years). 62
patients (72.1%) had a history of two or more previous treatment
failures. Three patients (3.5%) discontinued treatment
prematurely due to adverse events. 73 patients (85%) are
currently available for per protocol efﬁcacy analysis.
Successful eradication was conﬁrmed in 58 patients (79.5%). In
the patients with clinical failure (n = 15), post-treatment
resistance to the test drugs rifampicin and ciproﬂoxacin were
detected in 5 and in 3 patients, respectively.
Conclusion: One-week once-daily triple therapy with
esomeprazole, moxiﬂoxacin and rifabutin is effective and safe
for eradication of H. pylori resistant to both metronidazole and
clarithromycin in patients with a history of previous treatment
failures.
O154
Prospective randomized trial comparing
rifabutin-based triple therapy and high-dose dual
therapy for eradication of Helicobacter pylori
resistant to both metronidazole and
clarithromycin
S. Miehlke, K. Hansky, W. Schneider-Brachert, A. Madisch,
A. Morgner, C. Kirsch, C. Haferland, E. Ba¨stlein, M. Buchner,
E. Jacobs, M. Stolte, N. Lehn (Dresden, Regensburg, Gorlitz,
Cologne, Ribnitz-Damgarten, Bayreuth, DE)
Objectives: After failure of standard anti-H. pylori therapy post-
treatment resistance tometronidazole (MET)and/orclarithromycin
(CLA) frequently occurs. We investigated and compared the
effectiveness of a one-week triple therapy containing
esomeprazole, rifabutin and amoxicillin with a two-week high-
dose dual therapy containing omeprazole and amoxicillin for
eradication of H. pylori resistant to both MET and CLA.
Methods: Patients with H. pylori infection resistant to both MET
& CLA (E-test) were randomized to receive esomeprazole 20 mg
bid, rifabutin 150 mg bid, and amoxicillin 1 g bid for 7 days
(ERA), or omeprazole 40 mg tid and amoxicillin 1 g tid for
14 days (HD-OA). Follow-up endoscopy was performed 6 to
8 weeks after treatment. Cross-over therapy was performed in
cases of persistent H. pylori infection.
Results: 145 patients were randomized (91 females, median age
50 years, peptic ulcer disease 40%). Per protocol and intention to
treat eradication rates in the ERA and HD-OA group were 78%
vs. 75% and 72.6% vs. 69.5% (p > 0.05). Two patients of the ERA
group (2.7%) and 4 patients of the HD-OA group (5.5%)
discontinued prematurely due to side effects. Seven of 10
patients who failed HD-OA therapy were cured by cross-over
ERA therapy. Six of 8 patients who failed ERA therapy were
cured by cross over HD-OA therapy. Posttreatment resistance to
amoxicillin or rifabutin was not detected.
Conclusions: One-week triple therapy with esomeprazole,
rifabutin and amoxicillin is effective for eradication of H. pylori
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resistant to both metronidazole and clarithromycin. High-dose
dual therapy with omeprazole and amoxcillin is a valuable
alternative.
O155
A randomized study of cefuroxime vs. ampicillin-
sulbactam prophylaxis for obstetrical and
gynaecological operations: an effect on Gram-
negative anaerobic bacteria associated
postoperative surgical site infections
E. Ziogos, K. Kanellakopoulou, A. Dervisoglou, N. Galanakis,
A. Papadimitriou, H. Giamarellou (Nikaia, Haidari, GR)
Objectives: Cephalosporins are not active against gram-
negative anaerobic bacteria. Nevertheless they have been
widely used and considered to be clinically effective as
prophylaxis in obstetrics and gynecology surgery. We
performed a prospective randomized study to compare use of
cefuroxime vs. ampicillin-sulbactam (due to its activity against
gram negative anaerobic bacteria), as single dose prophylaxis in
obstetrical and gynecological operations.
Methods: During the time period from June 2004 through
October 2004, 120 patients who underwent elective or urgent
obstetrical or gynecological operation (either open or
laparoscopic), were randomized to receive a single dose of
either cefuroxime 1.5 gr iv (Group A), or ampicillin-sulbactam 3
gr iv (Group B), intraoperatively. All patients underwent
prospective assessment for development of postoperative
infection.
Results: The median age of the patients was 37.53 years old,
and median hospitalization time 4.64 days. Concerning
chemoprophylaxis, 62/120 (51.67%) were belonging to Group
A and 58/120 (48.33%) to Group B. Surgical site infection was
observed in 5/120 (4.17%) patients (4 in Group A and 1 in group
B). From them 3 (60%) patients suffered from intra-abdominal
infection (2 in Group A and 1 in group B). Also, 3/5 (60%) had
postoperative infection caused by gram-negative anaerobic
bacteria. All of them were Group A patients.
Conclusion: The patients were too few to come in any safe
conclusion. Nevertheless, it is worth to mention that all
postoperative surgical site infections due to gram-negative
anaerobic bacteria were observed in patients who received
cefuroxim as prophylaxis.
O156
The efﬁcacy and safety of cefepime: systematic
review and meta-analysis
M. Paul, D. Yahav, A. Fraser, N. Sarid, L. Leibovici (Petah Tikva,
IL)
Objectives: To assess the safety and efﬁcacy of cefepime, a
fourth generation cephalosporin widely recommended for
several indications.
Methods: Systematic review and meta-analysis of randomized
controlled trials. All trials comparing cefepime to another
b-lactam antibiotic, alone or with the addition of the same
non-b-lactam antibiotic to both study arms were included. We
searched CENTRAL, PUBMED, EMBASE, LILACS, new Federal
Drug Administration drug applications, conference proceedings
and references of included studies. Two reviewers
independently performed search and data extraction. Missing
data were sought from authors. No date, language, age or
publication limits were imposed. The primary outcome assessed
was 30-day all-cause mortality. Relative risks (RR) with 95%
conﬁdence intervals (CI) are reported.
Results: Fifty-ﬁve trials were included. All-cause mortality was
higher with cefepime compared to other b-lactams, RR 1.26
(95%CI 1.08–1.49), p = 0.005, with no heterogeneity. Mortality
was higher with cefepime vs. several comparators (Fig.).
Cefepime was assessed for different indications, including
febrile neutropenia, pneumonia, sepsis, bacteraemia,
meningitis, skin/ soft tissue and uro-gynecological infections.
All cause mortality was signiﬁcantly higher with cefepime in
febrile neutropenia, RR 1.42 (95%CI 1.09–1.84). Studies of higher
methodological quality were associated with a greater
disadvantage to cefepime, RR 1.36 (95%CI 1.09–1.70) for
studies reporting adequate allocation concealment and RR 1.52
(95%CI 1.20–1.92) with adequate allocation generation. No
signiﬁcant differences between cefepime and other b-lactams
were observed for clinical failure, RR 0.99 (95%CI 0.94–1.04),
microbiological failure RR 0.93 (95%CI 0.85–1.02), bacterial
superinfections, RR 1.01 (95%CI 0.74–1.38) and adverse events
requiring treatment discontinuation, RR 1.12 (95%CI 0.86–1.46).
Enlisting of speciﬁc adverse events reported did not reveal a
speciﬁc adverse event potentially responsible for the increased
mortality.
Conclusions: Our study shows a signiﬁcant 24% increase in all-
cause mortality among patients treated with cefepime in
randomized trials. Despite a broader in vitro spectrum of
coverage than most comparators assessed in these trials and
claims for reduced resistance induction, no advantage to
cefepime was observed with regard to clinical or
microbiological failure and bacterial superinfections. The use
of cefepime should be reconsidered.
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Fatal cases of inﬂuenza-associated
encephalopathy in the Netherlands
J. Gooskens, T. Kuiken, E. Claas, H. Harinck, H. Baelde,
W. Spaan, A. Kroes (Leiden, Rotterdam, NL)
Objectives: To investigate clinical, pathological and molecular
aspects of fatal cases of inﬂuenza-associated encephalopathy
(IAE) in the Netherlands.
Methods: Two fatal cases of IAE, occurring in 2004 and 2005,
were analysed for clinical details by review of medical records
and by pathological and molecular analysis on post-mortem
fresh and parafﬁn-embedded tissue in one case. A 5-year
hospital database search (2000–2005) and a MEDLINE
literature search (1955–2005) were performed for documented
fatal cases in the hospital and the Netherlands respectively.
Results: Two unrelated native Dutch patients, a 17-year-old
male adolescent and a 9-year-old girl, were admitted to the
hospital in shock and coma, with signs of profuse bleeding from
the gastrointestinal or respiratory tract. The patients had a short
prodromal illness consisting of ﬂu-like symptoms, vomiting and
increasing drowsiness. Inﬂuenza A virus H3N2 was cultured
from the respiratory tract of both patients. Only the 9-year-old
girl had respiratory symptoms on physical examination and an
inﬁltrate on the chest radiograph. Neuroimaging was normal in
both patients. Both patients died within 24 hours after
admission following rapidly progressive multi-organ failure
(MOF), disseminated intravascular coagulation and shock. Post-
mortem analysis of the lungs of the 17-year-old male revealed
extensive haemorrhages, bronchitis, early diffuse alveolar
damage and bronchial epithelial cells positive for inﬂuenza A
virus by immunohistochemistry. No pathological changes or
immunohistochemical positive cells were observed in other
organs. Inﬂuenza RNA was detected in multiple organs
including the brain, but not in blood specimens. No additional
fatal cases were uncovered in the hospital from 2000–2005. To
our knowledge, no fatal cases of IAE are documented in the
Netherlands after the 1957 Asian inﬂuenza pandemic, when 68
cases were reported.
Conclusions: Fatal IAE is extremely rare, except among
Japanese children with 50–100 deaths each year during 1995–
2001. These cases are commonly preceded by rapidly
progressive coma, MOF and severe thrombocytopenia. A
similar presentation described in two previously healthy
unvaccinated Dutch children warrants monitoring of severe
inﬂuenza to determine the true incidence of fatal IAE. Inﬂuenza
RNA was detected in multiple organs and the brain of one
patient, suggesting a causal relationship between viral
dissemination and severe neurological and systemic disease.
O159
Lack of discriminating signs in clinical diagnosis
of inﬂuenza
M. van der Hoeven, M. Scholing, P. Wever, M. Hermans,
R. Fijnheer, P. Schneeberger (’s-Hertogenbosch, NL)
Objectives: Rapid diagnosis of inﬂuenza in hospitalized
patients is important to prevent the transmission of the
infection in the hospital. This prospective study was designed
to determine the relationship between the clinical diagnosis of
inﬂuenza made by the physician at admission and the presence
of inﬂuenza virus in patients with respiratory tract infections.
Methods: The study was conducted in a large Dutch teaching
hospital during the inﬂuenza season in 2005 in a period of three
weeks. All patients of 18 years and older, admitted with
respiratory tract infections were included in the study. Clinical
and laboratory parameters, chest radiograph, blood and sputum
cultures and nasopharyngeal swab for polymerase chain
reaction (PCR) were obtained for each patient. In addition, the
physicians opinion at admission whether this patient had
inﬂuenza was recorded.
Results: A total of 78 patients were hospitalized with
respiratory tract infections. In 41 (53%) of them inﬂuenza virus
was detected by PCR. Among the patients with PCR proven
presence of inﬂuenza virus, the clinical diagnosis was made in
18 cases (44%). No false positive cases, i.e. clinical diagnosis of
inﬂuenza but no virus detected, were observed. Neither C-
reactive protein, nor leucocytes an inﬁltrate on chest radiograph
could discriminate between viral and bacterial infections of the
respiratory tract.
Discussion: The present ﬁndings failed to demonstrate a
signiﬁcant relationship between the clinical diagnosis of
inﬂuenza and PCR detection of the virus. More speciﬁcally,
the virus was present at least twice more often than inﬂuenza
was clinically diagnosed. As a consequence, the decision to take
protective measures to control spread of the virus should not
rely on the clinical diagnosis.
O160
Unusual summer inﬂuenza outbreak in a nursing
home. Diagnosis and prophylactic measures
J. Gaillat, G. Dennetiere, M. Valette, E. Rafﬁn-Bru (Annecy, Lyon,
FR)
Objectives: Despite vaccination ﬂu epidemic in nursing homes
does happen occasionally, but when it occurs during summer
time it is a rare event. To describe an inﬂuenza outbreak and to
assess the prophylactic measures in such a situation.
Description of the epidemic: The outbreak started on the 27
June and lasted 7 days up to 3 July 2005 in a nursing home of 81
residents (R) (mean age 88 years) and 51 health care workers
(HCW) Fever, cough and wheezing were reported as main
symptoms among 32/81 R and 6/48 HCW on duty during the
mentioned period. On day 4, one patient was hospitalized. The
knowledge of several similar cases and the clinical features
(short incubation, fever, wheezing and cough with normal
pulmonary Xray) gave grounds to perform a rapid diagnosis test
for inﬂuenza on a rhinopharyngeal sampling (RPS) despite the
season. The results turn out to be positive. At the same day, 10
symptomatic residents have had RPS and of which 3 rapid
diagnostic tests were performed at the time and all were
positive. In collaboration with the departmental medical
authorities and the staff of the nursing home, isolation of
patients plus wearing of surgical masks (HCW, visitors and
ambulatory residents) were decided and oseltamivir was
prescribed. and started on the 01/07/05. For 19 patients and
for 5/6 HCW symptomatic for <48 hours received oseltamivir
(O) at 75 mg BID for 5 days. A prophylactic treatment, 75 mg
OD 7 days, was given to 47 residents as well as to the 42
remaining HCW. The epidemic was stopped 24 hours later. The
viral strain was similar to the winter epidemic strain of the 2004–
2005 season: H3N2A/New York/55/2004. Case fatality rate was
15.6 (5/32) (2 had received O, the former only one dose, the later
15 days after the end of treatment due to a myocardial
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infection), 3 others had symptoms for more than 48 hours and
did not receive O. The ﬂu vaccine coverage in the resident was
93.5%. Because of the midsummer heat alert, all residents had
stayed in a single air-conditioned room from 26 to 28/06. It can
explain the high and rapid attack rate.
Conclusion: The rapid diagnosis test has been a clue to rapidly
intervene in the nursing home and to conﬁrm the ﬂu epidemic.
As soon as the outbreak was recognized, a crisis cell has been
put in place to apply the measures to control the epidemic as
described in the national instructions particularly O
prescription. The rapid control response was found to be quite
effective.
O161
Effects of statin therapy on the risk of serious
outcomes during inﬂuenza epidemics
E. Hak, T. Verheij, G. van Essen, M.J.M. Bonten, A. Hoes on
behalf of ESPRIT
Background: Studies have shown immune-modulatory and
anti-inﬂammatory properties of statins, therefore statins could
beneﬁt patients during inﬂuenza outbreaks.
Methods: The effects of statins were assessed in patients aged
50 years and older from the University Medical Center Utrecht
primary care network who were followed up during four
epidemic and non-epidemic inﬂuenza seasons from 1996 until
2004. Primary endpoint was a composite of community-
acquired pneumonia, prednisolone-treated acute respiratory
disease, myocardial infarction, stroke and death from all
causes. To control and quantify confounding, we obtained
estimates of reductions in outcome and control events
(dermatomycosis, irritable bowel syndrome) associated with
statin therapy after adjustments for demographic and health
characteristics.
Results: In the study, 22 638 persons provided 130 558 persons-
periods and statin therapy was used in 5.3%. In 3.2% of person-
periods the primary endpoint occurred and most events were
respiratory (72%). During inﬂuenza epidemics, statin therapy
was associated with a 33% reduction in the primary endpoint
(relative risk [RR] 0.67; 95% conﬁdence interval [95%CI]: 0.54–
0.83 [P < 0.001]), a 28% reduction in respiratory disease (RR 0.72;
95%CI: 0.57–0.90 [P = 0.004]) and 51% reduction in all-cause
mortality (RR 0.49; 95%CI: 0.29–0.82 [P = 0.007]). The ﬁndings
were consistent across subgroups according to age,
cardiovascular disease or exposure to inﬂuenza vaccination. In
non-epidemic inﬂuenza seasons, no signiﬁcant reduction in the
primary endpoint was observed while statin therapy was not
associated with reductions of the control event rates (n = 1.240)
in either season.
Conclusions: Statin therapy was associated with substantial
reductions in the risk of serious, mainly respiratory, outcomes
during inﬂuenza epidemics and these ﬁndings should direct
future studies into the potential implications during pandemics.
O162
Inﬂuenza vaccination in health workers included
in high-risk group population
A. Pin˜o´n, S. Oropeza, B. Acosta, C. Aragones, B. Galindo
(Havana, CU)
Inﬂuenza is a highly contagious acute respiratory disease of
global importance. A vaccination with inactivated Inﬂuenza
virus is currently the most effective measure for reducing the
impact of the disease and prevents its complications and
mortality in persons at risk.
Objectives: Determine antibody responses against vacunal
strains; identify antibody protector levels against each one of
the strains; detection of seroconvertion protection level in the
study population and identify differences of the response in the
different high-risk groups.
Methods: To evaluate the humoral immune response by
Inﬂuenza vaccination in high-risk groups, we conducted a
prospective longitudinal descriptive study. Haemagglutination
inhibition test was used to determine antibody levels against the
three strains included in the vaccine.
Results and conclusions: The studied population had
antibodies before vaccination against all the strains at the
vaccine, which is because of the circulation of similar strains in
the season and is in concordance with international reports. Pre-
vaccination GMTs agree with those results. We detected a high
percent of protection against the three strains as a response to
vaccination; GMTs increased to values higher than 40. The three
groups included in the study (asthmatic, diabetic and
hypersthenes) had a good response to vaccination and
diabetics are better responders than the other two groups,
with 100% of protection against two strains of the vaccine
(AH3N2 and B).
References:
(1) Hilleman MR. Realities and enigmas of human viral inﬂu-
enza: pathogenesis, epidemiology and control. Vaccine 2002;
20:3068–87.
(2) Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ,
Singleton JA. Prevention and control of inﬂuenza. Recom-
mendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep 2003; 52:1–34.
(3) Nancy JC, Kanta, S. Inﬂuenza. Lancet 1999; 354:1277–82.
O163
Efﬁcacy of inﬂuenza vaccination in patients with
liver cirrhosis
H.J. Cheong, C.W. Park, S.Y. Ki, Y.M. Cho, J.Y. Song, J.E. Yeon,
K.S. Byun, W.J. Kim (Seoul, KR)
Objectives: Cirrhosis is a major chronic disease in many Asian
countries. An estimate of the prevalence of cirrhosis cases in
Korea is around 460,000 cases and constitutes 15% among 6
major chronic diseases in Korea. Though WHO does not include
cirrhotic patients among inﬂuenza vaccine-target groups, they
have been considered as one of the priority groups in Korea.
However, available data on the impact of inﬂuenza in liver
cirrhosis is extremely limited up to now. Therefore, we decided
to evaluate the efﬁcacy of inﬂuenza vaccine in chronic liver
disease, and intended to study the clinical outcomes of inﬂuenza
in patients with liver cirrhosis.
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Methods: Two hundred sixty-ﬁve patients with liver cirrhosis
were, in October of 2004, persuaded to be vaccinated against
inﬂuenza. Among them, 198 patients were vaccinated with a
trivalent inﬂuenza vaccine and the others were not vaccinated.
Both of the vaccinated and unvaccinated groups were observed
until May of 2005; self reporting system was operated. If
inﬂuenza-like illness (ILI) was suspected in those patients,
diagnostic tests were performed with rapid diagnosis kit (Quick
ViewTM) and viral culture. We compared the incidence of ILI
and positive rates of diagnostic tests between vaccinated and
non-vaccinated groups.
Results: Most of demographic data were indistinguishable
between vaccinated and unvaccinated groups. However, the
proportion of patients with severe hepatic dysfunction was
somewhat larger in vaccinated group compared to those of the
unvaccinated: Child-pugh B and C (77.1% in vaccinees vs. 57.7%
in non-vaccinees). Overall incidences of ILI (P = 0.064) and
culture conﬁrmed inﬂuenza (P = 0.009) were signiﬁcantly
higher in unvaccinated group than those were in vaccinated
group. Most of the patients with inﬂuenza complained of febrile
sense (91.6%) and myalgia (83.3%), but typical manifestations
such as cough (41.6%) and sore throat (25.0%) were not
frequently noted. In some patients, inﬂuenza was
accompanied with aggravation of underlying hepatic
dysfunction: hepatic encephalopathy (16.6%), uncontrolled
ascites (25.0%) and oliguria (33.3%). One inﬂuenza patient was
complicated by secondary bacterial pneumonia.
Conclusions: Inﬂuenza vaccination against cirrhotic patients
was effective to prevent disease occurrence. Inﬂuenza in
cirrhotic patients showed atypical clinical presentation and
caused aggravation of underlying hepatic dysfunction though it
was not direct cause of mortality.
O164
Clinical effectiveness of inﬂuenza vaccination in
adults with diabetes mellitus
I. Looijmans-van den akker, T. Verheij, E. Buskens, G. Rutten,
E. Hak (Utrecht, NL)
Objectives: Evidence is conﬂicting regarding the potential
beneﬁts of inﬂuenza vaccination in patients with diabetes. As
part of the PRISMA study (Hak E, et al. Arch Intern Med, 2005)
we assessed the clinical effectiveness of inﬂuenza vaccination in
adults with diabetes and speciﬁcally examined potential
modiﬁcation of effect by age and prior inﬂuenza vaccination.
Methods: We conducted a case-control study nested in a large
cohort of patients recommended for inﬂuenza vaccination
during the 1999–2000 inﬂuenza A epidemic (n = 75,000). We
selected cases and controls with a diagnosis of diabetes from the
original study population (n = 9,238). Vaccination status was
recorded by the general practitioner. The primary endpoint was
the composite of all-cause mortality and hospitalization for
diabetes events, acute respiratory or cardiovascular disease
during the epidemic, and the separate components were
secondary endpoints. We evaluated the effect of vaccination
and the inﬂuence of prior vaccination by means of logistic
regression analysis controlling for age, gender, health insurance
coverage, prior health care use, medication use and co-morbid
conditions.
Results: We observed 131 hospitalizations and 61 deaths. In all,
the combined endpoint was reduced by 56% (95% conﬁdence
interval: 36–70%), hospitalizations by 52% (95% CI 22 to 70%)
and deaths by 58% (95% CI 13 to 80%. Among persons with
diabetes aged 18 to 64 years we observed somewhat higher
reductions in the primary endpoint than elderly persons with
diabetes over 65 years of age (72% versus 39%). In those
vaccinated for the ﬁrst time, the primary endpoint was
reduced by 47% (95% CI 0.2% to 72%) and in those who
received prior vaccination the reduction was 58% (95% CI 4 to
81%).
Conclusion: Adults with diabetes alike other recommended
risk groups as healthy elderly persons and patients with
cardiovascular or pulmonary disease beneﬁt considerably from
inﬂuenza vaccination and no difference in vaccine effectiveness
was observed between ﬁrst time and repeat vaccination.
O165
Immunogenicity of baculovirus-expressed
trivalent inﬂuenza HA vaccine: randomised,
double-blind, dose-escalation single institution
study in adult patients with B-cell lymphoma
A. Safdar, A. Rodriguez, F. Luis, J. Romaguera, F. Hagemeister,
P. McLaughlin, L. Kwak, R.B. Couch (Houston, US)
Background: Immunogenic response of conventional inﬂuenza
vaccine is markedly impaired in patients with hematologic
malignancies. We sought to evaluate possible beneﬁcial effect on
increasing vaccine dose on speciﬁc neutralizing
immunoglobulin response among patients with non-Hodgkin’s
lymphoma.
Methods: This prospective study was performed during the
later half of 2004 and was sponsored by the National Institutes
of Health (NIH). The randomization was undertaken by an
independent NIH designated agency. Pre- and 4 week post-
vaccination antibody titers were measured under a code at the
BCM. Test viruses for neutralizing assays were A/Moscow/10/
99 (H3N2) (antigenically similar to A/Panama/H3N2 virus)
was used in inﬂuenza A/H3N2 tests. A/New Caledonia/20/99
(H1N1), and B/Hong Kong/330/2004.
Results: Please refer to the table attached.All patients visiting
outpatient lymphoma clinic were screened and those who had
not received antineoplastic therapy within 3 months and/or
rituximab in the past 6 months were considered for the study.
Splenctomized patient, and those receiving systemic
corticosteroids were not included. There were no serous
adverse reactions noted in any of the 27 enrollees on 6 months
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post-vaccination follow up. Among inﬂuenza A/H1N1 and A/
H3N2, higher doses were associated with increased strain-
speciﬁc protective neutralizing antibody titers. Whereas, this
beneﬁcial effect was not seen in patients receiving higher doses
of inﬂuenza B vaccine.
Conclusions: Recombinant Baculovirus-Expressed inﬂuenza
vaccine was safe in our compromised patients with non-
Hodgkin’s B-cell lymphoma. These preliminary results
indicate potential immunogenic beneﬁt associated with
inﬂuenza A recombinant vaccine dose-escalation.
Rapid methods for the identiﬁcation of bacterial clones and
pathogens
O166
Mixed whole genome microarray technology
discerns a hospital-adapted subtype of
Enterococcus faecium, comparable to multilocus
sequence typing clonal complex (CC) 17
H.L. Leavis, W.J.B. van Wamel, R.J.L. Willems, F.H. Schuren,
A.C. Fluit, M.J.M. Bonten (Utrecht, Zeist, NL)
Objectives: Previously we identiﬁed a genotypically distinct
subset of epidemical Enterococcus faecium (Efm), designated
CC17 using multilocus sequence typing (MLST). We
investigated whether a whole genome microarray approach
would type strains similarly and if epidemic speciﬁc markers
could be identiﬁed.
Methods: A shotgun library was constructed of 9 Efm strains of
which 5700 ± 1.2 kb DNA fragments were spotted on a slide.
Cy5 labeled DNA of 100 MLST typed Efm isolates from different
sources (outbreaks, infections, surveys and animals) and 5
continents, vancomycin resistant and susceptible, were
hybridized to the array together with Cy3 labelled DNA of the
library strains. 2919 spots met quality criteria and were included
in normalization and EPP data transformation (Kim et al. 2002).
Transversal hierarchical clustering (HC) was performed based
on strains and spots (inserts). Inserts differentiating between
CC17 and non-CC17 were identiﬁed from the visualized data
matrix, PCR ampliﬁed and sequenced. Sequences were blasted
in Genebank (NCBI).
Results: HC resulted in 9 different clusters and a small cluster
of 2 strains and resembled MLST genogrouping. Four clusters
consisted of mainly CC17 strains, including all but two epidemic
strains. Approximately 60 % of inserts was conserved while 413
inserts (14.1%) were associated with the epidemic clusters. From
these, 190 were selected for sequencing. This revealed that
differentiating inserts were gene fragments encoding potential
virulence factors (24), resistance determinants (3), transposons
or IS elements (32), proteins involved in replication (13) or
regulation (3), as well as hypothetical proteins (10). 44 (23%) of
hits showed no signiﬁcant homology.
Conclusion: Comparative genomics of Efm based on a mixed
whole genome microarray discerned the epidemic MLST
subpopulation. From the analysis 14.1% of inserts were
identiﬁed differential for CC17 including both regulatory and
potential virulence genes. This technology may provide new
targets for diagnostics and for the development of selective
drugs for hospital-adapted Efm.
O167
Genetic relationship between Streptococcus
pneumoniae isolates responsible for a case of
meningitis and for asymptomatic carriage in
children attending a day-care centre in Lisbon
T. Figueiredo, M. Ramirez, I. Santos-Sanches, S. Nunes,
A. Brito-Avoˆ, R.M. Barros, I. Peres, H. de Lencastre (Lisbon,
Oeiras, PT; New York, US)
Objectives: Colonisation of the nasopharyngx by Streptococcus
pneumoniae although asymptomatic, is a prerequisite for the
development of a clinical infection. However, the underlying
mechanisms that turn the benign state of colonization into
clinical disease are poorly understood. Thus, in order to
understand the molecular mechanisms that deﬁne the
virulence of S. pneumoniae, a clear picture of the genetic
relationship between invasive and carried pneumococci is
needed.
Methods: We characterised 2 pneumococcal strains recovered
from the blood and cerebrospinal ﬂuid (CSF) of a child with
meningitis and 23 nasopharyngeal isolates from asymptomatic
carriers attending the same room in a day care centre (DCC),
using antimicrobial susceptibility proﬁling, serotyping, PFGE
and MLST. We also investigated the presence of lysogenic phage
since these were shown to be associated with virulence
determinants in other streptococci.
Results: Strains recovered from the sick child and seven
carriage isolates were fully susceptible, expressed serotype 6B
and belonged to a new clone by PFGE and MLST (ST896).
However, there was a band difference in the PFGE pattern of the
isolates from the CSF and carriage. The in vivo loss of a lysogenic
phage in the CSF isolate accounted for this difference and
suggested an involvement of the phage in the transition between
colonization and disease. However, the localization of the attB in
an intergenic region and the putative functions of the adjacent
genes do not support this hypothesis. The remaining 16 isolates
recovered from asymptomatic carriers belonged to other clones
including internationally clones previously found associated
with invasive disease (e.g. Spain23F-1).
Conclusions: The same pneumococcal clone was
simultaneously responsible for carriage and for invasive
disease in different hosts. The in vivo loss of a lysogenic
prophage, between the isolate recovered from the blood and the
one from the CSF, suggested an involvement of the
bacteriophage in this transition. The localization of the attB
site in an intergenic region and the suggested functions of the
adjacent genes do not support this hypothesis.
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Changes in the distribution of hypervirulent
complexes of Neisseria meningitidis in the Czech
Republic
P. Kriz, J. Kalmusova, M. Musilek, J. Felsberg, R. Haugvicova,
D. Caugant, K. Jolley, M. Maiden (Prague, CZ; Oslo, NO; Oxford,
UK)
Objectives: The distribution of major hypervirulent complexes
causing invasive meningococcal disease (IMD) in the Czech
Republic in the period 1993–2005 is presented. The case fatality
rate caused by individual hypervirulent complexes is analysed
and a corresponding vaccination strategy recommended.
Methods: Sequence types (ST) were identiﬁed by multilocus
sequence typing (MLST) presented on the MLST website
(http://pubmlst.org/neisseria/). The ﬁrst MLST was done in
Oxford, later in Oslo and ﬁnally in Prague. The total number of
N. meningitidis isolated from IMD in the Czech Republic in the
period 1993–2005 and investigated by MLST was more than 450.
Results: Four major hypervirulent complexes causing IMD in
the Czech Republic in the period 1993–2005 were detected: ST-11
complex (representing 32% of the whole collection of strains),
ST-18 complex (14%), ST-32 complex (10%) and ST-23 complex
(3%). ST-11 complex was represented mainly by strains of
serogroup C, ST-18 and ST-32 complexes by strains of serogroup
B and ST-23 complex by strains of serogroup Y. ST-11 complex
reached its maximum in the period 1993–2002, ST-18 complex in
the period 2000–2003, ST-32 complex in the period 1993–1996
and ST-23 complex in the period 2001–2005. The case fatality
rate recently caused by N. meningitidis Y belonging to ST-23
complex is extremely high (33%). Since 2005, meningococcal
tetravalent polysaccharide vaccine A, C, Y, W135 has been
imported to the Czech Republic and is recommended for
vaccination of children before they reach 14 years of age.
Registration of conjugate tetravalent vaccine A, C, Y, W135 is
desirable in the Czech Republic.
Conclusion: The prevalence of hypervirulent complexes has
changed in the Czech Republic in the period 1993–2005. A
decrease of N. meningitidis C belonging to ST-11 complex and an
increase of N. meningitiﬁs Y belonging to ST-23 complex
occurred recently. In addition to the conjugate MenC vaccine,
tetravalent polysaccharide vaccine A, C, Y, W135 is
recommended for children.
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Republic and research grant EU-MenNet Contract No. QLK2-
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European Union.
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Rapid diagnosis of bacterial vaginosis by
terminal restriction fragment length
polymorphism proﬁling
F. Thies, W. Ko¨nig, B. Ko¨nig (Magdeburg, DE)
Objectives: Bacterial vaginosis (BV) is an ill-deﬁned disorder of
the vaginal microﬂora associated with impaired health
conditions of women and, possibly, of fetuses and newborns.
As cultivation is of limited value, the diagnosis of BV is
currently based on microscopical techniques (e.g., Nugent’s
Gram stain criteria). Molecular identiﬁcation methods are
supposed to provide more detailed insight into the bacterial
composition of the disturbed vaginal ﬂora. However, most
techniques described so far, as sequencing of 16S rDNA clone
libraries, are time-consuming and not suitable for routine
purposes. Therefore, we adapted a culture-independent
method for bacterial community analysis, called terminal
restriction fragment length polymorphism (T-RFLP), to the
needs of a routine microbiology laboratory.
Methods: Vaginal swabs were collected from 50 patients with
BV and, as control, from 25 healthy subjects. Disease status was
assessed using Nugent’s criteria. We analysed the bacterial
community directly from the swab specimens by means of the T-
RFLP method. T-RFLP analysis is based on the restriction
endonuclease digestion of ﬂuorescently end-labelled PCR
ampliﬁcates (derived from the 16S rRNA gene). For the
identiﬁcation of bacteria from T-RFLP raw data, we developed
an in-house computer software.
Results: Using T-RFLP, analysis of the vaginal microﬂora could
be accomplished within 12 hours. In each BV sample, we found,
on average, 6 to 8 typical ﬁngerprints corresponding to deﬁnite
bacterial species. Atopobium vaginae (95 % of all BV samples)
and Gardnerella vaginalis (60 %) proved to be the predominant
species, followed by Lactobacillus iners (50 %), Prevotella sp. (30
%) and Peptoniphilus sp. (15%). At least 3 different, and so far
uncharacterized, bacteria from the Clostridiales order could be
regularly detected, with one of them (a presumed Megasphaera
sp.) at a frequency of 70 %. In healthy controls, only lactobacilli
were detected.
Conclusion: Molecular tools are currently favoured for the
analysis of the vaginal microﬂora. As such a tool, T-RFLP
proved to be very promising for the rapid and detailed analysis
of the bacterial communities inhabiting the vagina. This
technique may be especially helpful in the context of clinical
studies, when collecting reliable and extensive microbiological
data may be crucial for the interpretation of study results.
O170
Development and validation of real-time PCR
assays for a multi-centre study to assess the
prevalence and epidemiology of shiga-toxin
producing Escherichia coli in the Netherlands
T. Schuurman, A. Roovers, W.K. van der Zwaluw, A.A. van
Zwet, L.J.M. Sabbe, A.M.D. Kooistra-Smid, Y.T.H.P. van
Duynhoven (Groningen, Goes, Bilthoven, Arnhem, NL)
Objectives: Traditionally, laboratory surveillance for shiga-
toxin producing Escherichia coli (STEC) has focused on the
detection of E. coli O157 by stool culture on sorbitol-MacConkey
agar (SMAC). Infections by E. coli O157 range from mild, self-
limiting diarrhea to hemorrhagic colitis and hemolytic-uremic
syndrome (HUS). Recently, non-O157 strains are increasingly
associated with diarrhea and HUS in several European
countries. Therefore, a nationwide screening program will take
place in the Netherlands from November 2005 to November
2006. This screening will be real-time PCR-based (RT-PCR), with
subsequent STEC isolation from the positive stools. Prior to the
start of this program, RT- PCR assays were developed and
validated.
Methods: Assays targeting the stx1 and stx2 genes were
developed for both LightCycler (LC) and TaqMan (TM). The
LC assay has been described by Bellin et al (J. Clin. Microbiol.
2001 370–374). The TM stx1 assay was adapted from Jinneman et
al. (Appl. Environ. Microbiol. 2003 6327–6333), whereas the stx2
assay was a new design. Stools were processed by a miniMAG
stool protocol. The phocine herpes virus-1 was used as an
internal control (IC). Both assays were validated with a panel of
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well characterized E. coli strains (n = 31) and non-E. coli strains
(n = 38). Intra-, inter-assay variation and analytical sensitivity
were assessed by dilution series (n = 8), spiked in 2 faecal
matrices, analysed in 5-fold on the same day and once daily on 4
subsequent days.
Results: Both assays proved speciﬁc for stx1 and stx2 genes
and no cross-reaction was observed. The TM assay was capable
of detecting approximately 10000 CFU/g of stool with a 100%
hit rate for both semi-solid and liquid stools. Lower hit rates
were observed at approximately 1000 CFU/g (22% and 67%).
The LC assay proved to be 1 log less sensitive (100% hit rate)
compared to the TM assay for semi-solid stools. Furthermore,
the LC assay did not detect approximately 1000 CFU/g.
Coefﬁcients of variation (CV) were < 5% for both TM and
LC assays.
Conclusion: Both TM and LC assays proved to be very
reproducible, although their sensitivities were not equal. The
lower sensitivity of the LC assay compared to TM is however
still in line with other published fecal RT-PCR assays. Probably,
it will not be detrimental to the screening, since it is still 1 to 2
log more sensitive compared to the reported sensitivity for
SMAC screening. Both RT-PCR assays are currently in use in the
Dutch STEC screening program.
O171
Based upon repeat patterns: variable number of
tandem repeat pattern analysis to infer clonal
groupings of Staphylococcus aureus strains from
spa typing data
T. Weniger, C. Berssenbruegge, A. Mellmann, J. Rothga¨nger,
M. Sammeth, J. Stoye, D. Harmsen (Munster, Wurzburg, Bielefeld,
DE)
Objectives: For molecular typing of Staphylococcus aureus and
in particular MRSA, DNA sequencing of the polymorphic X
region of the protein A (spa) gene is a well established and
highly discriminatory method. This spa region consists of a
variable number of 21–27 bp long repeats varying in
composition that result in the different spa types. It was
hypothesized that this region reﬂects not only short- but also
long-term epidemiology due to two different mechanisms of
evolution, i.e. repeat-duplication/-deletion and point
mutations. However, until today, no algorithm exists to infer
the clonal relatedness from different spa types. Therefore, the
Based Upon Repeat Patterns (BURP) algorithm was developed
and evaluated in this study.
Methods: For evaluation of BURP, 36 S. aureus strains that were
previously characterized by whole genome micro-array, spa,
multi locus enzyme electrophoresis (MLEE), pulsed-ﬁeld gel
electrophoresis (PFGE), and coagulase (coa) gene typing were
used (Koreen et al., J. Clin. Microbiol. 42:792–9, 2004). BURP
clusters (spa-CC) from these strains were determined using the
Ridom StaphType version 1.2 (Ridom GmbH, Wu¨rzburg,
Germany) software. This algorithm takes repeat-duplication/-
deletion and point mutation events into account when
calculating the relatedness of different spa types. spa types
shorter than 6 repeats were excluded from analysis because no
reliable evolutionary signal could be extracted. Subsequently,
spa-CCs were compared to the clustering of the various other
typing methods by using concordance analysis.
Results: The maximum achievable concordance with various
parameters (exclude spa types shorter than ‘‘x’’, cluster spa
types into spa-CC if cost distances are less than ‘‘y’’) between
BURP spa-CCs and the other methods were: for whole-genome
micro-array lineages 97.1% (0.81 Pearson correlation coefﬁcient),
92.2% (0.5), and 89.0% (0.31), for MLEE lineages 85.9%, for
MLEE types 91.3%, for PFGE types 98.3%, for coa lineages
96.6%, and for coa types 95.6%. If 3 very short spa types were
excluded from analysis, a maximum of 99.8% concordance
between spa-CCs and manually by Koreen et al. grouped spa
lineages was obtained.
Conclusion: BURP was able to extract automatically an
evolutionary signal from spa repeat patterns rather congruent
to signals found by other typing approaches. Therefore, by using
just single variable number of tandem repeat sequences of S.
aureus - for the ﬁrst time - a meaningful clustering could be
realized.
O172
Multiple locus variable number tandem repeat
assays do not differentiate between community-
associated and healthcare-associated lineages of
methicillin-resistant Staphylococcus aureus
F. Tenover, R. Vaughn, L. McDougal, G. Fosheim, J. McGowan
Jr. (Atlanta, US)
Objective: The ability to type methicillin-resistant
Staphylococcus aureus (MRSA) strains rapidly in clinical
laboratories and differentiate between multi-resistant
healthcare-associated (HA) MRSA strains and the more
susceptible, but more virulent, community-associated (CA)
MRSA strains, could improve public health and infection
control efforts to reduce MRSA spread in hospitals and
communities, and guide empiric therapy. Published reports
suggest that multiple locus variable number tandem repeat
assays (MLVA) for S. aureus parallel results of pulsed-ﬁeld gel
electrophoresis (PFGE). Our objective was to determine if a
simple MLVA protocol, suitable for a clinical laboratory, could
differentiate known HA- and CA-MRSA types and replace the
more tedious and costly PFGE typing.
Methods: Eighty well-characterized isolates representing the 12
major lineages of S. aureus in the US. were selected from the
strain collections of the Centers for Disease Control and
Prevention (CDC) and Project ICARE. MLVA was performed
using a rapid DNA extraction method and a multiplex
polymerase chain reaction assay with primers for sdrCDE,
clfA, clfB, sspA, and spa, which generated 6–7 bands following
agarose gel electrophoresis. PFGE was performed using SmaI as
per CDC protocols. Banding patterns were analysed visually (as
would be done in a clinical laboratory) and using BioNumerics
software. For BioNumerics, Dice coefﬁcients were used with
UPGMA clustering algorithms to generate dendrograms.
Results: All isolates were typeable with MLVA, which
appeared initially to differentiate among the 12 PFGE lineages.
However, when additional isolates were typed, MLVA results
placed isolates of PFGE type USA300-0114, the most commonly
isolated CA-MRSA in the US., into several unrelated clusters
(<70% similarity). MLVA patterns for 2 USA300 (ST8) isolates
also clustered with patterns of USA1000 (ST59) isolates. MLVA
did not consistently differentiate CA-MRSA lineages (USA300,
USA400, USA1000, and USA1100) from HA-MRSA lineages
(USA100, USA200, USA500, or USA600).
Conclusions: Although MLVA is feasible for clinical laboratory
use, the results do not parallel those of PFGE for the major
lineages of CA-MRSA and HA-MRSA in the US. While MLVA
may be useful for rapid analysis of isolates from potential
outbreaks, it cannot replace PFGE since strains are clustered
differently. The epidemiologic and clinical utility of differences
between MLVA and PFGE results requires further study.
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Molecular typing of Mycobacterium tuberculosis
by mycobacterial interspersed repetitive unit –
variable-number tandem repeat analysis in
Lisbon in 2003
E. Fernandes, R. Macedo, C. Furtado, L. Brum, I. Portugal
(Lisbon, PT)
Objectives: In 2003, the Portuguese Health Authorities reported
a tuberculosis (TB) incidence of 41.1/100,000 population
nationwide and that 1.7% of tuberculosis cases were multidrug
resistant (MDR-TB). Despite the signiﬁcant decline of TB
incidence over the past decades, Portugal remains the country
with the highest rate of notiﬁed cases due to Mycobacterium
tuberculosis in Central and Eastern E.U., corresponding to an
incidence of about three and a half times more than the E.U.
average. Lisbon was the Portuguese districts with the highest
incidence, 58 cases per 100,000 inhabitants. Comparing to the
standard method IS6110 restriction fragment length
polymorphism (RFLP), typing methods based on
mycobacterial interspersed repetitive unit - variable-number
tandem repeat (MIRU-VNTR) analysis offer an alternative and
more accurate method for identifying epidemiological links
between patients with tuberculosis The aims of the present
study were to determine the genetic diversity of M. tuberculosis
strains circulating in Lisbon, to evaluate the possible continuous
prevalence of previous detected family Lisboa strains, and to
evaluate the proportion of recently transmitted disease between
patients.
Methods: Four-hundred clinical M. tuberculosis isolates
collected in several hospital and public health laboratories in
Lisbon area in 2003, were characterised at molecular level using
MIRU-VNTR typing, including 125 MDR-TB strains and 89
resistant strains other than MDR-TB.
Results: Among the 400 M. tuberculosis isolates in Lisbon, we
found 124 different MIRU-VNTR patterns. Fifty-three MIRU-
VNTR clusters were found in 265 analysed strains, and ranged
in size from two to 26 patients. The largest cluster was cluster
Lisboa 3, and included 22 MDR-TB strains. We have found
another three signiﬁcant clusters with 18, 12 and 8 isolates, being
the ﬁrst one cluster Lisboa 2, also majority MDR-TB.
Conclusion: Family Lisboa strains are still responsible for the
main tuberculosis in Lisbon area, particularly the MDR-TB
cases. Although epidemiological investigation is still going on,
we were able to establish epidemiologic relationships in a few
clustered patients carrying family Lisboa strains. This ﬁnding
supports the conclusion that these cases resulted from recent
transmission. Nevertheless, we did not detect any signiﬁcant
outbreak, as the clustered strains were mostly collected in
several hospital units.
O174
Clinical impact of a rapid PCR-based
identiﬁcation of staphylococci directly from
positive blood cultures
P. Agmon, I. Oren, R. Finkelstein, H. Sprecher (Haifa, IL)
Objective: Staphylococcal bacteremia is common among
hospitalized patients and associated with signiﬁcant morbidity
and mortality. Staphylococci are the major gram positive isolates
of blood culture in our medical center and 60% of them are
caused by Coagulase Negative Staphylococci (CoNS). Isolation
of CoNS, unlike bacteremia from Coagulase Positive
Staphylococci (CoPS), is often a result of contamination of the
blood culture. Rapid and accurate identiﬁcation of CoPS vs.
CoNS, and determination of susceptibility to methicillin is
crucial for instituting timely and appropriate therapy. However,
standard identiﬁcation and susceptibility testing requires on
average, three days. The aim of the present study was to
evaluate a rapid method for identiﬁcation of Staphylococci
directly from blood culture using a multiplex PCR assay.
Methods: A three-month prospective surveillance of patients
with Staphylococcal bacteremia was conducted, in which both a
standard microbiological approach and a PCR-based assay were
comparatively studied. DNA was extracted from positive blood
culture bottles using the benzyl alcohol-guanidine
hydrochloride method. Four sets of oligonucleotide primers
were used: universal bacterial 16S rRNA, staphylococcal speciﬁc
sequence in the 16S rRNA gene, the CoPS speciﬁc nuc gene and
the mecA gene which encodes resistance to methicillin.
Results: During the study 330 Staphylococci were isolated from
217 patients. CoNS were isolated in 85% of patients and 53% of
CoPS were methicillin-resistant Staphylococcus Aureus (MRSA).
The sensitivity of the PCR assay as compared with conventional
microbiological testing was 98.7 %. The PCR assay shortened the
turnaround time of identiﬁcation and susceptibility results by
20 hours, which translates in practical terms, to one calendar
day. The cost of the PCR assay was found to be lower than the
cost of the conventional approach. Application of the PCR assay
was found to prevent unnecessary therapy in patients from
whom CoNS were isolated (P = 0.0002) and to correctly direct
treatment choice against CoPS (P = 0.006).
Conclusions: PCR-based detection of Staphylococci directly
from blood culture bottles is rapid (4 h), and highly sensitive
(98.7). Implementation of this assay was shown to signiﬁcantly
improve the quality of patient management. Considering the
above results, we recommend application of the molecular assay
as the standard assay for identiﬁcation of Staphylococcal
bacteremia.
O175
Clinical evaluation of a molecular-based assay for
the detection of methicillin-resistant
Staphylococcus aureus and Staphylococcus aureus
in positive blood cultures
D. Fuller, T. Davis, M. Parker, R. Buckner, J. Talbott
(Indianapolis, US)
Objective: Staphylococcus aureus (SA) is a major cause of
bloodstream infections accounting for up to 20% of isolates
found in positive blood cultures. Methicillin-resistant
Staphylococcus aureus (MRSA) accounts for nearly 50% of
bacteremia caused by SA. Culture techniques for MRSA require
a minimum of 48 hours for conﬁrmation. Development of
sensitive molecular ampliﬁcation techniques now allows for
detection of only a few copies of bacterial DNA in clinical
samples which could affect patient treatment, prevent
transmission and control outbreaks.
Methods: The purpose of this study was to evaluate the IDI-
MRSATM and a prototype MRSA/SA assay (GeneOhm Sciences,
Inc., SanDiego, CA) for direct detection ofMRSA andmethicillin-
sensitive SA (MSSA) in positive blood cultures using real-time
PCR technology. The IDI-MRSA assay provides a positive result
only when MRSA is present in the sample; the MRSA/SA
combines a target speciﬁc to MRSA (the SCCmec/orfX junction)
and an SA-speciﬁc target which provides a separate result for
MRSAandMSSA thus allowing the direct detection ofMRSAand
MSSA (both assays also include an internal control). Aliquots
from positive blood cultures were directly processedwith the IDI
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lysis components and tested with each assay using the Cepheid
SmartCycler instrument.
Results: Of the 323 blood cultures tested to date, 127were known
to be positive for MRSA, 155 were positive for pathogens other
than MRSA (including coagulase negative staphylococci and
MSSA), and 80 were known negative blood cultures. The IDI-
MRSATM and MRSA/SA assays showed complete agreement
with conventional identiﬁcation and susceptibility results.
Conclusion: The IDI-MRSATM and the prototype MRSA/SA
assays are an excellent alternative for the detection of MRSA and
MSSA (only with the combined assay) directly from positive
blood cultures. These assays are rapid (2 hours after positive
blood culture, accurate (100% sensitivity & speciﬁcity), ﬂexible
(single sample or batch testing), and adapt easily to existing
laboratory workﬂow.
The pros and cons of combination antimicrobial treatment
S196
Combination therapy for community-acquired
pneumonia
A. Torres (Barcelona, ES)
Severe community-acquired pneumonia (SCAP) refers to those
patients with community-acquired pneumonia who are admit-
ted to an intensive care unit. The frequency of SCAP ranges
between 5 to 35% (1,2), which indicates the lack of uniformity
used in the criteria for ICU admission.The deﬁnition of SCAP is
a matter of interest. The most accurate criteria were described by
Ewig et al (3,4). The presence of one of two major criteria
(mechanical ventilation or septic shock) or two of the three
minor criteria (systolic blood pressure £ 90, multilobar involve-
ment, PaO2/FIO2 ratio <250) resulted in 78% sensitivity and
94% speciﬁcity (3). These criteria compared favourably to other
scores such as the PSI or the BTS rules (4,5) and, in summary, is
probably the best rule those patients with CAP who will beneﬁt
from ICU admission. Mortality of SCAP ranges between 20 to
50% (6). More than 40 prognostic factors are associated with
death from CAP (7). They can be divided into basic (before
admission), baseline (at admission) and disease progression
factors. The most important, to potentially reduce treatment
failure or mortality, are the inadequacy of antimicrobial therapy
and the delay in appropriate therapy. Two studies (8,9) showed
an increased mortality if antibiotic treatment is started 4 or
8 hours after emergency department arrival, respectively.
Adequacy of initial antimicrobial treatment refers to the right
antimicrobial coverage (including resistances) of causal micro-
organisms using correct dosages. In 50% of cases the etiology of
SCAP is unknown and experts have given recommendations for
empirical treatment based in the % of cases in which deﬁnite
microbial etiology is found.Microbial etiology of SCAP differs
according to age (10), presence of pulmonary commorbidities
(11), and HIV (12). Geographical and seasonal variables differ-
ences have to be taken into account for presence of atypical
microorganisms, Legionella, viruses and resistances to antibiot-
ics. These factors have to be considered when prescribing initial
antibiotics in SCAP. Nursing-home patients should be treated
for nosocomial pneumonia as recently recommended (13). All
the guidelines recently published (14, 15, 16) recommend a
antibiotic combination for the empirical treatment of SCAP. A
betalactam plus a macrolide (mainly clarithromycin or azithro-
mycin) or a respiratory quinolone (mainly levoﬂoxacin or
moxiﬂoxacin) are the two options. If Pseudomonas isa consid-
eration (11) a betalactam with antipseudomonal activity plus
ciproﬂoxacin is the best therapeutic option. Some ﬁndings
suggest that respiratory quinolones could be a better option than
macrolides when using combination therapy. Moxiﬂoxacin had
slightly better clinical efﬁcacy when compared to a combination
of third generation cephalosporin plus minus a macrolide (17) in
one study. In a large series of hospitalized CAP in which
treatment failure was investigated (18), respiratory quinolones
proved to be protective. None of the guidelines mentioned
above have recommended monotherapy for the initial treatment
of SCAP. One of the main reasons to avoid monotherapy is the
lack of extensive experience in SCAP. Another reason the body
of evidence that suggests that a combination of antibiotics may
improve mortality in bacteremic pneumococcal pneumonia.
Two retrospective studies (19, 20) found that combining at least
two antibiotics showed a better outcome compared to mono-
therapy. This ﬁnding is difﬁcult to explain but could be due to
the potential hidden presence of atypical pneumonia or Legio-
nella associated with Streptococcus pneumoniae and secondly to
the anti-inﬂammatory effects of some types of antibiotics such as
macrolides (21). Potential pitfalls of these two studies are the
lack of control for confounders and their retrospective design. A
recent observational and prospective multinational study, Bad-
dour et al (22) proved the beneﬁcial effect of combination
therapy compared to monotherapy in bacteremic pneumococcal
pneumonia (when septic shock was present). An open random-
ized clinical trial comparing levoﬂoxacin in monotherapy to a
combination of cefotaxime plus oﬂoxacin was published in 2005
(23). In this study the clinical success was similar in the two
arms (79%). The bacteriological response was also similar in
both groups. Importantly, patients with septic shock prior to
inclusion were excluded. Patients with treatment failure could
be included unless one of the antibiotics under study was
previously given. The conclusion of the authors is that levoﬂ-
oxacin was at least as effective as the combination in SCAP,
unless patients required vasopressors or mechanical ventilation.
However, the antibiotic combination chosen by the authors is
probably not the best that we currently have to treat SCAP
(14,15). Consequently, we cannot say that monotherapy with
levoﬂoxacin is as effective as the standard recommended
combination. On the other hand patients with septic shock
were excluded. Septic shock may be present in up to 30% of
patients with SCAP (2). Third, speciﬁc criteria of severity were
not prospectively used. In fact the inclusion criteria in the trial
were ICU admission. These criteria are subjective and depend
on each ICU and hospital availabilities and necessities. New trial
should use the speciﬁc criteria for SCAP described in the
literature (3). This will ensure the inclusion f a more heteroge-
neous population. Finally, 29 out of 139 from the monotherapy
treated group had failure at TOC visit. Similar rates were
reported with the combination. However, there were 7 cases of
insufﬁcient response (7/29; 24%) during treatment in the
monotherapy group vs 1 (1/27; 3%) in the combination group.
This ﬁnding and needs further evaluation. Fogarty et al (25)
investigated the safety and the efﬁcacy of levoﬂoxacin compared
to ceftriaxone plus erythromycin, followed by amoxiclavulanate
plus clarythromycin in the treatment of serious CAP in adults.
In this study, the term ‘‘serious’’ was not equivalent to ICU-
admitted patients. The overall clinical efﬁcacy was similar in
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both arms (close to 85%).The key issue in this topic is whether or
not antibiotic monotherapy can be used conﬁdently for the
treatment of SCAP. This is impossible to answer at the current
moment.It is important to avoid combination in such a small
and severe group of CAP patients? The answer is no. Using a
combination of antibiotics in SCAP may improve treatment
failure and mortality without an important impact in resistanc-
es. In addition, cost should not be an issue to consider in these
patients at all. In my opinion, we have to continue recommend-
ing a combination of antibiotics to treat SCAP and to avoid
monotherapy, at least in the ﬁrst 5 days of treatment. New RC
trails should be addressed to ﬁnd the safety and clinical efﬁcacy
de-escalation therapy and to determine which is the best
antibiotic combination.
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Combination antifungals: in dubio agite
M. Akova (Ankara, TR)
More than 25 years ago combination of amphotericin B (AmB)
and 5-ﬂuorocytosine was shown to be more effective than AmB
alone in the treatment of cryptococcal meningitis. Since then, the
accumulation of evidence in using antifungal combinations for
other invasive fungal infections has been slow. This was initially
due to the controversy related to in vitro antagonism between
azoles and polyenes and the lesser frequency of invasive fungal
infections which were, then, treatable with early azoles such as
ﬂuconazole in case of candidiasis and amphotericin B that
sufﬁciently provided coverage for most of mold infections.
However, the clinical picture has signiﬁcantly changed during
the last two decades. First, the incidence and of invasive fungal
infections has sharply increased and their epidemiology
changed. Secondly, newer, broader-spectrum antifungals with
previously non-existent mechanisms of effect have become
commercially available. Disseminated infections caused by
non-Candidal yeasts and not only Aspergillus spp., but also
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previously rarely seen non-Aspergillus mold infections have
emerged as signiﬁcant causes of morbidity and mortality among
immunosuppressed patients. Since these infections are usually
difﬁcult-to-treat and related mortality in infected patients
remains to be very high, especially in those who are persistently
immunosuppressed, the clinicians are tempted to use various
newer antifungals with novel mechanism of action in combina-
tion in different clinical settings, especially in invasive aspergil-
losis. The rationale behind this rekindled interest is to achieve
synergy and to a lesser extend, to reduce antifungal resistance.
Although, there has been no controlled clinical trials comparing
antifungal combinations with monotherapy so far, evidence
gathered from small series and anectodal experience clearly
indicates that antifungal combination therapy has become a
clinical reality, particularly in those patients with severe immu-
nosuppression and disseminated mould infections. The avail-
able data from above mentioned observations also pointed out
that combinations of newly approved imidazoles (e.g. voricon-
azole) and echinocandins (e.g. caspofungin) with other agents
are very unlikely to be antagonistic. Future studies are deﬁnitely
required whether combination therapy with these new agents
would improve survival and treatment outcome in the seriously
hampered patients with life threatening fungal infections.
Emerging viral exotica in Europe (Symposium jointly arranged
with the ISID)
S200
Rabies and other lyssaviruses in Europe 2006
M.J. Warrell (Oxford, UK)
Rabies and European bat lyssaviruses are enzootic in European
mammals. 13 people died of rabies in Europe in 2004. Ideal
rabies prophylaxis (pre-exposure immunisation with post-expo-
sure boosting) is 100% effective, so every human death must be
regarded as a preventable tragedy. Rabies was diagnosed in
5393 European domestic and wild animals in 2004. Although
indigenous rabies infection has been virtually eliminated from
terrestrial animals in Western Europe, it will be impossible to
control European bat lyssavirus infection, which is widespread
across the continent. 3.5%, of a total of 1305 bats tested, proved
rabid, but 60% of European countries did not report having
tested any bats at all in 2004. In Europe the risk of human
infection will therefore persist from two possible sources:
indigenous species and imported animals, as shown on 3
occasions in France in 2004. The publicity from one case
revealed >300 other illegally-imported cats and dogs. A far
greater risk is to travellers to countries where dog rabies is
endemic. Unrecognised rabies encephalitis in a woman who had
returned from India resulted in the deaths of 3 organ transplant
recipients in Germany in 2005.The global incidence of human
rabies is unknown. Recent WHO surveillance estimates a
mortality rate between 24,000 and 93,000 deaths annually in
Asia and Africa. The means are now available to eliminate
domestic dog rabies. If this were achieved, >99% of all human
disease would be prevented and the need for expensive vaccines
and rabies immunoglobulin (RIG) drastically reduced. Mean-
while rabies deaths occur due to ignorance, inaccessibility or
unaffordability of speciﬁc treatment, or occasionally to other
diseases inhibiting the immune response. Primary post-expo-
sure treatment is very effective if wound cleaning, RIG and
vaccine are given correctly on the day of the exposure, but this
cannot be guaranteed worldwide. Now that there is a global
shortage of RIG, it is increasingly important, to encourage the
use of pre-exposure vaccine treatment, which avoids the need
for passive immunisation should exposure occur. The often
prohibitive cost of prophylaxis for travellers and residents of
dog rabies endemic areas can be reduced by immunising a
group with 0.1 ml vaccine intradermally. Rabies in man remains
virtually always fatal, although in 2004 in Wisconsin, intensive
care and antiviral therapy has contributed to a remarkable
recovery in a girl who had not had any previous vaccine
treatment.
S201
Toscana virus: emergence in Southern Europe
R.N. Charrel (Marseille, FR)
Toscana virus (TOSV) is an arthropodborne virus ﬁrst identiﬁed
in 1971 from the sandﬂy Phlebotomus perniciosus in central Italy.
Many case reports in travellers and clinical research and
epidemiologic studies conducted around the Mediterranean
region have shown that TOSV has a tropism for the central
nervous system (CNS) and is a major cause of meningitis and
encephalitis in countries in which it circulates. In central Italy,
TOSV is the most frequent cause of meningitis from May to
October, far exceeding enteroviruses. In other northern Medi-
terranean countries, TOSV is among the 3 most prevalent
viruses associated with meningitis during the warm seasons.
Therefore, TOSV must be considered an emerging pathogen.
Here, we review the epidemiology of TOSV in Europe and
determine questions that should be addressed in future studies.
Despite increasing evidence of its major role in medicine as an
emerging cause of CNS infections, TOSV remains an unstudied
pathogen, and few physicians are aware of its potential to cause
CNS infections
S202
Viral haemorrhagic fever: diagnosis and
management of highly contagious diseases
C. Hatz (Basel, CH)
Four families of viruses are known to cause haemorrhagic fevers
in man. Most of them are zoonoses. People get infected while
undertaking activities in remote areas where the animal hosts
live. In general, tourists are unlikely to become infected with
viruses causing haemorrhagic fevers. Awareness of the problem
in endemic areas and simple precautions such as avoiding trips
to remote areas and to places where epidemics are ongoing,
protection against mosquito bites, and avoiding contact with
dead animals, further reduce the risk. A vaccination against
yellow fever is available. If the suspicion of a VHF is raised,
immediate action must be taken. A practical approach includes
consulting a specialist in tropical or infectious diseases, an
admission to a university hospital, and an immediate notiﬁca-
tion to the health authorities.
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Connexion between efﬂux pump expression and
virulence in Pseudomonas aeruginosa
J.F. Linares, P. Sanchez, J.L. Martinez (Madrid, ES; San Antonio,
US)
The ubiquity of multidrug (MDR) pumps supports the idea that
their original function is not just antibiotic resistance (AR). In
fact, the same MDR pumps are ﬁnd in P. aeruginosa isolates from
clinical and non-clinical environments (1). It was shown that
MDR pumps, besides contributing to antibiotic resistance, play a
role modulating bacterial virulence. P. aeruginosa MDR pumps
contribute to intrinsic and acquired AR. Since some P. aeruginosa
MDR pumps extrude quorum sensing (QS) autoinducers, and
QS response has a prominent role in P. aeruginosa virulence,
MDR pumps-overexpressing (multiresistant) bacteria might be
less virulent than wild-type ones. It has been established that P.
aeruginosa mutants overproducing MexAB-OprM or MexCD-
OprJ produce less amounts of QS-regulated virulence factors
and have reduced virulence (2–4). But the scenario is more
complex. Overexpression of either MexCD-OprJ or MexEF-
OprN reduces P. aeruginosa cytotoxicity and challenges Type III
secretion (T3S) via a QS-independent way (5). If MDR bacteria
are less virulent than wild-type ones, why they can be selected
during infection? Two possibilities are possible: (1) Under
antibiotic treatment, resistance can be considered a colonization
factor (6). (2) Antibiotic resistance might make bacteria more
proﬁcient for producing a speciﬁc type of infection. It was found
that neither MexAB-OprM nor MexCD-OprJ over expression
reduced bioﬁlm formation (2). P. aeruginosa is the major cause of
chronic infection in cystic ﬁbrosis patients, and bioﬁlm is very
important for persistent infections. Epidemiological data have
shown that, during chronic infection, P. aeruginosa evolves to
produce less amounts of QS-regulated virulence factors and
tends to be defective in T3S, maintaining bioﬁlm production.
Thus, the virulence factors required for either acute or chronic
infection might be different. Since overproduction of P. aerugi-
nosa MDR pumps is associated to the phenotype of chronic
infections’ isolates, MDR pumps-overproducing P. aeruginosa
strains might be impaired for developing acute infections, but
not for their maintenance during chronicity.
1. A. Alonso, F. Rojo, J. L. Martinez, Environ Microbiol 1, 421
2. P. Sanchez et al., J Antimicrob Chemother 50, 657
3. B. Ruiz-Diez, P. Sanchez, F. Baquero, J. L. Martinez, A. Navas,
J Theor Biol 225, 469
4. P. Cosson et al., J Bacteriol 184, 3027
5. J. F. Linares et al., J Bacteriol 187, 1384
6. J. L. Martinez, F. Baquero, Clin Microbiol Rev 15, 647
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Quinolone resistance and virulence in
uropathogenic Escherichia coli
J. Vila (Barcelona, ES)
Escherichia coli are the most common microorganisms causing
urinary tract infections. Uropathogenic E. coli (UPEC) strains
possess several virulence determinants that allow them to
colonize the urinary tract, avoid host defenses, and cause
damage to the uroepithelium. Bioﬁlm formation can also be
considered as a virulence determinant. Quinolone-resistant
E. coli strains have fewer virulence factors than quinolone-
susceptible strains. Several urovirulence genes are located in
pathogenicity islands (PAIs). We investigated the capacity of
quinolones to induce loss of virulence factors, such as hemoly-
sin, cytotoxic necrotizing factor-1, P-ﬁmbriae and autotransport-
er Sat, included in PAIs in three uropathogenic E.coli strains, as
well as the relationship between quinolone-resistance acquisi-
tion and bioﬁlm formation. Three quinolone-susceptible uro-
pathogenic E.coli clinical isolates belonging to phylotype B2
were chosen. In a multistep selection all three strains lost
hemolytic capacity between 1–4 passages when incubated with
subinhibitory concentrations of ciproﬂoxacin, showing a partial
or total loss of the PAI containing the hly (hemolysin) and cnf-1
(cytotoxic necrotizing factor-1) genes. RecA- mutants were
obtained from the two E. coli strains with partial or total loss
of the PAI. The inactivation of the RecA protein only affected the
partial loss of PAI induced by quinolones. No spontaneous loss
of PAIs was observed on incubation in the absence of quinolone
in either the wild-type or mutant E.coli strains. Growth of
bioﬁlm-producing E. coli in the presence of salycilate inhibits the
productions of bioﬁlm. A quinolone-resistant UPEC mutant was
obtained from a bioﬁlm-producing UPEC strain. The resistant
mutant did not produce bioﬁlm, had a mutation in the amino
acid codon Ser-83 of the gyrA gene and over expression of an
efﬂux pump. The complementation of this mutant strain with a
wild-type GyrA did not revert the production of bioﬁlm
suggesting that a mechanism of quinolone resistance rather
than mutation in the gyrA gene could be involved in the
decrease formation of bioﬁlm. In fact, the quinolone-resistant,
non-producing bioﬁlm UPEC mutant showed a decrease in the
expression of both ﬁmA and papA genes. In conclusion,
quinolones induce partial or total loss of PAIs in vitro in
uropathogenic E. coli by SOS dependent or independent path-
ways, respectively. Moroever the acquisition of quinolone
resistance may decrease the production of bioﬁlm in UPEC.
S210
Efﬂux pump expression and bacterial survival in
Neisseria gonorrhoeae
W.M. Shafer (Atlanta, US)
Neisseria gonorrhoeae is a strict human pathogen that causes the
sexually transmitted disease gonorrhea. Over 62 million cases of
gonorrhea occur each year worldwide. While gonorrhea remains
treatable with antibiotics, the recommended treatment regimens
are expensive compared to the relatively cheap cost of penicillin,
which was previously (prior to 1985) the drug of choice. Efﬂux
pumps possessed by N. gonorrhoeae contributed to the develop-
ment of resistance to certain antibiotics, such as penicillin. Efﬂux
pumps were expressed by bacteria, including N. gonorrhoeae,
long before antibiotics were used to treat bacterial infections. For
those bacteria capable of existing outside of a host for extended
periods of time, efﬂux pumps likely provided them with an
ability to resist antimicrobials in the soil or water. Why would
those bacteria that typically must exist within another living
system possess efﬂux pumps? The answer is that these bacteria
must have a rapid means of dealing with host-derived anti-
microbials that are either naturally present on surfaces or
become available in bodily ﬂuids or they will perish. Efﬂux
pumps have the ability to recognize structurally diverse
antimicrobials, which serve as ‘‘host antibiotics’’ and are on
the frontline of the innate immune response. A speciﬁc example
of the action of efﬂux pumps in recognizing and exporting these
antimicrobials is that of the MtrC-MtrD-MtrE efﬂux pump of N.
gonorrhoeae, which recognizes antibiotics (macrolides and certain
beta-lactams) and host antimicrobials such as antibacterial
peptides produced by phagocytic and epithelial cells. This
pump has been shown to be essential for gonococcal survival on
the vaginal mucosal surface in an experimental murine infection
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model. The expression of genes encoding efﬂux pumps is
regulated at the transcriptional level by both repressors and
activators. In N. gonorrhoeae, these DNA-binding proteins also
regulate other bacterial genes involved in virulence or bacterial
physiology. Thus, it is likely that efﬂux pumps are integrated
into the overall processes of bacterial survival.
Diagnostic and laboratory methods
O211
Impact on mortality and cost-effectiveness of
rapid bacterial identiﬁcation and antimicrobial
susceptibility testing in comparison with
standard methods
J.J. Kerremans, P. Verboom, W.H.F. Goessens, L. Hakkaart-van
Roijen, T. Stijnen, H.A. Verbrugh, M.A. Vos (Rotterdam, NL)
Objectives: Rapid and correct identiﬁcation and susceptibility
testing of bacteria is valuable for good patient care. Rapid
identiﬁcation and susceptibility results are shown to be cost-
effective and did reduce mortality in the United States. In this
study, we examined whether accelerated bacterial diagnostics
were cost-effective and if this resulted in a signiﬁcant difference
in mortality in a Dutch setting.
Methods: Inpatients of the Erasmus MC, Rotterdam, the
Netherlands, were randomly assigned to either the intervention
arm or the control arm, when they had a positive culture from a
normally sterile body ﬂuid (excluding urine samples). The
intervention was by using a fast automated method for bacterial
identiﬁcation and antimicrobial susceptibility testing (the VITEK 2
system, bioMe´rieux, Marcy-l’E´toile, France) combined with direct
inoculation of blood cultures. In the control arm our standard
method was used: the Vitek 1(bioMe´rieux, Marcy-l’E´toile, France)
system inoculated from subculture plates. Patients were
prospectively followed up for 4 weeks after inclusion for mortality
data and costs of health care. Total costs of hospitalization were
calculated by taking true cost if possible, otherwise charges were
used as deﬁned by the National Health Tariffs Authority (CTG).
Results: 1465 patients were included and randomized: 730 in the
intervention arm, 735 in the control arm. In both arms 70% of
patients were included based on a positive blood culture result,
the remaining 30% were included based on a positive cultures
fromanotherbodyﬂuid. These cultures containedGram-negative
rods in 37% of all cases, coagulase-negative staphylococci in 27%,
S.aureus in 14% and other organisms in 22%.The difference in time
between the two arms from randomization until a result of the
laboratory was available, averaged 22 hours for susceptibility
results and averaged 13 hours for identiﬁcation (P < 0.0001).The
treatment-costs of a patient in the intervention arm were on
average € 8.831,-, the costs in the control arm were on average €
8.641,-(difference not signiﬁcant). The number of deaths in the
intervention arm was 117 out of 730 patients (16%), in the control
arm 99 out of 735 patients (13,5%) (difference not signiﬁcant)
Conclusion: In our hospital, rapid bacterial identiﬁcation and
antimicrobial susceptibility testing does not lead to a signiﬁcant
difference in mortality and costs.
O212
Comparison of NucliSens easyMAG, NucliSens
miniMAG and Qiagen nucleic acid extraction
systems using throat swabs for the detection of
M. pneumoniae and C. pneumoniae
K. Loens, K. Bergs, D. Ursi, H. Goossens, M. Ieven (Edegem, BE)
Objectives: To evaluate the performance of the NucliSens
easyMAG NA extraction system on throat swabs with the
Qiagen extraction and the miniMAG as references for
subsequent DNA and RNA ampliﬁcation, respectively.
Materials and methods: 215 throat swabs from patients with
community-acquired pneumonia were included in the study:
On arrival in the lab, samples were aliquoted and nucleic acids
(NAs) were extracted using the Qiagen blood mini kit. NAs
extracts were analysed by real-time PCR for the detection of
M. pneumoniae DNA and C. pneumoniae DNA. NAs were
retrospectively extracted from other aliquots of the same
specimens using the NucliSens miniMAG and the NucliSens
easyMAG off-board protocol and subsequently subjected to real-
time PCR and real-time NASBA for the detection of DNA and
RNA of both organisms, respectively.
Results: The real-time PCR detected M. pneumoniae and
C. pneumoniae in 10 and 5 throat swabs after Qiagen extraction
and in 9 and 5 swabs after easyMAG extraction. Real-time
NASBA detected M. pneumoniae and C. pneumoniae in 9 and 5
throat swabs after both miniMAG and easyMAG extraction. For
the detection of the 9 M. pneumoniae positive specimens the
difference between the Lightcycler Ct values obtained after the
NucliSens easyMAG extraction and Qiagen extraction were
respectively -3.88, )0.6, )5.77, )2.83, )1.2, )0.46, )2.47, 1.9, and
)2.49. For the detection of 5 C. pneumoniae positive specimens
the Ct values obtained for the NucliSens easyMAG were
respectively )2.78, )2.32, )3.14, )2.02, and )6.62 as compared
to results obtained after Qiagen extraction. Similar results were
obtained after real-time NASBA ampliﬁcation for both
organisms. The number of invalid results in negative
specimens, due to inhibition, obtained after real-time NASBA
decreased from 3.2% to 0.7% when using the miniMAG and
easyMAG, respectively. Furthermore, the same NAs extracts
could be used for both RNA and DNA ampliﬁcation.
Conclusion: In this study the NucliSens easyMAG extracted
more efﬁciently the RNA and DNA of the clinical samples
(higher recovery and/or less inhibitors) by showing on average
lower ct values in the Lightcycler real-time PCR assays and less
invalid results in the real-time NASBA assays. The instrument
features user-friendly software, intuitive software, and delivers
high throughput capabilities with 40 minutes turn-around-
times.
O213
Intelligent sample preparation to improve nucleic
acid-based pathogen detection
S. Sachse, K.H. Schmidt, M. Lehmann, S. Russwurm, E. Straube
(Jena, DE)
Objectives: Culture independent pathogen detection methods
become increasingly interesting due to the limitations of the
blood culture technique, e.g. negative results after antibiotic pre-
treatment, non-cultivable micro organisms and time-to-result
delays of more than 4 days. However, existing nucleic acid-
based detection (NA) methods, e.g. PCR, have some serious
drawbacks if applied to clinical samples like whole blood.
However, their sensitivity is not adequate compared to the gold
standard blood culture technique. The reduced sensitivity of NA
methods for bacterial detection is due to very low amounts of
bacterial DNA compared to the human DNA background.
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Therefore, an improvement of NA methods can be achieved by
an innovative sample preparation procedure, which reduce the
human DNA background signiﬁcantly and enrich the bacterial
DNA simultaneously. Here, a sample preparation method is
shown, which overcomes the limitations of culture independent
NA systems.
Methods: A recombinant protein with speciﬁc binding afﬁnity
for prokaryotic DNA is the keystone of our innovative and easy-
to-use sample preparation method. To validate the properties of
this protein, we performed classical gel retardation, radioactive
experiment, classical as well as real time PCR experiments using
artiﬁcial DNA mixtures containing pro- and eukaryotic DNA as
well as spiked blood samples.
Results: Our experiments showed that prokaryotic DNA is
speciﬁcally retained by the described protein. The protein can be
immobilised to matrices and transferred to spin columns for
enrichment experiments. The DNA preparation procedure using
such columns enables an enrichment of prokaryotic DNA in
mixtures containing both pro- and eukaryotic DNA.
Furthermore, by means of radioactive and real time PCR
experiments, it could be shown that the application of this
procedure decreases the background of human DNA
signiﬁcantly (up to 90%), leading to an increased sensitivity of
the PCR methods for bacterial detection in blood samples.
Conclusion: The proposed unique pre-analytic method
improves the sensitivity of PCR or other NA methods for the
detection of small amounts of bacterial DNA in complex
samples (e.g. human whole blood), by a signiﬁcant reduction
of the eukaryotic DNA background and enrichment of bacterial
DNA simultaneously. This might be a milestone allowing ‘‘same
day diagnosis’’ of sepsis and SIRS as well.
O214
Point-of-care detection of group B Streptococci in
labouring women: a new approach to preventing
early onset neonatal GBS disease
E.H. Smith, P. Milner, J. Gray, L. Spicer (Birmingham, UK)
Objectives: GBS is the main cause of serious early-onset
neonatal sepsis in industrialised countries. Intrapartum
antibiotic prophylaxis (IAP) can prevent up to 80% of
infections. Currently decisions about which women receive
IAP are based on either risk factors present during labour, or
cultures of vaginal and rectal swabs at 36 weeks gestation.
Neither approach allows optimal targeting of IAP. The aims of
this project were to determine the accuracy of realtime PCR
(Smartcycler, Cepheid) and optical immunoassay (OIA,
Thermobiostar) and their feasibility as point of care tests
(POCT) on labouring women.
Methods: Healthcare Assistants with no laboratory background
were trained to undertake both tests within a competency
assessment framework. Test accuracy was determined using
enrichment culture as the gold standard. Neonatal ear swabs
were cultured for GBS to investigate the relationship between
maternal results and neonatal colonisation.
Results: All staff achieved competency in undertaking both
tests. However the high turnover of staff of this level created an
ongoing training need. Training times for the OIA and PCR
were 2 and 7 hours. Minimum hands-on testing time and results
turnaround time for the OIA were 20 and 35 min, and 40 and
90 min for the PCR. The greater training need and longer hands-
on test time for PCR signiﬁcantly increased the resource
required to provide reliable testing 24/7.The results of tests on
vaginal and rectal swabs from 226 women were as follows: 2/14
babies colonised with GBS were born to mothers with only rectal
colonisation.
Conclusions: Our early data indicate that PCR can accurately
detect GBS carriers in labour. PCR is feasible as a POCT, but
considerable staff time would be required to maintain a robust
clinical service with the SmartCycler platform. This drawback
should be overcome by the new generation of fully integrated
PCR systems (e.g. GeneXpert) which, by almost eliminating
manual specimen preparation, will reduce training and hands-
on test times. Evidence that vertical transmission can occur
without detectable vaginal colonisation suggests that an
intrapartum screening programme might require testing of
rectal and well as vaginal swabs, although whether rectal
colonisation alone is risk factor for GBS disease rather than
colonisation remains to be determined. Work funded by the
NHS HTA Programme (02/38/04).
O215
Sepsis diagnosis by real-time PCR (SeptiFast Kit,
Roche Diagnostics): preliminary results and
possible application
A. Raglio, M. Rizzi, M. Amer, M. Mangia, M.G. Luca`, A. Goglio
(Bergamo, IT)
Introduction: Traditional blood cultures (BC) have well known
limits: time to ﬁrst results (48 hours) and sensitivity (only 15–
25%). New methods are needed and molecular biology seems to
offer interesting opportunities. Our evaluation was a part of an
european multicenter study.
Objectives: The aim of the study was to evaluate a new PCR
based molecular assay (25 pathogens detected in six hours) and
its clinical impact in comparison with BC results.
Methods: BC were performed by BactAlert System
(BioMerieux) and incubated for 7 days. The SeptiFast test was
performed on LightCycler 2.0 (Roche Diagnostics). The principle
of the method will be explained. PCR samples were collected
after BC from patients fulﬁlling the SIRS criteria. For each
patient a data set was collected: clinical and laboratory data,
microbiological results from all specimens. The results were
ﬁnally discussed by a group of 4 clinicians.
Results: A total of 114 samples were collected from 74 patients.
73 samples were BC and PCR negative. Positive rate for BC was
11.4% and for PCR 27.2%. 13 samples were BC and PCR positive.
4 were BC positive for coagulase-negative staphylococci (CNS)
but PCR negative. 24 were BC negative but PCR positive: 6 of
them detected only CNS; 11 were of clinical importance. PCR
was able to detect: a) Streptococcus viridans group in a patient
with endocarditis; b) Staphylococcus aureus in a patient with
pancreatitis; and c) S. aureus in a patient with
spondylodiscitis.The PCR results were available after 16–
30 hours, the biopsy and valve culture results were reported
after 5–7 days. In 7 samples PCR detected a pathogen
(Aspergillus fumigatus, Stenotrophomonas maltophilia, Escherichia
coli, S. aureus, Enterococcus faecalis) but there were no additional
data that conﬁrmed these results.
Conclusion: In our study PCR detect all BC positive samples
and it was the best test able to help with the right diagnosis for 3
patients. PCR requires a DNA-free workﬂow and well-trained
workers, otherwise results could be misleading by the detection
of environmental DNA.PCR is faster and more sensitive than
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BC. Further studies will show the best use of this interesting
new method.
O216
Evaluation of four selective media for the
detection of methicillin-resistant Staphylococcus
aureus from surveillance specimens
B.M. Willey, N. Kreiswirth, P. Akhavan, A. Tyler, S. Malek,
V. Pong-Porter, G. Small, N. Nelson, A. McGeer, S.M. Poutanen,
T. Mazzulli, D.E. Low, M. Skulnick (Toronto, CA)
Objectives: Rapid, cost effective and practical detection
methods from surveillance specimens are integral to continued
MRSA control. This blinded study compared a standard-
subculture protocol using Oxoid Mannitol Salt Cefoxitin [MSF]
agar to direct identiﬁcation of MRSA from Oxoid Modiﬁed-MSF
[MOD] agar, Bio-Rad MRSASelect [BR] chromogenic agar, and
Becton-Dickinson CHROMagar MRSA [BD].
Methods: 2500 consecutive swabs (178 wound, 777 rectal, 823
nasals, 713 pooled nasal-axilla-groin-perineum, and 9 other)
from 1271 patients in 13 facilities were inoculated onto each
medium. MRSA yields, relative workloads and costs were
determined at 24 h and 48 h incubation at 37 C. MRSA were
conﬁrmed using Pastorex Staph Plus (Bio-Rad), tube coagulase,
PBP2a agglutination (Denka Seiken) and CLSI oxacillin screen
plate (performed directly from the primary media when
possible).
Results: 147 of the 2500 specimens (5.8%) grew MRSA from at
least one medium. Using this as the gold standard, each medium
was compared in terms of 24 h/48 h sensitivity, speciﬁcity,
positive and negative predictive value, % reported, and material
and labour costs (expressed as % increase or decrease compared
to the MSF protocol).
*Standard-subculture protocol: 18 h and 48 h reads only (no
24 h read) and no direct testing from primary medium
Conclusions: The BR read at 24 h performed signiﬁcantly better
(p < 0.00001) than all other media with no added cost; direct
testing reduced time to reporting for positive cultures. However,
when incubation exceeded 24 h, BR speciﬁcity was highly
compromised. The MOD, read at 48 h, performed the second
best overall and was signiﬁcantly (p < 0.00001) more speciﬁc
than MSF. The BD read at 48 h was comparable to the MOD but
was limited by mixed growth preventing direct testing thus
increasing turn-around-time.
O217
Diagnostic value of procalcitonin to distinguish
monomicrobial blood stream infection with
coagulase-negative staphylococci from
contamination: a pilot study
P. Schuetz, B. Mueller, A. Trampuz (Basel, CH)
Objective: Growth of coagulase-negative staphylococci (CNS)
in blood cultures does not always indicate a bloodstream
infection (BSI). Serum procalcitonin (ProCT) has been shown a
useful marker for bacterial infections and for antimicrobial
guidance. Therefore, we evaluated the diagnostic value of
ProCT to distinguish BSI from contamination with CNS.
Methods: From April through August 2005 we prospectively
evaluated all patients with growth of CNS in their blood
cultures. Patients with bacteremia caused by additional
microorganisms (polymicrobial infections) were excluded. An
infectious disease specialist classiﬁed the patients as having BSI
or contamination according to standard clinical and laboratory
criteria and blinded to ProCT results. Serum ProCT was
measured one day before (day )1), at the day of blood culture
collection (day 0), and on the following day (day +1) using a
ultrasensitive immuno-luminometric (functional assay
sensitivity < 0.05 ng/ml). Values were compared using the
Mann Whitney U test. A receiver operating characteristic (ROC)
curve analysis was performed.
Results: Of the 40 patients, 21 were excluded due to polymi-
crobial infection. From the remaining patients, 7 had monomi-
crobial BSI and 12 had contamination with CNS (Table 1).
Median (range) serum ProCT concentrations (ng/dl) were
signiﬁcantly higher in patients with BSI compared to those
with contamination at all three time points. In contrast, CRP
values and leukocyte counts were only signiﬁcantly discrimi-
native at day +1. A ProCT cut-off of 0.1 ng/dl showed a
sensitivity of 86%, 100% and 100% and speciﬁcity of 60%, 84%
and 80% at day –1, day 0 and day +1, respectively.
Conclusion: In this pilot study, ProCT was an early, accurate
biomarker to distinguish BSI from contamination with CNS. If
conﬁrmed in a larger trial, ProCT may prevent unnecessary
treatment courses for suspected CNS BSI and guide rapid
treatment for those, not yet meeting all criteria for CNS BSI.
O218
Borrelia burgdorferi serodiagnosis: evaluation of a
novel Luminex bead-based recombinant-antigen
assay
D. Burki, S. Reymann, M. Toelge, J. Schipper, L. Matter (Basel,
CH; Neuried, DE)
Introduction: Current screening for B. burgdorferi-infections
relies on a two-tier strategy combining sensitive EIA screening
with speciﬁc immunoblot conﬁrmation.
Objectives: To compare the performance of a single step bead-
based system with the conventional two-tier approach.
Materials and methods: Unselected sera which were sent to a
private commercial laboratory for primary serological screening
were tested for IgG and IgM by recombinant antigen EIA;
reactive samples were conﬁrmed by recombinant immunoblot
(recomWell and recomBlot Borrelia, Mikrogen, D-Neuried). Sera
were considered positive if reactive for at least one speciﬁc plus
one non-speciﬁc band and indeterminate if reactive for just one
speciﬁc band. Following storage at )20C samples were batch-
analysed by Luminex-bead-based assays (recomBead,
Microbionix/Mikrogen). For IgG, seven antigens (p100, VlsE,
p39, OspC from three strains, and p18) were tested, for IgM,
three OspC-antigens from three strains were tested. An internal
standard curve allowed for normalization of individual
immunoglobulin concentrations. For IgG, samples were
considered positive if positive for at least two bead-regions
and indeterminate if positive for one bead-region.For both
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systems, positive interpretation was based on presence of IgG
(± IgM) and negative interpretation was based on absence of
both IgG and IgM. Other situations were considered
indeterminate.
Results: 667 sera were analysed. Agreeing interpretations for
conventional and Luminex testing were found for 514 (77.1%)
samples: 65 positive, 104 indeterminate, 345 negative.3 sera were
positive in conventional and negative in Luminex testing, 9 were
negative in conventional and positive in Luminex testing.56
were indeterminate in conventional and negative in Luminex
testing. 61 were negative in conventional and indeterminate in
Luminex testing. Positive vs. indeterminate discrepancies were
considered minor and found in 24 sera (3.6%).
Conclusions: Overall, good qualitative agreement was
observed. Serious discrepancies, i.e. leading to potentially false
negative reports, were found in 17.5%. False-negative
conventional testing may be due to the introduction of VlsE in
the Luminex assay. Potentially false-positive conventional
testing may be attributed to improved IgM-speciﬁcity in the
Luminex assay. We conclude that single-step Luminex testing
may be suitable to replace conventional two-tier strategies.
O219
Development of a panfungal real-time PCR
H.P. Hinrikson, K. Jaton, D. Ciardo, M. Altwegg, J. Bille,
P.M. Hauser (Lausanne, Zurich, Lucerne, CH)
Objectives: To develop and evaluate a panfungal real-time PCR
for early detection and presumptive identiﬁcation of pathogenic
fungi directly in clinical specimens.
Methods: Based on a comprehensive sequence alignment, we
designed a panfungal PCR targeting the variable region 5 of the
small-subunit (18S) ribosomal gene. The assay consisted of 4
forward primers, 8 reverse primers and 1 ﬂuorescence-labeled
probe to ensure efﬁcient detection of ascomycetes,
basidiomycetes and zygomycetes. The sensitivity was assessed
by comparison to a quantitative Aspergillus fumigatus-speciﬁc
PCR. The speciﬁcity was tested using reference DNAs of fungal,
bacterial and human origins. A retrospective clinical evaluation
was conducted using DNA extracts from clinical specimens of
both patients with proven invasive fungal infections [N = 15]
and negative controls [N = 18]. The identity of amplicons was
determined by comparative sequence analysis.
Results: The analytical sensitivity of the panfungal PCR was
found comparable to that of the A. fumigatus-speciﬁc approach,
i.e. one target copy per reaction. However, in order to avoid
false positive reactions due to minute fungal contaminations
introduced occasionally while sampling or processing
specimens, the diagnostic detection limit was considered 5
target copies per reaction. The speciﬁcity for fungal DNA was
conﬁrmed by ampliﬁcation of all fungal reference DNAs
investigated and by the absence of positive reactions with
reference DNAs of bacterial and human origins. The clinical
sensitivity and speciﬁcity were 87 and 100%, respectively, when
considering a particular specimen as PCR positive if it exhibited
at least 2 positive reactions per triplicate testing. False negative
results were obtained with 2 specimens previously shown to
contain only trace amounts of target DNA. Sequencing of the
clinical amplicons allowed presumptive identiﬁcation of yeasts
(Candida [N = 5], Cryptococcus [N = 1]), molds (Absidia [N = 1],
Aspergillus [N = 2], Fusarium [N = 1]), Rhizomucor [N = 2] and
Pneumocystis [N = 1] to at least the species group level. For
instance, the usually more susceptible Candida species (e.g. C.
albicans, C. parapsilosis, and C. tropicalis) were clearly
distinguished from the usually less susceptible species such as
C. glabrata and C. krusei.
Conclusion: The present panfungal real-time PCR represents a
promising tool for improved diagnosis and empirical treatment




The International Circumpolar Surveillance
System for population-based surveillance of
invasive Pneumococcal disease, 1999–2004
M. Bruce, T. Cottle, S. Deeks, M. Lovgren, L. Jette, T. Hennessy,
D. Parks, K. Kristinsson, K. Brinklov Jensen, O. Lovoll, P. Nuorti,
A. Nystedt, E. Herva, A. Koch, A. Parkinson (Anchorage, US;
Ottawa, Edmonton, Montreal, CA; Reykjavik, IS; Nuuk, GL; Oslo,
NO; Helsinki, FI; Lulea, SE; Oulu, FI; Copenhagen, DK)
Background: The International Circumpolar Surveillance (ICS)
Project is a population-based surveillance network for invasive
bacterial disease in the US Arctic, Alaska (AK), Northern
Canada (N Can), Greenland (GN), Iceland (IC), Norway (Nor),
Northern Sweden (N Sweden), and Finland (Fin). Among
circumpolar countries, the 7-valent conjugate vaccine (pcv7)
has been used for routine infant immunization in AK since 2001
and in selected areas in N Can since 2002.
Methods: We deﬁned a case of invasive pneumococcal disease
(IPD) as illness in a surveillance area resident with isolation of
Streptococcus pneumoniae from a normally-sterile site. We
analysed data on IPD from AK and N Can (Jan 1999–Dec
2004), and from GN, IC, Nor, Fin (Jan 2000–Dec 2004) and N
Sweden (2003–2004) to determine: 1) Common clinical
syndromes, 2) Rates of disease by country, 3) Serotype
distribution and 4) Antimicrobial susceptibility patterns.
Results: A total of 9,251 cases of laboratory-conﬁrmed IPD were
reported from AK (647), N Can (226), GN (51), IC (236), Nor
(4,712), N Sweden (65) and Fin (3,314). Case-fatality ratios varied
from 5.0–27.0%. Pneumonia (46%), septicemia (26%), and
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meningitis (8%) were the most common clinical presentations.
Rates of IPD in aboriginals in AK and N Can were 43 and 38
cases per 100,000 persons, respectively. Rates of IPD in children
< 2 years of age and persons > 2 years of age ranged from 21–
137 and 9–24 cases per 100,000 persons, respectively. In AK, the
rate of IPD in children < 2 with pcv7 serotypes declined by >85%
after routine vaccination; from 137 in 1999–2000 to 18 in 2001–
2004 (p < 0.001). Rates of non-pcv7 serotypes in AK increased
from 26 in 1999–2000 to 56 in 2001–2004 in children < 2 years of
age (p = 0.02). Overall, 89% of isolates from persons > 2 years of
age were serotypes contained in the 23-valent polysaccharide
vaccine. The proportion of isolates fully-resistant to penicillin
varied by country from <1% in Fin to 5.6% in AK.
Conclusions: Rates of IPD are high in aboriginals and children
< 2 years of age residing in Arctic countries. After introduction
of pcv7 in AK, rates of disease in children < 2 years of age with
pcv7 serotypes rapidly declined; however, increasing rates of
non pcv7 serotypes are concerning and merit further
surveillance. Continued surveillance is needed to determine
the impact of pcv7 in AK and areas of N Can. High IPD rates in
children < 2 warrant consideration of pcv7 use in other
circumpolar countries.
O221
Invasive pneumococcal disease in the era of
human immunodeﬁciency virus infection
O. Perovic, A. von Gottberg, C. Feldman, O. Perovic
(Johannesburg, ZA)
Objectives: The main aims of the study were to describe
patients with invasive pneumococcal disease (IPD) in the era of
HIV infection and to determine factors associated with increased
mortality.
Methods: This was a retrospective record review of all cases
with IPD admitted to the Johannesburg Hospital between
December 1999 and November 2001. Demographic, clinical,
laboratory, microbiology and outcome data were recorded and
risk factors possibly associated with poor outcome were
compared in survivors and non-survivors.
Results: 211 cases were enrolled (103 male and 108 female). The
mean age was 35.7 yrs (range 17–87 yrs). 165 (78%) were HIV-
seropositive. Eleven patients had other underlying co-morbid
conditions (malignancy in 6, diabetes mellitus in 2, chronic renal
failure in 2, and renal transplant in 1). The source of bacteraemia
was lower respiratory tract in 193 (multilobar pneumonia in
114), meningitis in 11, unknown in 3, acute otitis media in 2, and
septic arthritis and skin soft tissue infection in 1 each.
Complications of infection were recorded in 70 cases
(sometimes multiple); pleural effusion in 36, signiﬁcant
haemoptysis in 12, renal failure in 7, pericardial effusion in 4,
suppurative in 4, jaundice, empyema, gastroenteritis and ARDS
in 2 cases each and haematemesis and CVA in 1 case each. 44
cases died (21%); 35 of the patients with pneumonia (1 each with
acute exacerbation of COPD, associated gastroenteritis,
associated empyema), and 9 with meningitis. HIV status,
underlying co-morbid illness, age, or complications had no
impact on outcome. Patients with meningitis had a signiﬁcantly
higher mortality than cases with pneumonia (mortality 81.8%
versus 18.1%; p < 0.0001). Overall 37 isolates (17.5%) showed
decreased susceptibility to penicillin (intermediate 15%, fully
resistant 2.5%) and 7 (3.3%) resistance to erythromycin.
Conclusion: Pneumococcal bacteraemia is a common infectious
complication in HIV-seropositive patients with a clinical course
and outcome in patients with pneumonia similar to that in HIV–
seronegative cases. However the outcome of cases in which the
primary diagnosis is meningitis is particularly poor.
O222
Are Pneumonia Severity Index and CURB-65
useful for prediction of 30-day mortality in
community-acquired pneumonia?
K. Stra˚lin, H. Holmberg (O¨rebro, SE)
Objectives: Two different indexes have been developed for
prediction of the 30-day mortality in community-acquired
pneumonia (CAP). The pneumonia severity index (PSI) score
is calculated from 19 parameters, and divides the patients into
severity risk classes I-V, while the CURB-65 score is based on 5
parameters (confusion, urea value, respiration rate, blood
pressure, and age) and yields a score of 0–5. We aimed to
compare the two scores for identiﬁcation of CAP patients with
low and high risk of death.
Methods: The records of all patients hospitalized at our clinic
with a discharge code of CAP during a 4-year period were
retrospectively screened. Patients with chest X-ray inﬁltrates
and two symptoms indicating CAP were included in the study.
The PSI and CURB-65 scores were calculated, and data on
survival at day 30 from admission was collected from the
population register. Clinical features not speciﬁed were
considered normal.
Results: Among 705 identiﬁed episodes of CAP an initial
serum-urea value was available in 612. Thirty-four of these
episodes (5.6%) were followed by death within 30 days. The
table shows the distribution of the PSI risk classes and the
CURB-65 score correlated to the 30-day mortality.
Conclusion: Both the PSI and CURB-65 scores identiﬁed CAP
patients with low-risk and high-risk of 30-day mortality. They
can support clinical judgment in decisions regarding outpatient
treatment or level of hospital supervision. CURB-65 is more
easily handled and can be preferable to PSI in clinical practice.
O223
Tigecycline is as safe and effective as levoﬂoxacin
in treating patients with community-acquired
pneumonia
N. Dartois, H. Gandjini, E.J. Ellis-Grosse on behalf of the
Tigecycline 313 Study Group
Objectives: Tigecycline (TGC), a ﬁrst-in-class glycylcycline that
has been approved for treating complicated skin and skin
structure infections and complicated intra-abdominal infections,
has an expanded spectrum of activity against Gram-positive,
Gram-negative, anaerobic, and atypical bacteria including
resistant strains. Primary objective was to compare TGC
efﬁcacy and safety with that of levoﬂoxacin (LEV) in patients
with community-acquired pneumonia (CAP).
Methods: In this phase 3, multicentre, randomised, double-
blind study, hospitalized patients with CAP received 7–14 days
of IV TGC (100 mg loading dose followed by 50 mg every
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12 hours) or IV LEV (500 mg once or twice daily). Co-primary
efﬁcacy endpoints were clinical response in clinically evaluable
(CE) and clinical modiﬁed intent-to-treat (c-mITT) populations
at test-of-cure (TOC). Secondary endpoints were microbiological
efﬁcacy and susceptibility data on TGC for a range of bacteria
that cause CAP. Safety evaluations included vital signs,
laboratory tests, chest radiographs, electrocardiograms, and
record of adverse events (AEs).
Results: 449 patients were screened, 428 were in mITT (TGC
216, LEV 212), 280 were in CE (TGC 144, LEV 136).
Demographics were similar in both groups and majority of
patients had a Fine Pneumonia Severity Index of 2 to 4 (84.8%
TGC, 79.0% LEV, mITT). At TOC (CE), TGC cured 128/144
patients (88.9%; 95% CI 82.6, 93.5) and LEV cured 116/136
patients (85.3%; 95% CI 78.2, 90.8), absolute difference of TGC-
LEV 3.6% (95% CI –5.0, 12.2, test for noninferiority p < 0.001).
For those CE patients with a Fine score of <3 or 3/4, TGC cured
89.6% and 88.0%, and LEV cured 87.3% and 83.3%, respectively.
In c-mITT, TGC cured 170/203 patients (83.7%; 95% CI 77.9,
88.5) and LEV cured 163/200 patients (81.5%; 95% CI 75.4, 86.6),
absolute difference of TGC-LEV 2.2% (95% CI –5.6, 10.1, test for
noninferiority p < 0.001). In c-mITT patients with a Fine score of
<3 or 3/4, TGC cured 85.4% and 81.6%, and LEV cured 80.8%
and 82.8%, respectively. Nausea (26.9% TGC vs 8.5% LEV,
p < 0.001), vomiting (16.7% vs 6.6%, p = 0.001) and leucocytosis
(6.9% vs 0.9%, p = 0.002) were statistically higher in TGC where
hypokalaemia was signiﬁcantly higher in LEV (0.5% TGC vs
3.8% LEV, p = 0.019). Overall treatment discontinuations due to
AE was low (TGC: 14 patients [6.5%], LEV 16 patients [7.5%]).
Conclusion: TGC was safe and efﬁcacious against the most
common respiratory pathogens observed in patients with CAP,
with TGC achieving similar efﬁcacy to that of the comparator.
O224
Risk factors for Pseudomonas aeruginosa isolation
in sputum at hospital admission in patients
hospitalised for acute COPD exacerbation
C. Garcia Vidal, P. Almagro, V. Romanı´, H. Monzo´n, L. Cuadra,
M. Rodriguez, E. Cuchı´, L. Canales, J.L. Heredia, J. Garau
(Terrassa, ES)
Background: The presence of Pseudomonas aeruginosa (PA) in
the sputum has been associated with severity of disease in
ambulatory COPD patients, but its clinical signiﬁcance in
hospitalized patients remains unclear. A better knowledge of
the clinical meaning of presence of PA in sputum in these
patients is important to choose an appropriate antimicrobial
treatment in the Emergency room.
Methods: We prospectively studied all exacerbated COPD
patients that were hospitalized between June 2003 to
September 2004 and we followed their readmissions during
one year. Sputum was collected at admission. Spirometry was
performed one month after discharge. Thoracic scanning was
done in a randomized manner (2:1) to determine the presence of
bronchiectasis, quantiﬁed following a validated scale expressed
in %. Data were analysed with t-test or Mann-Whitney test, and
v2 for qualitative data.
Results: 188 patients were included, with a mean age of
72 years (SD11). 96 (52%) patients had a hospital admission in
the previous year, 32 (17%) in the previous month, and 116
(62%) had been exposed to antimicrobials in the previous 3
months. Bronchiectasis was documented in 50 patients (56.2%);
the mean bronchiectasis score was 13.8% (SD16.9). 106 patients
required further readmissions for another episode(s) of acute
exacerbation during the study, so a total of 469 episodes were
analysed. A valid sputum was collected in 220 episodes; two
microorganisms were present in 93 episodes and three
microorganisms were isolated in 10 episodes. PA was present
in 51 (23%), H. inﬂuenzae in 24 (12%), S. pneumoniae in 21 (10.5%),
Enterobacteriaceae in 8 (4%) and normal ﬂora in 159 (79%).
Patients with bacterial infection had a FEV1 lower than those
with negative sputum cultures (p < 0.003). The presence of PA
in sputum was strongly associated with low FEV1 (p < 0.02),
worst walking test (p < 0.01) and number packs/year (p < 0.01).
Conclusions: The presence of PA in sputum at entry in patients
hospitalized for an exacerbation of COPD is higher than
previously reported and is associated to smoking history and
functional impairment. No relationship between the presence of
bronchiectasis and PA in the sputum could be demonstrated.
O225
Does low antibiotic consumption inﬂuence
microbiological ﬁndings in patients with COPD
exacerbations?
Z.B. Harboe, J.H. Wandall, J.D. Knudsen (Frederiksberg,
Hvidovre, DK)
Objectives: Chronic Obstructive Pulmonary Disease (COPD) is
a frequent cause of hospital admission. Antibiotic use is being
recognized as the main factor for development of resistance. The
Danish outpatient antibiotic consumption is low (14 DDD/1000
inh.-days) compared to most countries in Europe (20–30 DDD/
1000 inh.-days). The objective was to describe the epidemiology
of microbiological ﬁndings from COPD patients admitted with
exacerbations (COPD-ptt), and relate that to the efﬁcacy of
empiric ﬁrst-line treatments.
Methods: Retrospective study of all COPD-ptt admitted to three
InternalMedicine wards and an ICU in 2003, identiﬁed through a
hospital database. Sputum samples were spontaneously
expectorated or sucked for standard microbiological analysis.
Data were analysed by SPSS software. Survival was assessed by
Kaplan-Meier test. P-values < 0.05 were considered signiﬁcant.
Results: 340 COPD-ptt in 560 admissions were included, from a
population of app. 90,000 inhabitants. Sputum samples from 176
ptt (52 %) were obtained. The three months-mortality was 16 %;
19 % for ptt with ﬁndings in sputum, 9 % for ptt with negative
samples (p = 0.11). Potentially pathogenic microorganism
(PPM) grew in 113 samples (51 %) from 99 ptt (56 %), 88
samples (40 %) did not have PPM growth and 19 samples (9 %)
were not suitable for analysis. The ﬁndings for COPD-ptt were
S. pneumoniae 18%; H. inﬂuenzae 13 %; P. aureuginosa 13 %;
Candida spp. 14% and others PPM penicillin-resistent in 32% of
ptt. This is similar to ﬁndings reported in the rest of Europe.
Administration of i.v. penicillin was sufﬁcient in only 49 % of
admissions with positive ﬁndings.
Conclusions: Low antibiotic consumption does not inﬂuence
microbiological ﬁndings in COPD-ptt, compared to high-
consumptions settings. Penicillin is not sufﬁcient as ﬁrst-line
treatment, as it is recommended.
O226
Management of severe community-acquired
pneumonia
C. Brun-Buisson, A.T. Kouatchet for the French Severe Pneumonia
Study Group
Background: Severe community-acquired pneumonia (SCAP)
is the major source of infection and sepsis in the ICU. Early
therapy has been associated with improved outcome of patients
in retrospective studies.
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Objective: To identify characteristics and management of
patients with SCAP admitted to the ICU and analyse antibiotic
therapy (Rx) and its inﬂuence on outcome of patients.
Methods: Patients with SCAP admitted to 20 ICUs in a 1-yr
period were prospectively followed-up. Clinical features,
comorbidities, severity scores (incl. the Pneumonia Severity
score [PSI] and CURB-65 at hospital presentation, SAPS II and
LOD on ICU admission), aetiologies, and time to and selection
of Rx were recorded, and variables associated with mortality
identiﬁed.
Results: We included 235 pts aged 58 ± 16 yrs, 47 (20%) of
whom had ultimately or rapidly fatal underlying disease. Their
mean PSI score was 103 ± 35 (40% class I-III and 60% class IV–
V), mean CURB-65 2 ± 1 (41% > 2), and median SAPS II 39 [14–
78]; 97 (41%) had hypotension and 81 (35%) required
vasopressors on admission; 40 (17%) and 164 (70%) received
mechanical ventilation (MV) on and after ICU admission. There
were 190 (81%) and 186 (79%) survivors to ICU and hospital
discharge, respectively. Infection was microbiologically
documented in 64%. Thirty-nine (17%) had received antibiotic
Rx for >24 h before admission. In others (N = 196), the median
lag between hospital admission and antibiotic Rx was 4 [0–28]
hours; Rx was delayed for more than 4 h and 8 h after hosp.
admission in 21% and 19% pts, respectively. Pts were started on
Rx in the ICU (n = 100) within 1 [0–14] h; therapy was delayed
for more than 4 h and 8 h after ICU admission in 21 and 13 pts,
respectively. Initial empiric therapy included mostly co-
amoxiclav (45%) or a 3rd generation cephalosporin (38%),
combined with a macrolide or quinolone in 25% and 24%,
respectively. After adjustment for the PSI score, other general
severity scores, bacteremia, and GNB infection, the timing of
antibiotic therapy or use of a combination did not inﬂuence
outcome, although inappropriate Rx did in documented SCAP.
Conclusion: Antibiotic Rx in the hospital and ICU was delayed
by >8 h in 20% and 13% of pts, respectively. Although early
antibiotic Rx is desirable in with severe infection, its
appropriateness is likely more important for outcome of
patients.
O227
Treatment and mortality from bacteraemic
pneumococccal disease in Toronto, Canada
K. Green, A. Shigayeva for the Toronto Invasive Bacterial
Diseases Network TIBDN
Background: Several prospective studies suggest that choice of
antibiotic regimen inﬂuences mortality in patients with severe
pneumococcal infection. We examined the impact of treatment
choices on mortality from pneumococcal bacteremia (PB) in
Toronto/Peel, Canada.
Methods: Population based surveillance for PB in residents of
Toronto/Peel region, Ontario, Canada (pop = 4M) has been on-
going since 1995. Demographic and medical data are collected
from patients and their physicians. Since 2000, these data
include antibiotic therapy.
Results: From 1/1/2000 to 31/12/2004, 1581 episodes of PB
have been identiﬁed. Median age of patients was 58y (range 1st
day of life to 108y); 825 (54%) patients were male, 964 patients
had chronic underlying illness, including: cardiac disease (389,
26%), lung disease (279, 18%), diabetes mellitus (225, 15%),
cancer (231, 15%), liver disease (88, 6%), kidney disease (87, 6%),
HIV infection (79, 5%), asplenia/sickle cell disease (37, 2.5%).
205 of 1463 (14%) episodes for which isolates were available
were serotypes included in the 23-valent vaccine. 74 isolates
(5.1%) were resistant to penicillin, 206 (14%) to erythromycin, 30
(2.1%) to ceftriaxone, 18 (1.2%) to levoﬂoxacin, and 5 (0.3%) to
moxiﬂoxacin. Overall, 390 (26%) patients were admitted to the
ICU, and 273 (18%) required mechanical ventilation. 299 (20%)
patients died, including 9/335 (3%) children, and 290/1181
(25%) adults. 13 children and 10 adults received discordant
antibiotic therapy: no children, but 5/10 adults receiving
discordant therapy died (P = 0.05 vs other adults). Factors
associated with 30 day mortality in multivariable (MV) analysis
were: older age (MV odds ratio (OR)/decade, 1.36, 95%CI 1.23–
1.47), chronic organ system disease (MV OR 2.3, 95%CI 1.5–3.4),
nursing home acquisition (MV OR 3.8, 95%CI 2.6–6.1), hospital
acquisition (MV OR 2.1, 95%CI 1.2–3.8), and requirement for
mechanical ventilation (MV OR 7.1, 95%CI 4.9–10). Patients
treated with respiratory ﬂuoroquinolone monotherapy (MV OR
0.63, 95% CI 0.42–0.96) or with a macrolide in combination with
any other antibiotic (MV OR 0.65, 95% CI 0.42–1.0) were less
likely to die. Results were not different when all patients or
adults only were included in analysis.
Conclusion: BP disease in adults is associated with high
mortality (25%). Therapy with a respiratory ﬂuoroquinolone
alone, or combination therapy with a macrolide and any other
antibioticwas associatedwith a signiﬁcant reduction inmortality.
O228
Antimicrobial susceptibility of pneumococcal
isolates causing bacteraemic community-acquired
pneumonia in the public and private sectors in
Gauteng, South Africa
C. Feldman, A. Brink, A. von Gottberg, L. de Gouviea,
O. Perovic, K. Klugman (Johannesburg, ZA)
Objectives: Contradictory and very high rates of pneumococcal
resistance have been reported previously from different
surveillance studies conducted in South Africa. The aim of this
study was to review susceptibility data of isolates from adult
patients presenting with bacteremic pneumococcal community-
acquired pneumonia (CAP), comparing cases in the public and
private sectors in Gauteng, South Africa.
Methods: We wished to recruit 100 consecutive adult patients
with pneumococcal bacteraemia and CAP. Patients without
radiographic evidence of pneumonia, or with other clinical
diagnoses (e.g. meningitis) were excluded. Repeat isolates were
excluded. Antimicrobial susceptibility testing was done
according to CLSI guidelines, using disc screening and MIC
determination with agar dilution and E-tests.
Results: 149 cases were recruited, 97 in the public and 52 in the
private sector. Public sector patients were younger (median age
33 years vs. 45 years; p < 0.001),withmoreHIV infection and less
co-morbid illness. Cases in the private sector were more likely to
have received antibiotics in the past 3 months. The overall rate of
antimicrobial resistance was considerably lower than reported
previously in SouthAfrica. Resistance to penicillinwas 16% in the
public and 23% in the private sector (not signiﬁcantly different).
There were also no signiﬁcant differences in the susceptibility of
the isolates to ceftriaxone, chloramphenicol, tetracycline,
rifampicin or oﬂoxacin. However signiﬁcantly more resistance
was seen in the private sector isolates to erythromycin (28% vs.
4%; P < 0.001) and clindamycin (21% vs. 3%; p = 0.001).
Conclusion: A number of clinical differences were seen in
public vs. private sector patients with bacteraemic
pneumococcal pneumonia in Gauteng, South Africa. Rates of
antibiotic resistance were much lower than previously reported
from South Africa. The only differences noted were higher rates
of resistance to erythromycin and clindamycin in the private
sector (possible erm gene mutation as mechanism of macrolide
resistance).
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O229
Outcome of adults with penicillin high-resistant
and susceptible invasive Streptococcus
pneumoniae community-acquired pneumonia
M. Mufson, G. Chan, R. Stanek (Huntington, US)
Introduction: The emergence of Streptococcus pneumoniae
exhibiting high resistance to penicillin (PRSP) (MIC = 2.0–
4.0 lg/ml) evoked concerns that these infections would
respond poorly to the antibiotics usually used in the treatment
of community-acquired S. pneumoniae pneumonia due to
penicillin intermediate (PISP) (MIC = 0.1–1 lg/ml) isolates.
We investigated adults with invasive S. pneumoniae pneumonia
infected with PRSP or PISP and matched controls with
susceptible infections (PSSP) (MIC £ 0.06 lg/ml) to determine
whether resistance to penicillin was a key factor in clinical
outcome.
Methods: We identiﬁed 52 adults with invasive S. pneumoniae
pneumonia due to PNSP – 19 PRSP and 33 PISP - admitted to
hospitals in Huntington, WV, between 1983 and 2003 and
matched them by age and admission time period to a group of
133 patients with PSSP pneumonia. All isolates were capsular
types 6, 9, 14, 19 and 23. Deaths were counted if they occurred
before the seventh hospital day. MIC was determined by E-test
and capsular type by Quellung procedures.
Results: There were no signiﬁcant differences between the
PNSP and PSSP groups in mean age, the severity of admission
vital signs, days of fever, mean total leukocyte count, number of
lobes involved, pre-existing underlying diseases and antibiotic
treatment regimens. Both groups had tachypnea, modest
tachycardia, a moderate leukocytosis and in about 60% of
cases only one lobe of the lungs involved. Case-fatality rates
(CFRs) during the ﬁrst seven days of hospitalization did not
differ signiﬁcantly between invasive PRSP and PSSP pneumonia
cases, 10.5% and 6.8%, respectively (p = 0.63, Fisher’s exact test,
two-tailed). Similarly, CFRs were not signiﬁcantly different
between invasive PISP and PSSP pneumonia cases 15.2% and
6.8%, respectively (p = 0.16, Fisher’s exact test, two-tailed). The
PRSP, PISP and PSSP groups often received antibiotic regimens
comprised of a cephalosporin and a macrolide, and occasionally
a ﬂuoroquinolone, but there were no signiﬁcant differences in
CFRs between them when compared by antibiotic regimens.
Conclusion: These ﬁndings suggest that antibiotic regimens
effective in the treatment of invasive PSSP pneumonia are no
less effective in the treatment of PRSP with MIC’s between 2 and
4 lg/ml and PISP, obviating the need for more complex
antibiotic regimens in their treatment.
Keynote lectures I
K243
Antimicrobial intelligence: how eukaryotes
combat the quorum sensing strategy
A. Sbarbati (Verona, IT)
Microorganisms easily form bioﬁlms on medical devices but the
development of similar microﬁlms on mucosal surfaces may be
hampered by the presence of several lines of defence operated
by the epithelial cells. As an example, the biological interfaces
are electrically charged, secrete antibiotic compounds and can
modulate their hydrophobicity mainly by the production of
surfactant material. In addition, recent data demonstrated that
diffuse chemosensory systems continuously monitor the pres-
ence of microorganisms on mucosal surfaces. Bacteria can
communicate with one another via signal molecules: this
process is generally called quorum sensing. Quorum sensing
signals, not only act on different bacteria species but also
inﬂuence the behaviour and metabolism of plants and animals
suggesting that they are involved in interspecies and interking-
dom communication. The eukaryotes susceptible to infection by
bacteria that use quorum sensing have evolved natural therapies
designed to impede bacterial colonization by inhibiting quorum
sensing mediated processes. The detection of quorum sensing
signals would permits the host organism to mount an early and
localized response to bacterial invasion. New data have dem-
onstrate the expression of chemosensory receptors (T2R and
V1R), G proteins and other molecules of the chemoreceptorial
cascade (PLCbeta2, IP3R3) in secretory elements in direct
contact with bacteria. This expression suggests that secretory
processes could be controlled by chemoreceptor mechanisms.
Methods of functional magnetic resonance imaging allow an
in vivo evaluation of secretory responses expanding the know-
ledge obtained by in vitro approach. The work reviews studies,
which suggest that eukaryotic cells sense QS signals of bacteria
and describe a response to these signals. The work also proposes
models on how mammalians perceive bacterial signals based on
the idea that chemoreceptors may be involved in perception of
these signals and initiation of responses to them in addition to
the responses mediated by the immune system.
K244
Clean care is safer care: a WHO initiative to
improve patient safety worldwide
D. Pittet (Geneva, CH)
Health care-associated infection affects hundreds of millions of
people worldwide in developed, transitional, and developing
countries and is a major, global issue for patient safety. The
World Health Organization (WHO) supported the creation of an
international alliance to improve patient safety as a global
initiative and the World Alliance for Patient Safety was
launched in October 2004. The six actions areas of the Alliance
are: Patients for Patient Safety; Taxonomy; Research; Solutions
for Patient Safety; Reporting and Learning; and a biennial Global
Patient Safety Challenge. The topic chosen for the ﬁrst Chal-
lenge, covering 2005–2006, is health care-associated infection.
The Global Patient Safety Challenge, ‘‘Clean Care is Safer Care’’,
was launched in October 2005. It embraces existing WHO
strategies to reduce health care-associated infection and also
creates the momentum for new actions to improve hand hygiene
during patient care. The major objectives of ‘‘Clean Care is Safer
Care’’ are: to raise awareness of the impact of health care-
associated infection on patient safety and promote preventive
strategies within countries; to build commitment from countries
to prioritise reducing health care-associated infection; and to test
the implementation of the new WHO Guidelines on Hand
Hygiene in Health Care in speciﬁc districts worldwide as part of
an integrated package of actions derived from existing WHO
strategies in the ﬁelds of blood safety, injection and immunisa-
tion safety, clinical procedure safety, and water, basic sanitation
and waste management.
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K245
Human papillomaviruses: impact of disease and
vaccine intervention
M. Poljak (Ljubljana, SI)
Papillomaviruses are remarkably heterogeneous group of DNA
viruses that are causally involved in the etiology of different
benign and malignant neoplastic lesions of the anogenital,
oropharyngeal and cutaneous epithelium. They are classiﬁed
into 16 genera, and ﬁve of them (alpha, beta, gamma, mu, and
nu) are composed exclusively of human papillomaviruses
(HPV). Currently, more than 90 distinct HPV genotypes have
been fully characterized, and a substantial number of putative
novel HPV genotypes are predicted from ampliﬁed subgenomic
DNA fragments. Clinically, the most important are alpha-HPV,
which comprise HPV genotypes originally referred to as
‘‘genital’’ or ‘‘mucosal’’ HPV. These can be further subdivided
into ‘‘low-risk’’ and ‘‘high-risk’’ genotypes according to the risk
of malignant progression. Thus, the ‘‘low-risk’’ genotypes HPV-
6 and HPV-11 are etiologically associated with the development
of virtually all genital warts and laryngeal squamous cell
papillomas. In contrast, persistent infection with a subgroup of
at least 15 ‘‘high risk’’ HPV genotypes is considered as a
necessary, although insufﬁcient etiological factor in the devel-
opment of cervical carcinoma. As a consequence, HPV testing
has recently become an important part of the cervical carcinoma
screening and detection algorithms. Thus, several consensus
guidelines recommend the HPV testing: (i) for appropriate
triage of women with a borderline cytology results, (ii) as a test
of cure of treatment of high-grade cervical lesions, and (iii) as a
primary screening test for cervical carcinoma (in conjunction
with cytology) of women aged 30 years or more. The prevention
of HPV infection can be achieved by the induction of genotype-
speciﬁc neutralizing antibodies triggered by recombinant L1
viral-like particle (VLP) vaccines. VLP are attractive candidates
for prophylactic vaccines as they are empty, non-infectious,
DNA-free viral capsids morphologically indistinguishable from
the native viruses. Several multivalent VLP-based vaccines are
now being clinically developed. Phase I and II trials have shown
that the VLP-based HPV vaccines are well tolerated, that they
induce high titers of neutralizing antibodies (50–100 fold greater
than during natural infection), and protect with a very high
efﬁcacy against a persistent HPV infection and HPV-related
clinical disease. Phase III trials of HPV vaccines are currently
underway, and the public health beneﬁts associated with
vaccination may soon be realized.
Emergence of transferable quinolone resistance (Symposium
jointly arranged with the ICAAC Programme Committee)
S247
World emergence of qnr, a novel family of
quinolone resistance genes
D. Hooper (Boston, US)
Transferable plasmid-mediated quinolone resistance was ﬁrst
found in strains of Klebsiella pneumoniae in one region of the
United States in 1998 and shown to be due to qnr, which
encodes a member of the pentapeptide repeat (PPR) family of
proteins. Qnr protein causes low-level quinolone resistance and
binds and protects gyrase and topoisomerase IV from quinolone
action. Another PPR protein, MfpA, from Mycobacterium tuber-
culosis has a structure that mimics DNA and may bind gyrase in
its DNA-binding domain. Although qnr was not identiﬁed again
in early follow-up surveys, it was identiﬁed in 2003 in ciproﬂ-
oxacin- and ceftazidime-resistant clinical isolates of Escherichia
coli from Shanghai, China and subsequently in similar isolates of
K. pneumoniae and Enterobacter spp. from throughout the US. qnr
was also found in several different species of Enterobacteriaceae
in Europe and Thailand. qnr was located in class 1 integrons on
plasmids but was also found on the chromosome of an
environmental water bacterium, Shewanella algae, suggesting
that this organism may have been the source of the qnr gene.
Two other members of the qnr family, qnrS and qnrB, have been
found, and the original qnr is now termed qnrA. Other qnr
homologs have found in the genome sequences of several Vibrio
spp. and Photobacterium profundum. qnrS has been identiﬁed on
plasmids in Shigella and Salmonella spp., and qnrB has been
found in a variety of enteric bacteria from the US and India.
Notably all three qnr genes have been found in ciproﬂoxacin-
susceptible isolates as well as quinolone-resistant isolates,
suggesting that their presence promotes higher level resistance
due to chromosomal mutation, as has been shown in the
laboratory. In the US, ceftazidime-resistant isolates of Enterob-
acter spp. have a notably high prevalence of qnr genes, with 17%
having qnrA and another 26% having qnrB, and the prevalence
has increased over time. Unexpectedly in studies to evaluate the
fourfold differences in the MICs of ciproﬂoxacin between some
qnrA transconjugants, another plasmid-encoded quinolone
resistance determinant was identiﬁed, a variant of the aac(6’)Ib
gene encoding an aminoglycoside acetyltransferase that had
acquired the ability to acetylate ciproﬂoxacin and reduce its
activity fourfold. This aac(6’)Ib variant occurs independently of
and at a higher prevalence than qnrA in some strain sets. When
together with qnrA on the same plasmid, it causes additive
transferable resistance that approaches the clinical breakpoint
for ciproﬂoxacin susceptibility. It is likely that other qnr variants
and possibly other variant modifying enzymes may be identi-
ﬁed as quinolone selective pressures continue.
S248
The toxin-antitoxin systems: function and
distribution in the bacterial world
M. Wilbaux, N. Mine, L. Van Melderen (Gosselies, BE)
Toxin-antitoxin systems (TA) are small genetic elements com-
posed of two genes organised in an operon and encoding a
stable toxin and its unstable cognate antitoxin. ATP-dependent
proteases are responsible for antitoxin degradation. The anti-
toxin antagonizes the toxin by forming a tight protein-protein
complex. This complex is also responsible for the autoregulation
of the operon. TA were originally discovered on low copy-
number plasmids. In that genetic context, TA contribute to
plasmid stability in growing bacterial population by killing
selectively bacteria that have lost the plasmid.Database search-
ing revealed that plasmidic TA have many homologues in
bacterial chromosomes. Although it has been shown that some
chromosomal TA are activated during starvation or other types
of stress, their biological role as well as the selective advantage
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they confer to bacteria are still under investigation. The current
hypotheses are that TA serve as growth modulators or
programmed cell death systems in response to stress. We have
compared a well-studied plasmidic TA, the ccdF from the E. coli
F plasmid with one of its homologues, the ccdO157 located in
the chromosome of the pathogenic E. coli O157:H7. Despite a
low level of identity between the CcdF and the CcdO157
proteins, the CcdO157 proteins have conserved essential motifs
for their function as TA i.e. the toxin targets the DNA-gyrase
and the antitoxin is degraded by the Lon protease. However, the
toxin-antitoxin interaction domains of the two homologues have
diverged. This indicates that the plasmidic ccdF system is
functional despite the presence of its chromosomal homologue.
We propose that chromosomal TA might serve as ‘exclusion’
systems protecting bacteria from exogenous DNA carrying
identical TA. Therefore, only plasmidic TA able to evade cross-
interaction might co-exist with homologous chromosomal TA.
Although we showed that the chromosomal ccdO157 system is
expressed in its host, it is unable to mediate plasmid stabiliza-
tion when cloned in an unstable plasmid. This supports the idea
that plasmidic and chromosomal TA play different role(s). We
propose that homologous TA have derived from a common
ancestor and have reached different bacterial species and/or
location by horizontal transfer and that their function has
evolved according to their new location.
Management of endocarditis
S253
Antibiotic treatment of infective endocarditis due
to antibiotic resistant bacteria
J. Miro (Barcelona, ES)
Currently there are four clinical types of infective endocarditis
(IE): native valve IE in the general population (left-sided IE) or in
i.v. drug abusers (usually right-sided IE), prosthetic valve IE and
IE on pacemakers or deﬁbrillators. These types of IE have a very
different clinical characteristics, etiology and prognosis. Overall
mortality remains high (25%) despite the important advances in
the early diagnosis (transesophageal echocardiogram) and in
early cardiac surgery. The etiology has changed, being staphylo-
coccal IE more frequent than streptococcal IE and nosocomial IE
caused by highly aminoglycoside resistant Enterococcus spp. and
methicillin-resistant Staphylococcus aureus or S. epidermidis has
been increasing during the last decade. From the therapeutical
point of view, the antibiotic therapy of viridans group strepto-
cocci IE and S. aureus right-sided IE in drug abusers have been
shortened and simpliﬁed. These types of IE can be treated with
ceftriaxone plus gentamicin or cloxacillin plus gentamicin during
two weeks respectively. Furthemore, the introduction of ceftri-
axone and teicoplanin have allowed the administration of a
single daily dose of these drugs by i.v. or i.m. routes and they
make possible the out-patient antibiotic therapy of IE by
specialized home-care units. On the other hand, multiresistant
staphylococci (MRSA, GISA) and enterococci IE have high
mortality ratios and few antibiotic alternatives. In this way, the
preliminary in vitro, in vivo and clinical data with new antibiotic
combinations (e.g. ampicillin plus third generation cephalospo-
rins or fosfomycin plus beta-lactam antibiotics) or new antibiotics
classes (e.g. linezolid, quinupristin-dalfopristin, daptomycin and
telavancin) open new therapeutical alternatives to treat these IE
caused by multirresistant bacteria.
Infectivity and emergence of resistance in animal models
O257
Infectivity of probiotic Lactobacillus rhamnosus
and Lactobacillus paracasei in a rat model of
experimental endocarditis
V. Vankerckhoven, S. Piu, P. Moreillon, M. Vancanneyt,
H. Goossens, J.M. Entenza (Wilrijk, BE; Lausanne, CH; Ghent, BE)
Objectives: The aim of this study was to evaluate the potential
pathogenicity of different probiotic strains of Lactobacillus
rhamnosus and L. paracasei in a rat model of experimental
endocarditis.
Methods: A total of 10 L. rhamnosus (6 probiotic and 4
endocarditis) and 7 L. paracasei (4 probiotic, 1 faecal and 2
endocarditis) were tested. Rats with catheter-induced aortic
vegetations were inoculated i.v. with increasing numbers of
organisms (1E04 to 1E08 CFU/ml). After 72 h they were
sacriﬁced, and both the lowest inoculum size infecting 90% of
vegetations (ID90) and colony counts were determined. Bacterial
densities in infected vegetations were analysed using Mann-
Whitney U test. Adhesion properties of the lactobacilli were
revealed using crystal violet and measured with an ELISA
reader at 570 nm. Collagen type IX, ﬁbrinogen, ﬁbronectin and
laminin were used as substrates in twofold dilutions in
microtiter plates. Strains were classiﬁed as adherent
(A570 nm > 0.3), weakly adherent (0.1 £ A570 nm ‡ 0.3), or
non-adherent (A570 nm> 0.1). Platelet-induced killing was
assessed for ﬁbrinopeptide A (FPA).
Results: Four of the six probiotic L. rhamnosus strains showed
an ID90 which was at least 10 times higher (1E08 CFU/ml) than
that of the clinical isolates, while the two other probiotic L.
rhamnosus demonstrated an ID90 in line with the higher range
(1E07 CFU/ml) of the clinical isolates. Importantly, these two
strains shared the same genotype (type I) as the clinical isolate
showing the lowest ID90 (1E06 CFU/ml). L. paracasei tended to
have a lower infectivity than L. rhamnosus, with an ID90 of 1E07
to ‡1E08 CFU/ml for endocarditis as well as probiotic and
faecal isolates. All strains had comparable bacterial counts in
vegetations (P > 0.05). Except for one strain which adhered to
ﬁbronectin (A570 nm = 0.406) and laminin (A570 nm = 0.425),
all tested lactobacilli adhered only weakly or not at all
(A570 nm= 0–0.205). The platelet peptide FPA did not show
microbicidal activity against any of the lactobacilli.
Conclusions: Overall, these results indicate that probiotic
lactobacilli were, in general, less able to cause experimental
endocarditis than isolates from human endocarditis. Although, a
difference in infectivity between L. rhamnosus endocarditis and
probiotic isolates was seen, this could not be explained by
differences in adherence or platelet-microbicidal protein
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susceptibility. Other disease-promoting factors might exist in
these organisms and warrant further investigation.
O258
Dissemination of Borrelia burgdorferi sensu lato
in mice: inﬂuence of the species and of the
primary human isolation site
S.J. De Martino, C. Sordet, Y. Piemont, C. Barthel, E. Collin,
J. Sibilia, B. Jaulhac (Strasbourg, FR)
Objective: To study the inﬂuence of the Borrelia (B.) species and
of the primary human isolation site of the bacteria on the
dissemination of strains from the B. burgdorferi group in the
C3H/HeN murine model of Lyme borreliosis.
Methods: Seventeen human european and north american
isolates of the B. burgdorferi group (6 B. burgdorferi sensu
stricto, 6 B. garinii, and 5 B. afzelii) were used. These strains
have been isolated from erythema migrans (EM) (n = 7),
borrelial lymphocytoma (BL) (n = 1), acrodermatitis chronicum
atrophicans (ACA) (n = 1), neuroborreliosis (NB) (n = 6) and
Lyme arthritis (LA) (n = 2). Spirochetes (105/100 ll) of each
strain were inoculated by intradermal route into ﬁve mice.
Development of arthritis was sought by measurement of tibio-
tarsal joint. Four weeks later, mice were euthanased. Murine
infection was checked by seroconversion. Spirochetes
dissemination was investigated by culture and PCR of murine
target organs (skin, heart, joint).
Results: All mice were seropositive for B. burgdorferi at day 28
post infection. A clinical murine arthritis (redness, swelling) was
signiﬁcantly correlatedwith a joint diameter ‡ 3 mm (p £ 0.0005).
Low rate of discrepancies between B. burgdorferi culture and PCR
resultswere observed in skin andheartwhereas 40%of additional
joints were found positive by PCR only (p £ 0.0005). Regarding
the Borrelia species used formurine infection, B. burgdorferi sensu
stricto and B. garinii strains disseminated more frequently in
mouse skin than B. afzelii strains. B. afzelii strains disseminated
more frequently in joints than B. burgdorferi sensu stricto and B.
garinii strains (p < 0.005). Regarding their primary human
isolation site, strains from secondary and late cutaneous lesions
(BL, ACA) were signiﬁcantly more often detected in skin
(p < 0.005). Strains involved in human NB or LA, were more
frequently detected in murine joints (p < 0.005). Strains from EM
disseminated in all murine organs.
Conclusion: Dissemination of B. burgdorferi sensu lato in the
mouse model of Lyme borreliosis varied according to the Borrelia
species and the primary human isolation site. Human strains
isolated from secondary and late cutaneous manifestations were
preferentially detected in murine skin whereas strains able to
disseminate in humans were preferentially detected in murine
joints. EM strains for which human dissemination capability is
unknown had a wide dissemination in mice.
O259
Subinhibitory concentrations of phenyl lactic
acid produced by Lactobacillus probiotic strains
attenuate the virulence of Peudomonas aeruginosa
and Staphylococcus aureus in mouse infection
model
M.C. Balotescu, V. Lazar, A. Israil, L. Ditu, C. Larion, I.
Alexandru, C. Bleotu, R. Cernat (Bucharest, RO)
Introduction: The discovery of communication systems
(quorum sensing systems) regulating bacterial virulence has
afforded a novel opportunity to control infectious bacteria
without interfering with growth. Compounds that can override
communication signals have been found in the cell-free
Lactobacillus probiotic strains cultures. During a previous
in vitro screening of antimicrobial activities of soluble products
from Lactobacillus cultures, phenyl lactic acid (PLA) was found
to exhibit QS inhibitory (QSI) activity.
Purpose: In this study we try to demonstrate the role of PLA in
the bacterial virulence attenuation using an in vivo, mouse
infection model.
Study design: From overnight cultures of Ps. aeruginosa and
S. aureus grown with and without subinhibitory concentrations
of PLA, bacterial suspensions of ~107 UFC/ml were prepared in
PBS and used for mice inoculation in one single dose given by
intravenous (IV), intranasal (IN) and intraperitoneal (IP) route.
The mice were followed up during one week after infection and
the body weight, mortality and morbidity rate were measured
every day. The microbial charge was studied by viable cell
counts in lungs, spleen, intestinal mucosa and blood. The mice
lots infected with wild Ps. aeruginosa bacterial cultures exhibited
29% mortality rates after IV and IP route, exhibiting very high
cell counts (>1011 UFC/g or ml) in blood, lungs, intestine and
spleen. In exchange, the lots infected with PLA treated bacterial
cultures exhibited good survival rates (0 mortality), even
though, after euthanisation, high viable cell counts were found
in their intestine and blood (~109 CFU/ml or g). As concerning
the S. aureus infections, the experimental lots exhibited
comparable survival rates, but signiﬁcant differences were
noticed concerning the clearance of bacterial cells from the
infected mice, which was total in the experimental lots infected
with PLA treated bacterial cells, comparatively with those
infected with untreated cultures showing high microbial charge
in their intestine.
Conclusion: In this study, using a mouse infection model we
show that PLA can act as a potent antagonist of bacterial
quorum sensing regulated virulence factors in P. aeruginosa and
S. aureus, improving the survival rates as well as the clearance of
bacterial strains from the body, in a speciﬁc manner, dependent
on the infection route and the microbial strain.
O260
Rifampin induction of resistance in Acinetobacter
baumannii, in vitro and in an experimental
pneumonia murine model
M.E. Pacho´n-Iba´n˜ez, F. Ferna´ndez-Cuenca, F. Docobo-Pe´rez, J.
Pacho´n, A. Pascual (Seville, ES)
Objective: The aim of the present study was to determinate the
frequency of resistance to rifampin (RIF) in multiresistant
Acinetobacter baumannii (Ab) exposed to RIF, in vitro and
in vivo, and the prevention of the development of resistance
when RIF is used in association with other antimicrobials.
Methods: In vitro studies: a) in vitro selection of RIF-resistant
variants, using time-kill curves, at concentrations of 1, 2, and 4
times the MIC of RIF and all the possible combinations of RIF
with imipenem (IMP) or sulbactam (SB), at the same
concentrations (1, 2, and 4 times the MIC, respectively); b)
controls experiments with IMP and SB alone were performed; c)
MIC of RIF of single colonies growth after 24, 48, and 72 h of
incubation were determined; d) stability of RIF-resistant
variants: the stability of variants of Ab resistant to RIF was
tested with six daily passages in RIF-free agar plates. In vivo
studies: a) a pneumonia experimental model in C57BL/6 mice
was used; b) treatment groups (72 h): CON (without
treatment), RIF (100 mg/kg/ip/d), IMP (120 mg/kg/im/d),
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SB (240 mg/kg/im/d), IMP + SB, IMP + RIF, y SB + RIF; c) the
MIC of RIF for the isolates obtained from the mice was
performed; d) Frequency of RIF-resistant variants: the
experimental pneumonia model was used with two treatment
groups: CON (without treatment), and RIF (100 mg/kg/ip/d).
Results: In vitro results: a) the MIC of RIF increased from
4 mg/L to 128 mg/L for variants selected after 48 and 72 h of
incubation of Ab in presence of RIF alone; b) the susceptibility to
RIF did not change in the experiments with IMP or SB alone; c)
with the different combinations of RIF plus IMP or SB, the MIC
of RIF did not change; d) RIF-resistant variants maintained its
resistance (MIC 128 mg/L) over six daily passages in fresh RIF-
free agar plates. In vivo results: a) in mice treated with RIF alone,
the MIC of RIF changed to >128 mg/L; in mice treated with RIF
and IMP or SB the MIC of RIF remained at 4 mg/L; b) The
frequency of RIF variants obtained was 3 · 10)6.
Conclusions: These results suggest that rifampin must not be
used alone in the treatment of infections caused by
multiresistant A. baumannii due to the induction of RIF-
resistance at high frequency. In these cases, rifampin may be
used in combination with imipenem or sulbactam, which
prevent the development of resistance.
O261
Experimental dose regimen modelling of
intestinal emergence of Enterococcus faecalis
resistant to linezolid in gnotobiotic mice
N. Bourgeois-Nicolaos, B. Couson, L. Massias, A. Andremont,
F. Doucet-Populaire (Paris, Le Chesnay, FR)
Objectives: Linezolid (LNZ) is the ﬁrst of a new class of
antibiotics, the oxazolidinones. LNZ is approved for the
treatment of Gram-positive bacterial infections. Selection of
LNZ resistant (R) mutants during treatment has been reported.
The clinical resistance to LNZ has been associated with mutation
in the 23S rRNA domain V region. The aim of our study was to
develop an experimental model of emergence of LNZ-resistant
strains in the digestive tract.
Methods: We studied the rate of emergence of LNZ-R E. faecalis
mutants in the digestive tract of gnotobiotic mice mono-
associated with LNZ-susceptible E. faecalis and fed with water
containing 0.5, 0.05 or 0.005 g/L of Li (6 mice/group). Fecal S
and R E. faecalis were counted daily during 21 days on agar
containing or not 4 mg/L of LNZ. 23S rRNA mutations were
characterized by sequencing individually each of the 4 copies of
the rRNA operons. LNZ concentrations in mouse pellets were
measured by HPLC.
Results: In the 0.5 g/L group, a LNZ-R mutant (MIC 8 mg/L)
was isolated in one mouse once at day one of treatment and R
mutants (MICs 16 mg/L) were isolated in two mice after
21 days of treatment. In the 0.05 g/L treatment group, R
mutants (MICs 32 mg/L) were isolated in all mice after 5 days
of treatment and persisted at 9 log10 UFC/g of feces. In the
0.005 g/L treatment group, R mutants (MICs 8 mg/L) appeared
after 4 days of treatment but persisted at 3 log10 UFC/g. Fecal
concentrations of LNZ were 9.9, 0.6, 0.1 lg/g of feces for the 3
regimens, respectively. The R mutants selected in the 0.05 or
0.005 g/L groups had a G2576Umutation. By contrast, that from
the 0.5 g/L treatment group had a G2505A.We observed a
correlation between the number of 23S rRNA copies with the
G2576U or G2505A mutation and the level of resistance to LNZ
expressed by the mutants obtained in vivo.
Conclusions: Intestinal emergence of LNZ-R mutants could be
readily obtained in vivo using a wide range of treatment doses.
However striking differences were observed between dose
regimens in terms of rate of emergence and intestinal concen-
trations of the mutants and type of associated mutations.
Infection in the immunocompromised host (except HIV)
O262
Epidemiology of fungal infections in
haematological stem cells transplanted patients:
SEIFEM 2004 study
L Pagano, M. Caira, M.T. Van Lint, G. Irrera, A Bonini, A.
Candoni, C. Caramatti, M. Picardi, R. Invernizzi, D. Mattei, L.
Fianchi, P. Falcucci, G. Reddiconto, C.G. Valentini, L. Melillo,
M.R. Fadda, A. Nosari, C. Girmenia, F. Aversa on behalf of
SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine Nelle
Emopatie Maligne)
Objectives: To evaluate epidemiology and outcome of invasive
fungal infections (IFI) in patients (pts) who underwent
autologous (auto) or allogeneic (allo) hemopoietic stem cells
transplantation (HSCT).
Methods: A cohort-retrospective study, conducted over 1999–
2003, in HSCT patients admitted in 11 hematology divisions in
tertiary cares or university hospitals, who developed IFI (proven
or probable).
Results: We evaluated 3,228 pts who underwent HSCT: 1,249
(38.7%) allo HSCT and 1,979 (61.3%) auto HSCT. IFI occurred in
121 pts, with an overall incidence of 3.8%; we registered 91
episodes sustained by moulds (incidence 2.8%) and 30 by yeasts
(incidence 0.9%). The incidence rate depended upon the type of
transplant: 99 episodes occurred in allo HSCT (incidence 7.9%)
and 22 in auto HSCT (incidence 1.1%). [Table I]Among moulds,
the detected etiological agent was Aspergillus spp in 88 episodes
(incidence 2.7%). Candida spp. was responsible of all the 30 yeast
infections we registered (incidence 0.9%). As for aspergillosis,
the intraspecies characterization was possible only in 33 cases
(38% of total aspergillosis); A.fumigatuswas identiﬁed in 19 cases
(58%), A. ﬂavus in 4 (12%), A. terreus in 5 (15%), A.niger in 5
(15%). Diagnosis was proven in 23 of 79 cases (29%), in the other
56 cases aspergillosis was probable. Overall mortality rate was
5.6% in allo and 0.5% in auto HSCT. The case fatality rate (CFR)
registered in our population was 65% (79 deaths), with
differences between allo HSCT (71%) and auto HSCT (41%).
Etiology inﬂuenced the pts outcome: aspergillosis CFR was 72%
(75% in allo HSCT and 29% in auto HSCT), while that one due to
Candida spp. was 50% (53% in allo HSCT and 47% in auto
HSCT). Interestingly aspergillosis CFR varied during the study
period, decreasing from 93% in 1999 to 64% in 2003 (RR 0.69;
IC95% 0.51–0.95; p-value = 0.047).
Conclusion: IFI represent a frequent complication particularly
for pts undergoing allo-HSCT. Aspergillus spp is the most
frequently detected agent in these pts and it is characterized by a
high mortality rate. Rarely auto HSCT pts develop aspergillosis.
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Conversely we did not observe any difference in candidemia
incidence and in the CRF between the two groups.
O263
Clustering of Pneumocystis jirovecii pneumonia
cases in renal transplant recipients: coincidence
or a clue for patient-to-patient transmission?
M.G.J. de Boer, L.E.S. Bruijnesteijn van Coppenraet, A.
Gaasbeek, S.P. Berger, L.B.S. Gelinck, E.J. Kuijper, F.P. Kroon,
J.P. Vandenbroucke (Leiden, NL)
Objective: Between the ﬁrst of March and the ﬁrst of October
2005 a sudden rise in the incidence of Pneumocystis jirovecii
pneumonia (PCP) in renal transplant recipients was observed in
the Leiden University Medical Center. To investigate the
possibility of transmission from patient-to-patient or from a
common environmental source, clinical, epidemiological and
molecular characteristics of this cluster were analysed.
Methods: All renal transplant recipients in the Leiden
University Medical Center diagnosed with PCP between the
ﬁrst of January and the ﬁrst of October 2005 were included. The
diagnosis had to be conﬁrmed by direct microscopy or PCR of
the dihydropteroate synthase (DHPS) gene in bronchial alveolar
lavage ﬂuid. Data concerning underlying disease, medication,
co-morbidity, outpatient department visits and demographical
data were obtained from the ﬁles. A transmission card was
constructed to detect any contact between patients. Genotyping
of Pneumocystis strains was performed by sequence analysis of
the internal transcribed spacer number 1 (ITS1) and ITS2 gene
regions.
Results: Out of 20 suspected cases, 16 were identiﬁed as
conﬁrmed PCP cases; 10 with microscopy and PCR, 6 with
PCR only. All patients had clinical symptoms and radiological
signs compatible with PCP; none died. The background rate is
approximately 2 PCP cases per year. Risk factors for
development of PCP e.g. active cytomegalovirus replication
and treatment for rejection were present in 8/16 and 4/16
patients. No alterations in immune-suppressive regimens had
been implemented. The transmission card showed that patient-
to-patient transmission of Pneumocystis had been possible on
multiple occasions. Sequence analysis of the ITS1 and ITS2 gene
regions showed type ’Ne’ in 9/16 samples and type ’Bi’ in 1
sample. In 3 samples only the ITS2 genotypes could be
determined (type ‘e’ twice and ‘g’ once). Determination of ITS
genotypes failed in 3/16 samples.
Conclusions: In this cluster of PCP, clinical data as well as
molecular typing are compatible with patient-to-patient
transmission or with a common source of infection. However,
deﬁnitive proof of transmission cannot be given on these data.
O264
Nosocomial legionellosis outbreak occurring in
immunosuppressed patients in a cancer centre
C. Gudiol, J. Carratala, M.A. Dominguez, R. Verdaguer,
A. Fernandez-Sevilla, F. Gudiol (Barcelona, ES)
Objective: There is scarce information regarding the impact of
early diagnosis of nosocomial legionellosis by urine antigen
testing and levoﬂoxacin therapy on outcomes of
immunosuppressed patients with this infection. We report a
legionellosis outbreak due to Legionella pneumophila serogroup 1
occurring in a cancer center, in which these modalities of rapid
diagnosis and treatment were used.
Methods: The outbreak involved 12 patients. Legionnaire´s
disease was detected in the ﬁrst patient, on Feb 24th 2005, and
the outbreak lasted 4 weeks. After two more cases were
diagnosed within 48 h, universal urine antigen testing (n = 155
patients) was indicated. Pulsed-ﬁeld gel electrophoresis (PFGE)
typing was performed in all isolates from sputum and water
system samples. Superheating and ﬂushing of water system
were undertaken to control the outbreak.
Results: There were 6 males and 6 females, aged between 41
and 74 yrs. Seven patients had underlying hematologic
disorders (lymphoma 4, acute leukemia 2, aplastic anemia 1)
and 5 patients had solid tumors (lung cancer 3, disseminated
cancer 1, pancreas cancer 1). All but one patients were receiving
steroids and 6 patients other immunosuppressive drugs at the
time or few days before the infection. Three patients had
profound neutropenia and one of them had also invasive
aspergillosis requiring ICU admission. Ten patients presented
with pneumonia (multilobar 3, cavitated 1) while two patients
were asymptomatic at the time when the urine antigen test was
performed. Urine antigen test was positive in all 12 cases.
L. pneumophila serogroup 1 was isolated from the sputum of 5
patients, and from water system samples. Only the ﬁrst patient
who was treated with clarithromycin died, whereas the
remaining 11 patients who received levoﬂoxacin survived.
Overall mortality (<28 days) was 8.3%. PFGE typing
demonstrated identical clonal patterns among isolates
recovered from sputum and water samples. Superheating and
ﬂushing of water system successfully terminated the outbreak.
Conclusions: Early diagnosis of cases by universal urine
antigen testing and early levoﬂoxacin therapy were associated
with outcomes much better than those classically reported in
severely immunosupressed patients with legionellosis.
O265
Implications of the evidence for antibiotic
prophylaxis for cancer patients with neutropenia:
updated meta-analysis
L. Leibovici, A. Gafter-Gvili, M. Paul, A. Fraser, M. Cullen
(Petah Tikva, IL; Birmingham, UK)
Objectives: To deﬁne groups of neutropenic patients likely to
beneﬁt from antibiotic prophylaxis, we updated a previous
meta-analysis assessing antibiotic prophylaxis for afebrile
neutropenia. We assessed outcomes for patients with solid
tumors or lymphoma (SO/LY) and for patients with acute
leukemia or bone-marrow transplantation (AL/ BMT).
Methods: Systematic review and meta-analysis including
randomized controlled trials comparing any antibiotic
treatment vs. placebo or no treatment (control) for afebrile
cancer patients following chemotherapy. The last search was
conducted in September 2005. The primary outcome assessed
was all-cause mortality. Relative risks (RR, 95% conﬁdence
intervals) were calculated using the ﬁxed effect model. Numbers
needed to treat (NNT) were calculated using mortality rates
observed in the placebo group of the new trials.
Results: Two large trials including 760 patients with AL/BMT
and 1565 patients with SO/LY were added to the meta-analysis,
altogether comprising 56 trials. Quinolones were assessed in 22
trials. Compared to control, any antibiotic prophylaxis
signiﬁcantly reduced all-cause mortality, RR 0.66 (0.55–0.79).
The reduction was greater when limited to studies assessing
quinolones, RR 0.55 (0.40–0.75). Among AL/BMT patients,
signiﬁcant reductions in all cause mortality were observed for
any prophylaxis, RR 0.67 (0.55–0.83) and for quinolone
prophylaxis, RR 0.58 (0.40–0.84). The NNT to prevent one
death was 48 patients. Signiﬁcant reductions in mortality were
observed also in studies assessing SO/LY patients during the
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ﬁrst chemotherapy course: RR 0.58 (0.33–1.00) for any
prophylaxis and RR 0.48 (0.26–0.88) for quinolones, NNT 84
patients. All secondary outcomes were reduced both in AL/
BMT and SO/LY patients, including febrile neutropenia,
bacteremia, clinically documented infections and infection-
related mortality (Table). Both Gram-negative and Gram-
positive infection rates were reduced. Fungal infections did
not increase. Prophylaxis was not associated with serious
adverse events. No signiﬁcant difference in quinolone-resistant
infections between study arms was observed in studies
comparing quinolones to control.
Conclusions: Given the low NNTs for all-cause mortality,
antibiotic prophylaxis using quinolones should be considered
for all patients with AL/BMT. Among SO/LY patients,
prophylaxis may be warranted during the ﬁrst chemotherapy
course.
O266
Bacteraemia in Danish patients with
haematological malignancies: coverage and
impact of inappropriate empirical antibiotic
treatment on 7-day and 30-day mortality
M. Nørgaard, H. Larsson, G. Pedersen, H.C. Schønheyder,
H.T. Sørensen (Aalborg, Aarhus, DK)
Objectives: To examine the coverage of the empirical antibiotic
treatment in ﬁrst episode of bacteraemia in patients with
haematological malignancies and to determine the impact of
inappropriate treatment on mortality.
Methods: We conducted this population-based cohort study in
North Jutland County, Denmark from 1992–2002. We included
all patients ‡15 years with a new haematological malignancy
registered in both the Hospital Discharge Registry and the
Danish Cancer Registry and a successive episode of bacteraemia
registered in the County Bacteraemia Registry. Empirical anti-
biotic therapy was classiﬁed inappropriate if isolates were found
to be resistant to all administered antibiotics, or if the doses or
route of administration were insufﬁcient. Mortality within
30 days was determined through the Civil Registration
System. Cox’s regression analysis was used to compare mortal-
ity rates with adjustment for age, gender, and co-morbidity. The
analysis was stratiﬁed according to neutropenia (neutrophile
count <1.0 · 109/l).
Results: In total 358 patients were included. At ﬁrst notiﬁcation
of positive blood culture 19 patients had already died or a
decision to withhold therapy had been made because the
patients were terminally ill. Further 8 patients were excluded
due to missing information. In the remaining 331 patients
empirical antibiotic treatment was found to be appropriate in
225 (68%) patients and inappropriate in 106 (32%) patients. The
cumulative 7-day mortality in patients who were given
inappropriate empirical antibiotic treatment was 15% vs. 11%
in the appropriate group, yielding an adjusted mortality rate
ratio (MRR) on 1.2 (95% CI: 0.6–2.4). The corresponding
cumulative 30-day mortality was 35% vs. 25%, yielding an
adjusted 30-day MRR on 1.3 (95% CI: 0.8–2.0). For the 134
neutropenic patients adjusted MRRs for 7 days and 30 days of
follow up were 0.6 (95% CI: 0.2–1.7) and 0.7 (95% CI: 0.3–1.5),
respectively. The corresponding MRRs for non-neutropenic
patients were 2.1 (95%CI: 0.8–5.3) and 1.7 (95%CI: 1.0–3.0).
Conclusion: One third of haematological patients with
bacteraemia were given inappropriate empirical antibiotic
treatment, which is associated with increased mortality. Data
do not support that neutropenic patients with bacteraemia are in
particular sensitive to inappropriate empirical antibiotic
treatment.
Multidrug-resistant Gram-negative organisms in the hospital and
community
O267
Risk factors for faecal carriage of extended-
spectrum beta-lactamase producing Escherichia
coli and Klebsiella spp. in the community
O¨.K. Azap, H. Arslan, S.O¨. Karaman, T. Togan (Ankara, TR)
Objectives: Community acquired infections caused by
ESBL-producing bacteria is an emerging problem. Digestive
tract colonization is a prerequisite for infections by ESBL-
producing microorganisms. The aim of this study is to
determine the prevalence of and risk factors for fecal
carriage of ESBL-producing Escherichia coli or Klebsiella spp.
in the community.
Methods: A total of 928 stool samples admitted to the
laboratory during the 4-month period were included in the
study. Samples were diluted in saline and cultured in two
EMB agar plates supplemented with 1 mg/mL cefotaxime and
1 mg/mL ceftazidime, respectively. All isolates that grew were
identiﬁed to the species level. E.coli and Klebsiella spp. strains
were tested for ESBL production with ceftazidime and
ceftazidime-clavulonate discs acccording to the Clinical and
Laboratory Standards Institute (CLSI) Guideline.
Results: Of the 928 stool samples included 133 (14%) were
isolated from inpatients and 795 (86%) were isolated from
outpatients. Sixty-three (47.3%) of 133 hospitalized and 121
(15.2%) of 795 outpatients harbored ESBL-producing E. coli,
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Klebsiella spp. (p = 0.000). Chronic hepatic failure (OR: 8.7; CI:
1.65–46.12; p = 0.011) and recent antibiotic use (OR: 4.4; CI: 1.76–
11.16; p = 0.002) were found to be associated with ESBL
positivity for the hospitalized patients. Recent antibiotic use
(OR: 2.8; CI: 1.61–5.12; p = 0.000) was found to be the only
independent variable associated with ESBL positivity for the
outpatients.
Conclusion: The high prevalence (15.2%) of fecal carriage of
ESBL-producing bacteria in the community warrants further
study in this ﬁeld including the consequences of this
colonization in the hospital setting.
O268
Differences in the epidemiology of extended-
spectrum beta-lactamase producing Escherichia
coli according to the types of enzymes
J. Rodrı´guez-Bano, M.D. Navarro, L. Romero, M.A. Muniain,
J.R. Herna´ndez-Bello, A. Pascual (Seville, ES)
Objectives: Extended-spectrum beta-lactamase-producing
Escherichia coli (ESBLEC) are an emergent cause of community
and nosocomial infections. We analyse the epidemiology of
ESBLEC in our area according to the type of ESBL produced.
Methods: All patients from whom an ESBLEC was isolated in
our area (550,000 population) from January 2001 to May 2002
were included. The following data were collected: age, sex,
chronic underlying diseases, previous health-care relation
(HCR), invasive procedures, previous antimicrobial use, and
types of infection. ESBL production and antimicrobial
susceptibility were studied by microdilution (NCCLS
guidelines). ESBLs were characterized by isoelectric focusing,
PCR, and sequencing. Clonal relationships among the isolates
were determined by REP-PCR.
Results: Ninety-six cases were included; 77% of them had
previous HCR. Forty-nine (51%) were outpatients. Among
these, 65% were being attended in primary care, 20% in the
emergency service and 14% in the outpatient’s clinic. The other
47 patients (49%) were hospitalized. Seventy-four (77%) were
considered to have an infection: UTI, 66%; skin and soft tissues,
18%; primary bacteraemia, 10%; and respiratory tract, 6%.
Seventy-two percent of the isolates produced one ESBL, 26%
produced 2, and 2% produced 3; 63% of the isolates produced
CTX-M enzymes (mainly CTX-M-14), 47% produced SHV
(mainly SHV-12), and 21% TEM. Two homogeneous groups
were identiﬁed for comparison: patients with isolates producing
only CTX-M (n = 47) and those producing TEM + SHV but not
CTX-M (n = 14). Signiﬁcant differences were found in
nosocomial acquisition (36% vs 100%, p < 0.001), non-fatal
disease (70% vs 36%, p = 0.05), diabetes (49% vs 21%, p = 0.06),
urinary catheter (32% vs 64%, p = 0.03), and ﬂuoroquinolone
use (30% vs 64%, p = 0.01). Isolates producing only CTX-M
enzymes were more frequently susceptible to gentamicin (83%
vs 43%, p = 0.01) and ciproﬂoxacin (24% vs 0, p = 0.05). There
was no clonal relationship among the CTX-M-producing
isolates, while those producing TEM + SHV belonged to 2
clonal groups.
Conclusions: There are signiﬁcant differences in the
epidemiology of ESBLEC according to the types of enzyme
produced. Isolates producing CTX-M enzymes are most
commonly community-acquired, are less frequently resistant
to non-betalactams, and are not clonally related, while those
producing TEM + SHV cause nosocomial outbreaks. These
differences should be taken into account for the design of
control measures.
O269
Frequency and predictors of colonization of the
respiratory tract by Gram-negative bacteria with
the blaVIM gene in patients of a newly
established intensive care unit
M. Horianopoulou, N. Legakis, M. Kanellopoulou,
S. Lambropoulos, A. Tsakris, M. Falagas (Athens, GR)
Objectives: Our aim was to examine the frequency and
predictors of the colonization of the respiratory tract by Gram-
negative bacterial with the blaVIM gene in patients admitted to
a newly established intensive care unit (ICU) of a tertiary care
hospital.
Methods: Specimens of tracheobronchial aspirates were
obtained every day during the ﬁrst three days of the ICU stay
and subsequently every third day during the rest of the ICU stay
for microbiological studies. Also, cultures of specimens from the
axillary and the inguinal area of the patients were taken during
the ﬁfth day of the ICU stay. In addition, cultures of specimens
from several environmental sites as well as from the oropharynx
and the hands of the staff were taken. Molecular studies were
performed to identify bacteria with the blaVIM gene. Also, an
analysis of potential risk factors for colonization with Gram-
negative bacteria with the blaVIM gene was done.
Results: Thirty-ﬁve patients (20 male, 15 female) were
hospitalized during the initial three-month period of the
function of the ICU. Colonization of the lower respiratory tract
by Gram-negative bacteria was found in 29 of 35 patients (83%)
during the ﬁrst 6 to 20 days (median 13 days) following
admission to the ICU (Acinetobacter baumannii 13 patients,
Pseudomonas aeruginosa 10, Enterobacter aerogenes 3, Klebsiella
pneumoniae 2, and Stenotrophomonas maltophilia 1). A. baumannii
and P. aeruginosawere isolated from 6 and 4 out of 80 cultures of
specimens from patient bed bars, respectively. Six of 29 (21%) of
patients with colonization with Gram-negative bacteria had
microorganisms with the blaVIM gene. Previous use of
carbapenems (p = 0.01) or other b-lactams (p = 0.03) as well
stay in the ICU more than 20 days (p = 0.01) were associated
with colonization with a bacterium with the blaVIM gene.
Conclusion: Colonization by Gram-negative bacteria of the
respiratory tract of patients in this newly established ICU was
common (83%). Use of b-lactams including carbapenems was
associated with the subsequent colonization of the respiratory
tract with Gram-negative bacteria with the blaVIM gene.
O270
Epidemiological investigation of quinolone
resistance in infections due to extended-spectrum
beta-lactamase-producing Enterobacteriaceae in a
tertiary hospital
A. Katsandri, A. Vasilakopoulou, V. Mela, G.L. Petrikkos,
C. Kosmidis, J. Papaparaskevas, A. Avlamis (Athens, GR)
Objectives: The incidence of infections due to extended-
spectrum b-lactamase (ESBL)- producing Enterobacteriaceae has
increased markedly in recent years. Although treatment is
difﬁcult because of frequent multidrug resistance, quinolones
offer an effective alternative therapy. Aim of this study was the
identiﬁcation of risk factors for quinolone resistance in ESBL
infections.
Materials and methods: A prospective study of 84 consecutive
ESBL hospital infections in a tertiary care hospital during one
year period (15/1/2004–15/1/2005) was conducted. Data
collected included gender, age, ward type, duration of
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hospitalization, number of hospital days before infection,
infection site, invasive procedures, underlying diseases and
outcome. The antimicrobial proﬁle of the infecting organism, as
well as all antimicrobial therapy prior to recovery of an isolate
were documented. Infections by quinolone resistant ESBL
producing bacteria (QR-ESBL) were used as cases and those
by quinolone sensitive ESBL (QS-ESBL) producing isolates were
used as controls.
Results: 84 ESBL isolates were identiﬁed in clinical specimens
from 77 patients. The prevalence of QR-ESBL bacteria was
59.52%. The median age of patients was 60 years and the
percentage of females was 58.4%. The distribution of ESBL
isolates was: E. coli 51%, Klebsiella spp. 17%, Enterobacter spp. 9%,
Proteus spp. 3%, Serratia spp. 2% and others 2%. The site of
infection varied, the most frequent sites being: the urinary tract
(65.5%), wound or surgical site (14.3%), bacteraemia (10.7%), the
respiratory tract (7.1%) and other (2%). The overall mortality
was 26%. Isolates from kidney transplant patients were
signiﬁcantly more likely to be quinolone resistant (p = 0.047;
OR = 2.56; 95% CI, 0.99–6.58). Infection from QR-ESBL bacteria
was associated with increased hospital stay (mean days 46.28 vs
35.28, p = 0.028). On the average, QR-ESBL bacteria were
isolated from cultures later during hospitalization than
QS-ESBL bacteria (mean days 30.64 vs 19.44, p = 0.089).
Factors associated with quinolone resistance were the previous
use of carbapenems (p = 0.063) and quinolones (p = 0.058).
QR-ESBL bacteria were signiﬁcantly more likely to be resistant
to co-trimoxazole (p = 0.002), gentamicin (p = 0.047) and
tobramycin (p = 0.006).
Conclusions: Quinolone resistance is widespread among ESBL
producing bacteria and the risk factors associated were
increased hospital stay and the previous use of carbapenems
and quinolones.
O271
The changing epidemiology of sequential
outbreaks of multiresistant Acinetobacter
baumannii bacteraemia: a ten-year study in an
intensive care unit
J.J. Camarena, R. Gonzalez, R. Zaragoza, J.C. Navarro, S. Sancho,
A. Artero, J.M. Nogueira (Valencia, ES)
Objective: During the last ten years, multiresistant Acinetobacter
baumannii (MRAb) bacteremia remains like the most important
problem in ICU-nosocomial acquired infections in our teaching
hospital. The goals of this study were to describe the pheno-
genotypic characteristics of the MRAb bloodstream infections,
the temporal evolution of the clones associated to outbreaks or
endemic infections and the inﬂuence of adequate empiric
treatment (AET) or control measures.
Methods: Prospective study of all strains of A. baumannii
isolated in bacteremic patients of an ICU during the last
10 years. Genotypic analysis of DNA by PFGE and REP-PCR.
Susceptibility study of the isolates performed by disk-diffusion
and E-TestR. Clustering of the phenol-genotypic patterns and
analysis of their temporal evolution. Analysis of AET and
preventive control measures.
Results: A total of 507 isolates from 137 signiﬁcant Ab
bacteremia cases in ICU were analysed. The impact of Ab
bacteremia on ICU- acquired infections was differed in two
study periods. In the ﬁrst one (1995–2001) seventy-two episodes
(52.5%) were classiﬁed in six mainly clusters. The multiresistant,
including carbapenems, outbreaks was caused in this period by
two clusters which grouped the 66.6% of the cases: R3/97/C3
(96.5% of isolates in 1996–98), and R3B/99/C3B (58% of isolates
in 1999–2000). Since February 2001, with the description of the
R5C5 cluster carbapenem sensible, the MRAb problem seemed
to be eradicated and Ab remained endemic in the ICU until
2002. In the second period (2002–2005) MRAb problem
reappears with the detection of 65 news cases (47.4%) with 3
mainly clusters all of then carbapenems and doxicicline resistant
(R7/03/C7, 40.2% of isolates in 2003–04; R8/04/C8, 60.3% of
isolates in 2004–05; and R3/05/C10, only colistin sensible,
emergent in 2005 with 38.2% of the isolates, which is the actual
cause of the MR-Ab outbreak in the ICU.
Conclusions: Since the detection of the MRAb bacteremic cases
in 1995, an endemo-epidemic situation, with nine sequential
outbreaks pheno-genotipically characterized, has been described
in the ICU in our teaching hospital. After ten years, MRAb
bacteremia in our ICU continues to be, despite the AET
guidelines and preventive measures for the control of this
endemo-epidemic situation, a serious ICU-problem.
Infection control
O272
New World Health Organization alcohol-based
formulations to implement handrubbing as the
gold standard for hand hygiene worldwide
B. Allegranzi, A. Voss, M. Rotter, S. Sattar, W. Grifﬁths,
S. Dharan, L. Donaldson, D. Pittet (Verona, IT; Nijmegen, NL;
Vienna, AT; Ottawa, CA; Geneva, CH)
Objective: The advanced draft of the WHO ‘‘Guidelines on
Hand Hygiene (HH) in Health Care’’ was recently issued.
Although all means to ensure HH should be promoted, the
Guidelines recommend alcohol-based hand rubs (AHRs) at the
point of care as the gold standard for HH and provide
instructions for in-house local production of suitable, effective,
and low-cost formulations.
Methods: A group of international experts in microbiology and
infection control were consulted to identify the ingredients and
related proportions of a WHO alcohol-based formulation for
handrubbing. Issues related to the procurement of raw
materials, safety, distribution and storage of the ﬁnished
product were also discussed and solutions proposed.
Results: The two proposed formulations have different alcohol
content (ethanol 80% V/V and isopropyl alcohol 75% V/V)
and include H2O2 (ﬁnal concentration, 0.125%) as a
preservative against spores and the same humectant-like
substance to increase user acceptance. WHO-designated,
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independent laboratories are testing the formulations for
efﬁcacy according to ASTM International and the European
Committee for Standardization methods. Based on expert
opinion, these formulations, preferably in liquid form rather
than gel, are suitable for both hygienic hand antisepsis and
surgical hand preparation. For the latter, substances with
sustained antimicrobial activity could be added, but are not
considered necessary for routine hand antisepsis. Other
alcohol-based handrubs with equivalent safety and efﬁcacy
proﬁles may also be considered. The issue of alcohol content
should be considered in settings where its use is prohibited for
religious or cultural reasons. In case of reuse, containers should
be cleaned and decontaminated by autoclaving, boiling or
chemical disinfection with chlorine. Reusable bottles should be
reﬁlled only when empty and cleaned. In tropical climates, in
particular, additional care is needed in storage of alcohol-
containing materials.
Conclusions: Governmental authorities and healthcare
administrators should make every possible effort to provide
healthcare workers with AHRs at the point of care to achieve
maximum beneﬁt and optimal compliance with HH. The
proposed formulations are designed to be suitable for
worldwide use based on cost, efﬁcacy, procurement and
cultural factors. Within the pilot phase of the WHO Guidelines
implementation strategy the proposed formulations are being
evaluated for feasibility and acceptability.
O273
Decrease of external ventricular or lumbar drain
related infections by a multidisciplinary
approach
M.A. Leverstein-van Hall, T.E.M. Hopmans, H.E.M. Blok,
J.W. Berkelbach van der Sprenkel, M.J.M. Bonten on behalf of the
UMCU Working Party Neurosurgical Drain infections
Introduction: Extraventricular (EVD) and lumbar drains (LD)
are important temporary measures for patients requiring
continuous cerebrospinal ﬂuid (CSF) drainage. Reported
incidences of drain related meningitis have varied from 2.4 to
15%. In the UMCU, microbiologically conﬁrmed CSF infections
in patients with EVD/LD increased from 28% in 2001 to 47% in
2003. The aim of this prospective study was to reduce the
incidence of drain-related meningitis to less than 10% in 2005.
Patients: All patients who received EVD or LD from Jan–April
2004 (period I), Aug–Dec 2004 (period II), and Jan–May 2005
(period III).
Interventions: A multidisciplinary team (neurosurgery, clinical
microbiology, and hospital hygiene) designed a strategy based
on 4 pillars: (1) implementation of drain management protocols
for medical and nursing staff based on the ‘‘no-touch’’ concept,
optimal hygiene and strict criteria for placement and removal of
drains, (2) implementation of an algorithm on diagnostic and
therapeutic management of patients suspect of drain-related
meningitis, (3) implementation of a new protocol on pre-
operative prophylaxis, (4) introduction of a closed drain
system. Results are depicted in the table. The decrease of the
infection rate in period III versus I was more pronounced for
ELD than for EVD. The RR to acquire an infection per 100 days
at risk decreased for the ELD with 0.2 (95%-CI: 0.03–1.7) and for
the EVD with 0.7 (95%-CI: 0.2–2.2). From period I to III a sharp
shift was observed in the kind of micro-organisms isolated from
the CSF; in period III the typical nosocomial pathogens had
disappeared.
Conclusions: The incidence of drain-related meningitis has
decreased from 39% in 2003 to less than 10% in 2005. Awareness
of the problem and the interventions performed in 2004 were
probably important causative factors in this reduction.
Adequate prophylaxis remains a point of concern and new
strategy seems needed for improvement.
O274
Evidence for the effectiveness of ’Search and
destroy’ of methicillin-resistant Staphylococcus
aureus in the Netherlands
M.J.C.A. van Trijp, D.C. Melles, A. Ott, W.D.H. Hendriks
(Rotterdam, NL)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
is an important pathogen causing nosocomial infections.
Prevalence of MRSA varies widely among countries. In the
Netherlands MRSA prevalence in clinical isolates is below 1%,
due to a national ‘Search and destroy’ policy. The efﬁcacy of this
policy in endemic situations is debated. In this study we
describe a large MRSA outbreak with a highly transmissible
strain in a Dutch hospital, and the measures that were taken to
control the epidemic.
Methods: MRSA was isolated using conventional culturing,
including a selective broth. MRSA-isolates were typed using
Pulsed Field Gel Electrophoresis. Measures used to control the
epidemic included: screening of contacts (patients and hospital
staff), screening at re-admission and in some departments at
regular intervals and at discharge. In addition: strict isolation of
colonized or infected patients, decolonisation of patient and
hospital staff MRSA carriers using topical agents. Also an
electronic patient signalling, and personnel culture-information
system was developed.
Results: The epidemic started around November 2001. As the
involved strain had a low oxacillin MIC, it was not immediately
recognized as MRSA. In January, when gradually more contacts
were screened, it appeared that MRSA had spread to many
departments, and that members of staff were also colonized.
During Nov 2001 – Dec 2004 722 new isolates were detected
among 559 patients and 129 staff members respectively; some
persons were infected more than once. Of these isolates 87%
belonged to four epidemic clones, the remainder being sporadic
types. Since May–June 2004, when a last upsurge of one of these
clones occurred, only sporadic cases have been detected.
Conclusion: This study shows that with application of a strict
‘Search and destroy’ policy even endemic MRSA can be
controlled.
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Reducing the impact of methicillin-resistant
Staphylococcus aureus infection in an intensive
care unit: a nine-year analysis
A. Pan, E. Raineri, P. Mondello, L. Ferrari, G. Carnevale,
A. Acquarolo, S. Lorenzotti, S. Magri, L. Soavi, L. Crema
(Brescia, Cremona, IT)
Objective: To evaluate the effectiveness of a control system for
nosocomial transmission of methicillin-resistant Staphylococcus
aureus (MRSA) in an Intensive Care Unit (ICU) in a hospital with
hyperendemic MRSA.
Methods: We retrospectively analysed prospectively collected
data. This study was performed in a 10 bed general ICU in Italy,
with high rates of MRSA transmission and infection rates: 6.0
and 2.8 cases per 100 admissions respectively. Three phases
were identiﬁed over a 9-year time period. Period 1 (p1), 1996–
1997, prior to the introduction of the hospital MRSA control
program. Period 2 (p2), 1998–2002, after the introduction of the
MRSA control program guidelines. Period 3 (p3), 2003–2004,
after the ICU moved into a new ward, when MRSA modiﬁed
guidelines, including isolation or cohorting, were implemented.
All patients admitted to ICU were included in the analysis.
MRSA guidelines included active surveillance, contact
precautions and topical treatment of carriers. In 2003 modiﬁed
MRSA guidelines included isolation/cohorting of MRSA
positive patients.
Results: The rate of MRSA infected patients during p1, p2, and
p3 was: 2.8, 1.2, and 0.6 cases per 100 admissions, respectively. A
signiﬁcant reduction of the infection rate was observed
comparing p1 both with p2 (P = 0.002; RR: 0.4 CI95%: 0.22–
0.73) and p3 (P = 0.0008; RR: 0.22 CI95%: 0.08–0.56). No
signiﬁcant reduction of the infection rate was observed
between p2 to p3, (P = 0.2; RR: 0.54 CI95%: 0.21–1.37). A
signiﬁcant reduction of the methicillin resistance rate of
Staphylococcus aureus isolates was observed: 51%, 32%, and
16% during p1, p2, and p3 respectively (P < 0.0001 for trend).
Conclusions: The ‘‘search and destroy’’ strategy, based upon a
combination of active surveillance, contact precautions and
topical treatment might be effective in signiﬁcantly reducing
MRSA acquisition rate even in an ICU with high rates of MRSA
colonization / infection. Patients’ isolation or cohorting did not
further improve the results obtained with the ‘‘search and
destroy’’ strategy.
O276
Comparison of the bacterial efﬁcacy and
acceptability of an alcohol-based hand rinse with
2 alcohol-based hand gels during routine patient
care
F. Barbut, E. Maury, L. Goldwirt, D. Neyme, R. Aman, B. Rossi,
P. Boelle, G. Offenstadt (Paris, FR)
Most alcohol-based gels used for handrubbing have been
reported less efﬁcacious than alcohol based rinses using the
standard method EN1500, but usually better accepted by
health care workers (HCWs). We compared the bacterial
efﬁcacy of handrubbing with an alcoholic rinse with two
different alcoholic gels in reducing hand contamination under
practical use.
Material and methods: A prospective crossover clinical trial
was performed in a 14-bed medical intensive care unit in a
French university-afﬁliated hospital during 3 consecutive
6-weeks periods. For each period, only one product was
available for handrubbing: HCW used either Sterillium* rinse
(45% 2-propanol; 30% 1-propanol; 0.2% mecetronium ethyl-
sulfate) or Sterillium* gel (85% ethanol) or Manugel Plus*
(Ethanol 53%, isopropanol 17%). Immediately after a direct
contact with a patient, pre- and post-handrubbing hand
contamination was measured using the glove juice technique.
Bacterial counts were evaluated blindly on trypticase soy agar
plates. At the end of each period, a self-administered
questionnaire was completed by the HCWs. Skin tolerance
and acceptability were assessed using a visual analogical scale
(VAS). Data were entered and analysed using EpiInfo software
6.04d (CDC, Atlanta).
Results: We studied 242 hand-rubbing opportunities. Median
duration of handrubbing was 30, 27, and 35 sec. for Sterillium*
rinse, Sterillium* gel and Manugel Plus*, respectively. The mean
reduction factor (expressed as the log10 CFU/mL) of the
Sterillium* rinse, Sterillium* gel and Manugel Plu* were
1.28 ± 0.95, 1.29 ± 0.84 and 0.51 ± 0.73, respectively. Sterillium*
rinse and Sterillium* gel were both signiﬁcantly more effective
in reducing bacterial counts from the hands than Manugel Plus*
(p < 0.001). Sterillium* rinse and Sterillium* gel were also
signiﬁcantly better tolerated (VAS for dryness: 3.56 and 2.5
versus 7.5, p < 0.05), and better accepted (VAS 6.8 and 7.9
versus 4.9, p < 0.05) than Manugel Plus*.
Conclusion: When testing under practical use conditions,
Sterillium* gel was found similar to Sterillium* rinse but they
were both more efﬁcacious and better tolerated than Manugel
Plus*.
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Galactomannan antigen detection in invasive aspergillosis: test
optimisation and impact on patient management (Symposium
organised by Bio Rad)
S277
Optimisation of the cut-off value of the Platelia
Aspergillus ELISA
P.E. Verweij, C. Masson, R. Klont, C. Heinen, B. Crepin, J.
Maertens (Nijmegen, NL; Marnes-La-Coquette, FR; Leuven, BE)
Objectives: The Platelia Aspergillus (PA)-ELISA (BioRad,
France) is routinely used in many institutes for the early
diagnosis of invasive aspergillosis (IA). There is considerable
variability in the cut-off values used. Although a cut-off of 1.5 is
recommended by the manufacturer, most institutes use a lower
cut-off value varying between 1.0 and 0.5. In the USA the same
kit is used with an approved cut-off value of 0.5. The aim of the
current study was to re-evaluate the cut-off level of the PA-
ELISA.
Methods: A retrospective study was performed using
prospectively collected and analysed serum samples from
adult patients with hematological disorders at high risk for
developing IA. The data were collected between 2001 and 2005
in 2 different sites (site 1, University hospital Gasthuisberg,
Leuven, Belgium and site 2, Radboud University Nijmegen
Medical Center, Nijmegen, The Netherlands). Patients were
classiﬁed according to the EORTC/MSG consensus deﬁnitions
and a ROC analysis was performed in order to determine the
optimal cut-off value.
Results: 123 treatment episodes from 88 patients were enrolled
from site 1 (3929 serum samples) and 116 episodes from 115
patients from site 2 (944 serum samples). Among these
patients, 19 were diagnosed with a proven IA and 19 with a
probable IA. The analysis on the cumulated data of proven and
probable cases, showed that a decrease of the positivity index
from 1.5 to 0.5 corresponded with an increase of sensitivity of
21% (76.3% to 97.4%) and a decrease of speciﬁcity of 7 %
(97.5% to 90.5%). The performance at a cut-off value of 0.5 was
similar at both sites: sensitvity and speciﬁcity was 100% and
92.2% respectively at site 1 and 94.4% and 88.8%, respecitvely,
at site 2. Combined, at a cut-off of 0.5 the highest sensitivity
(97.4%) was achieved as well as an acceptable speciﬁcity
(90.5%) and a positive and negative predictive value of 66.1%
and 99.4%, respectively.
Conclusion: At a cut-off value of 0.5 the most favourable
performance characteristics were found with the PA-ELISA.
This cut-off value is identical to that approved in the USA.
S278
Galactomannan and computed tomography-
based preemptive antifungal therapy in
neutropenic patients at high risk for invasive
fungal infections
J. Maertens (Leuven, BE)
A timely and reliable diagnosis of invasive aspergillosis in
patients with an underlying hematological disorder remains
frustratingly difﬁcult and is seldom-achieved ante mortem.
Conventional laboratory diagnostic methods are insensitive and
time consuming, resulting in late diagnosis and treatment and
contributing to unacceptably high mortality. In response to these
diagnostic obstacles, prophylactic and empiric strategies have
been recommended, especially in prolonged neutropenic
patients and hematopoietic stem cell transplant recipients.
However, over treatment associated with these strategies results
in increased toxicity and cost. The use of sensitive and rapid
non-culture based diagnostic assays, such as the detection of
Aspergillus antigens (galactomannan, beta-D-glucan) or the
detection of genomic DNA sequences may allow a shift in
emphasis from empirical to pre-emptive therapy, especially
when substantiated by suggestive radiological ﬁndings. These
tools may be used to conﬁrm a presumed diagnosis of invasive
aspergillosis, or, when used to screen high-risk patients, may
identify an infection at the early stage of disease. The excellent
negative predictive value of these new tools may convince
clinicians to withhold antifungal therapy in persistently febrile
neutropenic patients with no other signs of fungal infection. On
the other hand, consecutive positive results in a high-risk
population should at least trigger a complete diagnostic work-
up.Whether pre-emptive strategies will ﬁnally improve patient
outcome and whether they will prove to be cost-effective
remains to be investigated in carefully designed randomized
clinical trials.
How to detect the next emerging pathogen
S282
How to detect new viral agents and what Europe
should do
X. de Lamballerie (Marseilles, FR)
Prediction of the emergence of viral pathogens is intrinsically
difﬁcult and highly pretentious. However, assessment of our
current knowledge and of the present time organisation of
diagnosis & research laboratories allows to propose a few
modest but practical guidelines.1. Is it possible to elaborate a
speciﬁcation sheet of good candidates for viral emergence?There
are ~20viruses that meet the 1992 WHO deﬁnition of emerging
pathogens and are responsible for several million of deaths each
year. They are not associated with speciﬁc clinical presentations
(hepatitis, immunosuppression, haemorrhagic fever, encephali-
tis, respiratory syndrome etc. are observed) and transmitted by
various routes (aerosols, oral-fecal, bite of arthropods, sexual
relations etc.). However, strikingly, 90% of these viruses have an
RNA genome and 90% have a zoonotic origin.2. Is it possible to
identify common features in previously observed scenarii of
emergence?In most of the cases, 3 steps can be reported: (i) the
transmission of an animal virus to humans: this step is poorly
understood but human activity (& not plasticity of virus
genomes) seem to be a crucial determinant. (ii) the inter-
human transmission: selection of virus mutants is a key factor
that allows the emergence of an "humanised" virus. (iii) the
massive spread of the disease in humans is, again, primarily
linked with human behaviour.Since parameters in relation with
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viral genetics will not to change in the future while risks in
relation with human behaviour (travels, deforestation, over-
population etc.) increase constantly, it is not expected that viral
emergence will decrease in the future. 3. Do we have the
appropriate laboratory capacity for diagnosis?Previous bioter-
rorist alerts have shown that centralised diagnostic structures
would be poorly adapted to the diagnosis of emerging patho-
gens in case of outbreak. The elaboration of standardized
diagnostic kits (especially real-time PCR assays) and their
availability in a large number of hospitals is necessary but
requires a large effort at organising things.4. Do we have the
appropriate laboratory capacity for research?(i) Efforts are
necessary to bring together medical & veterinary researchers
within common research and survey programmes. (ii) The
presence of European research institutions in Developing
Countries is important for studying emerging pathogens. It is
to date poorly organised, expensive and merits reassessment.
(iii) The study of animal viruses related to human pathogens
should be promoted and (iv) a tremendous effort is needed to
identify antivirals effective against RNA viruses.The role of the
EC is potentially of major importance. The EC can support large
research programmes aiming at promoting the diagnosis of
emerging viruses, studying virus groups likely to include
emerging viruses and identifying new antivirals.
Paediatric viral respiratory tract infections: the major killers
S287
The link between asthma and viral respiratory
infections
N. Papadopoulos (Athens, GR)
Viral respiratory infections have been related to asthma in
several ways. Severe bronchiolitis in early life is related to
subsequent wheezing and therefore may represent a marker of
susceptibility to asthma; alternatively it could be involved in the
initiation of the disease. It has also been proposed that some
infections may protect from the development of asthma and
allergies by promoting a type-1 host response. However,
whether respiratory or other viruses could mediate such a
protective effect is debated. Nevertheless, it is well established
that viral common colds are the major precipitants of asthma
exacerbations. Using sensitive diagnostic methodologies, epide-
miological studies during the last decade have allowed the
identiﬁcation of human rhinoviruses (RVs), generally recog-
nized as "common cold viruses", as major asthma precipitants.
This association was further established by evaluating the
impact of RV infection in airway obstruction and inﬂammation
during naturally acquired or experimentally induced RV colds.
There is now strong evidence that RVs are able to infect and
propagate not only in the upper but also in the lower airways.
Bronchial and pulmonary epithelia infected by RVs are rich
sources of inﬂammatory mediators, which may initiate and/or
augment airway inﬂammation and obstruction. Furthermore, in
an atopic environment, responses to the virus are skewed by
and towards an "atopic", Th-2 like, balance, which may further
enhance inﬂammation and exacerbate asthma. Recent evidence
indicate that such an immune environment may also affect the
epithelial inﬂammatory response to the virus: a reduced
production of proinﬂammatory mediators is observed, correla-
ting with increased viral proliferation and increased virus-
induced cytotoxicity. This is also associated with increased
production of growth factors such as TGF-b and VEGF which
affect with ﬁbrosis and angiogenesis respectively, suggesting
that viral infections may also be implicated with airway
remodelling in asthma.
S288
Paediatric inﬂuenza: severity and need for
protection
A. Linde (Solna, SE)
Children are the engines of inﬂuenza epidemics in interpan-
demic years. They have no or limited immunity to circulating
virus strains, and therefore the age-speciﬁc attack rate is highest
among children. Twenty to twenty-ﬁve per cent of young
children may contract the disease yearly. The main complication
is otitis media, and 5–8 children per100 are prescribed antibi-
otics yearly indirectly due to inﬂuenza. The risk for hospitali-
sation is highest in children below 2 years of age, and has been
estimated to be 103/105 person months. Main reasons for
hospitalisation are suspected septicaemia, lower respiratory
tract infection, asthma/bronchitis and febrile seizures. Inﬂuenza
infection is normally self-limiting in children, but fatalities
occur. Children with severe heart and/or lung disease or other
severely debilitating disease belong to risk groups of severe
inﬂuenza like adults. During the inﬂuenza season 2003–2004
more than 140 children were reported dead due to inﬂuenza in
the US, and in Japan there has been several cases of lethal
encphalopathia in inﬂuenza-infected children during recent
years. Most of the dead children did not belong to any known
risk group. Inﬂuenza may thus be a severe disease among
children, and children below three years of age are most
vulnerable. The ordinary inﬂuenza vaccine is more reactogenic
in children that adults, and vaccination of children demands
two doses. With a good strain match, vaccination has a
protective efﬁcacy of 70–90%, and it may reduce the incidence
of otitis media with around 30%. In the US vaccination of
children of 0.6 to 23 months has been recommended since 1993.
The measure is regarded cost-effective, and it may also be
diminish the spread of inﬂuenza to the elderly. Despite this, no
European country recommends general inﬂuenza vaccination of
children, and even the rate of vaccination of vulnerable children
at risk of complicated disease is low. One reason may be an
unproven fear that vaccination may prevent the development of
basic immunity against inﬂuenza. Intranasal vaccination with
live, cold-adapted virus has proven to induce similar heterol-
gous immunity to drifted inﬂuenza strains as wild-type infec-
tion in children, and a large study of the vaccine has recently
been conducted in Europe. The outcome has not been published
(Jan 2006), but if successful it may be an attractive option for
prevention of the consequences of inﬂuenza in children.
S289
Human metapneumovirus infections in children;
approaches for prevention
B. van den Hoogen (Rotterdam, NL)
Acute respiratory tract infections (RTI) are a major cause of
morbidity and mortality worldwide. In 2001, we detected a
previously unknown virus in samples from hospitalised
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children suffering from RTI. Classical virology and genetic
analyses revealed that this "novel" virus was the ﬁrst human
member of the genus Metapneumovirus in the Pneumovirinae
subfamily of the Paramyxoviridae family. This human meta-
pneumovirus (hMPV) is related to RSV, which belongs to the
Pneumovirus genus within the same subfamily. After the
identiﬁcation of hMPV researchers around the world have
begun to analyse the epidemiology and clinical presentation of
hMPV related disease, demonstrating that the virus circulates
world wide, primarily in the winter months. hMPV infections
account for approximately 5–25% of the reported RTIs in
hospitalised children, primarily between 6 and 12 months.
RSV often is found in children that are slightly younger.
hMPV infections in patients older than 5 years do occur, and
many of these patients have impaired immunity or underlying
disease. In the general community, hMPV accounts for 1–9% of
RTI-related visits to physicians. A wide spectrum of clinical
symptoms associated with hMPV infection has been reported in
patients of all ages, ranging from mild RTI to severe disease
requiring hospitalisation. In comparative studies, hMPV infec-
tions tend to be slightly milder than RSV infections, although in
many studies the differences are not statistically signiﬁcant.
Recombinant hMPV has been produced by using reverse
genetics techniques. These techniques are now used to develop
live attenuated vaccines, based on deletion of genes or insertion
of heterologous genes. In animal studies these viruses have
shown to be attenuated but are able to produce virus neutral-
ising antibodies and protect against infection, and therefore
could be future vaccine candidates. For RSV the prophylactic
and therapeutic use of a virus neutralising monoclonal antibod-
ies directed against the fusion protein has been reported to
decrease the severity of illness. Similar reagents are currently
being developed for hMPV.
Limiting antibiotic usage in the community: beneﬁts and collateral
effects
S296
What is the impact of reductions in antibiotic use
on antibiotic resistance in the community?
P. Huovinen (Turku, FI)
The goal of rational use of antimicrobial agents is effective
treatment with minimal amount of harmful side-effects. To deal
with bacterial infections we have to use antimicrobial agents, but
we also know that there is a substantial overuse of these drugs
in most parts of the world. The side-effects include not only
allergic reactions, antibiotic diarrhoea, costs and development of
bacterial resistance but also disturbance of the normal human
microbiota (normal ﬂora) that may be more important than we
have previously thought. Bacterial resistance is linked with
consumption of antimicrobial agents both in hospitals and in the
community. On the country level, less antimicrobial agents is
linked with less bacterial resistance, but resistance bacteria may
spread despite of low level of antibiotic use. Several articles
show that use of certain antibiotics has lead to increased
resistance against these drugs. However, there are only few
studies that show effect of reduction of antibiotic use on high
level of resistance. Due to multiresistance, reduction of antibiotic
use may not be the best way to decrease antibiotic resistance.
The most rational way to tackle antibiotic resistance is to try to
prevent development and spread of resistant bacteria. This
includes optimal antimicrobial prescribing but also improved
hygienic measures especially in child day care centres. Optimal
antimicrobial prescribing needs national current care guidelines
that are uniformly or widely accepted. The term ’optimal or
rational use’ includes careful clinical and laboratory diagnostics.
Automatic computer notiﬁcations may be the best way to guide
prudent antimicrobial prescribing. Current care guidelines have
also to be ﬂexible to react when bacterial resistance situation is
changing. Economical approaches, pricing and especially reim-
bursement policy, may also be reasonable approaches. There is a
need to increase public awareness on antibiotic use and harmful
effects linked to improper use. For this purpose, several
interesting publications have recently been published. These
reports show that healthy human microbiota seems to protect
use against allergy, obesity and cancer and antibiotic use may
greatly disturb this balance. Paradoxically, antibiotic use may
also increase risk of bacterial infections. Once more data is
accumulated, we may better understand the value of our
microbiota, and, hopefully, patients may not anymore be so
eager to ask for antimicrobial prescriptions. Bacterial resistance
is emerging, and we have to protect our normal microbiota.
Therefore, new therapeutic options should be developed to treat
and prevent bacterial infections. There are already interesting
new study ﬁelds, like bacteriotherapy and therapy with bacte-
riophages or their enzymes. Future will show the importance of
these approaches. Finally, I will also put my hope on unexpected
discoveries and totally new solutions that medical technology
may create. We need creative innovations.
S297
Have reductions in antibiotic use in general
practice led to re-emergence of infections?
R. Wise (Birmingham, UK)
The tools available to reduce the impact of antimicrobial
resistance are very limited and consist of infection control,
new agents including vaccines) becoming available and more
prudent (that is, in the main part, less) antimicrobial prescribing.
It is well known that there will be few agents coming on stream
in the near future and infection control, in the community
setting, is extremely difﬁcult. Therefore the main approach by
most countries is to control antibiotic use. However, are there
any risks associated with this approach?There is some evidence,
much of which is weak, that those countries which have either
low prescribing patterns or have recently reduced their prescri-
bing, have an increased incidence of adverse effects, such as
‘‘breakthrough’’ infections or other problems. These studies will
be examined critically and advice on how such events could be
approached by those seeking a more prudent approach to
antimicrobial prescribing.In most counties, the amount of
antibiotic prescribing is so high that any risks are low: there
are, however some suggestions that low prescribing countries
may be seeing some effects, but it must be stated that the risks
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are outweighed by the potential beneﬁts. There has to be a limit
in the ability of reducing antibiotic prescribing as a strategy for
preserving antibiotic efﬁcacy. However, most developed coun-
tries have yet to approach this limit.
S298
Clinical and public health impact of antibiotic
resistance
B. Dunais (Nice, FR)
Clinically, antibiotic resistance is responsible for delayed diag-
nosis, prolonged disease and eventual disability through chronic
infection, exposure to a succession of anti-microbial agents, with
potentially serious adverse events, hospitalisation with its
double risk of dissemination of patients’ resistant microbes
and acquisition of new resistant nosocomial pathogens, which
may then be introduced in the community.From the angle of
public health, resistant pathogens circulating in the community
represent a threat to its more susceptible population, i.e.
children and the elderly, individuals with chronic disease
and/or depressed immune responses. Exchange of genetic
information with commensal ﬂora can result in dissemination
of resistance traits and thus widen the reservoir. More patients
are hospitalised due to ineffective ﬁrst line treatments, entailing
high costs for the community and loss of revenue for the
patients. Escalation of antimicrobial use draws on the effective-
ness of compounds previously kept as a last resort and leads to
vanishing resources in antibiotic therapy. Increasingly rapid
resistance to new antibiotics discourage the industry from
conducting new research. Reinforced surveillance and attempts
to reverse the situation have become necessary, at considerable
cost. Speciﬁc examples will be brieﬂy examined.
Antibacterial susceptibility studies: activities, mechanisms and
drug interactions
O299
Evaluation of drug interactions and CYP450
inhibition with Faropenem medoxomil
A. Beaudry, F. Dean, S.C. Gill, C. Black, K. Khan (Louisville,
Austin, US)
Objectives: Faropenem medoxomil is a novel prodrug
antibiotic that is currently being developed as an orally
administered drug for treatment of community infections.
Faropenem medoxomil is rapidly converted to faropenem, the
active drug, following oral absorption by plasma esterases with
a high degree of bioavailablity of 72–84%. Faropenem is cleared
from the plasma by glomerular ﬁltration and active renal
secretion. Several clinical drug-drug interaction studies were
performed, where only one study, between faropenem and
probenicid, resulted in modest increases in both Cmax and AUC
values for faropenem. The objective of this study was to evaluate
the ability of faropenem to inhibit CYP450 enzymes in vitro and
evaluate the corresponding potential for clinically relevant drug-
drug interactions.
Methods: Faropenem was evaluated for potential to inhibit
human CYP450 enzymes in pooled human liver microsomes.
The isoforms tested were: CYP1A2, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, CYP2E1, and CYP3A4. In addition, the
stability of faropenem in pooled human liver microsomes was
evaluated.
Results: Stability analysis of faropenem (10 and 100 lM) in
human liver microsomes (37 C) showed no substantial
degradation over the time course required for CYP450
inhibition analysis. For the human CYP450 inhibition studies,
none of the CYP450 enzymes evaluated were inhibited by
faropenem at concentrations up to 100 lM (30 mg/L).
Conclusions: The absence of inhibition observed for faropenem
with all eight CYP450 enzymes evaluated indicates a low
potential for drug-drug interactions with faropenem. Previous
drug-drug interaction studies with Faropenem medoxomil and
the following drugs:theophylline, warfarin, digoxin,
furosemide, probenicid, ranitidine, Maalox, cholestyramine,
and Microgynon (oral contraceptive) have shown minimal
effects with the exception of probenicid, where faropenem
Cmax and AUC were increased by 1.26- and 2.44-fold,
respectively. This increase in total exposure of faropenem was
expected due to the effect of probenicid on blocking active renal
secretion. The overall observations from the nine drug-drug
interaction studies and the in vitro CYP450 inhibition study
indicate a low potential for interactions with Faropenem
medoxomil and other drugs that may be co-administered in
the clinic.
O300
Bactericidal activities of daptomycin and
vancomycin in vancomycin-susceptible
Staphylococcus aureus and heterogeneously
vancomycin intermediate S. aureus strains
M. Wootton, T.R. Walsh, A.P. MacGowan (Bristol, UK)
Background: Staphylococcus aureus is an important pathogen in
both the hospital and the community. Glycopeptides are
considered the drugs of choice when treating methicillin
resistant S. aureus (MRSA) infections however the emergence
of hVISA isolates has caused concern. Prospective new
treatments for MRSA, and especially VISA/hVISA include
daptomycin (D), an acidic cyclic lipopeptide that is cidally
active against Gram-positive bacteria. This study aims to
determine the bactericidal activity of D compared to
vancomycin (V) using time-kill curve analysis.
Methods: Time-Kill curves using V and D at 2x and 4x the MIC
was performed on 10 vancomycin-susceptible S. aureus (VSSA)
and 10 hetero-vancomycin intermediate S. aureus (hVISA)
strains. Viable counts were taken at 0, 1, 2, 4, 6 and 24 h and
plotted against antimicrobial concentration. Log reduction in
viable count (LRVC), area under bacterial kill curve (AUBKC)
and area under curve/MIC were calculated.
Results: At 6 h D was bactericidal (> than 3-log reduction)
against all VSSA and hVISA strains at both 2x and 4x the MIC
while V was not bactericidal. On average, D was 2-fold more
potent than V against VSSA strains at both 6 and 24 h. In
addition, only D was bactericidal at both 6 and 24 h against all
hVISA strains. At 2x the MIC V was not bactericidal against
either VSSA or hVISA strains at 6 or 24 h; however V was
bactericidal at 24 h with 4x MIC against some hVISA strains.
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Conclusions: D has considerably greater bactericidal activity
against VSSA and especially hVISA than V. This new agent is a
promising alternative for treatment of infections caused hVISA.
O301
The high activity of meropenem against Gram-
negative bacteria from a paediatric intensive care
unit in Poland (1997–2005)
J.A. Patzer, D. Dzierzanowska, A. Pawinska, P.J.
Turner (Warsaw, PL; Macclesﬁeld, UK)
Objectives: MYSTIC (Meropenem Yearly Susceptibility Test
Information Collection) is a longitudinal surveillance study
comparing the in vitro activity of meropenem (MEM) and other
antibiotics against bacterial strains from clinical units that use
MEM for treatment. The aim of this analysis was to assess the
in vitro activity of MEM and eight other antibiotics against
Gram-negative isolates from a paediatric ICU.
Methods: 1020 Gram-negative isolates were obtained from
clinical specimens of children hospitalized in the ICU in 1997–
2005. Duplicates from the same patients were discarded. The
isolates were identiﬁed using conventional methods. MICs of
MEM, imipenem (IPM), piperacillin/tazobactam (TAZ),
cefotaxime (CTX), cefepime (FEP), gentamicin (GM),
tobramycin (TM) and ciproﬂoxacin (CIP) were determined
using the NCCLS agar dilution method.
Results: The collection of Gram-negative isolates included
Escherichia coli (n = 147), Enterobacter cloacae (n = 193),
Klebsiella oxytoca (n = 87), Klebsiella pneumoniae (n = 171),
Serratia marcescens (n = 41), Acinetobacter baumanii (n = 99),
Pseudomonas aeruginosa (n = 203) and other species (n = 79).
MEM, IPM, and CIP were the most active against 93.9%, 91.9%
and 94.6% of Gram-negative isolates, respectively. The MIC90
(mg/L) of MEM was nearly identical in 1997 and 2005. It was
equal to 0.06 for Enterobacteriaceae, 1.0 for A. baumanii. However,
the MIC90 of MEM for P. aeruginosa increased from 8 in 2003, to
16 in 2004 and to 32 in 2005. The MIC90 of IPM was equal to 0.25
for Enterobacteriaceae, 1.0 for A. baumanii and 16 for P. aeruginosa.
From 1997 to 2005 among Enterobacteriaceae were only found
three isolates (two E. cloacae and one E. amnigenus) resistant to
carbapenems. Among IPM-resistant P. aeruginosa isolates no
metallo-beta-lactamase producing strains were found. The
overall order of susceptibility of tested isolates to other beta-
lactams was FEP (84.6%) > TAZ (71.8%) > CAZ (67.8%) > CTX
(50.8%). Susceptibility to aminoglycosides, GM and TM,
characterized 65% and 64.5% of Gram-negative isolates,
respectively. The incidence of AmpC beta-lactamase and
extended spectrum beta-lactamases producers among
Enterobacteriaceae decreased from 68.5% in 1997 to 32.9% in 2005.
Conclusion: MEM, IPM and CIP were the most active
antibiotics (> 90% susceptibility) against the tested strains,
with no observed reduction in activity over 9 years.
Carbapenems, such as MEM, can be used as an option in the
ﬁrst line therapy of nosocomial infections in ICU.
O302
Morphological and bactericidal effects of
amoxicillin and clarithromycin on Helicobacter
pylori
F. Can, M. Demirbilek, G. Karabay, H. Arslan (Ankara, TR)
Background: Coccoid forms of Helicobacter pylori are suspected
to play an important role on transmission and relapsing of
infection. Amoxicillin and clarithromycin are used for H. pylori
eradication therapy. This study focused on the growth kinetics
of H. pylori after being exposed to amoxicillin, clarithromycin
and different amoxicillin-clarithromycin combinations with the
conjunction of cell morphology.
Methods: H. pylori NCTC 11637 inoculated into Brucella Broth
with 2.5% fetal calf serum was exposed to -10xMIC, -1xMIC,
1xMIC, 10xMIC concentrations of antibiotics either alone or in
combination. Growth characteristics were determined by the
time kill assay. TEM was used for ultra structural morphology.
Results: Amoxicillin and clarithromycin alone decreased the
viable counts of H. pylori, depending on the antibiotic
concentrations. Exposure to these antimicrobials resulted in
morphological changes of cell shape, cell-wall disintegration
and cell lyses. Amoxycillin showed the most potent effect on
viability and morphology of H. pylori, which was accompanied
with the increase of coccoid forms at a concentration 10 fold
higher than the MIC, as rapidly as 6 hours inoculation. The
effects of clarithromycin were observed after 12 hours of
inoculation. Amoxicillin plus clarithromycin combinations
showed additive effect on viable counts and caused a decrease
in morphological changes.
Conclusion: Our results showed that amoxicillin-
clarithromycin combination caused a decreased frequency in
transformation to coccoid forms and higher growth inhibition
than amoxicillin exposure alone. Although the clinical
importance of coccoid forms is unknown; these forms should
be take in to consideration when anti-Helicobacter pylori agents
are tested in vitro.
O303
A comparison of susceptibility to antibiotics in
nosocomial and non-nosocomial infections in a
hospital in Israel
A. Zalounina, S. Andreassen, M. Paul, L. Leibovici (Aalborg, DK;
Tel-Aviv, IL)
Objectives: The purpose of this study was to compare the
susceptibility to antibiotics in nosocomial and non-nosocomial
infections from microbiological data collected at Rabin Medical
Center in Israel.
Methods: The retrospective study was based on a bacteraemia
database of clinically signiﬁcant blood isolates from 11520
bacteraemic patients collected in 1996–2001. The database
included the name of the pathogen, whether the infection is
nosocomial, and in vitro susceptibility to a set of antibiotics. For
each pathogen in the database the probability of susceptibility to
all antibiotics was determined in all nosocomial and all non-
nosocomial cases with exact two-sided conﬁdence intervals
based on the binomial distribution. Odds Ratios (OR) with 95%
conﬁdence intervals (CI) were calculated for the 14 pathogens
represented by 50 or more cases in the database by the Mantel-
Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
Haenszel method a) per pathogen and per antibiotic, b) per
antibiotic, c) per pathogen and d) across all pathogens and
antibiotics.
Results: The nosocomial and non-nosocomial infections are
represented by 60% and 40% of all cases in the database,
respectively. For the most prevalent pathogen Escherichia coli
(15%) the probability of susceptibility to ampicillin for non-
nosocomial infections is 33% (CI 29–36%) and 25% (CI 20–31%)
for nosocomial. This gives an OR of 1.4 (CI 1.1–2.0) for non-
nosocomial Escherichia coli being more susceptible than
nosocomial. The OR across all pathogens for the 27 antibiotics
for which ORs could be calculated ranged from 1.4 (CI 1.2–1.5)
for oﬂoxacin to 3 (CI 2.5–3.6) for ceftazidime. The OR for
Escherichia coli (across all antibiotics) is 1.6 (CI 1.5–1.7). Among
the microorganisms, the lowest ORs were observed for Proteus
(1.1, CI 0.95–1.5) and for Enterococcus spp. 1.2 (CI 1.1–1.6). The
highest ORs are for Klebsiella pneumoniae 2.6 (CI 2.4–2.8) and 4.1
for Acinetobacter sp. (CI 3.6–4.7). The average OR obtained across
all antibiotics and pathogen is 1.8 (CI 1.76–1.89).
Conclusion: The low ORs for Proteus sp. and for Enterococcus sp.
show that the antibiotic pressure for these two pathogens is
equal in the hospital and in the community. The highest OR was
for Acinetobacter sp. a bacterium that turned pathogen only in
the hospital. The high OR for ceftazidime is not surprising, since
cephalosporins are only used in hospitals. The ORs for the
ﬂuoroquinolones were small, indicating that the antibiotic
pressure is similar in the two compartments.
O304
Comparative minimum inhibitory and mutant
prevention concentrations of contemporary
(2004–2005) urinary tract pathogens tested against
ciproﬂoxacin and levoﬂoxacin
J. Blondeau, S. Borsos, C. Hesje (Saskatoon, CA)
Objectives: Urinary tract infection remains amongst the most
common clinical complaints in female patients and
ﬂuoroquinolones are important agents for treatment. The
comparative minimum inhibitory (MIC) approach determines
the drug concentration threshold required to block the growth of
ﬁrst-step mutants when > 1 billion cfu are exposed to drug. We
are interested in comparing MIC and mutant prevention
concentrations (MPC) values for contemporary E. coli (Ec),
K. pneumoniae (Kp) and Enterococcus (En) pathogens recovered
from urinary tract specimens in order to determine if urinary
drug concentration with ciproﬂoxacin (CPX) and levoﬂoxacin
(LFX) exceeded these values over the recommended dosages
and dosing intervals.
Methods: MIC testing was performed in accordance with the
recommended procedure of the Clinical and Laboratory
Standards Institute utilizing 100,000 cfu/ml exposed to
doubling dilution of drug in ambient atmosphere and
temperature. For MPC testing, 10 billionÆcfu were applied to
agar plates containing 2-fold concentration increments of drug.
Following incubation in ambient atmosphere and temperature,
the lowest drug concentration preventing growth was recorded
as either the MIC or MPC.
Results: A total of 135 Ec, 43 Kp and 18 En species that were
CPX and LFX susceptible were tested to determine MIC and
MPC values. Against Ec, CPX and LFX MIC50, MIC90 values
(ug/ml) respectively were 0.004 and 0.016 versus 0.008 and
0.031; MPC values were 0.125 and 2 versus 0.125 and 0.5. Nine
strains had CPX MPCs of 16- > 32 ug/ml as compared to 7
strains tested against LFX. For Kp, CPX and LFX MIC50, MIC90
values (ug/ml) respectively were 0.016 and 0.125 versus 0.05
and 4; MPC values were 0.5 and 0.5 versus 0.5 and 4. No strains
had MPCs > 4 ug/ml. For En, CPX MIC 50/90 and MPC 50/90
values (ug/ml) were 0.5/1 and 4/4 versus 1/1 and 2/4
respectively for LFX. One isolate had an MPC to LFX of
128 ug/ml. For Ec, 89–95% and for Kp, 93–100% of strains had
MPC values that were below the susceptibility breakpoints for
CPX and LFX.
Conclusion: MPC values for CPX and LFX against recently
collected uropathogens were £ 0.5–4 ug/ml and as such were
well within achievable and sustainable urine drug
concentrations based on conventional dosing. Dosing to ensure
drug concentrations in excess of the MPC will minimize
resistance selection and represents a rational approach for
treating UTIs. Minimizing resistance selection will prolong the
clinical utility of these compounds.
O305
Activity of moxiﬂoxacin against community-
acquired MRSA and other quinolone-susceptible
MRSA isolates
J. von Freyberg, S. Scherpe, M.A. Horstkotte, J.K. Knobloch
(Hamburg, DE)
Objectives: Current-generation quinolones are potential drugs
for the therapy of lower respiratory tract infections (LRTI) and of
skin and soft tissues infections (SSTI). In these infections MRSA
isolates susceptible to quinolones are observed with increasing
frequency. In the presented study we investigated the activity of
Moxiﬂoxacin (Mox) against such isolates.
Methods: 50 MRSA isolates classiﬁed as Ciproﬂoxacin (Cip)
susceptible by disc diffusion were collected consecutively from
the Hamburg area during a time period from February 2001 to
April 2005. The clonal relationship of these isolates was
determined using pulsed ﬁeld electrophoresis (PFGE). MIC
values of Oxacillin (Oxa), Cip, and Mox were determined for all
isolates using the E-test method.
Results: 47 isolates could be characterized by PFGE, whereas
for 3 isolates no PFGE-pattern could be determined even in
repeated assays. 11 isolates were identiﬁed as community-
acquired (CA)-MRSA with a homologous PFGE-pattern
compared to the CA-MRSA prevalent in France. Quinolones-
resistant CA-MRSA isolates were not detected during the study
period of more than four years. The Panton-Valentine-
Leucocidin genes could be detected in all CA-MRSA by PCR.
Additionally, four other clonal groups were observed by PFGE
analysis comprising 12, 4, 3, and 3 isolates. The remaining
isolates were distributed in 14 sporadic PFGE-patterns. 37
isolates, including all CA-MRSA, displayed a MIC for Oxa of
64 mg/L or lower, whereas only 5 isolates displayedMIC values
for Oxa greater than 256 mg/L. The MIC50 values of Cip and
Mox were determined as 0.5 mg/L and 0.064 mg/L,
respectively. The MIC90 values were determined as 1 mg/L
and 0.125 mg/L for Cip and Mox, respectively. In contrast to the
initial results of disc diffusion testing two isolates displayed a
MIC for Cip of 2 mg/L. These isolates displayed MIC values for
Mox of 0.064 mg/L and 0.125 mg/L. The observed MIC data
indicate a four to eightfold higher activity of Mox compared to
Cip against the investigated MRSA isolates.
Conclusions: All CA-MRSA isolated in the Hamburg area since
2001 were susceptible to quinolones. For the modern quinolone
Mox a four to eightfold higher activity was observed compared
to Cip. These data indicate that modern quinolones are highly
active drugs for the therapy of LRTI and of SSTI even in areas
where CA-MRSA are endemic.
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O306
Antimicrobial susceptibility patterns correlate
with staphylococcal cassette chromosome mec
types for hospital- and community-acquired
methicillin-resistant Staphylococcus aureus
A. Kilic, H.J. Li, S.E. Sefers, C.W. Stratton, Y.W. Tang (Nashville,
US)
Objectives: MRSA is becoming the most commonly isolated
Gram-positive pathogen and can cause both community
acquired (CA) and hospital acquired (HA) infections, each
with different antimicrobial susceptibility patterns. The aim of
this study was to compare antimicrobial susceptibility patterns
with Staphylococcal cassette chromosome mec (SCCmec) types.
Methods: Both invasive and non-invasive MRSA isolates
recovered at Vanderbilt University Medical Center (VUMC)
were collected from October 1, 2004 to September 30, 2005. A
real-time PCR assay (TaqMan) was developed to detect and
differentiate four SCCmec types, which are associated with HA-
MRSA (SCCmec-I, II, and III) and CA-MRSA (SCCmec-IV).
Antibiotic susceptibility for amoxicillin-clavulanate, cefazolin,
clindamycin, erythromycin, gentamicin, levoﬂoxacin,
minocycline, penicillin, rifampin, trimethoprim/
sulfamethoxazole (SXT) and vancomycin was determined by a
disc diffusion method and inducible clindamycin resistance was
determined by a D zone test.
Results: Among the total 1,315 MRSA isolates collected, 448
(34.1%) were SCCmec-II, 847 (64.4%) were SCCmec-IV, 2 (0.2%)
were mixed SCCmec-II/IV, and 18 (1.4%) were untypeable.
More SCCmec-II was detected in invasive isolates than SCCmec-
IV (72.5% vs. 19.3%, p = 0.00) and vice versa in non-invasive
ones (24.7% vs. 79.6%, p = 0.00). CA-MRSA strains, which carry
SCCmec-IV, showed greater susceptibility than SCCmec-II-
carried HA-MRSA strains to clindamycin (89.6% vs. 4.2%,
p = 0.00), erythromycin (9.3% vs. 1.8%, p = 0.00), levoﬂoxacin
(89.6% vs. 5.1%, p = 0.00), gentamicin (99.4% vs. 93.5%,
p < 0.01), rifampin (99.9% vs. 96.2%, p < 0.01), minocycline
(100.0% vs. 99.3%, p > 0.05), and SXT (98.9% vs. 98.0%,
p > 0.05). Within clindamycin-resistant isolates, 152 (35.4%) of
the HA-MRSA strains were erythromycin induced in
comparison to 36 (40.9%) of the CA-MRSA strains (p > 0.05).
Non-invasive strains showed signiﬁcant greater susceptibility
than the invasive ones to clindamycin (73.9% vs. 23.1%, p = 0.00)
and levoﬂoxacin (75.0% vs. 23.9%, p = 0.00). All isolates were
resistant to methicillin, amoxicillin-clavulanate, cefazolin and
penicillin. No isolates was resistant to vancomycin.
Conclusion: These data indicate that MRSA isolates
predominantly recovered at VUMC carried either SCCmec-IV
(CA-MRSA, 64.4%) or SCCmec-II (HA-MRSA, 34.1%). The
SCCmec typing correlates with major antimicrobial
susceptibility patterns. CA-MRSA strains possessed
signiﬁcantly greater susceptibility to several commonly used
antibiotics.
O307
Comparative MIC and MPC results for ﬁve
quinolone compounds repeatedly tested against
American type culture collection control strains:
suggested MPC quality control value ranges
J. Blondeau, C. Hesje, S. Borsos, L. Blondeau, B. Blondeau
(Saskatoon, CA)
Objectives: The minimum inhibitory concentration (MIC)
determines the minimum drug concentration inhibiting
100,000 cfu/ml of bacteria in vitro whereas the mutant
prevention concentration (MPC) determines the minimum
drug concentration required to block the growth of ﬁrst-step
mutants when ‡ 1 billion cfu are applied to drug containing
agar plates. While MIC testing is standardized and controlled
using American Type Culture Collection (ATCC) strains, similar
standardized protocols are not yet available for MPC testing. We
compared MIC andMPC results with 2 ATCC strains repeatedly
tested against 5 quinolones to document MIC and MPC QC
ranges.
Methods: MIC testing was based on current Clinical and
Laboratory Standards Institute procedures using a
100,000 cfu/ml inoculum and for MPC testing ‡ 1 billion cfu
was inoculated to drug containing media-each in 2-fold
concentration increments. Optimal media, incubation in
established atmospheres and temperatures were used. For
each organism type, lowest drug concentration preventing
growth was recorded as either the MIC or MPC. ATCC strains
included S. aureus (SA) 29213 and S. pneumoniae (SP) 49619
tested against garenoxacin (GAR), gatiﬂoxacin (GAT),
gemiﬂoxacin (GEM), levoﬂoxacin (LFX) and moxiﬂoxacin
(MFX).
Results: Following 12–42 repeat MIC assays, MICs were within
acceptable QC limits with the majority of MICs being at the
middle of the QC range (53–87%) for all organisms/compounds
tested. By MPC testing, the following QC organism MPC results
(ug/ml) were noted against ATCC strains 29213, 49619:GAR
0.063–2, 0.063–0.5; GAT 0.125–0.5, 0.25–2; GEM 0.063–0.5, 0.125–
2; LFX 0.5–1, 1–4; MFX 0.063–0.25, 0.125–2. As with MIC results,
the QC strains MPC values fell within the middle of the MPC
ranges (62–86%) for the majority of the compounds and strains
tested.
Conclusion: As with MIC testing, MPC testing provides
reproducible QC organism results that are consistent over
narrow drug concentration ranges with the majority of MPCs
being at the middle of the range. The MPC drug concentration
ranges presented may serve as a useful guide to insuring MPC
assay accuracy for clinical isolates of SP and SA tested against
quinolones.
O308
Investigation of tolerance to triclosan of ﬁve
international MRSA clones
Z. Al-Doori, D. Morrison, G.F.S. Edwards, C.G. Gemmell
(Glasgow, UK)
Triclosan is a broad spectrum biocide that has been in use for
more than 30 years. It is used in hospitals to decolonise patients
with MRSA. The ability of bacteria and especially MRSA to
develop resistance to antimicrobials and biocides is well
reported. It is important that products should be tested for
any resistance arising from repeated and continued exposure.
Two hundred thirty two MRSA isolated in 30 Scottish hospitals
(1997–2000) were tested for MIC triclosan by NCCLS method.
Adaptation/tolerance studies were performed on representa-
tives of the ﬁve major international MRSA clones (CC5, CC8,
CC22, CC30 and CC45) by growing in BHI broth in the presence
of increasing concentrations of triclosan for up to 67 days.
Triclosan tolerant isolates were checked for their stability by
ﬁfteen serial passages in triclosan free broth. To investigate
susceptibility to triclosan, MIC for ‘‘parents’’, triclosan tolerant
isolates and passaged isolates were determined. The triclosan
MIC of 232 MRSA was MIC50 of 0.03 lg/ml and MIC90 of
0.06 lg/ml (range £ 0.015–4 lg/ml). The triclosan MIC of the
‘‘parent’’ isolates used in the adaptation were CC5 (0.03 lg/ml),
CC8 (4 lg/ml), CC22 (0.015 lg/ml), CC30 (0.015 lg/ml) and
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CC45 (4 lg/ml). During adaptation studies, MRSA small colony
variants (SCV) emerged in different clones and at different times
of exposure to triclosan. After up to 67 days triclosan exposure
the triclosan MIC of all ﬁve adapted/tolerant derivatives was
4 lg/ml. Following serial passage, the MIC remained 4 lg/ml.
In a bactericidal assay triclosan was less effective against
tolerant isolates (5-Log reduction in 5 min) than the parents
(5-Log reduction 0.5 min). In conclusion, MRSA clones respon-
ded differently to increasing concentrations of triclosan. Three of
the ﬁve clones tested [CC22 (EMRSA-15), CC30 (EMRSA-16) and
CC5] produced tolerant derivatives with a very high increase in
the triclosan MIC when compared to their parents.
Epidemiology of MRSA in Europe
O309
MRSA incidences and proportions: how well do
these correlate on a European level?
M.E.A. de Kraker, N. van de Sande, J. Monen, M.A. Borg,
G. Kahlmeter, J. Kolman, H. Grundmann and EARSS
participants
Objectives: Resistance proportions, as used by the European
Antimicrobial Resistance Surveillance System (EARSS), are often
presented to indicate the magnitude of the antimicrobial
resistance in different countries. Nevertheless, their comparab-
ility is biased by variable sampling and ascertainment proce-
dures. Incidence rates are superior and provide patient based
risks, but are mostly not available, due to lacking denominator
data. EARSS collects resistance data, as well as, denominator
information. In this study, the incidence of antimicrobial
resistance was calculated and related to resistance proportions.
The possible effect of differential sampling of blood cultures was
examined as well.
Methods: Since 1999, EARSS collects routine antimicrobial
susceptibility test data amongst others from invasive S. aureus
isolates, tested according to standard protocols. In 2005, a
questionnaire was sent out to collect denominator information
(number of patient days, blood culturing rates etc.). To calculate
MRSA incidence per 1,000 patient days, we linked the
information on patient days to resistance results in the
database. The Spearman correlation coefﬁcient, Wilcoxon rank-
sum test and linear regression were used for statistical analysis.
Results: This year, 735 of 1205 hospitals (61%) and 483 of 758
laboratories (64%) from 28 of 30 EARSS countries responded to
the questionnaire and reported of, overall, 18,729 S. aureus
isolates in 2004. In the different countries, MRSA proportions
ranged from < 1% to 40% and incidence rates varied from 0.26 ·
10)2 to 19.29 · 10)2. Overall, the resistance proportions and
incidence rates highly correlated (Spearman coefﬁcient : 0.85, p
< 0.05). In subgroup analysis, separating Eastern and Western
European countries, correlation coefﬁcients were even higher,
being highest for the latter. Western European countries had a
signiﬁcantly higher culturing rate than Eastern European
countries. From regression analysis it became clear that blood
culturing rates did inﬂuence the relationship between MRSA
resistance proportions and incidence rates for Eastern European
countries, whereas it did not for Western.
Conclusion: Resistance proportions seem to be very similar to
resistance incidence rates, in the case of MRSA. Nevertheless,
this relationship appears to be dependent of some
preconditions, for example the level of blood culturing.
O310
Statistical analysis of trends in mandatory MRSA
bacteraemia in NHS acute hospital trusts
A. Pearson, A. Charlett (London, UK)
The paper summarises the 4 years of local, regional and national
statistical analyses of the Department of Health’s mandatory
Staphylococcus aureus bacteraemia surveillance scheme required
to be done throughout the acute healthcare system in the NHS in
England.
Methods: The number of MRSA bacteraemia in each trust in
each quarter has been used as the dependent variable in a
Negative Binomial regression analysis. The denominator data
has been calculated by multiplying the reported KH03
average bed occupancy for the particular ‘‘ﬁnancial’’ year
within which each quarter falls by the actual number of days
within the quarter. The natural logarithm of this denominator
has then been used as an offset within the regression model
to allow direct estimation of incidence rate ratios. Semester,
type of trust and region have been used as independent
factors. When it has been required to assess linear trends,
semester has been ﬁtted as a covariate rather than a factor
within the regression model.
Results: National: in the ﬁrst four years, from April 2001 to
March 2005 of this mandatory surveillance scheme, a total of
29,479 MRSA bacteraemias were reported from the 173 NHS
Trusts within England from an estimated 168,136,172 occupied
bed-days giving an estimated incidence density of 1.75 MRSA
bacteraemias per 10,000 bed-days.There is no evidence to
suggest that the rates differ by quarter. A signiﬁcance test of
heterogeneity of rate using the negative binomial regression
model gives a likelihood ratio test statistic of 15.84 on 15 degrees
of freedom, p = 0.39. Regional: there was evidence of an
increasing trend over time in one region. In the other eight
regions negative binomial regression models showed little
evidence of temporal trends. Trust: strong evidence that the
trends are different by trust category. District general hospitals
had three times the number of hospitals with increasing trends
in MRSA bacteraemia rates as compared to those with
decreasing trends in rates. In specialist hospitals there were
twice as many with decreasing trends in rates as compared to
those with increasing trends.
Conclusion: Mandatory surveillance revealed strong evidence
of trends at local level and related to the type of hospital. As yet
there was no evidence of reduced rates of MRSA bacteraemia
nationally or regionally in the acute sector of NHS hospital
practice in England.
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O311
Massive spread of the New York/Japan MRSA
clone (ST5-SCCmec II) in a European country
T. Conceic¸a˜o, M. Aires de Sousa, M. Fu¨zi, A´. To´th, J. Pa´szti,
E. Ungva´ri, W. van Leeuwen, A. van Belkum, H. Grundmann,
H. de Lencastre (Oeiras, PT; Budapest, HU; Rotterdam, Bilthoven,
NL; New York, US)
Objectives: Earlier reports on the prevalence of methicillin-
resistant Staphylococcus aureus (MRSA) in Hungary showed that
a major epidemic MRSA clone designated as the ‘‘Hungarian
clone’’ [ST239-SCCmec III, spa type t989/389 (Ridom Spa Type/
B. Kreiswirth ID) or related] was widely dispersed in Hungarian
hospitals between 1993 and 1998. In the present work we
provide an update of the MRSA clonal types circulating in
Hungary between 2001 and 2004.
Methods: The 159 MRSA isolates included in this study
comprise: (i) 24 isolates previously characterized by
antibiogram and pulsed-ﬁeld gel electrophoresis (PFGE),
which were selected as representatives of each of the different
PFGE types circulating in Hungarian hospitals between 1994
and 1998, and (ii) 135 representatives of a total of 391 invasive
isolates recovered between 2001 and 2004 from several hospitals
located in 20 Hungarian counties. All isolates recovered between
2001 and 2004 were analyzed by antibiogram, phage typing and
PFGE. Representatives of all PFGE proﬁles were also
characterized by spa typing, multilocus sequence typing
(MLST) and SCCmec typing.
Results: Although the 135 MRSA recovered between 2001 and
2004 were distributed into 14 PFGE patterns, almost half of the
isolates (49%) showed a single PFGE proﬁle A associated with
ST5-II and spa type t002/2, which corresponds to the New
York/Japan clone. In addition, 19% belonged to the Southern
German clone (PFGE B, ST228-I, spa types t001/385 or t041/
388), 4% to the Brazilian clone (PFGE C, ST239-III, spa types
t030/351 or t984/392), 4% to the Hannover clone (PFGE F,
ST254-IV, spa type t139/649) and only 5% of the isolates showed
the genetic background of the Hungarian clone (ST239-III but
PFGE similarity with the Brazilian clone of 49.7% only), the
earlier predominant clone in Hungary. The characterization of
the 24 isolates from 1994–1998 by spa typing, SCCmec typing
and MLST grouped them into 4 clones and evidenced the
absence and the low prevalence of the New York/Japan and
Southern German clones, respectively.
Conclusion: This study documents the complete replacement of
the Hungarian clone by the New York/Japan and Southern
German epidemic clones among the hospital setting in Hungary
between 2001 and 2004. Moreover, we described for the ﬁrst
time the dominance and massive spread of the New York/Japan
clone in a European country.
O312
Molecular characterisation of MRSA in the
South-Eastern part of Norway from 1991 to 2005
A.E. Fossum, K. Alm-Kristiansen, G. Bukholm (Lørenskog, NO)
Objectives: The incidence of methicillin-resistant Staphylococcus
aureus (MRSA) isolates discovered in the South-Eastern part of
Norway has increased during the years 1991–2005. In this study
we characterised all MRSA isolates from the time period 1991–
2005, and compared isolates from 2 groups: the health care
institutions and the primary health care.
Methods: The isolates were analyzed using multilocus
sequence typing (MLST), staphylococcus cassette chromosome
mec typing (SCCmec) and polymerase chain reaction to verify
the presence of the Panton-Valentine Leukocidin (PVL) gene
loci.
Results: MRSA was isolated from 180 persons. The incidence of
MRSA increased from being less than 7 isolates per year during
the period 1991 to 1999, to an estimated number of above 40 in
2005. This trend was observed in both groups. Twenty-seven
different sequence types (ST) were discovered. Among these 27,
ST8-IV and ST80-IV were dominating, representing over 40% of
the isolates. Most STs were represented in both groups, but were
not evenly distributed between the groups. Of the different
SCCmec types discovered in MRSA, type IV is the dominating
type in this study. Type IV has increased from being represented
in less than 50% of the isolates in 2001 to above 90% in 2005. The
increase has been approximately equal for isolates from both
groups. Of all SCCmecIV isolates in this study, over 50%
contained the PVL gene loci. The percentage of MRSA
containing SCCmecIV and the PVL gene loci differed between
the 2 groups. Among the primary health care isolates, over 80%
of SCCmec type IV contained the PVL gene loci, which were
higher than for the health care institutions isolates.
Conclusion: In the South-Eastern part of Norway the incidence
of MRSA isolates are increasing in both health care institutions
and in the primary health care. The incidence of MRSA isolates
containing SCCmec type IV has increased, and today this type is
represented in more than 90% of the isolates. The PVL gene loci
were found almost exclusively in MRSA having SCCmec type
IV, and were markedly more prevalent in the isolates from the
primary health care than from the health care institutions.
O313
National Danish case-control study of community
onset infections caused by methicillin-resistant
Staphylococcus aureus
S. Bo¨cher, A. Gervelmeyer, D.L. Monnet, K. Mølbak, R. Skov
(Copenhagen, DK)
Objectives: Denmark has for more than 25 years been a low
prevalence country for MRSA (< 1percnt;). However, during the
last 3 years a signiﬁcant rise in MRSA infections especially with
community onset (CO-MRSA) has been observed. In order to
characterise patients with staphylococcal infections and to
identify possible risk factors for CO-MRSA infection we
conducted a nationwide case-control study.
Methods: During 2004 patients with community onset MRSA in
Denmark were identiﬁed; controls were selected from a random
sample of patients with community onset methicillin sensitive
S. aureus (MSSA). After informed consent the patients were
interviewed by telephone regarding type of infection, previous
antibiotic treatment, chronic illnesses, household infections,
hospitalisation, or contact to health care or other institutions,
travel abroad, sports and occupation. The general practitioners
of the patients received a questionnaire regarding clinical signs,
localisation of infection and chronic illnesses.
Results: 99 CO-MRSA patients were identiﬁed, 37 had both GP
and patient questionnaires completed. 330 MSSA controls were
identiﬁed by the laboratories, 84 of these had both
questionnaires completed. Skin and soft tissue infections were
the predominant manifestation in both cases (68%) and controls
(60%). A large proportion of cases (27%) and controls (38%) had
underlying skin disease. Skin lesions prior to infection was
associated with a reduced risk of MRSA (OR: 0.2, 95% CI 0.1–
0.7). Most cases (69%) and controls (59%) had received
antibiotics within the last 6 months and 47% resp. 30% had
been hospitalized within the last year. More MRSA patients had
been hospitalised for > 7 days (OR 4.1, 95% CI 1.2–14.3). Foreign
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ethnicity was associated with an increased risk of MRSA (OR
19.1, 95% CI 2.2–872.3).
Conclusion: Prior hospitalization within the last year of
> 7 days and other ethnicity than Danish was found to be
signiﬁcant risk factors for CO-MRSA infections. CO-MRSA
infections were dominated by skin and soft tissue infections and
the majority of MRSA patients had received antibiotics within
the last 6 months. The apparent protective effect of skin lesions
is not yet fully understood.
O314
EUREGIO MRSA-net Twente/Mu¨nsterland: A
Dutch-German cross-border network for
surveillance and control of methicillin-resistant
S. aureus
A.W. Friedrich, F. Verhoeven, A. Mellmann, A.K. Sonntag,
L.J.E.W.C. Gemert-Pijnen, I. Daniels-Haardt, M.G.R.
Hendrix (Munster, DE; Enschede, NL)
Objectives: Hospital infections caused by methicillin-resistant
S. aureus (MRSA) are particularly critical due to limited
therapeutic options. During the last years the rate of MRSA
increased in Germany from 2% (1990) to 23% (2003). In contrast,
in the Netherlands the MRSA prevalence remains under 1% due
to a consequent search & destroy policy. This difference
becomes a problem at the bordering regions. Furthermore,
CA-MRSA has also been noted in Germany and the
Netherlands.
Methods: In order to control these problems we established
‘‘EUREGIO MRSA-net’’, an EU-Interreg IIIA funded network
for cross-border co-operation in the Twente/Mu¨nsterland
region. The main goal of this network is to understand the
epidemiology of MRSA and to co-ordinate the action of health
care providers (i.e. hospitals, laboratories, public health
services, GPs) ﬁghting MRSA on a local level in order to
lower the prevalence of MRSA and CA-MRSA on both sides of
the border in and outside hospitals. MRSA-guidelines of both
regions must be synchronised and user-centered. The
epidemiological backbone of the project is a spa-typing
network providing a common nomenclature for the typing of
MRSA.
Results: The sequence based typing is performed in the 6 major
laboratories. More than 1000 isolates from patients in hospitals
and nursing homes of the region have already been typed and
the results could be compared within the whole region and
across the border. Spa-type t003, t032, t001 are the most frequent
clones in the region. The results of a questionnaire for the
German hospitals about screening of patients, typing, and
eradication policy showed that although 83% of the hospitals
say that they screen patients from risk groups on admission,
65% of them screen e.g. patients with chronic ulcers. 53% of the
German hospitals type every ﬁrst MRSA isolate of a patient,
while 75% type outbreak associated MRSA. 97% indicate that
they isolate patients with MRSA and perform an eradication
therapy, but only in 45% of the cases only the eradication
therapy is continued after dismissal of the patient from the
hospital.
Conclusion: Cross-border transfer of patients and health-care
providers becomes more and more important. EUREGIO
MRSA-net sets up a network at two bordering regions of very
low and medium size endemicity of MRSA. The project wants to
elucidate the euregional epidemiology of MRSA and will
provide a backbone to diminish the ‘‘MRSA-barriers’’ existing
for high quality of cross-border health care.
O315
Prospective surveillance and decolonisation of
Panton-Valentine leucocidin-positive MRSA
among residents and staff of three German
nursing homes
F.M.E. Wagenlehner, H.J. Linde, E. Bambl, U. Raab, D. Kahlau,
C. Ho¨ller, N. Lehn, W. Witte, K.G. Naber (Straubing, Regensburg,
Oberschleissheim, Wernigerode, DE)
Background: Panton-Valentine leucocidin-positive methicillin
resistant S. aureus (PVL-MRSA) was ﬁrst noticed in our hospital
in the ﬁrst half of 2004 by screening of nursing home residents at
hospital admission [6 index patients of three nursing homes (A,
B and C), 2 of each nursing home]. Systematic screening of all
residents and staff for PVL-MRSA was initiated. Subsequent
decolonisation and control of carrier status were performed 1
and 12 months later.
Methods: Screening for MRSA and PVL-MRSA of all residents
and staff was initiated in nursing homes A, B and C from
January to December 2004. Swabs from anterior nares (residents
and staff) and wounds were collected. Routine microbiology
techniques were used, including MRSA selective screening agar
(Mueller-Hinton agar supplemented with 2% of sodium chloride
and 5 lg/ml oxacillin). The presence of the genes nuc (S. aureus
speciﬁc), mecA (penicillin-binding protein 2A), lukS/F-PV
(Panton-Valentine leucocidin) was determined by block-cycler
PCR. Colonized residents and staff were treated for 5 days
using mupirocin nasal ointment and antiseptic washings
(chlorhexidine in most cases). Decolonization was controlled
by follow up swabs after treatment. Systematic screening of all
was repeated 6 to 12 months later in 2005. Hygienic training of
nursing home staff and presentation of surveillance data was
performed in each nursing home.
Results: Screening results of 2004 and 2005 are shown in the
table 1. A signiﬁcant decrease in the rate of PVL-MRSA
carriers (p < 0.001) was achieved from 2004 (9.1%) to 2005
(3.4%) by implementing systematic screening of nursing home
residents and staff and hygienic training. The MRSA rate did
not change.
Conclusions: PVL-MRSA was highly prevalent in residents and
staff of three nursing homes. The carrier rate could be lowered
signiﬁcantly by systematic screening, decontamination efforts
and hygienic training of staff. We conclude that outbreaks with
PVL-MRSA in nursing homes may happen and possibly could
be sensed by screening nursing home residents at hospital
admission. Detection of PVL-MRSA in nursing home residents
should prompt systematic screening of all residents and staff.
Approved methods (screening, decolonisation, training of staff)
to control MRSA may be applied to control PVL-MRSA in
nursing homes. Table 1: Residents and staff of three nursing
homes positive for PVL-MRSA and/ or MRSA of all screened
persons (n/n).
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The ﬁrst national methicillin-resistant
Staphylococcus aureus prevalence study in
Belgian nursing homes indicates high carriage
rates among residents
B. Jans, C. Suetens, O. Denis, M. Struelens (Brussels, BE)
The increasing incidence of imported Methicillin resistant
Staphylococcus aureus (MRSA) cases in acute-care facilities in
Belgium led us to investigate the prevalence of MRSA carriers
among nursing home (NH) residents.
Objectives: To study the national prevalence of MRSA
colonisation in Belgian NH-residents, to identify risk factors
for MRSA carriage.
Methods: In 2005, a prevalence survey was performed in a
random stratiﬁed sample of 60 NH, representative of the
geographic regions of the country and patient care proﬁle. For
each NH, maximum 50 residents were randomly selected for
screening (nose, throat, skin wound/ urinary meatus) during a
single day survey. Risk factors for MRSA carriage were collected
by questionnaire, at resident - and at NH level.
Results: The mean size of the NH was 106 beds, 46% of which
were high-care beds. Most of these facilities (68%) were private,
36 were located in the Flanders region, 18 in the Walloon region
and 6 in the Brussels region. From all screened residents, 50.7%
were S. aureus carriers and 19.0% (95%CI, 16.5–21.5) were MRSA
carriers. There were no statistically signiﬁcant differences in
MRSA prevalence by region, by proportion of high-care beds in
the NH’s or by NH size. MRSA carriership was more frequent in
private (20.9%) than in public NH’s (17.6%) (p = 0.004). In NH
with an infection control protocol the MRSA prevalence is lower
(17%) than in NH without such protocol (22.2%) (p = 0.046).
Among S. aureus carriers the mean resistance proportion was
37.8% (95% CI, 33.4–42.1). A linear relation was observed
between resistance proportion and prevalence of MRSA
carriership (Pearson: 0.88, p £ 0.001).
Conclusions: This ﬁrst national prevalence survey in Belgian
NH’s revealed that colonisation with MRSA is affecting one in
ﬁve residents in all regions of the country. Bad infection control
practices are associated with higher MRSA prevalence rates.
Analysis of risk factors at resident- and NH level should clarify
the determinants of high prevalence of MRSA carriage.
O317
The EPISA study: characterisation of fusidic acid
and methicillin-resistant Staphylococcus aureus
causing skin and soft tissue infections in
outpatients in France
A.R. Larsen, A. Santerre Henriksen, V. Jarlier, P. Menday,
R.L. Skov (Copenhagen, Ballerup, DK; Paris, FR)
Objective: Two Staphylococcus aureus (S. aureus) clones have
recently been associated with skin and soft tissue infections
(SSTI) in different European countries. The European
community acquired MRSA, Panton-Valentine leukocidin (pvl)
positive clone (ST80-IV) and the European epidemic impetigo
clone. Both clones are resistant to fusidic acid, caused by the
fusB gene. As part of the EPISA study, S. aureus causing SSTI in
the French community was characterized with respect to
resistance to methicillin (MRSA) or fusidic acid (FARSA). The
MRSA and FARSA isolates found were typed in order to see if
the two mentioned pan- European clones were also
disseminated in the French community.
Method: A total of 480 patients with SSTIs were enrolled in the
EPISA study. S. aureus isolates were grown from lesional swabs
from 205 patients. All MRSA and FARSA isolates were subjected
to PFGE and Spa typing and representative isolates were typed
by MLST. Toxin gene proﬁles were obtained by PCR for pvl,
Toxic Shock Syndrome Toxin (TSST-1), Exfoliative toxinA (etA)
and B (etB). SCCmec type I-IV was analysed for all MRSA.
Fusidic acid resistance mechanism; FusB was analysed by PCR
using fusB speciﬁc primers.
Results: A total of twelve (5.9%) MRSA and nine (4.4%) FARSA
were found. One isolate was resistant to both antibiotics.
Sequence type (ST) 8 was the dominating genetic lineage (12/
21). However, all ST8 isolates displayed different PFGE patterns.
The remaining 9 isolates belonged to ST1 (2/21), ST5 (2/21),
ST15 (1/21) ST59 (1/21), ST80 (1/21) and ST45 (2/21). All MRSA
carried SCCmecIV. No isolates harboured any toxin genes,
except for the ST80-IV, which were pvl positive. Resistance
against fusidic acid was caused by fusB for the ST80-IV and one
of the ST8 isolates. None of the fusB positive, European
epidemic impetigo clone was found.
Conclusion: MRSA isolates comprised 6% of the total S. aureus
isolates causing SSTI in out patients in France. ST8 isolates
dominated among the MRSA/FARSA isolates. Surprisingly, no
ST8 isolates harboured the pvl or other toxin genes. The study
identiﬁed only one isolate of the European community acquired
MRSA pvl positive clone (ST80-IV) known to cause SSTIs in the
community. None of the fusB positive, European epidemic
impetigo clone was found. The results indicate that the
epidemiology of S. aureus causing SSTI is different in France
than in other European countries as the UK, Ireland, Germany
and the Scandinavian countries.
O318
Methicillin-resistant Staphylococcus aureus in
children with allergy
I. Kuznecovs (Riga, LV)
Objectives: Staphylococcus aureus (SA) enterotoxins have been
suggested to have an impact on speciﬁc local IgE production in
nasal polyps in patients with allergy. Hypothetically high level
of the local IgE during long period maybe associated with
methicillin-resistant Staphylococcus aureus (MRSA) formation in
the upper respiratory tract in this enlarging group of children
with allergy. The aim of the present investigation was to detect
the amount of MRSA carriers among children with allergy: nasal
polyposis (NP) and allergic rhinitis (AR).
Methods: Nasopharyngeal swabs for SA and MRSA and nasal
tissue samples were taken from 1020 children (ages 2–3, 4–7, 8–
12) with NP (456 persons) and AR (564 persons) and 980 healthy
children (ages 2–12) enrolled for long-term study from 1999
through 2004. Patient’s age, gender, diagnosis of allergy,
therapy, IgE levels, and use of antibiotics was recorded.
Antibiotic resistance of the strains was determined with the
disc diffusion method. Nasal tissue samples were analyzed for
total and speciﬁc IgE to SA.
Results: The rates of nasal carriage of SA were found to be 15%
(147/980) in the control group and 62% (632/1020) in patients
with NP and AR. MRSA was found in 2% of control and in 29%
of patients with NP and AR in 1999, 3% and 32% in 2000, 2% and
37% in 2001, 1% and 40% in 2002, 1% and 52% in 2003, and 1%
and 66% patients in 2004. B1 MRSA strain was predominant.
Children ages 4–7 years (p = 0.02), glucocorticoid use in NP
(p = 0.02), rate of hospitalization (p = 0.005), and speciﬁc local
IgE level (p = 0.001) were signiﬁcantly associated with MRSA
colonization.
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Conclusion: The nasal carriage of MRSA in patients with nasal
polyposis is high, undetectable, and growing. It is possible that
allergy maybe the cause of nasal carriage of MRSA. Children
with NP and AR are an unidentiﬁed and less well studied group
at high risk for spreading MRSA in children’s hospitals, day-
care centers, and schools.
Pathogenesis and therapy of sepsis (Symposium jointly arranged
with ISF)
S336
The pathophysiological role of blood monocytes
for the release of soluble triggering receptor
expressed on myeloid cells – 1 (sTREM-1) in
patients with sepsis
E.J. Giamarellos-Bourboulis, C. Routsi, D. Plachouras,
I. Andrianakis, M. Raftogiannis, C. Roussos, H. Giamarellou
(Athens, GR)
Objective: sTREM-1 is the soluble counterpart of the surface
receptor TREM-1 that is highly expressed on neutrophils and
mature monocytes after bacterial and fungal triggering. The
exact site of production of sTREM-1 remains unclariﬁed. The
present study aimed to investigate the role of monocytes in
the release of sTREM-1 in patients with sepsis and its correlation
with monocyte apoptosis.
Methods: Peripheral blood monocytes were isolated from 90
patients with septic syndrome due to ventilator-associated
pneumonia on seven consecutive days after presentation of
sepsis, by density gradient centrifugation of whole blood,
incubation in RPMI and removal of non-adherent cells.
Apoptotic rate on the ﬁrst day was measured by ﬂow
cytometry after incubation with FITC-conjugated monoclonal
antibodies to Annexin-V and Propidium Iodide. Monocytes
were cultured in the absence and presence of LPS and
concentrations of sTREM-1 in supernatants were estimated by
an enzyme immunoassay.
Results: Concentrations of sTREM-1 in supernatants of isolated
monocytes were higher on the ﬁrst day compared to the next six
days (a: p < 0.05, see Figure). No increase was observed after
triggering of monocytes with LPS. Median sTREM-1 of
supernatants of monocytes isolated on the ﬁrst day from
patients sepsis severe sepsis and septic shock were 26.78, 39.13
and 11.79 pg/10000 cells (pNS between sepsis and severe sepsis;
p: 0.038 between severe sepsis and septic shock). Negative
correlations were observed between sTREM-1 of monocyte
supernatants and their apoptotic rate (rs: -0.404, p: 0.0001).
Median sTREM-1 of supernatants of monocytes of day 1 of
patients who eventually survived was 20.64 pg/10000 cells
compared to 17.41 pg/10000 cells of non-survivors (p: 0.048).
Conclusions: sTREM-1 is released from monocytes isolated
form patients with septic syndrome. That release is inversely
correlated to monocyte apoptosis being lower in the event of
septic shock. The above data signify sTREM-1 as an anti-
inﬂammatory mediator in sepsis.
S338
Host defence in pneumococcal pneumonia
T. Van der Poll (Amsterdam, NL)
Introduction: The lungs are repeatedly exposed to respiratory
pathogens, either by inhalation or (micro-) aspiration of
microorganisms that colonize the oropharynx. Infectious
agents that have passed the structural defences and have
entered the terminal airways may cause pneumonia, one of
the most common infectious diseases. Streptococcus pneumoniae,
the pneumococcus, the most frequently isolated pathogen in
patients with community-acquired pneumonia (CAP) [1]. In the
United States alone, more than half a million cases of
pneumococcal pneumonia are reported each year, with a
fatality rate of 5–7%. Bacteremia with S. pneumoniae is in
almost 90% of cases the consequence of pneumococcal
pneumonia. In addition, in recent sepsis trials, S. pneumoniae
was an important causative pathogen especially in the context of
pneumonia. The mortality rate of 40,000 per year caused by S.
pneumoniae in the United States is larger than the mortality rate
caused by any other bacterial pathogen. Infections caused by S.
pneumoniae are increasingly difﬁcult to treat due to the
emergence of antibiotic resistant strains. Altogether it is clear
that respiratory tract infection by S. pneumoniae represents a
major health care problem.
Innate immunity: Three cell types present in the lung are
primarily responsible for host defence against pneumonia, i.e.
respiratory epithelial cells, macrophages and granulocytes. The
respiratory epithelium plays an important role in preventing
colonization and infection by inhaled bacteria by physical
removal of microorganisms through ciliary clearance and the
presence of broad-spectrum antimicrobial agents in the mucus
lining the epithelium. The alveolar macrophage is the primary
phagocytic cell in the airways, ideally positioned to orchestrate
the initial response to an infectious challenge that reaches the
lower airways. Likely, if the bacterial challenge is small and/or
of low virulence, the macrophage can eliminate the invading
bacteria without recruiting granulocytes into the airspaces. If,
however, the challenge is more extensive, large numbers of
granulocytes are recruited into the alveolar spaces from the
marginated pool of granulocytes in the pulmonary vasculature.
This process is regulated by a variety of soluble mediators such
as cytokines, chemokines and leukotrienes. A few aspects of the
innate immune response will be discussed here.
Toll-like receptors: The innate immune system discriminates
potential pathogens from self through a series of receptors that
recognize conserved motifs on pathogens that are not found in
higher eukaryotes. These motifs have been termed "pathogen-
associated molecular patterns" or PAMPs, whereas their cognate
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binding partners on host cells involved in the innate immune
response have been named "pattern-recognition receptors" or
PRRs. Examples of PAMPs include lipopolysaccharide (LPS)
from the outer membrane of Gram-negative bacteria,
peptidoglycan (present in most bacteria), lipoteichoic acid (in
many Gram-positive bacteria) and mannans in the yeast cell
wall. The Toll family of receptors, which is conserved
throughout evolution from ﬂies to humans, has been
implicated to play a central role as PRRs in the initiation of
cellular innate immune responses. TLR2 is considered the most
prominent PRR for the recognition of PAMPs expressed by
Gram-positive bacteria. Nonetheless, TLR2 played a limited role
during pneumococcal pneumonia [2]. Mice lacking TLR2 had
lower chemokine concentrations in lung tissue together with a
reduced pulmonary PMN inﬂux, but cytokine levels, bacterial
outgrowth and survival did not differ when compared to wild-
type animals [2]. This ﬁnding can be explained by another report
that revealed pneumolysin, one of the crucial virulence factors
of S. pneumoniae, as a TLR4 ligand [3]. The recognition of
pneumolysin by TLR4 has been demonstrated to correlate with
the invasiveness of pneumococcal disease in vivo [3]. In addition,
a moderately impaired survival and increased bacterial
outgrowth was found in TLR4-mutant mice with invasive
pneumococcal pneumonia [4].
Cytokines: There is ample evidence that underlines the
importance of TNF and IL-1b in host defence in bacterial
pneumonia: In a murine S. pneumoniae pneumonia model,
treatment with a neutralizing anti-TNF moAb strongly
impaired antibacterial defence [5]. Anti-TNF-treatment
resulted in an enhanced outgrowth of S. pneumoniae from the
lungs, and anti-TNF-treated mice died signiﬁcantly earlier from
pneumococcal pneumonia than control mice. Comparable
results were obtained for IL-1. IL-1 receptor type I deﬁcient
mice infected with S. pneumoniae displayed an increased
bacterial outgrowth together with a reduced capacity to form
inﬂammatory inﬁltrates [6]. Of considerable interest, treating IL-
1 receptor deﬁcient mice with a neutralizing anti-TNF antibody
made them extremely susceptible to pneumococcal pneumonia -
more so than IL-1 receptor knockout mice treated with a control
antibody and wild type mice treated with anti-TNF [6]. Thus,
whereas excessive production of pro-inﬂammatory cytokines at
the systemic level causes organ failure and death in animal
models of fulminant sepsis, the local production of pro-
inﬂammatory cytokines importantly contributes to host
defence during pulmonary infection. Coagulation and
ﬁbrinolysis: In recent years the interaction between
coagulation and inﬂammation has received much attention.
We have demonstrated local activation of coagulation and
ﬁbrinolysis, within the bronchoalveolar compartment, of
patients with pneumococcal pneumonia [7, 8]. Inhibition of
coagulation by recombinant NAPc2, an inhibitor of tissue factor,
did not inﬂuence the outcome of murine pneumococcal
pneumonia [8]. Moreover, mice deﬁcient for plasminogen
activator inhibitor type 1 (PAI-1) showed an unremarkable
host defence against S. pneumoniae pneumonia [7]. Thus, the role
for coagulation and ﬁbrinolysis seems limited in pneumococcal
pneumonia.
Conclusion: Pneumoccocal pneumonia remains a major
challenge for clinicians. Knowledge of host defence
mechanisms against S.pneumoniae is rapidly increasing. This
abstract represents a selection of recently acquired information
on the immune response to the pneumococcus in the airways. It
is our hope that such knowledge will enlarge our therapeutic
arsenal in the near future.
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Non-pneumococcal community-acquired RTIs – current state
of the art
S342
Changing drug susceptibility in H. inﬂuenzae
with special reference to macrolides, azalides,
ketolides and quinolones
P.C. Appelbaum (Hershey, US)
Untypeable Haemophilus inﬂuenzae strains are important patho-
gens of community-acquired respiratory tract infections [pneu-
monia, otitis media, sinusitis and (particularly) acute
exacerbations of chronic bronchitis]. In countries without Hib
vaccine, systemic bacteremia and meningitis are also important.
The main mechanism of resistance to ß-lactamases in H. inﬂuen-
zae is production of TEM-1 or (rarely) ROB-1 ß-lactamases.
Ampicillin-resistant ß-lactamase resistant (BLNAR) strains (with
mutations in PBP3) also occur and have recently been described
with increasing frequency in Europe (especially France, Spain,
Portugal, the U.K, Ireland and Poland). The incidence of BLNAR
strains in Japan approaches 30%. ß-Lactamase producing strains
with mutations in PBP3 have been reported in France and Japan.
Intrafamilial spread of H. inﬂuenzae with different genotypes
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from pediatric carriers has been described. Although quinolones
are active against most H. inﬂuenzae strains, resistant organisms
with mutations in QRDR have been described. A clinical
outbreak of quinolone resistant strains from a long-term-care
facility associated with levoﬂoxacin use has been described in
New York City. A recent fatal case of pneumonia caused by a
quinolone resistant H. inﬂuenzae strain in a patient treated with
levoﬂoxacin emphasizes the need for susceptibility testing: the
strain was not tested for quinolone susceptibility prior to
levoﬂoxacin therapy. Macrolides, azalides and ketolides are
recommended for treatment of community-acquired respiratory
tract infections including those caused by H. inﬂuenzae: these
drugs yield a unimodal MIC distribution. However, a macro-
lide, azalide and ketolide efﬂux mechanism has been detected in
strains with ‘‘baseline’’ MICs that are susceptible by CLSI.
Strains without efﬂux with signiﬁcantly lower macrolide,
azalide and ketolide MICs occur clinically with an incidence of
approximately 2%: these strains are also clindamycin suscept-
ible. Approximately 2% of strains are highly resistant to
macrolides by efﬂux plus one or more ribosomal protein
mutations (L4, L22, 23S rRNA). In the light of the ﬁnding of
an efﬂux mechanism in ‘‘susceptible’’ strains it is suggested that
macrolide, azalide and ketolide H. inﬂuenzae breakpoints are all
to high and should be reevaluated. Strains should also be
regular monitored for BLNAR and development of quinolone
resistance.
Risk assessment in primary care: clairvoyance or evidence-based
medicine? (Symposium arranged with ESPRIT)
S346
Cystitis, mostly simple but not always
T. Christiaens (Ghent, BE)
We want to discuss the problems general practitioners face
when managing the "simple" issue of a potential uncomplicated
upper urinary tract infection with a qualitatively high standard.
In the ﬁeld of cystitis there are at least three major diagnostic
and two therapeutic problems of interest that concern both
clinical microbiologists and general practitioners. The ﬁrst
diagnostic problem deals with the gold standard, the threshold
of what is considered a signiﬁcant infection, or in other words
the 20 years old discussion between "Kass and Stamm". Sec-
ondly, the basic diagnostic problem is which test can substan-
tially improve the diagnostic accuracy, given that the prior
probability of clinical signs is more than 80%. Thirdly, even
without such a test, we need to rule out the only frequent serious
problem that is misleading, i.e. Chlamydia trachomatis infections
resulting in potential PID and fertility problems. The choice of
therapeutic strategy is still complicated by the multitude of
possible treatment regimes. A recent Cochrane review compar-
ing 3-day treatment regimes with 5 days or more offers an
interesting point of discussion: a course of 3 days is as effective
as a longer one with regard to symptomatic cure and relapse,
but less effective for bacteriological eradication. So what should
we do?Finally the problem of empirical treatment remains.
Already for decades we ﬁnd the same pathogens in primary care
all over the world, with Eschericia coli in nearly 80% of the cases.
But although the uropathogens are the same, their antimicrobial
resistance proﬁles are different. Periodically alarming resistance
data are released by regional bacteriological laboratories.
Apparently bacteriologists are convinced that these worrying
data will make clinicians use less broad-spectrum antimicrobial
agents. But often the effect is the opposite: the growing
resistance rather encourages general practitioners to use more
and newer broad-spectrum agents, since they fear their patients
will not be cured if they carry resistant bacteria. One of the key
issues in this debate is the reliability of the resistance data. Even
when limited to ambulatory patients the data strongly overes-
timate the real situation, since general practitioners only send
urines for further investigation if they suspect a complicated
infection. We investigated this issue in two countries with a very
different use of antimicrobial drugs (Belgium and Norway). This
difference in use was reﬂected in the resistance of uropathogens
found in the microbiological laboratories, but not in a popula-
tion of "typical" patients consulting the GP with cystitis (healthy
adult women). Only this kind of surveillance can convince
clinicians to continue using antimicrobial drugs such as trim-
ethoprim or nitrofurantoin empirically. Perhaps some simple
criteria could make the easily accessible laboratory data more
reliable and applicable to primary care. We shall discuss this
issue. One of the major goals of general practice is to treat simple
things with high standards of care. Clinical microbiologists can
help us greatly in this task by collaborating in our research.
S348
Bacterial meningitis in adults
D. van de Beek (Amsterdam, NL)
Bacterial meningitis is a life-threatening disease. The estimated
incidence is 2–5 per 100.000 people per year in developed
countries and is up to ten-times higher in less developed
countries. Bacterial meningitis is often considered in adults but
can be difﬁcult to recognize. Optimal use of the clinical
examination aids physicians in identifying patients at sufﬁcient
risk for meningitis to require further deﬁnitive diagnostic testing
with a lumbar puncture. Patients in whom meningitis is
suspected require this invasive procedure to effectively establish
or refute the diagnosis. Studies show that physical examination
lacks adequate sensitivity to accurately identify meningitis. In
adults presenting with community-acquired acute bacterial
meningitis, the sensitivity of the classic triad of fever, neck
stiffness, and altered mental status is low (44%), but almost all
such patients present with at least two of four symptoms-
headache, fever, neck stiffness, and altered mental status (as
deﬁned by a score below 14 on the Glasgow coma scale).
Textbooks provide tables with classically described lumbar
puncture results for viral and bacterial disease, but the available
literature suggests that these ﬁndings cannot reliably predict the
risk of bacterial meningitis in individual patients. In fact, several
published studies report signiﬁcant numbers of patients with
bacterial meningitis who do not have ﬁndings on initial lumbar
puncture that would traditionally predict bacterial meningitis.
As delay in the initiation of antimicrobial therapy can result in
poor outcome in this disease, in some countries family doctors
are advised to give (parenteral) antibiotics before transferring
the patient to hospital if meningococcal meningitis is suspected.
A ﬁrst difﬁculty in this setting is how to identify a patient with
meningococcal meningitis. A second dilemma is whether
patients beneﬁt from such pre-hospital treatment. And when
general practitioners decide to treat patients with suspected
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bacterial meningitis with parenteral antibiotics, should dexa-
methasone be given before or with this ﬁrst dose? New
approaches to the treatment of bacterial meningitis are estab-
lished and recommendations for antimicrobial therapy are
changing as a result of emergence of antimicrobial resistance.
Furthermore, the management of the critically ill neurologic
patient with bacterial meningitis poses important dilemmas.
These important and controversial areas will be reviewed and
relevant literature will be discussed in the framework of current
treatment guidelines.
Update on the inﬂuenza pandemic threat
S349
H5N1 and other pandemic threats
R. Fouchier (Rotterdam, NL)
In 1997, an outbreak caused by highly pathogenic H5N1
inﬂuenza A virus occurred in the live bird markets of Hong
Kong, which also resulted in the ﬁrst reported case of human
infection and fatality attributable directly to avian inﬂuenza
virus. The virus resurfaced again in 2002, 2003 and 2004,
devastating the poultry industry in a large part of SE Asia.
Subsequently, the virus appeared in Mongolia, Kazakhstan,
Russia, Turkey, Romania, and Croatia. During these outbreaks,
the virus was transmitted to 147 humans, leading to 78 deaths
(as of January 13, 2006) and was isolated from pigs, cats, tigers
and leopards in addition to poultry and wild birds. So far, all
human cases resulted from bird-to-human transmission. It is
still largely unknown why this virus is so fatal to humans.
Recent studies suggest that the virus may be replicating beyond
the respiratory tract in mammals, as is generally the case only
with highly pathogenic viruses in birds. Whether this virus
could become transmissible between humans, and start a new
pandemic is still one of the key questions. To prepare for a
potential H5N1 pandemic, candidate vaccines have been pre-
pared using reverse genetics technology and are currently tested
in humans. However, there are several problems related to such
vaccines, making it unlikely they could become available for
human use in the short term. Drugs such as the neuraminidase
inhibitors are another tool to protect against disease from H5N1
infection. However, it is possible that resistance to such drugs
could become a problem when they are used on a large scale.
Mathematical and epidemiological models suggest that neura-
minidase inhibitors could be useful to control outbreaks in
humans if they are used for early intervention. Real-time
diagnostic methods are available for H5N1 surveillance in
humans and animals, facilitating the intensiﬁed surveillance
studies around the globe.Recent developments in the H5N1
outbreaks will be discussed. Some of the key observations
during these H5N1 outbreaks will be discussed in the context of
other outbreaks, such as the Dutch H7N7 inﬂuenza virus
outbreak in the Netherlands in 2003, and in the context of the
pandemics of the last century.
Antimicrobial PK/PD
O353
Impact of sample size on the performance of
multiple model pharmacokinetic simulations
V.H. Tam, S. Kabbara, R.F. Yeh, R.H. Leary (Houston, Los
Angeles, US)
Objectives: Stochastic forecasting methods such as Monte Carlo
simulations (MCS) have been increasingly used to predict
pharmacokinetic (PK) variability of antimicrobials in a
population, based on well-characterized data from relatively
few subjects. We have previously shown that a multiple-model
(MM) approach to stochastic PK simulation is associated with a
higher precision than conventional MCS for a well-characterized
cohort (Tam, ICAAC 03). However, the ability to extrapolate to
other cohorts is dependent on the size of the sample population.
We investigated the sample size necessary to provide robust PK
predictions using MM simulation.
Methods: A universal population consisting of 500 subjects
with a 2-compartment linear model was constructed. Using
known model parameter values (Kel = 0.3 h-1, Kcp = 1 h-1,
Kpc = 0.3 h-1, V = 20 L) and dispersions (CV = 25% for all
parameters), serial concentrations (0.25, 0.5, 1, 2, 4, 8, 12 and
24 h) in the central compartment were simulated after a 1000 mg
bolus dose. Normal distribution of parameter values and no
correlation among the parameters were assumed. System noise
was incorporated as a ﬁxed proportional to the drug
concentrations. The best-ﬁt parameter estimates were
determined using the Non-Parametric Adaptive Grid program
using various sample sizes (5, 10, 25, 50, and 125 PK proﬁles)
randomly picked in quadruplicate. Based on these estimates, the
mean ± SD AUC0-inf for each sample population was simulated
using the MM approach (weighted average of the simulations
from each of the discrete vector support points), and they were
compared to those derived from the known values of the
universal population.
Results: With increasing size in sample population, a trend
towards more accurate and consistent estimation of AUC0-inf of
the universal population was observed. A sample population
size ‡ 50 was found to be necessary to achieve < 10% and < 25%
error in the mean and SD estimates of AUC0-inf, respectively.
Conclusions: Our results suggest that the inferring capability of
MM PK simulation is dependent on the sample population size.
In order to obtain reasonably robust PK predictions, a non-
parametric model derived from a sample population size ‡ 50
may be necessary as the input information.
O354
Continuous versus intermittent intravenous
administration of antibiotics with time-
dependent antibacterial action: a systematic
review of pharmacokinetic and
pharmacodynamic parameters
S. Kasiakou, K. Lawrence, N. Choulis, M. Falagas (Athens, GR)
Objectives: To compare the pharmacokinetic and
pharmacodynamic properties of the continuous versus the
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intermittent mode of intravenous administration of various
antibiotics.
Methods: Data for this systematic review were identiﬁed from
Pub Med (01/1950 to 01/2005), Current Contents, Cochrane
central register of controlled trials, and references from relevant
articles, and reviews. Randomized clinical trials comparing
continuous with intermittent intravenous administration of the
same antibiotic regimen, and examining the pharmacokinetic
and pharmacodynamic properties were included in this
systematic review. Two reviewers extracted independently
data regarding the clinical setting, number of participants,
antimicrobial agents and dosages used, as well as maximum
serum concentration (Cmax), trough serum concentration (Cmin),
steady state or plateau serum concentration (Css), area under the
concentration-time curve (AUC), time above MIC (T > MIC),
AUC/MIC, elimination rate constant, elimination half-life,
volume of distribution, and systematic clearance.
Results: A total of 17 randomized clinical trials that compared
pharmacokinetic and pharmacodynamic data of antibiotics
administered by the continuous or intermittent intravenous
mode were included in the analysis. The mean Cmax of the
intermittently administered antibiotics was higher compared
with Css achieved by the continuous infusion of the same
antibiotic in all eligible studies (Cmax was on average 5.5 times
higher than Css, range: from 1.9 to 11.2). Css was on average 5.8
times higher than the Cmin of the intermittently administered
antibiotics (range, from 1.2 to 15.6). In 3 out of 6 studies, the
length of time that drug concentration was above the MIC of
the responsible pathogens was longer in patients receiving the
antibiotics continuously.
Conclusion: The mode of intravenous antibiotic administration
seems to be of greater importance at least when confronting
bacteria with high MICs. Continuous infusion of antibiotics with
time-dependent bacterial killing seems to be a superior mode of
administration, from a pharmacodynamic point of view,
compared to the intermittent in cases of multiresistant
bacterial infections.
O355
Testing the mutant selection window hypothesis
with in vitro dynamic models: pros and cons
A. Firsov, I. Lubenko, S. Zinner (Moscow, RU; Cambridge, US)
Objectives: Contradictory reports on the enrichment of
resistant mutants in in vitro model studies that simulate
antibiotic pharmacokinetics probably relate to inappropriate
experimental design and data analysis. The mutant selection
window (MSW) hypothesis that provides a better understanding
of this phenomenon might also be useful to properly relate
resistance to simulated ratios of area under the curve (AUC) to
MIC. To test this hypothesis, the selection of resistant
Staphylococcus aureus was studied with lypopeptides,
glycopeptides and ﬂuoroquinolones, by simulating their
concentrations within and out of the MSW.
Methods: Three to ﬁve-day treatments were mimicked with
once-daily daptomycin, gatiﬂoxacin, levoﬂoxacin and
moxiﬂoxacin, and twice-daily vancomycin and ciproﬂoxacin
over an 8–16-fold range of 24 h AUC/MICs. Peak antibiotic
concentrations were simulated to be close to the MIC, between
the MIC and the mutant prevention concentration (MPC), and
above the MPC. Changes in the susceptibility of S. aureus were
examined by daily MIC determinations.
Results: Both in terms of susceptibility testing and population
analysis, selection of resistant mutants occurred at antibiotic
concentrations that fell into the MSW but not at concentrations
out of the MSW. Similar bell-shaped AUC/MIC relationships
with resistance were established with daptomycin, vancomycin
and the four ﬂuoroquinolones. Based on these ﬁndings, an
AUC/MIC ratio that protects against the selection of resistant
mutants was predicted at 125–250 h for the lypopeptide and
glycopeptide and at 200–250 h for the ﬂuoroquinolones. These
estimates are in concordance with reported data on
ciproﬂoxacin- and garenoxacin-exposed S. aureus although
relationships of resistance and the time when antibiotic
concentrations are within the MSW (TMSW) are controversial.
Conclusions: Overall, the available data are in support of the
MSW hypothesis, but additional testing with other groups of
antibiotics is needed. Also, further examination of the TMSW
relationships to resistance is suggested.
O356
Pharmacodynamic evaluation of the bactericidal
activity of telavancin against extracellular and
intracellular MSSA and MRSA
M. Barcia-Macay, M. Mingeot-Leclercq, P.M. Tulkens, F. Van
Bambeke (Brussels, BE)
Objectives: Telavancin (TLV) is a lipoglycopeptide with
multiple mechanisms of action that exhibits rapid
concentration-dependent bactericidal activity against Gram
positive bacteria, including MRSA. We demonstrated
previously that TLV is bactericidal against intracellular MSSA
(ICAAC 2005, A1831). We compare here the activity of TLV
against extracellular and intracellular forms of MSSA andMRSA
using a pharmacodynamic model that analyses the time- and
dose-responses of bacteria to the drug over a wide range of
clinically achievable concentrations.
Methods: MSSA ATCC 25923 and 29213 and MRSA ATCC
33591 and 43300 were used to infect mouse (J774) and human
(THP-1) macrophages. Cells were then exposed for up to 24 h to
TLV (0.01 to 1,000 x MIC). Activity was assessed by examining
the change in CFU recovered from infected cells compared to
the initial, post-infection inoculum. Extracellular activity was
measured in parallel (using whole culture medium) by CFU
counting.
Results: TLV MICs were 0.5 lg/mL for all strains.
Extracellular bactericidal activity developed in a bimodal
fashion over concentration at 3 h, with zones of
concentration-dependency (i) around the MIC and (ii) at
concentrations higher than 10 to 100 X MIC. At 24 h, - 5 log
(limit of detection) was reached for all strains at Cmax (90 lg/
mL). Intracellular activity developed more slowly and to a
lesser extent, but also showed a bimodal response with respect
to extracellular concentration. The table describes the bimodal
concentration-effect relationships at 3 h (extracellular) and 24 h
(intracellular), and the effects observed at Cmax (with
concentration ranges expressed in X MIC, and effects, in
change of log CFU from the initial inoculum).
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Conclusions: TLV displayed concentration- and time-
dependent bactericidal activity against both extracellular and
intracellular MSSA and MRSA. The bimodal dose-responses
observed may be related to the multiple mechanisms of action of
TLV. These data support the use of TLV in infections where
intracellular S. aureus are present.
O357
Comparative pharmacodynamics (PD) of
moxiﬂoxacin and levoﬂoxacin against
S. pneumoniae following exposure to
bioequivalent PD-surrogate parameters
A. Dalhoff, S. Schubert, H. Stass (Kiel, Wuppertal, DE)
Objective: Usually, in vitro pharmacodynamic (PD) studies
simulate pharmacokinetics (PK) when monitored in serum of
humans following the administration of standard doses of drug.
As a consequence, mechanistic comparisons between drugs are
difﬁcult to perform, since their PK/PD parameters (e. g. the
AUC/MIC and Cmax/MIC ratios) are different. The aim of this
study was to investigate the kill kinetics of LFX and MFX against
S. pneumoniae (Spn) wild type and ﬁrst step mutants after
exposure to drug concentrations leading to equal AUC/MIC
and Cmax/MIC ratios in order to draw conclusions on their
mechanism of action.
Methods: A one-compartment model was used to simulate the
ﬂuctuating serumconcentrations in vitro. Themoxiﬂoxacin (MXF)
serum concentrations declined with a t½ of 13 h, those of
levoﬂoxacin (LFX) with a t½ of 8 h. The simulated AUC/MICs
of MXF and LFX ranged from 34 h to 1,200 h. Viable counts were
determined every 2 hours from 0–12 h and at 24 h; in parallel the
actual drug concentrations were quantitated. The time needed to
reduce the inoculum by 3 log10 titres, the time to eradication and
the area under the bactericidal kill curve (AUBKC) normalized to
the initial inoculum were calculated. A wild type and one gyrase
and topoIV-mutant each of Spn served as test strains.
Results: In general, increasing MXF-AUC/MIC ratios
translated into a more rapid reduction of viable counts and
thus an earlier eradication from the test system. MXF exerted a
concentration-dependent antibacterial effect against all strains,
so that the AUBKC values decreased continuously throughout
the entire range of drug exposures. LFX exhibited a bi-modal
anti-Spn effect. The activity of LFX against all the Spn strains
increased up to AUC/MIC = 300 h; a gain in antibacterial
activity was not achieved by a further increase in LFX exposure.
This phenomenon was most pronounced by exposing 1st step
mutants to increasing LFX AUCs.
Conclusion: Exposure of Spn wild type and 1st step mutants to
equivalent AUC/MIC and Cmax/MIC ratios of either MXF or
LFX resulted in different antiSpn effects. Bio-equivalence in
drug exposures to either MXF or LFX did not translate into
equal bactericidal efﬁcacy against Spn indicating that MXF and
LFX do not share the same PD-targets to maximize their
antibacterial effects. Thus, one PK/PD surrogate parameter
does not ﬁt all ﬂuoroquinolones.
O358
Pharmacokinetics of moxiﬂoxacin in tissues of
the female urogenital tract
H. Stass, H. Delesen, D. Kubitza, A. Halabi, C.H. Gleiter
(Wuppertal, Kiel, Tubingen, DE)
Objectives: To study the pharmacokinetics (PK) of
moxiﬂoxacin in the urogenital tract of female patients
undergoing surgery due to gynecological indications in an
open-label, prospective, single-centre study.
Methods: PK of moxiﬂoxacin in plasma and tissue samples
(predominantly uterus biopsies) was determined in 40 patients
after a single intravenous 1 h infusion of moxiﬂoxacin 400 mg.
Biopsies were collected at 1, 2, 4, 7 and 24 h (Groups A, B, C, D
and E respectively) after start of infusion. Plasma samples were
collected over 24 h. Moxiﬂoxacin concentrations were analysed
using a validated HPLC ﬂuorescence assay. PK analysis used
non-compartmental methods. Statistical analysis of PK used
ANOVA.
Results: Plasma PK was comparable to results obtained in other
studies with healthy volunteers or patients undergoing
abdominal surgery. Moxiﬂoxacin concentrations in plasma/
genital tract tissues are shown in the Table (geometric mean/
%CV). Moxiﬂoxacin penetrates well into tissues of the female
urogenital tract. Moxiﬂoxacin concentrations exceeded the MICs
of susceptible pathogens encountered in gynecological
infections during the entire study period, with concentrations
signiﬁcantly higher than those found in the plasma (see Table
incl. 95% CI).
Conclusion: These PK data suggest that moxiﬂoxacin is a
suitable option to treat female patients suffering from infections
of the urogenital tract.
O359
Pharmacokinetics of moxiﬂoxacin in tissues of
the GI-tract
H. Stass, A.D. Rink, H. Delesen, D. Kubitza, M.W. Buechler,
C.M. Seiler, K.-H. Vestweber (Wuppertal, Heidelberg, Leverkusen,
DE)
Objective: To determine the pharmacokinetics (PK) of
moxiﬂoxacin in the gastrointestinal (GI) tissues of patients
eligible for elective surgery in a randomized, open-label,
prospective, multicentre study.
Methods: The PK of moxiﬂoxacin in plasma and GI tissues was
determined in 40 male and female patients after a single
intravenous 1 h infusion of moxiﬂoxacin 400 mg immediately
prior to surgery. Surgery was timed to allow GI tissue sample
collection (gut wall specimen) 1, 2, 4, 7, and 24 h (Groups A, B,
C, D and E respectively) after the start of infusion. Plasma
samples were collected over 24 h. Moxiﬂoxacin concentrations
were analysed using a validated HPLC ﬂuorescence assay. PK
analysis used non-compartmental methods. Statistical analysis
of PK used ANOVA.
Results: Plasma PK was comparable to results previously
obtained from healthy volunteers. Moxiﬂoxacin concentrations
in plasma and GI-tissues are shown in the Table (geometric
mean/%CV). Moxiﬂoxacin penetrated well into tissues of the
GI-tract. Moxiﬂoxacin concentrations exceeded the MICs of
susceptible pathogens encountered in intra-abdominal
infections (e.g. E. coli) during the entire study period with
concentrations signiﬁcantly higher than those found in the
plasma (see Table incl. 95% CI).
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Conclusion: The PK data suggests that moxiﬂoxacin is a suitable
option to treat patients suffering from abdominal infections.
O360
Evaluation of tigecycline penetration into colon
wall tissue and epithelial lining ﬂuid using a
population pharmacokinetic model and Monte
Carlo simulation
C.M. Rubino, L. Ma, S.M. Bhavnani, J. Korth-Bradley, J. Speth,
E.J. Ellis-Grosse, P.G. Ambrose, G.L. Drusano (Albany,
Philadelphia, US)
Objectives: To assess the penetration of tigecycline into colon
wall tissue and epithelial lining ﬂuid (ELF).
Methods: These analyses included data from patients without
infection (Phase 1) and those with intra-abdominal infections
(Phase 2/3). All patients received a 100 mg loading dose,
followed by 50 mg every 12 hours of intravenous tigecycline in
ELF and Phase 2/3 patients only. Steady-state serum samples
were collected from all patients (n = 577), while colon wall and
ELF specimens were obtained from patients without infection
(n = 23 and n = 30, respectively). Separate models were created
for ELF and colon wall tissue. For both models, tissue and serum
data were simultaneously co-modelled using BigNPAG, and
distinct three-compartment, open models with zero-order IV
input and ﬁrst-order elimination was employed. To examine the
full range of tissue penetration and their associated
probabilities, two 9,999 subject Monte Carlo simulations were
performed, one for ELF and one for colon wall.
Results: Data were well ﬁt using models described above with
all r2 values above 0.94. Results of the Monte Carlo simulations,
tigecycline exposure and penetration into serum, colon wall
tissue, and ELF stratiﬁed by infection status, are presented in the
table below. For patients without infection, the median colon
wall and ELF penetration ratios were 1.3 and 0.43, respectively
(see Table). Estimates of colon wall penetration were higher, 2.6,
in patients with intra-abdominal infection, most likely due to
tissue inﬂammation.
Conclusion: Simulation results indicate that tissue penetration
varies considerably by patient, and likely explains unexpected
clinical outcomes for those patients infected with strains at




efﬁcacy using estimates of serum and effect site
tigecycline exposures in patients with
complicated intra-abdominal infections
S.M. Bhavnani, C.M. Rubino, P.G. Ambrose, J. Korth-Bradley, J.
Speth, E.J. Ellis-Grosse, G.L. Drusano (Albany, Philadelphia, US)
Introduction: Tigecycline has demonstrated efﬁcacy in the
treatment of complicated intra-abdominal infections (cIAI).
These analyses were designed to examine the relationship
between tigecycline exposure, as measured by the ratio of the
area under the concentration-time curve to the minimum
inhibitory concentration of the drug to the organism (AUC:
MIC) in two matrices, serum and colon wall, and outcome.
Methods: PK analyses used drug concentrations from Phase 1
(serum and colon wall concentrations in non-infected patients)
and Phase 2/3 cIAI (serum) studies, (n = 420). Drug
concentration data were co-modelled using NPAG. PK-PD
analyses utilized clinical outcome, patient covariates, and
serum- and colon wall-based AUC: MIC estimates (which
were based on the infecting organism with the highest MIC
value). Univariate and multivariate logistic regression with
backwards stepping were performed. Covariates with p values
< 0.1 in univariate analyses were considered for inclusion in the
multivariate models. Tree-based modelling was used to identify
PK-PD breakpoints predictive of clinical cure. PK-PD
breakpoints were used to evaluate potential susceptibility
breakpoints using Monte Carlo simulation.
Results: The median tissue penetration (AUCcolon
wall:AUCserum) ratio was 1.3 and 2.6 in Phase 1 and Phase
2/3 patients, respectively. 121 patients were included in the PK-
PD analyses. MIC values driving AUC: MIC estimates were
primarily based on those from Enterobacteriaceae (70%) followed
by anaerobes (21%) and gram positive organisms (9%). The ﬁnal
model evaluating serum exposures included diagnosis, weight,
APACHE II breakpoint (‡ 13), presence of Pseudomonas and
AUCserum:MIC breakpoint (7.24) (McFadden’s rho-
squared = 0.403; p < 0.001). The ﬁnal model evaluating colon
wall exposures included race, weight, APACHE II breakpoint
(‡ 13), presence of Pseudomonas and AUCcolon wall:MIC
breakpoint (4.06) (McFadden’s rho-squared = 0.256; p < 0.001).
Based on Monte Carlo simulations, the probability of PK-PD
target attainment for serum exposures exceeded 0.9 for MIC
values up to 0.5 mg/L. For colon wall exposures, the probability
of PK-PD target attainment was 0.99 and 0.83 for MIC values of
1 and 2 mg/L, respectively.
Conclusion: Patient outcome is multi-faceted. One component,
tigecycline exposure, is directly linked to outcome. In addition
to considerations of patient status (clinical assessment) and
microbiology milieu, effect-site exposure adds to our
understanding of drug effect in deep-seated infections.
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O362
Ceftazidime dose and dosing interval determine
the selection of resistant Enterobacter cloacae
isolates in the intestinal ﬂora of rats treated for a
Klebsiella pneumoniae pulmonary infection
W.H.F. Goessens, J.W. Mouton, M. ten Kate, A. Ott,
I.A.J.M. Bakker-Woudenberg (Rotterdam, Nijmegen, NL)
Objectives: Emergence of resistance has been suggested to
depend on the dosing regimen and or pharmacodynamic
indices (PDI) from numerous in vitro studies. We studied the
effect of ceftazidime (caz) dosing increments and frequency of
dosing on the selection of caz-resistant E. cloacae in the intestine
during treatment of a pulmonary infection caused by
K. pneumoniae in rats.
Methods: Rats with pulmonary infection (n = 10 per group)
received doses of 3.1 to 400 mg/kg/day of caz in a frequency of
6,12 or 24 h during 18 days, starting 24 h after bacterial
inoculation. Emergence of resistance in E. cloacae was
monitored by culturing fresh stool specimens at days
0,8,15,22,29,36 and 43 on agar plates with (0.4 lg/ml) and
without caz. Caz pharmacokinetics was assessed in infected rats
to determine PDIs as well as the time inside the mutation
selection window for each regimen. Caz-resistant mutant
E. cloacae isolates were characterised in various ways among
which determination of the ß-lactamase activity under cefoxitin-
induced and non-induced conditions.
Results: A reduction of susceptible E. cloacae isolated in the
faeces was observed at days 8, 15 and 22 and showed a
signiﬁcant correlation with the fAUC. Signiﬁcantly more caz-
resistant E. cloacae were isolated at day 15 in animals exposed to
doses of 25 or 50 mg/kg/day administered with the 6 h
injection frequency compared to the 24 h injection frequency.
The number of caz-resistant E. cloacae at days 8 and 15 correlated
with the time during which caz plasma concentrations were
inside the mutation selection window. Caz- resistant mutants
(MIC > 128 lg/ml) were characterised as stable de-repressed
mutants.
Conclusions: Reduction in E. cloacae was dependent on total
daily dose of caz. Emergence of resistance was correlated to time
within the selection window. Signiﬁcantly more stably
derepressed caz resistant E. cloacae mutants are selected when
doses of 25 and 50 mg/kg/day of caz are administered in a
frequency of 6 h instead of 24 h.
Microbial pathogenesis: a diversity of mechanisms and host
responses
O363
The role of triggering receptor expressed on
myeloid cells-1 (trem-1) and of its soluble form
for the evolution of septic syndrome
M. Raftogiannis, V. Markaki, D. Plachouras, I. Validakis,
M. Kontogiorgi, E.J. Giamarellos-Bourboulis, C. Roussos,
H. Giamarellou (Athens, GR)
Objectives: Aim of the present study was to assess whether
expression of Triggering Receptor Expressed on Myeloid Cells-1
(TREM-1) on the surface of blood neutrophils and monocytes
and concentration of its soluble form correlate to progression of
septic syndrome.
Methods: 73 patients were enrolled in the study, presenting
with septic syndrome (ASCP/SCCM 1992 criteria) induced by
ventilator associated pneumonia. Peripheral blood was collected
upon the onset of sepsis, and on days 3, 5 and 7 thereafter for
estimation of TREM-1 on the surface of neutrophils and
monocytes, and soluble TREM-1 in the serum. Red blood cells
were lyzed in ammonium chloride and leukocytes washed three
times in PBS. They were then stained with a phycoerythrin-
conjugated monoclonal anti-TREM-1 antibody (R&D Systems)
and analysed by ﬂow cytometry. Soluble TREM-1 in the serum
was estimated by an immunoassay.
Results: Of the enrolled patients, 24 presented with sepsis, 18
with severe sepsis and 31 with septic shock. Median values of
sTREM-1 and surface TREM-1 are given in the table (*p < 0.05
compared to sepsis and severe sepsis, **p < 0.05 compared to
sepsis and septic shock).A positive correlation between the
expression of surface TREM-1 on neutrophils and monocytes
was detected on all days examined (p < 0.0001). No correlation
was observed between the expression of TREM-1 on the surface
of myeloid cells and the concentration of its soluble form.
Conclusions: Increased expression of TREM-1 on the surface of
neutrophils and monocytes over the course of the septic
syndrome may reﬂect a pivotal role for surface TREM-1 in the
transition from sepsis/severe sepsis and septic shock. The
decrease of sTREM-1 in patients with septic shock may
designate the anti-inﬂammatory role of the soluble counterpart
of TREM-1.
O364
Caenorhabditis elegans killing model: a new tool
to study uropathogenic Escherichia coli virulence
J.P. Lavigne, A.B. Blanc-Potard, G. Blossier, D. O’Callaghan,
A. Sotto (Nıˆmes, FR)
Objective: Several studies have suggested a correlation
between resistance to quinolones and a low level of virulence
factors (VF). This relationship between resistance and virulence
is based on the presence/absence of VFs. No animal studies
have been conducted to monitor virulence in vivo. We have
examined a collection of Extended Spectrum Beta-Lactamases
(ESBL)-producing uropathogenic E. coli strains for the level of
virulence using the nematode C. elegans.
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Methods: We have tested 24 uropathogenic E. coli strains
isolated from a surveillance program in Nıˆmes University
Hospital. These strains included 14 ESBL-producing E. coli
(7 CTX-M-15, 6 TEM-24, 1 TEM-3) and 10 sensitive E. coli strains
susceptible to all antimicrobial tested. All isolates were tested
by PCR for the presence of 15 genes encoding known VFs. The
C. elegans infection assay used the N2 worms. To compare the
entire survival curves in nematode killing assays, we used a Cox
regression (SPSS 6.1.1).
Results: The 7 CTX-M-15, the 6 TEM-24, the TEM-3 and the 10
sensitive strains possessed 1 to 4, 5 to 8, 6 and 10 to 15 VFs
respectively. The mean survival time for C. elegansN2 infected at
the L4 stage were 3.01 days (± 0.13) for sensitive strains, 4.66
(± 0.36) for TEM strains and 6.28 (± 1.24) for CTX-M strains. The
mean survival times for worms fed with OP50 (a control strain)
are 10.33 days (± 0.98). All the worms infected with sensitive E.
coliwere killed in 8 days (± 0.5). This time was longer for worms
infected with TEM-producing E. coli (10.25 ± 0.5) and CTX-M-15
producing E. coli (12.5 ± 0.5). Cox regression showed that an
infection with sensitive E. coli strains reduced larval survival by
a factor of 4.29 (P < 0.0001) compared to nematodes infected
with CTX-M-producing E. coli strains. This result was highly
repeatable since there was no difference between three
repetitions.
Conclusion: We have developed a novel in vivo assay to assess
the virulence properties of numerous E. coli strains. The effects
of the uropathogenic E. coli strains on C. elegans demonstrate
signiﬁcant parallels to molecular data. The ability to kill worms
was signiﬁcantly correlated with the presence of VFs; the
antibiotic sensitive strains killing faster than the TEM or CTX-M
strains. The molecular virulence proﬁles and the in vivo
behaviour suggest that the CTX-M-group genotype, although
adapted for survival in an antibiotic-rich environment such as
the hospital milieu have a little intrinsic virulence potential.
O365
Clumping factor B is essential for human
Staphylococcus aureus nasal colonisation
H. Wertheim, H.A.M. Boelens, D.C. Melles, H. Verbrugh,
T. Foster, A. van Belkum (Rotterdam, NL; Dublin, IE)
Objective: Staphylococcus aureus persistently colonizes the
vestibulum nasi in a signiﬁcant fraction of humans. This a risk
factor for subsequent infection. The mechanism for nasal
colonisation is unknown and has only been studied in vitro
studies and in small rodents. Here we present study the ﬁrst
results of a human nasal colonization model in which S. aureus
adhesins can be studied.
Methods: We deﬁne the role of the staphyloccal cytokeratin-
binding protein-clumping factor B (ClfB) in the colonization
process by artiﬁcial inoculation of human volunteers with a wild
type strain and its single locus ClfB knock out mutant.
Persistence was followed up by quantitative nasal culture and
bacterial genotyping for 28 days.
Results: Our results show that the mutant strain is eliminated
from the vestibulum nasi of volunteers signiﬁcantly faster than
the wild type: median of 8 days versus 3 days (p = 0.0174). The
number of S. aureus CFUs after inoculation were always higher
for the wild type strain (Figure 4). The load was statistically
signiﬁcantly higher at days 7 and 21. After 1 week the average
numbers of CFUs (log CFU) per culture were higher for the wild
type strains (0.85 CFU versus 0.26 CFU; p = 0.022).
Conclusion: Here we present the ﬁrst ‘‘in homo’’ data showing
that the ClfB protein by itself is already a prime determinant of
nasal S. aureus carriage.
O366
Alanine esters of enterococcal lipoteichoic acid
have a role in bioﬁlm formation and resistance to
antimicrobial peptides
F. Fabretti, C. Theilacker, A. Kropec, S. Koch, J.
Huebner (Freiburg, DE; Boston, US)
Objectives: E. faecalis is one of the leading causes of nosocomial
infections, and the increasing occurrence of enterococcal strains
resistant to multiple antibiotics underscores the necessity of a
better understanding of the pathogenicity of these
microrganisms. The aim of the present study was to evaluate
the effect of D-alanine esters on teichoic acids in bioﬁlm
production, autolysis, antimicrobial peptides sensitivity,
neutrophile killing, and opsonisation.
Methods: A nonpolar deletion of the dltA gene was created in
the clinical E. faecalis strain 12030. The resulting dltA- mutant
was compared to the wild-type strain in a microtiter bioﬁlm
assay, in Triton X100 induced autolysis, opsonophagocytic
assay, and susceptibility to antimicrobial cationic peptides.
Results: LTA was puriﬁed from the wt strain and the dltA
deletion mutant, and the absence of D-alanine in LTA isolated
from the mutant was conﬁrmed by NMR. While the wild-type
strain and the deletion mutant did not show any signiﬁcant
differences in autolysis, neutrophile killing and
opsonophagocytosis, the mutant strain produced a
signiﬁcantly less bioﬁlm when grown in the presence of 1%
glucose (51.1% compared to wild type). In the mutant strain the
sensitivity to Polymixin B was considerably increased (MIC 32
vs. 512 ug/ml), Colistin (128 vs. > 512 ug/ml), and Nisin (2 vs.
8 uM).
Conclusions: Our data conﬁrm that the main effect of the
absence of D-alanine on LTA and WTA is an increased
sensitivity to cationic antimicrobial peptides, probably due to
the increased net negative charge on the surface. Alanine
residues also seem to enhance bioﬁlm production, which has
been shown to be a multifactorial process and probably involves
also electrostatic interaction mediated by zwitterionic molecules,
such as teichoic acids.
O367
Quinolones induce the partial and total loss of
uropathogenic Escherichia coli pathogenicity
islands by two different pathways
S. Soto, M.T. Jimenez de Anta, J. Vila (Barcelona, ES)
Objectives: Previous studies have demonstrated that
quinolones induce the loss of pathogenicity islands (PAIs) in
uropathogenic Escherichia coli (UPEC). The objective of the
present study was to analyse the pathway used for quinolones
to induce this loss.
Methods: Two haemolytic clinical UPEC (HC14366 and HC109)
and their non-haemolytic derivatives obtained when the wild
type strains were submitted to sub inhibitory concentrations of
ciproﬂoxacin were selected. A knockout mutant of the recA gene
was generated from each wild-type strain by interruption of the
recA gene with a cassette presenting tetracycline resistance. The
original strain and the knockout mutants were submitted to
subinhibitory concentrations of ciproﬂoxacin to determine if
recA was involved in the loss of PAI. The presence of the hly,
cnf1, and hra genes was tested by PCR using gene-speciﬁc
primers.
Results: The HC14366 recA- did not show loss of haemolysin
capacity when the strain was submitted to subinhibitory
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concentrations of ciproﬂoxacin, indicating the involvement of
recA in this procedure. The presence of the hra gene (which was
located in the extreme of PAI) in the HC14366 non-haemolytic
derivatives indicated the partial loss of this PAI. On the other
hand, the HC109 recA- showed a loss of haemolysin capacity
similar to the wild-type strain, indicating that, in this case, recA
was not involved in this procedure. Moreover, HC109 non-
haemolytic derivatives did not present the hra gene, indicating
the total loss of this PAI.
Conclusions: Quinolones induce the loss of PAIs by two
different pathways: i) Partial loss of the PAI containing the hly
and cnf1 genes through the SOS system; and ii) total loss in
which the SOS system is not implicated.
O368
Recombinant expression and characterisation of
putative streptococcal pyrogenic exotoxins
SPEGdys, SPELdys, and SPEMdys from
Streptococcus dysgalactiae, subsp. equisimilis
K.H. Schmidt, S. Sachse, S. Ro¨diger, D. Gerlach, E. Straube,
J. Ro¨del (Jena, DE)
Objectives: Besides human pathogenic Streptococcus pyogenes
(GAS) group C (GCS) and G (GGS) streptococci can be
pathogenic for different mammalians. Human pathogenic GCS
and GGS (hpGCS/GGS, Streptococcus dysgalactiae, subsp.
equisimilis) can cause, like GAS, wound infections, otitis media,
pharyngitis and streptococcal toxic shock syndrome. Recently,
we found a superantigen (SAG) like gene, speGdys in hpGGS.
Later genes encoding SPELdys and SPEMdys were also detected
in hpGGS. The sequences of the encoding proteins (SPE’s) were
highly homologeous but not fully identical to the corresponding
genes from group A streptococci.
Methods and Results: We cloned all three genes derived from
hpGGS in E. coli. In all constructs the putative signal peptides
were omitted. All three recombinant proteins were expressed as
inclusion bodies and remained soluble in urea buffers at a
minimum concentration of 6 M. Renaturation succeeded by
stabilisation with 15 mg/ml albumin following stepwise
reduction of the urea concentration by dialysis against 0.05 M
Tris, 0.15 M NaCl buffer, pH 8.0. The preparations were tested
in the lymphocyte transformation test (LTT). The culture ﬁltrates
of the original hpGGS strains did not show human T cell
stimulating activity. In the same manner, the in E. coli expressed
recombinant proteins rSPEGdys as well as rSPELdys did not
stimulate human T lymphocytes. rSPEMdys is still under
investigation. The absence of biological activity was
surprising, because each of the recombinant putative SPE’s
from hpGGS contain zinc binding region (H-F-D) and other
binding sites like SPEG and SPEA from GAS. These recombinant
proteins, cloned from GAS, stimulated T cells. It seems that the
few differences in the AA sequences between the hpGGS
putative SAG’s and the GAS SAG’s were responsible for the
decreased biological activity of the proteins derived from
hpGGS.
Conclusion: Until now, an active mitogen for human T cells has
not been isolated from hpGCS and hpGGS. Active mitogens, so
far, came from group C and group G streptococci isolated from
horse or other animals. Instancing SPEGdys, in this case we
found gene transfer from hpGGS to GAS. We suggest that after
the gene transfer of SPE’s from GGS to GAS, the genes in the
receiving strains were altered. In GAS they may have changed
resulting in production of active SAG’s. Using the putative SPE’s
from hpGGS, LTT experiments with T cells from blood of
animals, susceptible to GCS/GGS infection, are in progress.
O369
Release of activin A by microglial cells upon
stimulation with bacterial TLR-agonists
S. Ebert, R. Nau, U. Michel (Gottingen, DE)
Objectives: Activin A, a member of the transforming growth
factor-beta (TGF-beta) family of growth and differentiation
factors, is a multifunctional cytokine, with one of its roles being
in the immune system and inﬂammatory processes. Follistatin
(FS) is a high afﬁnity binding protein of activin and antagonises
its actions. We previously demonstrated that concentrations of
both activin and FS are elevated in the serum of patients with
septicemia and in the cerebrospinal ﬂuid (CSF) of patients with
meningitis. The sources of the elevated concentrations of both
proteins in CSF have not yet been discovered.
Methods: Primary mouse microglial cell cultures were exposed
to the TLR agonists Pam3Cys (Tripalmitoyl-S-glyceryl-cysteine;
TLR 2), endotoxin (LPS; TLR 4) and oligonucleotides containing
unmethylated cytosin-guanosin motifs (CpG; TLR 9) for
24 hours in the presence of interferon-gamma (IFN-gamma;
100 U/ml). Concentrations of activin A and FS in the cell culture
supernatants were measured by ELISA (R&D Systems GmbH).
Mann-Whitney-U-test was performed to analyse differences in
activin concentrations between groups (n = 10, respectively);
p-values < 0.05 were considered statistically signiﬁcant. Data are
expressed as median (minimum/maximum).
Results: After treatment of microglial cultures with IFN-gamma
alone (control group), activin A concentrations in the cell culture
supernatant were below the detection limit of the ELISA. After
combined treatment with IFN-gamma and one of the TLR-
agonists, activin A concentrations in the cell culture supernatant
were signiﬁcantly elevated: 279 pg/ml (196/337) after treatment
with 1 ug/ml LPS (p < 0.0001), 117 pg/ml (0/167) after
treatment with 1 ug/ml Pam3Cys (p = 0.007), and 77 pg/ml
(0/185) after treatment with 10 ug/ml CpG (p = 0.02). FS
concentrations in all groups were below the detection limit of
the ELISA.
Discussion: Our results show for the ﬁrst time that microglial
cells release activin A upon activation by bacterial TLR-agonists.
This ﬁnding provides further evidence for a role of activin in the
innate immune response and suggests that microglial cells are a
source of elevated activin A concentrations observed in the CSF
during bacterial meningitis.
O370
Regulation of putative extra cellular virulence
factors in Staphylococcus epidermidis by the
alternative sigma factor sigmaB
J.C. Kneschke, S. Jaeger, D. Mack, J.K. Knobloch (Hamburg, DE;
Swansea, UK)
Objectives: Despite the regulation of PIA synthesis the sigmaB
regulon of S. epidermidis is still almost uncharacterized. To
investigate the inﬂuence of sigmaB activity on secreted proteins
we investigated culture supernatants of sigmaB mutants
(1457sigB, 8400sigB, 1057sigB) generated in clinical isolates
S. epidermidis 1457, 8400, and 1057.
Methods: The proteins of culture supernatants were compared
using SDS-PAGE between wild type and mutant strains.
Proteins identiﬁed to be differentially expressed were further
characterised using MALDI-TOF mass spectroscopy.
Transcription of the genes identiﬁed to be differentially
expressed was analysed using quantitative RT-PCR.
Results: Two proteins identiﬁed as serine protease (SE1543) and
cystein protease (SE0184) were signiﬁcantly upregulated in
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sigmaB mutants compared to the respective wild types.
Transcriptional analysis revealed that the respective genes were
repressed in a sigmaB dependent manner. Phenotypic analysis
revealed a signiﬁcantly increased protease activity in all
investigated sigmaB mutants. Thereby, strain 1057 displayed
the highest proteolytic activity, which was further induced in
1057sigB. Mutants with inactivation of the antisigmafactor RsbW
and still intact sigB gene displayed a reduced protease activity
compared to the respective wild type strains, corroborating the
negative regulation of extra cellular proteases by sigmaB. One
protein identiﬁed as the (pre) proenzym of the lipase GehD was
upregulated in 1457sigB and 8400sigB, whereas in 1057sigB this
protein was signiﬁcantly reduced. However, transcriptional
analysis of the gehD gene revealed an increased transcription in
all sigmaB mutants. Zymographic and quantitative enzymatic
analyses revealed also a differential behaviour of the investigated
wild types and mutants. 1457sigB and 8400sigB displayed an
increased lipolytic activity, which seem to be caused by increased
processing of the proenzym to the fully active lipase. In 1057sigB a
reduced lipolytic activity was detected, which resulted from a
rapid proteolytic degradation of both, the proenzyme and the
active enzyme.
Conclusion: The presented data indicate that sigmaB is a
negative transcriptional regulator of proteases SE1543 and
SE0184 leading to an increased proteolytic activity of sigmaB
mutants. Additionally, sigmaB acts as a negative regulator of
lipase GehD. However, the lipolytic activity of individual strains
is also determined by their proteolytic activity.
O371
Oral lactobacilli and periodontitis
A.K. Szkaradkiewicz, B. Tukiendorf, J. Stopa (Poznan, PL)
Objectives: Etiopathogenesis of periodontitis still remains
unclear and its diagnosis requires complex procedures.
Therefore, in this study we aimed to examine the role of
Lactobacillus spp. present in the whole saliva in adult patients
with moderate or severe periodontitis.
Methods: Material for the studies involved samples of the full
saliva obtained from 23 patients (35–49 years of age), in whom
clinic criteria permitted to diagnose moderate (in 8 patients) or
severe periodontitis (15 patients). Samples full saliva from 14
healthy individuals (with stationary caries), 20–42 years of age,
served as the control. The samples of saliva were quantitatively
plated on Rogosa agar and the cultured isolates obtained in
anaerobic conditions were identiﬁed using API 50 CHL
(bioMerieux). In parallel, for detection of hydrogen peroxide
production by the isolated Lactobacillus spp. TMB-Plus agar was
applied. Moreover, using TMB method, salivary peroxidase
activity was estimated in saliva supernatants.
Results: In all patients of the moderate periodontitis group
presence of hydrogen peroxide-producing Lactobacillus spp. was
disclosed (mean content of lactobacilli: 0.25 million/ml saliva),
while in all the patients of the severe periodontitis grouppresence
of Lactobacillus spp. unable to produce hydrogen peroxide was
observed (mean content of lactobacilli was 1.6 million/ml saliva).
In the control group saliva of 12 patients was found to contain
hydrogen peroxide-producing Lactobacillus spp., and in the
remaining two patients saliva contained Lactobacillus spp.
unable to produce hydrogen peroxide (mean content of
lactobacilli amounted to 0.4 million/ml saliva). In parallel,
activity of saliva peroxidase in patients with severe
periodontitis amounted to 10.4 ± 3.3 u/ml and it did not differ
from activities in the remaining groups (p > 0.05).
Conclusions: Hydrogen peroxide produced by Lactobacillus
spp. exerting anti-microbial effects seems to protect against
progression of periodontitis. Detection of hydrogen peroxides,
produced by Lactobacillus spp. in saliva, may be of diagnostic
importance in evaluation of the risk of periodontitis progression.
Keynote lectures II
K386
Mitochondria: a newly discovered target for
Gram-positive and -negative bacterial toxins
P. Boquet (Nice, FR)
Mitochondria as potential intracellular targets for bacterial
toxins and bacterial virulence factors have been ignored for a
long time although many viruses were already well known to
interfere with this organelle. In the past 5 years, following the
description by our group that the vacuolating toxin (VacA) from
Helicobacter pylori targets mitochondria, many reports have
appeared in the literature showing that mitochondria, the
classical power plants of cells as well as the central executioner
of the death sentence, were targets of bacterial toxins and
virulence factors. In particular it appears that pore forming
toxins might exert their pathological effects on host cells through
a direct activity on mitochondria inducing necrosis or apoptosis,
as recently reported for the Staphylococcus aureus Panton-Valen-
tine leukocidin. However, in addition to pore-forming toxins
non-pore forming virulence factors secreted by bacteria via the
type III secretion system may impact mitochondria and by
provoking a necrosis or apoptosis may alter the normal host
physiology, for instance, the barrier function of epitheliums.
This presentation will show why mitochondria may be consid-
ered by pathogenic bacteria as good targets for their virulence
and how this event can lead to pathogenicity.
K387
Implications of chemotherapy-related mucosal
barrier injury
N. Blijlevens (Nijmegen, NL)
Mucositis of the alimentary tract is the clinical manifestation of
the mucosal barrier injury induced by receiving chemotherapy,
with orwithout irradiation and affects themouth and throughout
the intestines and is also associated with adverse clinical and
economic outcomes. In recent years we have begun to unravel the
pathogenesis of mucositis to reveal a complex and dynamic
pathobiological process that provides a biological basis for
targeted, molecular-based interventions. Mucositis is thought to
occur in ﬁve phases: (1) initiation, (2) upregulation and message
generation, (3) ampliﬁcation and signalling, (4) ulceration and (5)
healing. Risk factors have not been systematically evaluated but
the character, onset and progression of mucositis is markedly
inﬂuenced by the nature and intensity of the cytotoxic insult.
Anticancer therapy activates nuclear transcription factor NF-kB
resulting in the production and release of pro-inﬂammatory
cytokines TNF-a, IL-1a, IL-6, IL-8 and LPS-Binding Protein by
epithelial cells. The systemic inﬂammatory response seen in
HSCT recipients following myeloablative therapy mirrors the
pattern of mucosal barrier injury as measured by gut integrity
(L/R ratio), daily mucositis score and serum citrulline concen-
trations. The concentrations of IL-8, LBP and CRP are already
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signiﬁcantly elevated by the ﬁrst week after transplant during
profound neutropenia even before the onset of fever or bacter-
aemia. These inﬂammatory response markers reach their peak as
serum citrulline concentrations reach their nadir, the maximum
DMS is attained and when there is signiﬁcantly decreased gut
integrity. This suggests that mucosal barrier injury rather than
systemic infection eg bacteraemia determines the onset and
intensity of the inﬂammatory response.Epithelial cells are an
integral component of the anatomical and immunological
mucosal barrier functioning as the front line of host defences
against microorganisms. Gram-positive bacteraemia tend to
occur far more often among stem cell transplant recipients than
Gram-negative bacillary infections and is not simply the result of
using antimicrobial prophylaxis with ﬂuoroquinolones. Bacter-
aemia due to oral viridans streptococci (OVS) of the mitis group
(Streptococcus mitis Streptococcus oralis) is related to mucosal
damage and can be associated with more serious complications
such as sepsis and adult respiratory distress syndrome, which
carries a high mortality (80%), though mucosal barrier injury is
not a predictor of the viridans streptococcal shock syndrome.
Coagulase-negative staphylococci (CoNS) are more frequent
causes of bacteraemia, which, though frequently related to the
use of central venous catheters, is also related to mucositis, as
mucosal sites are also an important source of these staphylococci.
Notwithstanding this, the role of bacteria in augmenting the
inﬂammatory response during mucosal barrier injury remains
intriguing. Anticancer therapy blocks clonogenic epithelial stem
cell renewal resulting in apoptosis and necrosis, which manifests
itself as epithelial atrophy and ulcerative lesions. OVS are
universal commensal residents of the oral cavity. Hence these
lesions might offer a portal of entry for the bacteria, which could
either be pathogens or passengers? In other words, is OVS
bacteraemia a useful marker of markedly disturbed mucosal
barrier rather than a harbinger of systemic infection? Does OVS
bacteraemia indicate those HSCT recipients at risk of developing
serious infectious complications or even signify an increased risk
of mortality. Mucositis has been reported as a risk factor for
bacteraemia due to Acinetobacter species, Stenotrophomonas malto-
philia, Capnocytophaga species and Fusobacterium nucleatum. In
addition, bacteraemia due to Staphylococcus aureus, Pseudomonas
aeruginosa, certain Clostridium species and Candida species is
associated with neutropenic enterocolitis (typhlitis). This
extreme manifestation of treatment-induced mucosal barrier
injury appears to be the result of disturbing the delicate balance
between host and microbial ﬂora in the setting of prolonged
exposure to antibiotics. Given the complex relationship of fever,
neutropenia and infections in the context of mucosal barrier
injury it seems an exercise in futility to attempt to circumvent
bacteraemia by tackling only one facet of the process. Indeed
antimicrobial therapy alone with or without the use of haema-
topoietic growth factors has not been successful in preventing
febrile neutropenia. Rather, it may be more fruitful to aim either
at down-regulating the inﬂammatory response or at restoring the
mucosal barrier or both.
Issues in travel medicine
S389
Treatment of imported malaria
T. Jelinek (Berlin, DE)
According to WHO, more than 300 million people suffer from a
malaria episode annually, in 2–3 million with letal outcome.
Around 90% of transmission occurs in sub-Saharan Africa.
Falciparum malaria poses an increasingly common problem in
endemic regions and treatment failures are increasing due to
drug resistance. Several endemic areas now suffer from multi-
resistant Falciparum malaria. Approximately 1000 cases of
imported malaria are registered annually in Germany. Conser-
vative estimates put the risk of an infection with Plasmodium
falciparum in East and West Africa at 1–2% per month. Recent
studies show that this rate can be as high as 30%, depending on
the behaviour of the traveller. As mortality rates reach 80% in
non-immune, untreated patients, fast diagnosis and effective
treatment are mandatory. Treatment for malaria depends on
several factors: the species of malaria causing infection, severity
of infection, the age of the infected individual, and the pattern of
drug resistance to malaria treatment in the area where the
individual acquired the infection. If identiﬁed early and treated
appropriately, almost all malaria can be completely cured.
However, even short delays in the diagnosis of malaria can
make treatment more difﬁcult and less successful. Current
recommendations offer a variety of highly effective antimalari-
als for treatment that can be chosen according to the speciﬁc
needs of the individual patient. Data from the European
network on imported infectious disease surveillance (TropNe-
tEurop) show a widely disparagous use of treatment regimen in
malaria throughout Europe. This translates to signiﬁcant differ-
ences in treatment costs and inpatient time in various European
countries. Publication of expert statements for European treat-
ment standards seems highly desirable in view of future
streamlining of strategies. In 2005, TropNetEurop has done
ﬁrst steps in that direction with the publication of statements for
the treatment of severe Falciparum malaria in Europe and for
malaria chemoprophylaxis (www.tropnet.net).
Sexually transmitted diseases and urinary tract infections
O390
Rectal lymphogranuloma venereum in San
Francisco in the 1980s
J. Schachter, J. Moncada, J. Spaargaren (San Francisco, US;
Amsterdam, NL)
Objective: To present the results of diagnostic testing for LGV
proctitis in MSM in San Francisco in the 1980s, and the typing of
the isolates, in the context of the ‘‘outbreak’’ of LGV proctitis
described in 2003–2005, initially in The Netherlands, and then
elsewhere.
Methods: Rectal swabs were collected fromMSM being seen for
proctitis in medical clinics in San Francisco. Attempts to isolate
Chlamydia trachomatis were made in cycloheximide treated L
cells. In the 1980s LGV strains were differentiated from the
trachoma biovar by growth characteristics (not requiring
centrifugation). In 2005, 51 LGV isolates that were still
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available were sent to Amsterdam, and tested by PCR, and by
sequencing of ompA genes for typing.
Results: Isolation and typing results are shown in the Table.
Early in the 1980s chlamydiae were commonly recovered from
proctitis cases, but the isolation rate dropped from about 1/3
of cases to < 10% by 1984. Throughout this time, LGV strains
were about 2/3 of the isolates. In 2005 modern molecular
methods conﬁrmed the earlier biological identiﬁcation of LGV
biovars. All 51 San Francisco isolates were positive for LGV
variants by real-time PCR. By sequencing variable segment 2 of
the ompA gene (VS-2), we identiﬁed 15 as L1, 18 as L2
prototype, and 18 as the L2b genovariant (Spaargaren, et al,
Emerg Infect Dis, 2005).
Conclusions: Chlamydiae were commonly recovered from
rectal swabs from MSM with proctitis in the early 1980s. But
the isolation rate dropped from about 1/3 in the early 1980s to
< 10% in 1984. Throughout the time, about 2/3 of the isolates
were LGV. L2b, thought to be a ‘‘new’’ strain when it was ﬁrst
identiﬁed in The Netherlands, as the major cause of the recent
outbreak was actually about 1/3 of the isolates obtained in San
Francisco > 20 years ago. These results suggest that chlamydiae
became less common as causes of proctitis as the gay
community modiﬁed its behaviour in response to AIDS; that
LGV proctitis was common then and likely maintained by a core
group that continued risky behaviours, and may have expanded
in recent years with the relaxation of safe-sex behaviours and the
concomitant increase in STDs.
O391
The role of Chlamydia trachomatis in chronic
prostatitis/chronic pelvic pain syndrome
M. Sukhorukova, R. Kozlov, I. Malev, O. Shipulina,
L. Stratchounski (Smolensk, Moscow, RU)
Objectives: The aim of this study was to determine the role of
Chlamydia trachomatis in patients with different forms of chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Methods: The patients with at least 3 months of clinical
evidence of CP/CPPS as well as healthy volunteers were
included in the study. All patients and healthy individuals
with no antibiotic treatment during preceding month were
evaluated with the Meares and Stamey localization technique.
The categorization of CP/CPPS was performed according to
National Institute of Health (NIH) classiﬁcation. Commercial
PCRs (Amplisens, Russia) with primers speciﬁc for
C. trachomatis on urethral swab (US) and expressed prostatic
secretions (EPS) were performed for 14 patients with chronic
bacterial prostatitis (CBP) (NIH category II), 77 patients with
inﬂammatory CPPS (NIH category IIIA), 79 patients with
noninﬂammatory CPPS (NIH category IIIB) and 42 healthy
volunteers.
Results: According to PCR data, among the patients with CBP
C. trachomatis has been found in 2 (14.3%) of the cases both in the
US and EPS, among the patients with inﬂammatory CPPS - in 1
(1.3%) of the cases in US as well as in EPS and among the
patients with noninﬂammatory CPPS - in 4 (5.1%) and in 5
(6.3%) of the cases in US and EPS correspondingly. Among the
healthy volunteers C. trachomatis has been found in 4 (9.5%) of
the cases. Only in 1 patient with noninﬂammatory CPPS EPS
sample was PCR-positive whereas US sample was PCR-negative
for C. trachomatis. There were no statistical signiﬁcant
differences among frequency of the detection of C. trachomatis
in patients with CBP, inﬂammatory CPPS, noninﬂammatory
CPPS and healthy individuals both in US an in EPS samples.
Conclusion: The same rate of PCR-positive results for
C. trachomatis both in patients with clinical prostatitis
syndrome and in healthy individuals has demonstrated the
doubtful etiological role of this infection in CP/CPPS. However
taking into account the high virulence of C. trachomatis for
reproductive system, the routine evaluation of the patients
with prostatitis syndrome for this pathogen might be useful.
C. trachomatis may be assessed as causative agent of CP/CPPS
only in men with PCR-positive EPS sample and PCR-negative
US sample for this organism.
O392
Acceptability of self-taken vaginal swabs and
ﬁrst-catch urine samples for the diagnosis of
urogenital Chlamydia trachomatis and Neisseria
gonorrhoeae with an ampliﬁed DNA assay in
young women attending a public health STD
clinic
C.J.P.A. Hoebe, C.W. Rademaker, E.E.H.G. Brouwers,
H.L.G. Ter Waarbeek (Heerlen, NL)
Objectives: Most common sexually transmitted bacterial
pathogens are Chlamydia trachomatis (CT) and Neisseria
gonorrhoeae (NG). The purpose of this study was to evaluate
the acceptability and feasibility of self-taken vaginal swabs (SVS)
and ﬁrst-catch urine samples (FCU) samples for the detection of
CT and GC in young women attending a public health STD
clinic.
Methods: 413 young women (age 14–35) visiting a public health
STD clinic between August 2003 and August 2004 participated.
Patients were instructed in taking a SVS and a FCU by educated
STD-nurses. All patients ﬁlled out a questionnaire concerning
demographic data, reason(s) for STD examination, acceptability
of both methods and preferable examination method. Samples
were tested for the presence of CT and GC by a NAAT with
internal inhibition control (strand displacement ampliﬁcation
assay (SDA), Becton Dickinson ProbeTec ET system). We
compared test results from SVS and FCU specimens, focusing
on the analysis of percent agreement between results of both
methods.
Results: CT and NG were diagnosed in 10.9% and 1.5% of the
patients, respectively. 68% of the female participants never
previously had a STD examination of whom 11% tested STD
positive. More than 13% mentioned ‘not having to undergo
intimite vaginal examination’ as one of the reasons to go to a
public health STD clinic. Self collection of vaginal swabs was
almost uniformly reported as easy to perform (99%). Self
collection of urine samples and vaginal swabs were preferred
(84%) above a gynaecologic examination (1%). The percent
agreement of both tests is 98.9% (408/413) for CT and 99.3%
(410/413) for GC.
Conclusions: CT and NG are prevalent among young women,
yet willingness to undergo traditional gynaecologic STD testing
is limited. Efforts to enhance compliance with testing among at-
risk women are needed. SVS and FCU are appropriate
specimens for highly sensitive STD diagnosis. SVS and FCU
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are highly accepted and feasible among this risk group.
Therefore, these easy sampling methods would be good to use
in clinical and non-clinical settings. These tests provide new
opportunities in STD control to increase STD testing coverage
among young women, enabling the non-invasive detection of
many STDs that would otherwise remain undiagnosed and
untreated.
O393
Asymptomatic bacteriuria, a lasting or ﬂuctuating
condition among elderly living in the
community?
N. Rodhe, M. Andre´, L. Englund, S. Mo¨lstad (Falun, Jo¨nko¨ping,
SE)
Background: Asymptomatic bacteriuria (ABU) is common
among the elderly in institutional care but less is known about
its prevalence among the elderly living in community settings
and even less is known about the turnover of ABU in this
population. Better knowledge in this area is a brick in the
important work to reduce unnecessary use of antibiotics.
Objectives: To study the prevalence and turnover of ABU in a
population of elderly people, ages 80 and over, living in a non-
institutional community setting.
Methods: Design: A longitudinal cohort study. Setting: The
catchment area of a primary health care center in a Swedish
middle-sized town. Participants: Every resident in the area age
80 and over was invited and of those 74%, 294 women and 138
men, participated. Measurements: At baseline and after 6 and
18 months a urine specimen was cultured and if positive, the
culture was repeated within two weeks to conﬁrm ABU. The
presence of leukocyte esterase and urinary nitrite was recorded.
Results: The percentage of bacteriuria was 22.4, 22.4 and 25.7 in
women and 9.4, 9.6 and 7.9 in men. Corresponding ﬁgures for
ABU was 19.0, 18.7 and 19.9 in women and 5.8, 7.8 and 6.9 in
men. Of those tested all three times, ABU was found at least
once in 34% of the women and 15% of the men and in 8.2% ABU
occurred each time. Following consecutive samplings the
positive conversion rate (going from an ABU negative to an
ABU positive result) was 7% and the negative conversion rate
31%. E. coli was found in almost 70% of subjects with ABU.
Conclusion: Bacteriuria is common and the rate of turnover is
considerable among the elderly living in non-institutional
community settings. Whether persisting ABU is caused by the
same or different strains of E. coli will be further analysed.
O394
Recurrent urinary tract infections caused by
Escherichia coli
S. Gualandris, A. Endimiani, G. Brigante, F. Luzzaro,
A. Toniolo (Varese, IT)
Introduction: Escherichia coli is the most common pathogen
isolated from urinary tract infections (UTI). These infections
occur frequently in healthy women. Of them, 25% are reinfected
within six months after the ﬁrst UTI episode. Fluoroquinolones
(FQ) and trimethoprim-sulfamethoxazole (SXT) are the most
frequent empirical treatments used for UTI. Notably,
underestimate UTI can progress to serious illnesses, as
bloodstream infections (BSI).
Methods: All urinary samples collected during 2004 at our
institution were studied retrospectively. Identiﬁcation and
antimicrobial susceptibility tests (AST) were achieved using the
Phoenix system (Becton Dickinson, Diagnostic Systems, Sparks,
MD). The Epicenter (Becton Dickinson) and the Powerlab
(Unitech, Milano) systems were used to obtain clinical and
microbiological data. ‘‘Reinfection’’ was deﬁned as a new UTI
occurring at least two weeks after the ﬁrst infectious episode.
Results: During the study period, 3706 patients diagnosed with
UTI due to E. coliwere observed. Reinfections were found in 495
(13.4%) patients. The majority of them were women (85.0%) and
with community-acquired UTI (91.5%). On the average, 2.5
UTI/year for patient were detected. The majority of patients had
2 or 3 episodes/year (71.5% and 16.5%, respectively). The most
prevalent age groups were 60–70 years, and 70–80 years (19.1%
and 23%, respectively). With regard to the ﬁrst isolates that were
responsible of recurrent UTI, AST results showed the following
resistance incidences: FQ (23.4%), SXT (31.3%), ampicillin
(50.1%), amoxicillin/clavulanate (15.9%), and ceftriaxone
(1.6%). Isolates causing subsequent infections were
characterized by increased resistance: FQ (29.4%), SXT (36.5%),
ampicillin (55.9%), amoxicillin/clavulanate (21.8%), and
ceftriaxone (5.8%). Patients with recurrent UTI were more
liable to develop BSI than patients having only one infectious
episode (2.0% and 0.6%, respectively).
Conclusions: E. coli recurrent UTI episodes occur commonly in
aged woman with community-acquired infections. Recurrent
infections may evolve to BSI more frequently than patients
showing single UTI episodes. The high incidence of isolates
resistant to antimicrobials (e.g., FQ and SXT) underlines the
ineffectiveness to plan an adequate empirical therapy.
Therefore, for recurrent UTI is opportune to use the more
suitable therapy based on etiological and AST results.
AIDS and HIV
O395
AIDS indicative diseases across Europe
G. Likatavicius, I. Devaux, J. Alix, A. Nardone on behalf of
EuroHIV
Introduction: The incidence of AIDS in Western-Europe has
stabilised since a peak in the mid-1990s; In Eastern-Europe,
there has been a continued increase in AIDS reports since the
late 1990s and for the ﬁrst time, in 2004, AIDS incidence rate was
greater than in Western-Europe.
Methods: EuroHIV collates information on HIV/AIDS from 52
countries the WHO European Region. Individual data are
compiled into the European non aggregate AIDS data set; up
to four AIDS indicative diseases (AIDS ID) can be reported for
one case. We present here data from 36 countries on AIDS
indicative diseases in adults and adolescents. Data for 2004 are
analysed by geographic region (West, Centre and East) and by
sex. Data on AIDS cases were unavailable for eight countries
and a further eight were excluded as AIDS ID was missing for
more than 25% of AIDS cases.
Results: In 2004, 10297 AIDS cases were reported in the 36
countries (7002 in the West, 329 in the Centre and 2966 in the
East). The most frequent AIDS ID were: in the West, tuberculosis
(TB) (24% among all AIDS ID), Pneumocystis carinii pneumonia
(PCP)(24%), Oesophageal candidiasis (16%), HIV wasting
syndrome (8%), toxoplasmosis (7%), Kaposi’s sarcoma (6); in
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the Centre, HIV wasting syndrome (24%), PCP (20%), TB (19%),
Oesophageal candidiasis (18%), HIV encephalopathy (10%),
toxoplasmosis (7%); in the East, TB (56%), HIV wasting
syndrome (39%), Oesophageal candidiasis (30%), HIV
encephalopathy(11%), recurrent pneumonia (10%), candidiasis
of bronchi, trachea and lungs (5%). Among women, TB was the
most frequently reported AIDS ID in the West (29%), the Centre
(29%) and the East (45%). Among men the most frequently
reported AIDS ID was PCP in the West (25%), HIV wasting
syndrome in the Centre (28%) and TB in the East (59%).
Conclusions: In the West, the two most common AIDS ID were
TB and PCP, whilst in the Centre, HIV wasting syndrome and
PCP were the most common. The AIDS epidemic in the East is
closely related to the TB epidemic. Nevertheless the higher
proportion of certain indicative diseases (HIV wasting
syndrome, encephalopathy, recurrent pneumonia) raises
questions about access to treatment and under diagnosis of
AIDS.
O396
Polymorphisms in toll-like receptors inﬂuence
susceptibility to HIV infection and its clinical
course
P.-Y. Bochud, M. Hersberger, P. Taffe´, M. Bochud, C. Stein,
T. Calandra, P. Francioli, A. Telenti, R.F. Speck, A. Aderem &
The Swiss HIV Cohort Study
Objectives: Toll-like receptors (TLRs) have a key role in innate
immunity and participate to antiviral defence mechanisms. We
examined whether single nucleotide polymorphisms (SNPs) in
TLRs 2, 3, 4, 7, 8 & 9 inﬂuence susceptibility or the course of HIV
infection in the Swiss HIV Cohort.
Methods: 28 SNPs in TLRs were analysed in 1255 HAART
naive HIV+ patients (cases) & 128 blood donors (controls) using
the Sequenom technology. The distribution of SNPs frequencies
was compared between cases and controls. In HIV+ patients, the
CD4+ T-cell decline was calculated using a least squares
regression line and a model using a latent variable. The
impact of TLRs SNPs on CD4 cells decline and HIV RNA was
evaluated using a linear regression model. A logistic regression
model was used to estimate the risk associated with SNPs
comparing rapid progressors (slope < percentile 15) and slow
progressors (slopes > percentile 85) to others patients.
Results: 3 SNPs in TLR8 that are in linkage disequilibrium
[C645T (H215H), G1953C (L651L) and C2253A (I751I)] were
more frequent in HIV+ patients than in controls (645T carrier
status frequency 0.45 versus 0.31, OR = 1.8, 95% CI 1.2–2.7,
P = 0.005; 1953C frequency 0.45 versus 0.30, OR = 1.9, 95% CI
1.9–2.9, P = 0.001 and 2253A frequency 0.40 versus 0.28,
OR = 1.7, 95% CI 1.1–2.6, P = 0.01). Among HIV cases, two
SNPs in TLR9 that are in linkage disequilibrium [Gp1174A
(untranslated) & A1635G (P545P)] were independently
associated with faster CD4 decline. The A1635G SNP showed
an additive effect on CD4 decline with a mean slope of )1.78 for
A/A, -1.88 for A/G (P = 0.2) and -2.08 for G/G (P = 0.008).
When we stratiﬁed HIV+ patients into progression groups, we
observed that 1635G carriers were more frequent among rapid
progressors than others (OR = 1.8, 95% CI 0.98–3.2, P = 0.058 for
G/A versus A/A and 2.7, 95% CI 1.4–5.2, P = 0.003 for G/G
versus A/A). Similar results were found for Gp1174A and when
we calculated the slope with individual regression or latent
variable.
Conclusion: This is the ﬁrst demonstration of an association of
TLR SNPs (TLR9) with the progression of HIV infection. In
addition, we found a different distribution of 3 SNPs in TLR8 in
HIV+ individuals and healthy blood donors. Genetic studies in
other cohorts will help to further assess the role of these SNPs as
prognostic markers of HIV infection. In vitro studies will allow
to understand the functional role of TLRs and their mutations in
HIV infection.
O397
Chronic immune activation as a major
determinant of AIDS pathogenesis: role of the
type I interferon response
S. Staprans, S. Klucking, A. Barry, R. Chavan, K. Dalbey,
G. Silvestri, M. Feinberg (Atlanta, US)
Objectives: Pathogenic simian immunodeﬁciency virus (SIV)
infection of non-human primates (e.g. rhesus macaques) and
HIV infection of humans are characterized by CD4 T cell
depletion in association with high viremia and generalized
immune activation. In contrast, SIV infection of primates that are
natural host reservoirs for SIV, such as sooty mangabeys, are
characterized by CD4 T cell preservation and the absence of
aberrant immune activation despite high-level viremia,
suggesting that chronic generalized immune activation and its
associated immunopathology are more important determinants
of AIDS than the direct cytopathic effects of virus replication.
Current studies aim to elucidate the cellular and molecular basis
of whether or not chronic immune activation and attendant
immunopathology follow CD4 T cell tropic lentivirus infection.
Methods: We developed a comparative infection model to
study how and when host innate and adaptive immune
responses diverge following SIV infection of mangabeys and
macaques, and compared these results with those obtained in
studies of HIV-infected humans.
Results: Differences in innate immune responses (e.g., dendritic
cell [DC] activation and migration) to SIV infection are evident
from the ﬁrst days of infection. These differences in the in vivo
behaviour of DCs are recapitulated following ex vivo exposure of
plasmacytoid DCs (pDCs) to speciﬁc toll-like receptor (TLR)
ligands and to inactivated SIV. In contrast to pDCs from
macaques and humans, mangabey pDCs produce signiﬁcantly
lower levels of interferon alpha in response to TLR7/9 ligands
and to SIV- apparently the result of divergent propagation of
activation signals along post-receptor pathways. At the
organismal level, gene expression proﬁling studies indicate
that a major feature distinguishing pathogenic from non-
pathogenic HIV/SIV infection is the extent to which type I
IFN production and response proﬁles are manifest.
Conclusion: Mangabeys avoid AIDS by the genetically
programmed failure of their innate immune systems to
respond to SIV with a type I IFN response. This enables an
anti-inﬂammatory immune response that protects these natural
hosts from the bystander damage seen in pathogenic HIV
infection.
O398
Elevated circulating HLA-G levels in HIV-
infected patients with and without visceral
leishmaniasis
L. Donaghy, F. Gros, L. Amiot, C. Mary, A. Maillard,
C. Guiguen, J-P. Gangneux (Rennes, Marseille, FR)
Objectives: HLA-G are non classical class I histocompatibility
complex molecules capable of inhibiting T cell proliferation and
cytotoxic T cell and NK mediated lysis. HLA-G molecules seem
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to be involved in viral persistence, and their surface expression
is markedly increased on peripheral blood mononuclear cells of
HIV-infected patients. No comparative data are available on the
expression level of plasma soluble HLA-G (sHLA-G) isoforms in
HIV-infected patients with and without opportunistic infections.
We measured full length sHLA-G isoforms in HIV-seropositive
and -seronegative patients with and without visceral
leishmaniasis (VL), and in healthy controls.
Methods: sHLA-G (sHLA-G1 + HLA-G5) levels were
measured with an ELISA sandwich method in serum from 94
subjects (39 HIV-seronegative, 31 HIV-1-seropositive, 17 with
VL, 7 with both VL and HIV-1 infection).
Results: sHLA-G concentrations were statistically different
among the groups of subjects (P < 0.0001). The frequency of
sHLA-G positivity in each group was statistically different
between groups (P < 0.00000001). sHLA-G ELISA was positive
in 81percnt; of HIV-infected patients and in 57percnt; of HIV-VL
co-infected patients. sHLA-G ELISA was positive in 30percnt; of
HIV-seronegative patients with VL, and in 3percnt; of healthy
controls.
Conclusion: These results conﬁrm the strong cell surface
expression of HLA-G molecules during HIV infection, and
demonstrate that levels of the plasma soluble forms are also
elevated. In HIV-Leishmania co-infected patients, sHLA-G
secretion could contribute to the tolerogenic environment and
might help Leishmania parasites to evade cell-mediated
immune responses in some patients.
O399
Study on the genotypic resistance of archived and
circulating viral strains in blood of treated HIV-
infected individuals
O. Turriziani, C. Scagnolari, C. Stano, G. Forte, M. Bucci,
F. Bellomi, C. Fimiani, I. Mezzaroma, G. D’Ettorre, C.
D’Agostino, E. Riva, S. Vita, C. Ajassa, G Antonelli (Rome, IT)
Objective: To study the patterns of resistance of HIV-1 in
peripheral blood mononuclear cells (PBMCs) and in plasma of
treated infected individuals and to determine whether drug-
resistant variants of HIV-1 persist in blood after treatment
interruption.
Methods: Plasma and PBMCs were collected from 71 heavily
treated HIV infected individuals. Genotyping of the reverse
transcriptase (RT) and protease gene (pro) of HIV-1 was
performed using ﬂuorescent dideoxy-terminator method
(TRUGENE HIV-1-BAYER). HIV drug resistance was deﬁned
according to the HIV-1 genotipic resistance interpretation
algorithm of the GUIDE LINESTM RULE 9.0-BAYER.
Results: Comparison of the amino acid sequence of the RT and
pro genes in cell-associated variants of HIV-1 with that of the
plasma revealed that 27 of the 71 patients tested (38%) exhibited
different genotypic resistance patterns (discordant samples: DS)
and consequently a different resistance report. 39% of samples
showed a concordant resistance report but the resistant pattern
detected in cell-associated compartment differed from that of
the plasma virus for the presence and/or absence of one more
than mutations. In the 23% of samples studied the patterns of
resistance, detected were concordant in the two compartments.
In the 70% of DS, as expected, plasma was the compartment
with the higher number of mutations, however in the remaining
cases of DS the higher number of mutations was found in the
proviral DNA. The analysis of genotypic resistance of HIV-1 in
PBMCs and plasma, before and after treatment interruption,
performed so far only in 5 patients, revealed that the rebound of
wild type virus in plasma strictly depends on the viral
population archived in PBMCs.
Conclusions: The HIV mutation patterns detected in plasma do
not necessarily reﬂect the mutation pattern detected in cell-
associated compartment. The observation that the proviral DNA
may contain an archive of different resistant variant makes this
proviral reservoir an interesting substrate for analysis of the
‘‘resistance-potential’’ in a given patient.
Molecular epidemiology: a tool for public health (Symposium
jointly arranged with EUPHA)
S408
Reconstructing HCV transmission history using
phylogenetic and population genetic methods
O.G. Pybus (Oxford, UK)
The hepatitis C virus (HCV) is a genetically diverse RNA virus
that infects at least 170 million people worldwide. HCV-associ-
ated mortality is expected to increase substantially in the future
with an estimated cost of $5 billion per year in the USA alone.
To be successful, HCV treatment and prevention strategies must
be grounded in a clear understanding of HCV transmission
dynamics. However, standard longitudinal surveys are not
particularly informative because (i) the HCV epidemic began
before the virus was discovered in 1989, (ii) there are insufﬁcient
archived strains to reliably measure seroprevalence retrospec-
tively and (iii) the absence of speciﬁc symptoms hinders the
estimation of past prevalence from medical records. As a result,
analyses of partial genome sequences, particularly those from
the E1 and NS5B genes, have proven crucial to investigating
HCV epidemiology. Recently developed methods based on
phylogenetic and population genetic models can be used to date
the origin of HCV outbreaks, estimate past rates of transmission
and track the migration of different strains among locations or
risk groups.
S410
Genotyping of measles viruses to monitor the
elimination process of the disease
S. Santibanez, A. Wolbert, A. Mankertz, A. Siedler, D. Burki,
A. Tischer (Berlin, DE; Basel, CH)
WHO has set the goal for elimination of measles in the European
Region by the year 2010. A very low incidence of measles (< 1
case per 1 Mio population and year) and an absence of endemic
transmission have to be achieved. This implies that the trans-
mission of indigenous measles virus (MV) has been interrupted
and that an imported MV can not establish long-term circula-
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tion. Therefore, the level of measles susceptibility in the
population has to be kept as low as possible by maintaining
very high immunization coverage (> 95%) with two doses of
measles vaccine. Genetic data of the detected MVs are essential
to trace the pathway of the virus transmission. This information
is required to discriminate whether local appearance of measles
is due to virus importation or if it reﬂects a still ongoing
circulation of an indigenous virus. The standardized nomencla-
ture for genotyping of MVs, introduced by the WHO in 1998,
enables description of MV circulation in a global context. At
present, 23 distinct MV genotypes are recognized by the WHO.
Experience shows that in countries with an area-wide and
continuous monitoring of measles, the level of incidence
correlates with the pattern of MV genotypes. This can be
demonstrated for Germany where a laboratory supported
nation-wide measles sentinel was established in 1999. Genotyp-
ing data over a period of > 6 years revealed that the few
sporadic cases observed recently in the eastern part were mainly
caused by imported MVs (genotypes B3, D4, D5, G2, H1, B2). In
contrast, in the western part, endemic transmission has been
observed until 2002. It was associated with the MV genotypes
C2, D6 and the newly emerged D7. In 2003, endemic transmis-
sion was tapering off and in 2004, measles occurred only
sporadically. The nation-wide incidence of measles decreased
from 7.3 in 2001 to 0.2 in 2004. However, in 2005, local outbreaks
occurred in the federal states of Hesse and Bavaria. The Hesse
outbreak was due to importation of a D4 MV from Romania
where an epidemic has been observed since the last quarter of
2004. The origin of the D6 MV that caused the Bavarian
outbreak, however, remains unknown. The observation of two
independent outbreaks demonstrates that despite the decline of
measles incidence in recent years, the potential for a limited
circulation of MV is still present in Germany. A study
performed in Switzerland from 2003 onwards also indicates
absence of endemic transmission. Imported MVs (genotypes D5,
D8, D4) were predominantly detected and some could even
establish limited circulation in 2003. This corresponds with the
incidence of measles that remarkably increased from 0.8 in the
years 2001/2002 to 10.2 in 2003 and decreased again to 0.8 in
2004/ 2005. Our studies demonstrate that for assessment of the
level achieved in the process of measles elimination, it is
essential to combine both MV genotype information and
epidemiological data, even in the WHO European Region
where the circulation of the former widespread MV genotypes
may be interrupted in many countries, but nonetheless contin-
ues in some other countries.
Mycobacterial infections
S412
Molecular biology for diagnosis and
identiﬁcation of mycobacteria
E. Tortoli (Florence, IT)
The availability of new tools of molecular biology has deeply
affected diagnostic microbiology in particular for what concerns
the organisms characterized by problematic growth in culture or
even not cultivable. Since the early development of the nucleic
acids ampliﬁcation techniques Mycobacterium tuberculosis was
considered one of the most attractive targets and the dream of
the rapid diagnosis of tuberculosis appeared within reach.
Immediately after the pioneering period, characterized by the
development of various home-made techniques, the ready-to-
use commercial kits spread worldwide. It is now evident that, in
routine practice, the standardization, convenience and robust-
ness offered by commercial systems, advantageously counter
balance the higher sensitivity ant the lower cost of the home
made methods. Three commercial methods monopolize at
present the market. Ampliﬁed Mycobacterium tuberculosis Direct
(Gen-Probe, USA) is based on the transcriptase-mediated
ampliﬁcation of a M. tuberculosis-speciﬁc trait of the 16S rRNA.
AMPLICOR (Roche, USA) ampliﬁes, using the classic PCR
procedure, a genus-Mycobacterium-speciﬁc segment of 16S
rDNA. The BDProbeTec ET relies on the strand displacement
ampliﬁcation aiming to a portion of the IS6110. Hundreds of
papers evaluated and compared such kits without ﬁnding
substantial differences among them, with all being easy to
perform, suitable to routine, highly speciﬁc and poorly sensitive.
The possibility of detecting inhibitors, present in only two such
methods, is the sole really important distinctive feature.
Although commercial ampliﬁcation kits are licensed for respir-
atory specimens only, they are commonly used with extra
pulmonary specimens too. Such use should not be considered
improper with the moderately lower sensitivity emerging with
such samples being imputable to the lower bacterial charge
characterizing them. It is universally agreed that the reliability
of ampliﬁcation methods for the direct detection of M. tubercu-
losis is not as satisfactory as for other microorganisms because of
the unsatisfactory sensitivity. Among the possible reasons of
such limitation the problematic extraction of DNA, imputable to
the extremely simpliﬁed procedures which may have problems
with the unique structure of the mycobacterial cell wall, and the
uneven texture of the mucous matrix of respiratory samples,
which are, by far, the most commonly investigated specimens.
Standing such limits is unquestionably excluded the possibility
of using ampliﬁcation technique as a substitute of microscopy
and culture which therefore remain the backbone of diagnostic
mycobacteriology. A new generation of nucleic acids ampliﬁca-
tion systems, based on real time PCR, is round the corner;
although they seem to have the potential to replace the present
methods, too little information is so far available about them. A
not less important ﬁeld of application of molecular methods in
mycobacteriology concerns the species identiﬁcation. The tax-
onomy of the genus Mycobacterium is revealing a complexity
unsuspected until a few years ago. The number of ofﬁcially
recognized species exceeds nowadays 120 and is likely it will
still substantially increase. It is undoubted that the rapid
differentiation of the non tuberculous mycobacteria from the
members of the M. tuberculosis complex is crucial; the identiﬁ-
cation of every strain at the species-level, however, is also
important to assess the clinical signiﬁcance of the ﬁnding and, in
case, to set up the proper treatment. The most popular methods
for identiﬁcation of mycobacteria include PCR-restriction ana-
lysis (PRA) and genetic probe hybridization (DNA-probe). The
PRA, ﬁrst developed by Telenti more than 10 years ago, is based
on the enzymatic digestion of a fragment of hsp65 gene by
separately using two different restriction enzymes: BstEII and
HaeIII. A proper algorithm drives the microbiologist to the ﬁnal
identiﬁcation once the size of the restriction fragments has been
carefully determined by means of electrophoresis. The method
is inexpensive and easy to perform. The increasing number of
species showing overlapping proﬁles is its major limit, while the
presence of multiple patterns within a single species, although
confusing, is counterbalanced by the opportunity of recognizing
different biotypes. While the PRA is essentially a home-made
Abstracts
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
method, the DNA-probes almost solely relies on commercial
kits. Several approaches, commercialized by three different
ﬁrms are at present available, they aim to different regions
within the ribosomal DNA operon. The target of the method
based on the liquid phase hybridization (AccuProbe, Gen-Probe,
USA) is 16S rRNA; no ampliﬁcation is required and the positive
result is revealed by the production of a chemio-luminescent
signal in a hybridization-protection assay. The method is highly
speciﬁc, rapid and handy, it is however suitable to identify a
very little number of species and may result very costly once the
testing with more than one probe is required. The alternative
methodology is the solid phase reverse hybridization relying on
multiple probes immobilized at different positions of a cellulose
strip. Once the ampliﬁed, biotinylated, genetic target hybridizes
with the speciﬁc probe a coloured band develops following the
addition of the avidin-enzyme conjugate and the chromogenic
substrate. The known position on the strip of different species-
speciﬁc probes leads to the identiﬁcation on the basis of the
location of the coloured hybridization band. It becomes there-
fore possible to identify, with a single test, multiple species.
INNO LiPA Mycobacteria (Innogenetics, Belgium) aims to the
internal transcribed spacer (ITS) and can identify 18 different
species. Two different strips became recently available with the
rival system GenoType Mycobacterium (Hein, Germany), direc-
ted to the 23S rDNA. The combination of two strips allows to
identify as many as 33 species. Speciﬁcity and sensitivity of the
reverse hybridization-based tests are excellent even if minor
cross reactions with rarely encountered species have been
reported. The sequencing-based identiﬁcation relies on the
same insight as DNA probe technology: i.e. the investigation
of highly conserved genetic regions harbouring species-speciﬁc
variability. Several such regions have been detected in myco-
bacteria: 16S rDNA, ITS, 23S rDNA, hsp65, sodA, recA, rpoB.
The 16S rDNA is by far the most frequently investigated; it is
characterized by the presence of two hyper variable regions
within the ﬁrst 500 bp trait which allow the identiﬁcation of
almost all the ofﬁcial species and, within which, the intra-species
variability is extremely limited. The corresponding database,
available in the Internet is very rich. In the ITS a much larger
variability is present and many species are characterized by
several sequevars in this region; thanks to this characteristic it
can be useful to differentiate species presenting overlapping in
the 16S rDNA. Despite the importance of the ITS database not
yet reported sequences are frequently detected. The 23S rDNA
is, in contrast, poorly variable with several species not being
identiﬁable in such region. The rpoB gene has been recently
proposed as particularly suitable for the identiﬁcation of rapid
growers; the high variability characterizing such region seems in
fact particularly suited for such organisms which include
species sometime undistinguishable at level of 16S rDNA.
Genetic sequencing is the reference method for identifying
mycobacteria, all the more as, differently from the DNA probes,
no limit exists in the number of species it can identify. It
represents furthermore a powerful research tool thank to which
the number of species and variants has enormously increased in
the last years. The handily searchable publicly available
databases, mainly GenBank and EMBL, represent the core of
genetic sequencing. The open access for everyone to depose new
sequences represent, at the same their time major value and
limit. While, from one hand, the new depositions, keep the
databases up to date, from the other hand, because off the lack of
any control, they may result misleading with the query sequence
presenting at time the best resemblance with a short and
unreliable sequence such hindering more signiﬁcant ones.
Although disregarded by some, the differentiation of the species
belonging to the M. tuberculosis complex is important, both
because of the different susceptibility to pyrazinamide charac-
terizing M. tuberculosis and M. bovis and for epidemiological
reasons. A reverse hybridization system (Genotype MTBC,
Hein) targeting different genomic regions (23S rDNA, gyrB,
RD1) allows the easy and accurate differentiation of most
frequently encountered members of the complex. For what
concerns M. tuberculosis, molecular biology made available a
number of techniques providing very useful information. This
branch, known as ﬁngerprinting, allows the differentiation of
M. tuberculosis families and even of single strains. The epidemi-
ology is the ﬁeld which more beneﬁts from such investigations
but not less important is the utility in recognizing mixed
infections or to distinguish new disease from relapse. Of great
practical importance is ﬁnally the monitoring of laboratory
contaminations. The spoligotyping, which is based on the
polymorphism of the spacers present in the DR region, is not
suitable for ﬁne differentiations but is optimal to group the
strains in large groupings like Beijing family and many others.
The restriction fragment length polymorphism of IS6110 targets
an insertion element present, in variable number of copies and
at different positions, within the M. tuberculosis genome. It is at
present considered the gold standard and is suitable to differ-
entiate practically almost every M. tuberculosis strain. A more
recently developed method investigates the polymorphism of 12
tandem repeat sequences known as mycobacterial interspersed
repetitive units. Such system which is characterized by high
discriminatory power has, being fully automatable; the potential
of providing real time results and is candidate to become the
future reference method. Microarrays, which are essentially
miniaturized multi-probe systems, can be considered the last
development of solid phase hybridization technique. It seems
very likely that they will pay a major role in the future of
mycobacteriology, several prototypes have already been devel-
oped and the commitment of commercial companies in this ﬁeld
is yet important. With microarrays it becomes possible to inquire
a large number of genetic targets suitable to provide important
information for the identiﬁcation, the antimicrobial susceptibil-
ity and the ﬁngerprint of mycobacteria. A risk which should not
underrated is the spreading of such techniques out of the
reference laboratories; most of the reliability of more and more
sophisticated technologies relies in fact in the high specialization
of the user.
S413
Infections due to mycobacteria other than
M. tuberculosis (MOTT) in non-HIV patients
R. Wallace (Tyler, US)
Nontuberculous mycobacteria (NTM), also known as Mycobac-
teria other than tuberculosis (MOTT), are an increasingly
diverse group of organisms. More than 90 species are currently
recognized with clinical disease observed in multiple species
including man. Mycobacterium avium, M. intracellulare, and
M. kansasii are the major causes of chronic pulmonary disease,
with M. fortuitum, M. abscessus, M. marinum, and M. ulcerans the
major cause of chronic skin/soft tissue disease. Emerging NTM
disease include folliculitis following the use of foot spas,
M. abscessus disease in cystic ﬁbrosis, and disease due to
previous animal pathogens including M. porcinum and
M. senegalense. Treatment of chronic pulmonary infections due
toM. avium complex,M. abscessus, andM. xenopi remain difﬁcult
and disease control but not microbiologic cure are the endpoint
of therapy for many patients. Cutaneous and soft tissue disease
in developed countries is usually readily treatable. Drug
resistance due to target site mutation or the presence of erm
genes (M. fortuitum group) complicate drug therapy of both
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slowly growing and rapidly growing species. An approved CLSI
(Clinical Lab Standards Institute, formerly NCCLS) standard for
susceptibility testing of the NTM was approved in the U.S. in
2003. Most recommended test methods involve broth macrodi-
lution or microdilution. Laboratory identiﬁcation increasingly
involves molecular methods as older methodology often fails to
recognize newer species. Current identiﬁcation involves a
number of genes for sequencing, including 16S r-RNA gene
(initial 500 bp), the 16S-23S internal transcribed spacer region,
the hsp65 gene and the rpoB gene. The use of RFLP patterns and
sequencing of these and other housekeeping genes has opened
the door to molecular-based population studies of individual
species. M. kansasii has been studied in the greatest detail using
the hsp65 gene; with type I strains now recognized as the major
human pathogen. Other studies are ongoing involvingM. avium,
M. simiae, and M. lentiﬂavum. These studies suggest that
individual clones or subspecies are associated with different
hosts and different geographic sites. Complete genomic sequen-
cing of multiple strains from many of the NTM is a major need
for better understanding of the NTM, their diversity, and their
pathogenicity. Such studies are slowly taking place. Because of
the environmental reservoir, NTM will remain an important
animal, bird, and human pathogen of increasing clinical signi-
ﬁcance.
RTI in the community revisited
O416
The management of sore throat by Finnish
general practitioners
P.O. Honkanen, U.-M. Rautakorpi, S. Huikko, T. Klaukka,
P. Huovinen, E. Palva, R. Roine, H. Sarkkinen, H. Varonen,
M. Ma¨kela¨ for MIKSTRA collaborative study group
Objectives: To assess the quality of the management of sore
throat among Finnish general practitioners. The determinants of
a good management of sore throat are focusing the
microbiological tests to those with possible group A
streptococcal (GAS) tonsillitis, prescription of antibiotics to
those with a positive test result for GAS, prescription of
analgesics to all patients with sore throat.
Methods: One-week survey in mid November in 30 Finnish
health centres (the population of 800 000) in 2002. The symptoms
were reported by the patients or their parents. The physicians
reported diagnosis, diagnostic tests and treatment.
Results: There were 823 patients with sore throat as one of the
symptoms, of those with 142 as the only complaint. 681 patients
had also coryza or cough. Among the 142 patients the diagnoses
were 64 (45%) tonsillitis, 26 (18) pharyngitis, 33 (23) URTI, and
some other respiratory infection 19 (13). The corresponding
ﬁgures among those 681 patients were 57 (8), (9), 277 (41), and
289 (42). Of those 123 (out of 142) patients with tonsillitis,
pharyngitis or URTI, a microbiological test was done to 72 (59),
antibiotics were prescribed to 61 (50), and analgesics to 15 (12).
The corresponding ﬁgures for 392 patients (out of 681 with sore
throat, coryza or cough) were 111 (29), 90 (23), and 33 (8).
Conclusions: Microbiological tests were used quite frequently.
Most of the tests were done to those with coryza or cough, and a
low prevalence of GAS. Because of a good likelihood ratio of the
tests, the result can guide the treatment decision correctly even if
the pretest probability of GAS is low. However, excessive use of
tests without careful clinical consideration increases costs of the
management. The frequency of the prescription of antibiotics
was lower than that of microbiological tests. However, this
analysis does not show how many prescriptions were given
without a test. The divergence of routine management from a
good clinical practice was widest in the use of analgesics. The
points to be emphasised in the information delivered to Finnish
general practitioners: The importance of clinical diagnosis
preceding the use of microbiological tests, and in treatment,
the use of analgesics.
O417
Prevalence of Streptococcus viridans isolates in
nasopharyngeal samples from children attending
day-care centres in the Alpes Maritimes, France
H. Carsenti Dellamonica, G. Melica, C. Pradier, B. Dunais,
G. Mancini, M. Sabah, P. Bruno, P. Toubol, P. Dellamonica for the
GEPIE Group
Objective: To monitor prevalence rates and antibiotic
susceptibility of Streptococcus viridans (SV) nasopharyngeal
carriage strains among children aged 3 to 40 months attending
day-care centres in the Alpes Maritimes, France, in the context of
antibiotic prescription-reducing campaigns (Alpes Maritimes
2001, 2003, France 2003).
Method: Nasopharyngeal aspirates were obtained from a
random 2-stage cluster sample of children attending day-care
centers in the Alpes Maritimes (AM) areas during 2 consecutive
surveys conducted between January and March 2002 and 2004.
Susceptibility of SV isolates to beta-lactams, macrolides,
tetracycline, chloramphenicol and ﬂuoroquinolones was tested
by disk diffusion and E-test for penicillin, amoxicillin and
cefotaxime.
Results: In 2002, 26 out of 294 (9.18%) children carried 27 strains,
of which 14 were S. mitis and 7 were Gemella morbillorum group, 2
to theS. oralisgroup, 1 to theS. sanguisgroupand, respectively 1, 1,
2 to theA. viridans, S. bovis, S. adjacens. In 2004, 57 out of 337 (17%)
children carried 63 strains, of which 39 were S. mitis, 6 S. oralis,
4 Gemella morbillorum, 1 G. haemolysans, 1 Lactococcus lactis, 1
leuconostoc sp., 2 S. acidominimus and 9 S. pyogenes. Penicillin
decreased susceptibility was 59.25% in 2002 and 53.97% in 2004.
Carriage of penicillin I and R strains was 25.9% and 33.3% in 2002
and33.3%and20.6% in 2004.Amoxicillindecreased susceptibility
was 22.2% in 2002 and increased to 50.8% in 2004 associated with
cefotaxime decreased susceptibility of 44.4% the same year.
Erythromycin resistance rate was 66.67% in 2002 and 58.73% in
2004, while 3.17%R and 7.93% I to telithromycin strains appeared
in 2004. The erm phenotype of resistance predominated in the
2 periods. Ciproﬂoxacin R of 7.4% in 2002 increased to 23.8% in
2004 and 3.17% of the strains showed associated R to levoﬂoxacin
sparﬂoxacin and moxiﬂoxacin in 2004.
Conclusion: A small decrease in strains of VGS resistant to
penicillin or erythromycin was observed as for S. pneumoniae in
this children population in the two periods. However the same
trend in increase of intermediate strains to amoxicillin and
cefotaxime is of concern such as the increase in ﬂuoroquinolone
resistance rate observed, not easily explicable in children
populations and which requires further evaluations. Ongoing
surveillance of the resistance proﬁle is important among VGS since
they are able to transfer resistance to other bacterial populations.
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O418
Erythromycin resistance in commensal throat
Streptococci in asylum seekers
C.J.P.A. Hoebe, E.J.W.N. Niekamp, P.J.P. Tolsema,
E. Stobberingh (Heerlen, Maastricht, NL)
Objective: Commensal streptococci form a large reservoir of
transferable erythromycin resistance (genes) for potential
pathogenic microorganisms. The aim of this study was to
assess the rate of erythromycin resistance in asylum seekers as a
potential resistance (genes) reservoir for the Dutch population.
As the bacterial resistance of asylum seekers reﬂects very likely
the resistance situation in their home country, it is to be expected
that these resistance is higher than those in the Netherlands.
Therefore, treating asylum seekers with antibiotics effective for
the Dutch population might be not appropriate for them.
Methods: The prevalence of erythromycin resistance in
commensal throat streptococci was determined in two random
groups of asylum seekers from ﬁve different asylum seeker
centers. Study groups were from Armenia (n = 64) and from
Africa (n = 64) and we included a control group of 185 Dutch
volunteers. A throat swab was used to collect the commensal
throat ﬂora. The swab was suspended in 1 ml. saline and
inoculated on bloodagar plates without and with 16 mg/L
erythromycin using a spiralplater. All asylum seekers ﬁlled out
a questionnaire concerning demographic data, length of stay,
number of household members, use of antibiotics and history of
hospital admission. Asylum seekers were mostly men (59%),
had a mean age of 31 years (SD 10), their duration of stay was
mainly between 1 to 2 years (49%; 32% less than 1 year and 19%
more than 2 years), 31% had hospital admission in home
country and 11% in the Netherlands and 7% used antibiotics
in the last year.
Results: The prevalence of erythromycin resistance among
asylum seekers was 48.4% (95%CI = 39.3–56.7) and among the
Dutch volunteers 24.9% (95%CI = 17.8–30.2). Within the group
of asylum seekers the prevalence among Armenians was 40.6%
(95%CI = 28.6–52.6) and 56.3% (95%CI = 44.2–68.4) among
Africans. Resistance decreases in relation to length of stay in
the Netherlands. For asylum seekers shorter than one year in the
Netherlands the prevalence was 54%, between 1 year and
2 years this was 41% and longer than 2 years this was 33%.
Discussion: The prevalence of erythromycin resistance among
asylum seekers was two times higher than among Dutch
volunteers. This ﬁnding needs a reﬂection in antibiotic use for
treating potential pathogenic throat bacteria in asylum seekers
in general practice. Resistance in asylum seekers shows an
adaptation to the Dutch population with longer stay.
O419
The role of antibiotics in acute uncomplicated
maxillary sinusitis in ambulatory care: a
randomised controlled trial
L. Prezas, A. Antoniadou, P. Panagopoulos, T. Tsaganos,
A. Agathagelides, G. Danielides, T. Stathas, M. Rigatou,
N. Karvelis, E. Moshavakis, T. Papaeliadis, E. Ferekidis,
S. Symeonidis, H. Giamarellou (Athens, Salonica, Patra, GR)
Introduction: Acute maxillary rhinosinusitis is a common
diagnosis in primary care medical practice and an area of
antibiotics overuse. Principles of treatment published a few
years ago advocated that antimicrobial treatment should be
reserved for patients with rhinosinusitis symptoms lasting
7 days or more (maxillary pain or tenderness in the face or
teeth -especially when unilateral- and purulent nasal secretions)
or those presenting with severe symptoms. Aim of the study
was to assess the hypothesis that acute, uncomplicated, with
moderate symptoms and less than 7 days duration maxillary
rhinosinusitis can be managed and resolve without antibiotics
through a randomised controlled trial.
Patients and Methods: From 4/2002 to 1/2005 238 adult
patients, 113 male and 125 female, (mean age = 34.4 years,
SD = 11.9) with a history and clinical signs of maxillary sinusitis
of less than 7 days duration enrolled in the study. These patients
were clinically evaluated for severity of signs and symptoms
and randomly assigned to receive treatment with cefprozil or
doxycycline (n = 136) or no treatment (n = 102). Both groups
were also offered symptomatic treatment with the same
analgesics and decongestants. Clinical course was assessed
after 8 days, at the end of antibiotic therapy, and at telephone
follow-up visits at 1 and 6 months post treatment. Total
remission was deﬁned as complete resolution of signs and
symptoms, partial remission as improvement but not complete
resolution and failure as persistence of symptoms.
Results: At the 1-week visit, total remission was reported in
118/136 (86.7%), partial remission in 13/136 (9.6%) and failure
in 5/136 (3.7%) of the patients who received antibiotics.
Respectively, in the no treatment patient group 85/102 (83.3%)
patients showed total remission, 11/102 (13.3%) showed partial
remission and in 6/102 (5.9%) patients failure was recorded. No
statistically signiﬁcant differences were found in the output
proportions between the two groups. Follow-up at 1 and
6 months revealed no differences between the two groups in
relapses and late complications.
Conclusion: Antibiotic treatment does not offer a better
outcome in the treatment of acute adult maxillary sinusitis of
moderate severity and of less than 7 days duration.
Symptomatic treatment with decongestants and analgesics is
sufﬁcient for the resolution of the disease.
O420
Prevalence of respiratory diseases in sheltered
homeless in Marseille, France
S. Badiaga, H. Richet, P. Azass, F. Rey, H. Tissot Dupont,
C. Foucault, C. Rovery, M. Drancourt, D. Raoult,
P. Brouqui (Marseille, FR)
Objectives: To describe the characteristics and the prevalence
of respiratory diseases in the homeless population in Marseilles.
Methods: Snapshot study 2 nights in January 2005, by a medical
team of 40 persons including infectious diseases senior,
residents and fellows, pneumologists, nurses, X-ray
technicians in the 2 shelters in Marseilles. Homeless were
interviewed, examined, and received care. Blood was sampled
for cell count, detection of bacteraemia and antibodies to
Chlamydia, Mycoplasma, Legionella pneumophila, and Coxiella
burnetii. A chest-X radiograph was performed.
Results: A total of 221 homeless persons were enrolled. The
mean age was 41 years ± 13 and 94% of the population were
men; 38% were born in North Africa, 37% in France, and 14% in
Central/Eastern Europe; the subjects have been homeless less
than 7 months in 43%, from 7 to 12 months in 12%, from 13 to
24 months in 8.1%, and more than 24 months in 36%. Among
study population, 77% were current smokers, 65% were alcohol
abusers, 2 persons were infected by HIV, 30% reported prior
contact with tuberculosis patients (in shelter 23% and in family
and relatives in 77%). The most frequent reported symptoms
were weight loss (43%), chronic cough (39%), sputum
production (33%), sweats (16%), and dyspnoea (16%). Clinical
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diagnosis was established as bronchitis in 19%, chronic
obstructive bronchitis in 17%, asthma in 2%, and acute
pneumonia in 1%. All blood cultures; as well as serological
tests were negative. Chest radiographs performed in 219
persons and subsequently analysed showed abnormalities in
14 persons (6%). Of these 14 homeless persons, 4 have not been
reached for follow up and 10 have hospitalized for further
investigations. The ﬁnal diagnosis made were active
tuberculosis in 2 persons (1%) who have been homeless for 10
and 11 years, sequels of tuberculosis in 4 (2%), lung cancer in 1
(0.5%), obstructive lung disease in 1 (0.5%), acute pneumonia in
1 (0.5%), and no speciﬁc diagnosis in 1 (0.5%). A speciﬁc care
was given for each of these homeless persons.
Conclusion: This snapshot investigation revealed that 6 % of
this homeless population had life threatening respiratory
diseases in which 1% had active contagious tuberculosis.
Systematic chest radiography could be an efﬁcient strategy to
rapidly identify and prevent the spread of this transmissible
disease among homeless population of shelters.
Treatment, antifungal resistance and epidemiology of fungal
infections
O421
Posaconazole as prophylaxis for invasive fungal
infections in high-risk patients: efﬁcacy and
safety results from 2 clinical trials
J. Maertens, A.J. Ullmann, S. Durrant, J. Holowiecki, J.H. Lipton,
D. Stockelberg, D.J. Winston, J. Perfect, N. Boparai, C. Hardalo,
D. Angulo-Gonzalez, O.A. Cornely (Leuven, BE; Mainz, DE;
Brisbane, AU; Katowice, PL; Toronto, CA; Gothenburg, SE; Los
Angeles, Durham, Kenilworth, US; Cologne, DE)
Objectives: Efﬁcacy and safety of posaconazole (POS), an
extended-spectrum triazole, as prophylaxis for invasive fungal
infections (IFIs) were evaluated in 2 large, randomised, active-
controlled, parallel-group trials. The trials were conducted in 2
populations at high risk for IFI: allogeneic haematopoietic stem
cell transplant (HSCT) recipients with graft-versus-host disease
(GVHD) and neutropenic patients undergoing intensive
chemotherapy for acute myelogenous leukemia (AML) or
myelodysplastic syndrome (MDS).
Methods: In study 1, HSCT recipients with GVHD received
either oral POS 200 mg three times daily or oral ﬂuconazole
(FLU) 400 mg once daily for up to 16 weeks. In study 2, patients
with newly diagnosed or ﬁrst relapse of AML or MDS received
oral POS 200 mg three times daily or oral standard azole [FLU
400 mg once daily or itraconazole (ITZ) solution 200 mg twice
daily] with each cycle of chemotherapy until complete remission
or for up to 12 weeks. The incidence of proven or probable IFI
was the main endpoint in each study. IFI incidence was
evaluated 7 days after the last dose of study drug and at
predetermined times (ie, 112 and 100 days after randomization
for studies 1 and 2, respectively). IFI diagnoses were adjudicated
by blinded expert panels using EORTC/MSG criteria.
Results: In study 1,600 patients were enrolled: 301 POS and 299
FLU. In study 2,602 patients were enrolled: 304 POS and 298
standard azole (240 FLU, 58 ITZ). In both studies, fewer IFIs
occurred with POS; for almost all endpoints, the difference was
signiﬁcant (Table). Safety and tolerability between treatment
arms were comparable within each study. In study 1, the 3 most
common treatment-related adverse events (AEs) were nausea
(7% vs. 9%), vomiting (4% vs. 5%), and diarrhoea (3% vs. 4%) in
the POS and FLU groups, respectively. In study 2, the 3 most
common treatment-related AEs were also nausea (7% vs. 8%),
diarrhoea (7% vs. 7%), and vomiting (5% vs. 7%) in the POS and
FLU/ITZ groups, respectively. Incidence of treatment-related
AEs resulting in discontinuation was similar between POS and
comparator therapy in both studies (3% for each arm in study 1;
7% vs. 6%, respectively, in study 2).
Conclusion: These ﬁndings show POS is superior to standard
azole therapy (FLU or ITZ) in preventing aspergillosis and other
IFIs in HSCT recipients with GVHD and in AML and MDS
patients with chemotherapeutic-induced neutropenia. Safety
and tolerability of POS were comparable to standard azole
therapy.
O422
Mortality in patients at high risk for invasive
fungal infection: effect of Posaconazole
prophylaxis
O.A. Cornely, J. Maertens, S. Durrant, J. Holowiecki, J.H. Lipton,
D. Stockelberg, D.J. Winston, J. Perfect, R. Suresh, L. Pedicone,
H. Patino, A.J. Ullmann (Cologne, DE; Leuven, BE; Brisbane, AU;
Katowice, PL; Toronto, CA; Gothenburg, SE; Los Angeles, Durham,
Kenilworth, US; Mainz, DE)
Objectives: Patients with acute myelogenous leukaemia (AML)
or myelodysplastic syndrome (MDS) undergoing chemotherapy
and haematopoietic stem cell transplant (HSCT) recipients with
graft-versus-host disease (GVHD) are at high risk for fungal
infections and their associated mortality. Antifungal
prophylaxis with a standard azole [ﬂuconazole (FLU),
itraconazole (ITZ)] is frequently used in these patients, but a
survival beneﬁt has not been consistently demonstrated. We
report all-cause and fungal-related mortality from 2
randomized, active-controlled, parallel-group clinical trials that
evaluated posaconazole (POS), an extended-spectrum triazole,
as prophylaxis for IFI.
Methods: In study 1, HSCT recipients with GVHD (N = 600)
received either POS 200 mg three times daily or FLU 400 mg
once daily for 16 weeks and were followed for 8 additional
weeks. In study 2, neutropenic patients (N = 602) with new
diagnosis or ﬁrst relapse of AML or MDS undergoing intensive
chemotherapy received either POS 200 mg three times daily or
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oral standard azole therapy (FLU 400 mg once daily or ITZ
solution 200 mg twice daily) until complete remission or for up
to 12 weeks; patients were followed for at least 100 days after
randomisation. Overall and investigator-determined IFI-related
mortality, which were secondary endpoints in the studies, were
evaluated using Kaplan-Meier (KM) analysis of time to death.
Survival comparisons were based on log-rank test.
Results: In study 1, although fewer patients died in the POS
group, there was no statistically signiﬁcant difference in the
overall survival between treatment groups using log-rank test
(Table). In study 2, signiﬁcantly fewer overall deaths occurred in
the POS group, and the probability of survival at day 100 after
randomisation was signiﬁcantly higher with POS. Signiﬁcantly
fewer IFI-related deaths were observed with POS in both
studies.
Conclusion: Prophylaxis with POS provided a signiﬁcant
overall survival beneﬁt among AML or MDS patients
undergoing chemotherapy, when compared with other azoles.
In addition, POS prophylaxis signiﬁcantly reduced IFI-related
mortality in HSCT recipients with GVHD as well as AML and
MDS patients with neutropenia. These results suggest that
future prophylaxis trials should be designed with adequate
power to detect differences in overall and IFI-related mortality.
O423
Epidemiology of fungal infections in
haematological malignancies in Italy: SEIFEM-
2004 study (Sorveglianza Epidemiologica
Infezioni Fungine nelle Emopatie Maligne)
L. Pagano, M. Caira, A. Candoni, L. Corvatta, M. Ofﬁdani,
B. Martino, D. Pastore, M. Picardi, A. Bonini, A. Chierichini,
R. Fanci, C. Caramatti, C. Benatti, A. Gallamini, M.R. Fadda,
L. Melillo, B. Allione, L Fianchi, P. Falcucci, C.G. Valentini,
M.T. Van Lint, A. Nosari, C. Girmenia on behalf of
SEIFEM Studio Epidemiologico Infezioni Fungine nelle Emopatie
Maligne
Objectives: To evaluate the incidence and the outcome of
fungal infections (FI) in patients (pts) affected by hematological
malignancies (HM).
Methods: A retrospective study, conducted over 1999–2003, in
pts with HM, admitted in 18 Italian haematology divisions in
tertiary cares or university hospitals, which developed proven
or probable FI.
Results: The population included 11,802 pts: 3,012 with AML
(25.5%), 1,173 with ALL (9.9%), 596 with CML (5%), 1,104 with
CLL (9.4%), 1,616 with MM (13.7%), 3,457 with NHL (29.3%),
844 with HL (7.2%). Pts who underwent autologous or allogenic
HSCT were included in a speciﬁc different analysis. A proven or
probable FI occurred in 538 pts, with an incidence of 4.6%; in
particular we registered 346 episodes sustained by moulds
(incidence 2.9%) and 192 by yeasts (1.6%). The incidence rate
depends upon underlying HM (12.3% in AML, 6.5% in LLA,
2.5% in CML, 0.5% in CLL, 0.5% in MM, 1.6% in NHL, 0.7% in
HL). Among moulds, the detected etiological agents were
Aspergillus spp. (310 episodes, incidence 2.6%), Mucorales spp.
(14 episodes, 0.1%), Fusarium spp. (15 episodes, 0.1%), and other
rare fungi (7 episodes, 0.1%). Among yeasts we registered
septicemia sustained by Candida spp. (175 pts, incidence 1.5%).
Other yeast infections were caused by Cryptococcus spp. (8 pts,
incidence 0.1%), Tricosporon spp. (7 pts, 0.1%) and other rare
agents (2 pts). The overall mortality rate was 1.8%. Among 538
pts with FI, case fatality rate (CFR) was 39%, with differences
between aspergillosis (42%), zygomycosis (64%), fusariosis
(53%) and candidemia (33%). There was not variation in
mortality rate during the study period; comparing these pts
with those observed in our previous epidemiological studies
during the period 1987–1988 we observed a signiﬁcant reduction
of deaths due to aspergillosis (RR 1.90; 95%CI 1.17–3.09), but no
differences in mortality rate due to Candida spp.
Conclusion: Our study conﬁrms the general trends already
described: infections due to moulds continue to be more
frequent than those caused by yeast. Among all fungi,
Aspergillus spp. remains the main etiologic agent, followed by
Candida spp. Other agents (Mucorales spp., Fusarium spp.,
Trichosporon spp.) remain rare. AML represents the most
frequently involved category. The mortality rate due to
aspergillosis is actually about 40%, with a remarkable decrease
when compared to past years; as for candidemia, we observed a
reduction in the incidence, but not in the mortality rate.
O424
Micafungin versus liposomal amphotericin B in
the treatment of invasive candidiasis in
neutropenic and non-neutropenic patients
O. Lortholary, E. Kuse, P. Chetchotisakd, C. Arns da Cunha,
M. Ruhnke, C. Barrios, D. Raghunadharao, J.S. Sekhon, S.
Koblinger (Paris, FR; Hannover, DE; Khon Kaen, TH; Curitiba, BR;
Berlin, DE; Porto Alegre, BR; Hyderabad, Ludhiana, IN; Munich, DE)
Objectives: To compare micafungin (MICA), an echinocandin
agent with broad-spectrum fungicidal activity against Candida
species, and liposomal amphotericin B (AmBisome, L-AMB),
an established treatment of invasive candidiasis (IC), for ﬁrst
line therapy of IC.
Methods: This was a Phase III, 1:1 randomized, double blind,
non-inferiority study. Adult patients were randomized to MICA
(100 mg/day) or L-AMB (3 mg/kg/day). Inclusion in the per
protocol population (PPS) required conﬁrmed diagnosis of IC,
evaluation at end of therapy and received at least 5 doses of
study drug. Patients were stratiﬁed by neutropenic status
(< 500 cells/mm3). The primary endpoint was overall
treatment success (deﬁned as clinical and mycological
response) in the PPS at end of therapy assessed by the
investigators.
Results: 531 patients received at least one dose of study drug.
The PPS comprised 202 (MICA) and 190 (L-AMB) patients. The
treatment groups were balanced with regard to baseline
characteristics, including neutropenic status (MICA 11.9% vs.
L-AMB 7.9%) and Apache II scores (mean MICA 14.7 vs. L-AMB
14.9). Overall, 84.2% (MICA) and 85.8% (L-AMB) of patients had
conﬁrmed candidaemia; sites of IC were primarily peritoneal
(MICA 7.9% vs. L-AMB 5.8%). Non-albicans Candida infections
comprised 62.4% (MICA) and 58.9% (L-AMB) of patients.
Overall treatment success was experienced by 89.6% (181/202)
and 89.5% (170/190) of patients in the MICA and L-AMB
groups, respectively. Criteria for non-inferiority were met; the
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difference (MICA-L-AMB) adjusted for neutropenia and
corresponding 95% CI was 0.7% ()5.3%, 6.7%). Treatment
success rates were similar for C. albicans infections (MICA
88.4% vs L-AMB 89.3%) and non-albicans C. infections (MICA
89.7% vs. L-AMB 89.3%). In the modiﬁed intent to treat
population (conﬁrmed IC and at least one dose of study drug)
overall treatment success was 74.1% (183/247) in the MICA
group and 69.6% (172/247) in the L-AMB group. During the
12-week post-treatment period, there was no difference in
recurrent invasive fungal infection between both groups. Pre-
deﬁned safety parameters showed MICA to have an advantage
over L-AMB in renal function as assessed by estimated
glomerular ﬁltration rate and a lower incidence of infusion-
related reactions (p < 0.001).
Conclusion: This study demonstrates the non-inferiority of
micafungin versus AmBisome in ﬁrst line treatment of IC
and an advantage for micafungin in predeﬁned safety
parameters.
O425
Clinical effects of micafungin, an echinocandin
antifungal agent, on systemic fungal infection in
the areas of surgery, emergency, and intensive
care medicine
N. Aikawa, S. Kusachi, S. Oda, Y. Takesue, H. Tanaka (Tokyo,
Chiba, Hiroshima, JP)
Objectives: Micafungin (MCFG) has been approved in Japan
for treatment of fungemia and invasive infections caused by
Candida and Aspergillus. To our knowledge, there are no
reports that evaluated the effects of MCFG treatment in the areas
of surgery, emergency, and intensive care medicine. We
therefore studied its efﬁcacy and safety in patients with fungal
infection in a multicentre study.
Methods: The study was conducted from July 2003 to March
2005 in patients with a fever of 37.5C or higher, who met any of
the following criteria as the rationale for the diagnosis: #1
Patients with a causative fungus identiﬁed by mycological or
pathological examination; #2 Patients with fungi detected at
multiple sites by surveillance culture or with a positive beta-D-
glucan test. Patients who met requirement #2 had to have a high
risk factor for the development of systemic fungal infection.
Patients who met these requirements were enrolled to the study,
after registration with a third party before the start of MCFG
treatment. Efﬁcacy was evaluated by assessing the improvement
in each of the following items: 1) clinical symptoms/ﬁndings
possibly attributable to mycosis; 2) mycological ﬁndings; 3)
imaging ﬁndings such as chest X-ray; 4) fungal serological tests.
Efﬁcacy was rated in 2 grades, namely "effective" and
"ineffective", based on an algorithm combining these indices
(called AKOTT algorithm assessment).
Results: Out of 180 registered patients, 116 patients (71 males,
the mean age: 61.4 ± 18.2) were evaluated for efﬁcacy by the
steering committee. The mean dosage and duration of dosing
were 106.0 ± 62.2 mgÆperÆday and 14.8 ± 8.6 days, respectively.
Common underlying diseases included perforation of the
digestive tract, burns, stroke, and trauma. Clinically, 74 of 102
patients (72.5%) were rated as effective. By major diagnosis, the
effective rates in patients with candidemia and pulmonary
candidiasis were 77.8% and 84.6%, respectively. MCFG was
effective not only against C. albicans but also against non-
albicans Candida species. Adverse drug reactions occurred in 38
of 180 patients (21.1%), and the most commonly observed
reaction was hepatic function disorder. There were no serious
adverse drug reactions with a clear causal relationship to MCFG.
Conclusion: MCFG demonstrated excellent clinical effects on
systemic fungal infection in the areas of surgery, emergency,
and intensive care medicine, indicating its usefulness as a new
therapeutic drug.
O426
Universal role of glucan synthase subunit Fks1p
in echinocandin resistance
D. Perlin, S. Park (Newark, US)
Objective: An association between reduced susceptibility to the
echinocandin drug caspofungin (MIC > 8 ug/ml) and amino
acid substitutions in the Fks1p subunit of the beta (1,3)-D-glucan
synthase (GS) was recently reported (Park et al. 2005
Antimicrob. Agents Chemother. 49: 3264–3273). Speciﬁc
mutations in FKS1 genes were identiﬁed from both laboratory
and clinical isolates of C. albicans, and two ‘‘hot spot’’ regions
affecting susceptibility were deﬁned as Phe641-Pro649 and the
residues around Arg1361. To better understand the universality
of FKS1 mutations for reduced echinocandin susceptibility,
we examined cross-reactivity of mutants to micafungin and
characterized the ‘‘hot-spot’’ regions in isolates of non-
C. albicans species showing reduced drug susceptibility.
Methods: Antifungal susceptibility testing on yeasts was
performed using the broth micro dilution method of the
NCCLS document M27-A2. Puriﬁcation of glucan synthase
and IC50 values were determined as described by Park et al.
2005. A 2.4 Kb region of FKS1 from C. glabrata, C. guilliermondii,
C. krusei, C. lipolytica, C. parapsilosis, C. rugosa, C. tropicalis and
C. dubliniensis was PCR ampliﬁed using consensuses FKS1
primers. All PCR products were subjected to automated DNA
sequencing in both 5’ and 3’ directions.
Results: The fks1 mutants showed comparable reduced
susceptibility to both caspofungin and micafungin in growth
assays, and speciﬁc mutations were associated with a > 1000-
fold reduction in the inhibition of GS activity by both
echinocandin drugs. Characteristic mutations associated with
reduced susceptibility in C. albicans were also found in
C. tropicalis, C. dubliensis and C. krusei, which correlated with
reduced IC50 values in assays of glucan synthase activity.
Conclusion: The data supports the notion that reduced
susceptibility to echinocandin drugs in clinical isolates can
arise from amino acid substitutions in deﬁned regions of the
highly conserved Fks1p subunit of glucan synthase.
O427
Human serum alters antifungal efﬁcacy of
echinocandin drugs
D. Perlin, S. Park (Newark, US)
Objective: The echinocandin drug Mycamine (micafungin)
shows superior in vitro antifungal drug efﬁcacy relative to
Cancidas (caspofungin). Yet, echinocandin-class drugs show a
high level of bound serum protein, and it has been suggested
that differential binding to different drugs could alter their
relative antifungal efﬁcacy. To explore this possibility, the
differential effects of serum on micafungin in direct comparison
with caspofungin were examined in assays of in vitro antifungal
susceptibility with an epidemiologically distinct collection of
clinical isolates of Candida spp. and Aspergillus spp.
Methods: Determine the MIC or MEC values of caspofungin
and micafungin for a wide range of clinical isolates of Candida
spp. and Aspergillus spp. in the presence of 50% human serum.
Assess effect of human serum on inhibition of glucan synthase
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activity. Highly enriched preparations of glucan synthase
obtained by the product-entrapment technique were used to
determine IC50 values for inhibition enzyme from Candida
albicans and Aspergillus fumigatus in the presence and absence of
human serum.
Results: Human serum decreases the antifungal properties of
both caspofungin and micafungin. However, human serum
shifts the in vitro antifungal potency of micafungin to a much
greater extent than caspofungin for diverse Candida spp. and
Aspergillus spp. This shift reﬂects the more potent in vitro
antifungal properties of micafungin in the absence of serum. Yet,
the presence of serum yields nearly equivalent MIC or MEC
values effectively negating the apparent in vitro superiority of
micafungin relative caspofungin. The reduced potency of both
drugs in the presence of serum is also manifested as an increase
(less potent) in IC50 levels for inhibition of glucan synthase (GS)
activity. GS is slightly more sensitive to caspofungin than
micafungin in the absence of serum suggesting the in vitro
superiority of micafungin is unrelated to its action at the target.
Conclusion: Overall, our data suggests that the presence of 50%
serum signiﬁcantly reduces the efﬁcacy of micafungin relative to
caspofungin in clinically important Candida and Aspergillus spp.
The impact of serum was to effectively neutralize the in vitro
antifungal superiority of micafungin relative to caspofungin.
The in vivo signiﬁcance of this ﬁnding is presently being
assessed.
O428
In vitro resistance to amphotericin B and
caspofungin in clinical isolates of C. glabrata
were conﬁrmed in a mouse model
M. Krogh-Madsen, M.C. Arendrup, L. Heslet, J.D. Knudsen
(Hvidovre, Copenhagen, DK)
Objectives: Candida glabrata isolates from an ICU patient were
found to be resistant to amphotericin B and/or caspofungin in-
vitro. Three clinical C. glabrata isolates were studied in a mouse
model.
Methods: The MICs were determined for four C. glabrata strains
by two microdilution methods, CLSI and EUCAST using RPMI
and AM3, and by E-tests. Time-kill curves were done for both
drugs and both media. Outbreed NMRI mice were challenged
i.v., and treated i.p. in groups of six, once daily for 3 days with
amphotericin B (6 mg/kg/day), caspofungin (5 mg/kg/day), or
saline. The mice were sacriﬁced on day ﬁve, kidneys were
removed, homogenized in saline, and the cfu’s were
determined. The differences between cfu’s (control versus
treated mice) were used as effect parameter, and a p-value of
< 0.05 was considered signiﬁcant.
Results: For amphotericin B, the E-tests for the four strains
resulted in higher MIC-values (1.5, 6–8, 8–12, > 32 lg/mL),
when compared to the broth microdilution methods (0.5, 1, 1–2,
2–4 lg/mL), respectively. Both microdilution methods and the
different media separated the amphotericin B susceptible and
the amphotericin B resistant isolates poorly, but caspofungin
susceptible from resistant isolates were separated quit clearly. In
the mouse model, the strains with amphotericin B E-tests of
> 32, 6–8, and 1.5 lg/mL, were found to be resistant,
intermediate susceptible and susceptible, respectively. In the
mouse model, the susceptibility/resistances to caspofungin
were conﬁrmed.
Conclusion: Amphotericin B resistance in isolates of C. glabrata
of possible clinical signiﬁcance can be determined using E-test,
but easily be overlooked in the microdilution methods.
Resistance to amphotericin B determined by the E-test was
conﬁrmed in the mouse model. The susceptibilities determined
in-vitro to Caspofungin in isolates of C. glabratawas conﬁrmed in
a mouse model.
O429
Effects of amphotericin B formulations on
antifungal activity of human monocytes and
neutrophils against medically important
ﬁlamentous fungi
J. Dotis, M. Simitsopoulou, M. Dalakiouridou, T. Konstantinou,
T. Walsh, E. Roilides (Thessaloniki, GR; Bethesda, US)
Objectives: Amphotericin B formulations (AMBF), both
deoxycholate (DAMB) and lipid associated [liposomal
(LAMB), lipid complex (ABLC) and colloidal dispersion
(ABCD)] have various immunomodulatory activities. We
compared their effects on the oxidative antifungal activity of
human Monocytes (MNC) and Neutrophils (PMN) against
hyphae of Aspergillus fumigatus and Fusarium solani.
Methods: After isolation from healthy blood donors, MNC and
PMN were incubated with 1 or 5 mg/L DAMB and 5 or 25
mg/L LAMB, ABLC and ABCD at 37C and 5% CO2 for 24 or
2 hr, respectively. Super oxide anion (O2
–) production was
assessed by reduction of cytochrome c in response to hyphae.
Hyphal damage was assessed by XTT assay at effector cell:
hyphae ratios 5:1, 10:1 or 20:1. ANOVAwith Dunn test was used
for analysis (n = 5 with MNC and n = 6–8 with PMN).
Results: O2-produced by MNC or PMN upon hyphal challenge
was not generally affected by the drugs except for 1 mg/L
DAMB and 25 mg/L ABCD, which reduced O2-production by
PMN in response to A. fumigatus (p < 0.05). By comparison,
AMBF resulted in a signiﬁcant increase of damage induced by
MNC and PMN on A. fumigatus and F. solani hyphae (p < 0.05)
at all ratios as compared to untreated MNC and PMN, especially
at the high drug concentrations. ABLC induced the highest
increases on hyphal damage achieved by both types of
phagocytes as compared to the other AMBF. While the effects
of AMBF on hyphal damage induced by MNC and PMN were
concentration-dependent, the effects of the drugs on PMN
hyphal damage were much higher than those on MNC.
Conclusion: The lack of enhanced O2-production and the
general increase of hyphal damage induced by MNC and
PMN against the two ﬁlamentous fungi indicates that other non-
oxidative destructive mechanisms are responsible for the
increased hyphal damage. The immunomodulatory differences
of AMBF may be of clinical signiﬁcance in the management of
invasive aspergillosis and fusariosis.
O430
Determination of the effect of aminocandin on
Aspergillus fumigatus and Candida albicans
morphology and ultrastructure using confocal
scanning laser microscopy and scanning electron
microscopy
M.A. Ghannoum, S. Dutta, J. Chandra (Cleveland, US)
Objective: Aminocandin (AC) is a new member of the
echinocandin class of antifungals that is undergoing
development. The aim of this study was to assess the effect of
AC on the morphology of Aspergillus fumigatus and Candida
albicans using confocal scanning laser microscopy (CSLM) and
scanning electron microscopy (SEM).
Methods: For CSLM, A. fumigatus and C. albicans were grown in
the presence of different concentrations of AC and stained with
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two speciﬁc ﬂuorescent stains, FUN-1 TM (10 lM) and
concanavalin A-Alexa ﬂuor 488 conjugate (CONA; 25 lg/ml).
FUN-1 is converted to orange-red cylindrical intravacuolar
structures by metabolically active cells, while CONA binds with
green ﬂuorescence to glucose and mannose residues of fungal
cell and hyphal wall polysaccharides, differentiating intact and
damaged structures. To determine the structure of each cell, a
series of horizontal (xy) optical sections were taken throughout
the full length of the cell and hyphal forms, and images of red
(FUN-1) and green (CONA) were conceived simultaneously
using a multitrack mode. Isolates was prepared for SEM by a
series of ﬁxative and dehydration steps, sputter coated with Au/
Pd (60/40), and viewed with an Amray 1000B scanning electron
microscope.
Results: Unlike untreated controls, A. fumigatus hyphal forms
treated with AC (0.125 lg/ml) were lysed, with bulging ends
and stunted growth. Treatment of C. albicanswith AC (0.008 and
0.015 lg/ml) resulted in swelling of yeast cells and thinning of
the cell wall. Increasing concentration (0.03 to 0.06 lg/ml)
resulted in complete cell inhibition, with only remnants of cell
walls seen. SEM conﬁrmed the results obtained by CSLM for
both isolates.
Conclusion: Our data show that AC treatment alters the
morphology of A. fumigatus and C. albicans consistent with the
mode of action of echinocandins that inhibits the 1,3 beta-D-
glucan synthase, leading to cell wall inhibition, collapse and
eventual death.
Antibiotic prescribing quality indicators
O431
Developing valid antibiotic prescribing quality
indicators for ambulatory care based on European
Surveillance of Antimicrobial Consumption
(ESAC)
S. Coenen, M. Ferech, H. Goossens and the ESAC Project
Group xxxx
Objectives: Indicators to measure the quality of health care are
increasingly being developed and used both by health care
professionals and policy makers. In the context of increasing
antimicrobial resistance we aimed to develop valid antibiotic
prescribing quality indicators for ambulatory care, producible on
the basis of present ESAC (http://www.ua.ac.be/ESAC) data.
Methods: Twenty-seven experts from 15 countries participated
in a European Science Foundation workshop with plenary
sessions and smaller work groups and building on the
interdisciplinary expertise within ESPRIT (ESCMID Study
Group on Primary Care Topics), EuroDURG (European Drug
Utilisation Research Group), WHO (World Health Organisation),
ESAC and other experts in this ﬁeld. The development of
antibiotic prescribing quality indicators was discussed from the
perspective of both professionals and policy makers. A set of 23
proposed indicators was produced during the workshop using a
general format. The numbered list is shown in the table. All
participants were asked to score the relevance of each of the
proposed indicators to 1. reducing antimicrobial resistance, 2.
patient health beneﬁt, 3. cost-effectiveness, and 4. public health
policy makers; using a scale ranging from 1 (= completely
disagree), over 5 (= uncertain) to 9 (= completely agree). The
scores were processed according to the UCLA-RAND
appropriateness method and taking into account the
participants’ comments. Proposed indicators were judged valid
if the median score was 7 or higher and if the number of scores
within the 1–3 interval was less than one third of the panel.
Results: Twenty-two participants scored. Nine indicators were
rated as valid antibiotic prescribing indicators on all four
dimensions (1, 13–19 and 21), and three additional indicators
were rated valid if only relevance to reducing antimicrobial
resistance and to public health policy makers was taken into
account (3, 6 and 7). The indicator values allow individual
countries to position themselves and to deﬁne their own
benchmark, in relation to the epidemiology of infectious
diseases and national guidelines.
Conclusion: From a set of proposed ESAC based antibiotic
prescribing quality indicators at least nine indicators seem to be
valid. In line with the main objectives of antimicrobial
surveillance at the European level, this subset can be used to
describe antibiotic use in ambulatory care in order to assess the
quality of antibiotic prescribing.
O432
Surveillance of antimicrobial use and
antimicrobial resistance in German intensive care
units (SARI) – data summary from 2001 to 2004
E. Meyer, F. Schwab, P. Gastmeier, H. Ruden, K. de With,
F. Daschner, D. Jonas (Freiburg, Berlin, Hannover, DE)
Objective: To report the experience gained over four years in
working with the German SARI project (Surveillance of
Antimicrobial Use and Antimicrobial Resistance in Intensive
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Care Units) and to compare SARI with data from the Swedish
STRAMA and the US-American AUR surveillance system.
Methods: Prospective unit and laboratory based surveillance
in 40 German ICUs from 2001–2004. WHO ATC 2004
deﬁnitions of deﬁned daily doses (DDD) per 1000 patient
days were used to express antimicrobial consumption (AD);
The proportion of resistant isolates is calculated by dividing
the number of resistant isolates by the total number of isolates
belonging to this species multiplied by one hundred (RR). The
incidence density of resistant isolates is deﬁned by the number
of resistant isolates per 1000 patient days (RD). Temporal
changes in individual ICUs were calculated by Wilcoxon
signed rank test.
Results: From 1/2001 through 12/2004, 40 ICUs provided data
on 53,399 isolates, a total of 789,569 DDD and 597,592 patient
days. Total antimicrobial AD ranges from 426.7–2798.2 with a
median of 1350. There was no statistically signiﬁcant change in
total antimicrobial use, but statistically signiﬁcant decrease in
the use of aminoglycosides (2001–2004, test for paired samples).
RD were highest for MRSA with 4.4 and imipenem resistant
P. aeruginosa with 1.7 resistant isolates/1000 pd. Corresponding
RR were 21.5% and 23.2%. Signiﬁcant increases over 4 years
(2001–2004) were found for the RR of 3rd generation
cephalosporin and ciproﬂoxacin resistant E. coli, looking both
at aggregated data and at individual ICU data (paired samples).
Mean RR reached 3.6% and 15.5% respectively in 2004.
Correlation of RR and RD with antimicrobial consumption
was highest for imipenem use and imipenem resistant
P. aeruginosa (cc 0.6, p < 0.001). RR for selected pathogens was
highest in the US ICUs and lowest in Swedish ICUs with the
exception of imipenem resistant P. aeruginosa.
Conclusion: Antibiotic consumption remained stable in
German SARI ICUs with a mean 1.3 DDD/patient/ICU-day
over a period of four years. The same applies to the resistance
situation of S. aureus, enterococci, P. aeruginosa and K.
pneumoniae. For most pathogens RR of the SARI ICUs was
higher than in Swedish, but lower than in US American ICUs.
O433
Marked change in the distribution of antibiotics
used in Danish hospitals: is Denmark becoming
less conservative?
A. Muller, C.T. Brandt, L. Bagger-Skjøt, N. Frimodt-Møller,
D.L. Monnet (Copenhagen, DK)
Objective: The consumption of antibiotics in Danish hospitals is
low compared to European hospitals, in general, and even lower
than hospital consumption in Sweden and The Netherlands
(SWEDRES 2004, NETHMAP 2005). The present study aimed at
identifying changes in class distribution of antibiotics used in
Danish hospitals between 1997 and 2005.
Materials/Methods: Since 1997, Danish hospital pharmacies
have reported each month to the Danish Medicines Agency on
the hospitals’ consumption of antibiotics. These data are
converted to Deﬁned Daily Doses (DDD) and the antibiotics
classiﬁed according to the Anatomical Therapeutic Chemical
(ATC) classiﬁcation system. For 2005, consumption was based
on data reported to the Agency until August 2005. Consumption
was compared between 1997 and 2005 as a number of DDD and
not as a rate per occupied bed-days or per discharges because
rates reﬂects not only changes in the number of DDD used, but
also changes in hospital activity, i.e. a decreasing number of
bed-days and an increasing number of discharged patients.
Results: The distribution of antibacterials for systemic use (ATC
group J01) in various therapeutic groups, as well as changes
between 1997 and 2005 are presented in the Table. Table.
Antibiotic consumption in Danish hospitals, 1997 and 2005.
Discussion and conclusion: With 55% of the total DDD used in
2005, penicillins (mainly phenoxymethylpenicillin) remain the
most commonly used antibiotics. However, antibiotics
traditionally used in Danish hospitals, i.e. broad spectrum
penicillins (mainly amoxicillin), aminoglycosides and
macrolides, are progressively being abandoned and replaced
by newer, broad spectrum antibiotics, i.e. cephalosporins,
carbapenems, ﬂuoroquinolones and, to a lesser extent,
amoxicillin-clavulanic acid. Resistance to these antibiotics
remains below 5% and recent changes in patterns of antibiotic
consumption may provide better empirical coverage. However,
preliminary data show that resistance is increasing, e.g. to
cefuroxime and ﬂuoroquinolones in E. coli from clinical samples
from hospitalized patients. Surveillance of both antibiotic
consumption and resistance is therefore paramount to the
appropriate treatment of infected patients in Danish hospitals
in the next few years to come.
O434
Dose regimen as an explanatory factor for the
variation of outpatient antibiotic use between
European countries
M. Ferech, S. Coenen, P. Stephens, H. Goossens and the ESAC
Project Group
Objectives: Inter-country comparison revealed striking
differences in outpatient antibiotic use expressed in DDD per
1000 inhabitants per day (DID) in Europe. We aimed to assess to
what extent this is due to variation in either the number of
prescriptions or the number of DDD per prescription, which is a
function of treatment duration and the prescribed daily dose.
Methods: Data on outpatient antibiotic use in 25 European
countries expressed in DID were collected by European
Surveillance of Antimicrobial Consumption (ESAC Project),
while outpatient prescription data, based on a sample of
ambulatory physicians, were obtained for a pilot set of
countries from IMS Health. For each presentation we
multiplied the strength per item, the average number of items
per day and the average number of treatment days to calculate
the number of DDD per prescription (ATC/DDD, version 2005).
Subsequently we calculated and compared between countries
the weighted average of DDD per prescription for the most used
antibiotics.
Results: In France, Italy, Spain and England together,
amoxicillin, amoxiclav and clarithromycin represented the
most used antibiotics in ambulatory care in 2003 (52% of
the total antibiotic use in DID). For amoxicillin and amoxiclav
the number of DDD per prescription varied from 6.3 and 6.9 in
England to 14.5 and 15.6 in Spain respectively. While there was
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less than one day difference in the average length of treatment
between these countries (6.7 vs. 7.6 for amoxicillin and 7.8 vs. 8.2
for amoxiclav), the average number of DDD prescribed per day
was more than double (0.9 vs. 1.9 for both antibiotics). For
clarithromycin the difference in the average number of DDD
prescribed per day was only 0.2 DDD, whereas the length of
treatment varied by three days (7.4 days in France vs. 10.2 in
England).
Conclusions: Differences in antibiotic use in Europe might be
explained for a substantial part by variation of the number of
DDD per prescription. This could be determined by availability
of different presentations and strengths of a particular antibiotic
in individual countries, which in turn has been driven by
reduced susceptibility to beta-lactam antibiotics.
O435
Antimicrobial prescribing practices by physician
specialty in the United States
K.J. Suda, K.W. Garey, C.T. Bertram, L.H. Danziger (Memphis,
Houston, Deerﬁeld, Chicago, US)
Objective: Little data is available on trends of antibiotic
prescribing by physician specialty. The objective of this
study was to examine prescribing patterns (PP) of oral
antibiotics by physician specialty over 3 years in the United
States (US).
Methods: Outpatient antibiotic prescriptions dispensed in
2001–2003 were evaluated from nine health care plans.
Antibiotics were stratiﬁed into class as deﬁned by the
American Hospital Formulary Service (AHFS). A Chi-squared
was used for statistical analyses. A p value < 0.05 was
considered signiﬁcant.
Results: 7,613 physicians prescribed 48,182 AB RXs for 26,875
patients. Physician specialties included medicine [56% (39%
family practice, 14% internists, 2% generalists)], paediatrics
(21%), specialists (5%), emergency medicine (5%),
dermatologists (4%), OB/GYNs (3%), surgeons (3%), and other
(3%). Dermatologists prescribed tetracyclines most often;
emergency medicine-macrolides; OB/GYNs-nitrofurans;
pediatricians-penicillins; and surgeons-ﬂuoroquinolones (Table
1). When comparing medicine physicians, family practitioners
prescribed penicillins most often while internists prescribed
ﬂuoroquinolones (p < 0.001 for all).
Conclusions: Interesting antibiotic PP was observed by
physician specialty. OB/GYNs and pediatricians prescribed
agents classiﬁed as safe for their patient population. The
Specialist group and internists prescribed broader-spectrum
agents. Interestingly, surgeons prescribed ﬂuoroquinolones
more frequently than any other group.
O436
Impact of a French local community-oriented
antibiotic-reducing programme on the incidence
of invasive diseases
A. Malicki, V. Blanc, P. Bruno, P. Touboul, F. Berthier,
P. Hoﬂiger, T. Fosse, B. Dunais, P. Dellamonica, C. Pradier
on behalf of GEPIE
Objectives: Peer conducted academic detailing visits (PCADV)
were organized to improve antibiotic prescribing in paediatric
out-patient care in 2000 and 2003 in the Alpes Maritimes, France,
as part of a local public health campaign conducted by a multi-
disciplinary group (Groupe d’Etude et de Pre´vention des
Infections de l’Enfant, GEPIE). The aim of the present study
was to survey the evolution of invasive disease related to
bacterial respiratory pathogens. Indeed, practitioners often
declare they prescribe antibiotics due to their fear of
complications, as expressed in Focus Group studies as well as
to visitors during the academic detailing visits within the GEPIE
project.
Method: A retrospective survey was conducted from 1998 to
2003 in the Alpes Maritimes among children aged 1 month to
15 years of age, to study the incidence of invasive infections due
to S. pneumoniae, H. inﬂuenzae, S. pyogenes, and N. meningitidis.
All local laboratories were contacted for bacterial samples
originating from normally sterile sites among the selected
population. Bacterial resistance data to the main antibiotics
were recorded. A further investigation of clinical complications
following ENT bacterial infections such as mastoiditis and
rheumatic fever was also conducted on local hospital databases.
Results: 113 cases of invasive infections (72% due to S
pneumoniae) and 74 clinical complications were recorded over
the 6-year study period. There was no signiﬁcant statistical
difference in the annual average incidence rate before and
during the campaign. Pneumococcal resistance rates to peni-
cillin and erythromycin showed no signiﬁcant change although
the percentage of S. pneumoniae with diminished susceptibility
to penicillin was lowest in 2003. A 20% drop in regional
paediatric antibiotic prescriptions was observed between 2001
and 2003.
Conclusion: The stability of invasive infection and clinical
complication rates as well as that of bacterial resistance during
such campaigns is reassuring. These results encourage
continuing promotion of rational antibiotic prescribing and
could allay practitioners’ fears concerning the consequences of
reducing antibiotic prescriptions. This message will be relayed
to local practitioners.
O437
Evolution of antibiotic consumption in a geriatric
ward of a university hospital: results of a ﬁve-year
policy involving a multidisciplinary
collaboration team
B. Delaere, D. Schoevaerdts, C. Swine, Y. Glupczynski (Yvoir,
BE)
Objectives: Infections represent a frequent cause of
hospitalization and of intercurrent complications in elderly
people hospitalised in geriatric units. Since 1998, a
multidisciplinary ambulatory team (MAT) involving infectious
disease specialists, clinical microbiologists, pharmacists and
infection control practitioners was initiated in the institution.
General and speciﬁc diagnosis and treatment issues are
discussed regularly on a weekly basis by the team with
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clinicians during staff meetings in the geriatric unit (30 beds) in
order to optimize the diagnosis of commonly encountered
infectious diseases and to the improve the quality of antibiotic
prescription. This study aimed to assess the impact of this
multidisciplinary approach on the antibiotic consumption
patterns in the geriatric unit between 2000 and 2004 and to
compare it to the data gathered for the whole hospital during the
same period.
Methods: Antibiotic consumption data available through the
general pharmacy services were monitored with the ABCCalc
software according to the ATC/WHO 2003 methodology and
data were expressed both in Deﬁned Daily dose (DDD) and
Prescribed Daily Doses (PDDs)/100 beds. Susceptibility testing
of bacterial isolates (CLSI methods and interpretative criteria) as
well as surveillance of nosocomial bacteraemia in the geriatric
unit were registered and analysed.
Results: Between 2000 and 2004, the global consumption of
antibiotics in the whole hospital decreased gradually by 15% in
DDD and by 24% in PDDs and the total saving costs of
acquisition for anti-infective drugs (ATC J01) amounted 27%.
Over the same period, the consumption decreased by 45% in the
geriatric unit (40.3 to 22.8 PDDs) and it concerned all classes of
antibiotics, the greatest decrease in usage being recorded for
ﬂuoroquinolones (8 to 2.5 PDD; )67%) and for amoxicillin/
clavulanate (13.5 to 6.2; )54%). Also there was a general
decrease of parenteral antibiotic usage ()92% for quinolones;
)67% for amoxicillin/clavulanate) reﬂecting a marked increase
in the frequency of parenteral-oral switch of antibiotic therapy.
Conclusion: The implementation of a close collaboration
between geritricians, infectious diseases specialists,
microbiologists and infection control practitioners led to a
signiﬁcant reduction of the antibiotic consumption ()45% of
PDD/100 beds over 4 years) and to a parallel improvement of
the quality of anti-infective therapy without any negative impact
on the patient outcome.
O438
Determinants of antibiotic over prescribing in
lower respiratory tract infections in primary care
M. Kuyvenhoven, A. Akkerman, J. van der Wouden, T. Verheij
(Utrecht, Rotterdam, NL)
Objectives: To assess determinants of antibiotic over
prescribing in Dutch primary care patients with acute
bronchitis and exacerbations of COPD.
Methods: GPs (n = 146) from the middle region of the
Netherlands included all patients with acute bronchitis and
exacerbations of COPD during a 4-week period in the winter of
2002/2003, and registrated patient characteristics, clinical
presentation and management. Over prescribing of antibiotics
was assessed using the recommendations of the national
guidelines as benchmark.
Results: In about 60% of all 1023 lower respiratory tract
infection (LRTI) consultations the antibiotic prescribing
decisions were in accordance with the recommendations of the
guidelines. Over prescribing was higher in bronchitis than in
exacerbations of COPD (63% and 24% of all consultations,
respectively). Under prescribing was seen in 3% and 6 %,
respectively. Patients, who did get an antibiotic prescription
while this was not in accordance with the guidelines, had more
inﬂammation signs like fever and sputum (ORs 3.04 and 4.54,
respectively), as compared to those who did not get an antibiotic
prescription. Purulent sputum (OR 24.41) and auscultation
abnormalities with left-right difference (OR 17.73) were strong
determinants of inappropriate prescribing in patients with
exacerbations of COPD. In addition, for bronchitis as well as
exacerbations of COPD inappropriate prescribing occurred
more, when patients were more severely ill according to their
GP (ORs 2.37 and 1.82 respectively) and when the GPs assumed
their patients to expect an antibiotic (ORs 2.11 and 2.25,
respectively).
Conclusion: GPs overestimate symptoms and probably
patients’ expectations in applying recommendations in LRTI
cases in daily practice. Correct interpretation of combinations of
symptoms for antibiotic treatment should be emphasised
combined with adopting more patient-centred consulting skills
to rationalise prescribing antibiotics.
O439
Antibiotic use in two cohorts of German
intensive care units, 2001–2002
K. de With, E. Meyer, M. Steib-Bauert, F. Schwab, F.D. Daschner,
W.V. Kern (Freiburg, Berlin, DE)
Objectives: To evaluate antibiotic use density in two cohorts of
intensive care units (ICUs) in Germany that differed in overall
antibiotic use density. One cohort included ICUs participating in
the SARI programme (SARI-ICUs, n = 34), a programme that
started in 2000 and collects antibiotic use and bacterial resistance
data with quarterly feedback of the data including reference
data derived from the cohort to the providers. The second ICU
cohort participated in the MABUSE network (MABUSE-ICUs,
n = 58) and represented a convenience sample from hospitals in
the southwestern part of the country in which the analysed data
were not made available to providers until after the study
period.
Methods: Two dose deﬁnitions were used, the WHO/ATC 2001
deﬁnition of deﬁned daily doses (DDD), and a deﬁnition of
prescribed daily doses (PDD) used previously. In a subgroup of
both SARI-ICUs and MABUSE-ICUs (n = 9) we performed a
point prevalence survey (pps) to evaluate truly prescribed doses
as compared with DDD and PDD. Data were expressed as DDD
or PDD per 100 patient days. Hospital size and afﬁliation, year
of study and ICU type were examined as variables potentially
inﬂuencing overall use.
Results: Overall antibiotic use density was similar in the
2 years of study, but differed between the two ICU cohorts
irrespective of the dose deﬁnitions used. Regression analyses
showed that antibiotic use density was primarily associated
with hospital afﬁliation (university vs. non-university) and
hospital size while ICU type and cohort type were not
independent factors. Mean overall antibiotic use density in
non-university hospital ICUs for different hospital bed size
categories ranged between 106 and 111 DDD/100 (59–67
PDD/100) compared with 140 DDD/100 (87 PDD/100) in
university hospital ICUs. Of 97 daily doses prescribed to 71
patients on the day of the pps, 66% corresponded to the PDD
deﬁnition employed by us, and 23% corresponded to the
WHO/ATC 2001 DDD deﬁnition. Of 31 doses not
corresponding to either of the deﬁnitions, 25 were higher
than deﬁned in the DDD or PDD. Thus, PDD, in fact, better
reﬂected currently high dosages of parenteral drugs in
hospitalized patients.
Conclusion: Comparing antibiotic use density between ICU
cohorts and assessing trends over time need adjustment of the
data at least for hospital afﬁliation and size. Using the WHO/
ATC 2001 dose deﬁnition leads to substantial overestimation of
true treatment days in the intensive care area.
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Beneﬁt of appropriate empirical antibiotic
treatment: 30-day mortality and duration of
hospital stay
A. Fraser, M. Paul, N. Almanasreh, E. Tacconelli, U. Frank,
R. Cauda, S. Borok, S. Andreassen, A.D. Nielsen, L. Leibovici on
behalf of the TREAT Study Group
Objectives: To evaluate the effect of inappropriate antibiotic
treatment on mortality and duration of hospital stay in a
relatively low-risk study population of medical inpatients with
bacterial infections.
Methods: Two cohorts of febrile patients, hospitalized in 3
medical centers in Israel, Italy and Germany were included.
Patients’ data were collected prospectively. Initial empirical
treatment was deﬁned as appropriate if an antibiotic prescribed
within 24 hours of the ﬁrst encounter with the patient, matched
the in-vitro susceptibility of a pathogen deemed to be the likely
cause of infection. Results of cultures and serological or direct
tests as well as data on outcomes were collected 30 days after
initiation of empirical treatment. A multiple logistic regression
model was constructed to assess the impact of inappropriate
antibiotic treatment on mortality while adjusting for medical
center and other variables. A General Linear Model (GLM) was
used to examine the association between inappropriate
antibiotic treatment and duration of hospitalization while
controlling for medical center and other variables.
Results: Nine hundred and twenty patients (26% of 3529
included patients) had microbiologically documented
infections and mortality data were available for 895 patients
(97%). Inappropriate initial antibiotic treatment was prescribed
in 36% of patients (N = 319), with similar proportions in all 3
participating centers (p = 0.33). All-cause 30-day mortality rates
were 20.1% (N = 64) and 11.8% (N = 68) in patients who
received inappropriate and appropriate treatment, respectively
(OR = 1.88, 95%CI: 1.29–2.72, p = 0.001). When adjusting for
medical center and other clinical variables, the association
between inappropriate antibiotic treatment and mortality was
OR = 1.58 (95%CI: 0.99–2.54, p = 0.058) (Table). In all 3 medical
centers, mean duration of hospital stay was at least 2 days
longer for patients prescribed inappropriate antibiotic treatment
(overall p = 0.002). This association was consistent after
adjusting for other clinical variables (p = 0.006).
Conclusions: Appropriate empirical antibiotic treatment is
associated with a better survival and shortened duration of
hospital stay in medical patients.
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